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Abstract 
Urinary pharmacokinetic methods have been introduced to identify the relative lung and 
systemic availability of inhaled drugs but have not been extended to corticosteroids. The 
main aims were to validate the urinary pharmacokinetic methodology when applied to 
inhaled beclometasone dipropionate (BDP), demonstrate the usefulness of the method 
and compare its indices to the in-vitro characteristics of the emitted dose. 
A simple and sensitive LC-MS method for quantifying BDP and its metabolites in 
methanol (for in-vitro studies) and urine samples was identified and validated in 
accordance with the FDA and ICH guidelines. The accuracy, precision, and recovery of 
the method were within acceptable limits (±15%).  
Twelve healthy volunteers completed the in-vivo urinary pharmacokinetic validation of 
the methodology to determine the relative lung bioavailability of inhaled beclometasone 
following inhalation. Twelve healthy volunteers received randomised doses, separated by 
>7 days, of  2000μg BDP solution with (OralC) and without (Oral) 5g oral charcoal, ten 
100μg inhalations from a Qvar® Easi breathe metered dose inhaler (pMDI) with (QvarC) 
and without (Qvar) oral charcoal  and eight 250μg inhalations from a Clenil® pMDI 
(Clenil). Subjects provided urine samples at 0, 0.5, 1, 2, 3, 5, 8, 12, and 24 hours post 
study dose. Urinary concentrations of BDP and its metabolites, 17-beclometasone 
monopropionate (BMP) and beclometasone (BOH) were measured. No BDP, BMP, or 
BOH was detected in any samples post OralC dosing. Post oral dosing, no BDP was 
detected in any of the urine samples and no BMP or BOH was excreted in the first 30 
minutes. Significantly more (p<0.001) BDP, BMP and BOH was excreted in the first 30 
minutes and cumulative 24 urinary excretions post Qvar and Clenil compared to Oral. 
Using 30 minute urinary excretion the mean ratio (90% confidence interval) for Qvar 
compared to Clenil was 231.4 (209.6, 255.7).  The results confirm that the relative lung 
and systemic bioavailability can be identified from urinary excretion of BDP and its 
metabolites over the first 30 minutes and 24 hours respectively. The 2-fold difference 
between Qvar and Clenil is consistent with related clinical and pharmacokinetic studies. 
The low inter and intra-subject variability of the study confirms the reproducibility of 
this method.  When compared to the in-vitro aerodynamics characteristics of the emitted 
dose, using standard compendial methods, the in-vivo indices showed a relationship to 
the fine particle dose (FPD) and the emitted dose (ED), respectively. 
The application of this urinary pharmacokinetic method was demonstrated in further 
studies to compare the effect of different spacers and different washing methods on the 
in-vivo drug delivery post inhalation from Clenil and Qvar inhalers in healthy volunteers. 
In addition, the in-vitro aerodynamic particle size distribution of the same inhalation 
methods has been investigated using the Andersen Cascade Impactor according to the 
standard compendial methodology. Urinary excretion, using 24 hour excretion, revealed 
that relative bioavailability to the body was reduced with spacers for both inhalers.  
There was no increase in the relative lung bioavailability when Qvar was used with 
spacers.  When Clenil was attached to a spacer (either AeroChamber or Volumatic) the 
relative lung bioavailability was significantly greater only if the spacers were not rinsed 
after washing with detergents. Consistent with the above study there were correlations 
between the in-vivo urinary indices and the in-vitro characteristics of the emitted dose.  
The thesis highlights the extension of the urinary pharmacokinetic method to inhaled 
beclometasone dipropionate and provides further evidence of in-vitro in-vivo correlations 
between the urinary methodology and the aerodynamic characteristics of the emitted 
dose. 
Keys words:  beclometasone dipropionate, metabolites, urinary excretion, metered dose 
inhalers, spacers, relative lung bioavailability, and in-vitro dose emission. 
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1.1. Introduction 
Pulmonary delivery has long been recognized as the most efficient route of drug 
administration for asthma and other diseases of the respiratory tract (Everard, 2001). 
Drugs are delivered directly to the site of action, where they exert a local effect and thus 
have a fast onset of action. The inhalation of drugs produces high local concentrations in 
the lungs, avoiding the high systemic concentrations that would result from equipotent 
oral and parental doses. Hence the lower doses used translate to a much lower incidence 
of systemic side effects which is particularly important in the case of inhaled 
corticosteroids (ICS) treatment (Chrystyn, 1994; Pedersen et al., 2010).  
Inhaled corticosteroids are the most effective anti-inflammatory drugs available to 
clinicians for the control of inflammation in asthma. Inhaled corticosteroids effectively 
suppress the inflammatory processes in the airways of most asthmatics. Their clinical 
benefits include; decreased asthma symptoms, decreased airway hyperresponsiveness, 
improved pulmonary function, fewer exacerbations, fewer hospitalisations, and fewer 
asthma related deaths (Suissa et al., 2000; Adams et al., 2005; Sobande and Kercsmar, 
2008). Among various ICS available in the market, beclometasone dipropionate was the 
first one introduced in 1972 in a pressurized metered dose inhaler and later in a dry 
powder inhaler and an aqueous nasal spray (Daley-Yates et al., 2001). Beclometasone 
dipropionate (BDP) is a powerful topically active inhaled corticosteroid that is used in 
treatment of asthma. It is actually a prodrug that is metabolised by esterases in the human 
lung to three different metabolites; 17-beclometasone monopropionate (17-BMP), 21-
beclometasone monopropionate (21-BMP), and beclometasone (BOH). 17-
beclometasone monopropionate (17-BMP) is the active metabolite whereas BOH and 21-
BMP have a very low binding affinity to the glucocorticoid receptor (Wurthwein and 
Rohdewald, 1990; Derendorf et al., 2006). Since the early introduction of beclometasone 
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in the mid 1970s, a great number of new formulations, propellants, and inhaler devices 
were developed. 
Worldwide, MDIs are the most widely used inhalation devices for the treatment of 
asthma as it is relatively inexpensive, widely available and portable devices that use a 
propellant under pressure to deliver a metered aerosol dose through an atomisation 
nozzle (Smyth, 2003). Although correct use of a MDI looks simple, several studies have 
reported failure of a large proportion of patients to use it properly. Adding a spacer 
device to MDIs or using a breath-actuated device such as the Autohaler or the Easi-
Breathe device helps to solve the problem of poor hand breath coordination (Newman et 
al., 1991c). Furthermore, the use of spacers enables the aerosol cloud produced from the 
MDI to slow down and the propellant to evaporate, thus increasing drug delivery to the 
lung. Spacers also have a size selective function and retain the larger non-respirable 
particles on spacer walls, thus limiting oropharyngeal deposition. However, the presence 
of electrostatic charge on spacer surfaces may markedly interfere with drug delivery. 
Therefore, spacers should be washed with detergent and allowed to drip dry at least each 
month to limit electrostatic charge effect (Chrystyn and Price, 2009; Pedersen et al., 
2010; Vincken et al., 2010).  
Pressurized MDIs were routinely formulated with Chlorofluorocarbon (CFC) propellants 
for several decades, but due to their ozone depleting potential, they have been phased out 
and replaced by the more environmentally safer hydrofluoroalkane (HFA) alternatives. 
Nevertheless, switching to HFA propellants in MDIs was not straightforward due to their 
different physico-chemical properties as well as incompatibility with the conventional 
surfactants used in CFC-MDIs. These challenges forced everyone to consider new 
approaches and develop better ways to accommodate the new propellants and deliver 
inhaled medications. Two approaches were used in the reformulation of HFA-MDIs. The 
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first approach was to match the new HFA formulations to their chlorofluorocarbon 
counterparts on a microgram for microgram dose; therefore, no dosage modification was 
required on switching from the HFA-MDI to the CFC-MDI. An example of this approach 
is the development of Clenil Modulite® (Chiesi, Italy) which is the first CFC free BDP 
metered-dose inhaler directly interchangeable with CFC-BDP containing inhalers. It has 
a mass mean aerodynamic diameter of 2.9μm and its particle size distribution more 
closely matches that of CFC containing MDIs (Ganderton et al., 2002). The second 
approach has focused on tailoring the particle size distribution of the aerosol generated to 
produce extra fine particles for more efficient lung targeting (Ganderton et al., 2002; 
Lewis et al., 2005). An example of the second approach is the development of Qvar® 
(Teva Pharmaceuticals, UK) inhalers that has a mass median aerodynamic diameter of 
1.1µm. The smaller median particle size of Qvar® (HFA-BDP) has been shown to 
improve drug delivery and produce equivalent asthma control to chlorofluorocarbon-
based BDP inhalers, at approximately half the daily dose in both adults and children 
(Leach et al., 1998a; Leach et al., 2002; Janssens et al., 2003). Despite the improved lung 
deposition of Qvar®, it has a favourable safety profile (systemic and overall) compared 
with other inhaled corticosteroids (Thompson et al., 1998; Ayres et al., 1999).  
After inhalation, up to 20% of the dose is delivered to the lungs whilst the majority is 
swallowed (Chrystyn, 1997). The proportion of the dose that enters the lung is either 
cleared from the body, either by mucociliary clearance (Borgstrom et al., 1992) then 
swallowed or by absorption through the airway wall into the systemic circulation. It is 
the latter delivered by the pulmonary route that has the potential to exert a therapeutic 
effect; this is termed the effective lung dose. 
The amount of drug that deposits in different regions of the respiratory tract can be 
determined by in-vivo methods such as gamma scintigraphy, using radioactive tagged 
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aerosol particles (Leach et al., 1998a; Leach et al., 1998b), pharmacokinetic methods  
using plasma (Clark et al., 1996) or urine samples (Hindle and Chrystyn, 1992), and  in-
vitro methods mostly using the Andersen Cascade Impactor.  
In-vitro methods are used as a quality assurance procedure to identify the total emitted 
dose and dose uniformity. In addition, they measure the aerodynamic particle size 
distribution of the aerosol cloud generated by the product yielding information about the 
mass fraction that has the potential to enter the deeper part of the lung. Various studies 
have shown that the aerodynamic particle size distribution of aerosols generated by 
inhalation products correlates with the amount of drug deposited in the lungs (Seale and 
Harrison, 1998; Silkstone et al., 2002). 
Pharmacokinetic methods using plasma or urine samples can be used to identify the 
relative lung deposition of the drug and total systemic delivery. Borgstrom and Nilsson 
(1990) developed a charcoal block method to identify the relative lung deposition. They 
reported that the concurrent oral administration of activated charcoal blocked all 
absorption of the drug from the gastrointestinal tract. In this case, the amount of drug 
eliminated in the urine gives an absolute value for the total lung dose. However, because 
this method uses oral charcoal it would be unethical to extend it to patient studies due to 
their concomitant oral therapy (Chrystyn, 2001). 
Hindle and Chrystyn (1992) first reported a urinary pharmacokinetic method to 
determine the relative bioavailability of salbutamol to the lung and to the body following 
an inhalation. Drugs delivered to the lungs are very rapidly absorbed into the body 
whereas there is a lag time after oral administration before its delivery to the systemic 
circulation. The body starts eliminating drugs as soon as they are delivered to the body. 
Using this principle, Hindle and Chrystyn (1992) found that the amount of salbutamol 
excreted in the urine over the first 30 minutes post inhalation was significantly greater 
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than the amount eliminated following oral administration. They have validated how this 
index represents the amount of the inhaled dose deposited in the lungs. This 
measurement represents the effective lung dose because it measures the drug delivered to 
the body following passage through the airway wall. Hindle and Chrystyn (1992) also 
reported that the amount of salbutamol and its metabolites excreted in urine over the 24 
hours period post inhalation is an index of systemic delivery. This index is the relative 
bioavailability to the body following inhalation. 
1.2. Aim and objectives 
1.2.1. Aim 
The aim of this research work is to: 
- Develop and validate a urine pharmacokinetic methodology to identify the relative 
lung and systemic bioavailability of beclometasone following inhalation. 
- Investigate the pharmacokinetics and in-vitro performance of beclometasone 
dipropionate inhaled from two different HFA-BDP formulations with or without 
spacer devices. 
1.2.2. Objectives 
1. To develop and validate a sensitive, robust and reliable LC-MS assay for the 
determination of beclometasone dipropionate and its metabolites in methanol samples 
for in-vitro testing of inhaled products and human urine samples following oral and 
inhaled administrations to subjects. 
2. To identify and validate the Hindle and Chrystyn urinary pharmacokinetic method to 
determine the relative lung and systemic bioavailability of beclometasone following 
inhalation. 
3. To determine the aerodynamic characteristics of the emitted dose of beclometasone 
dipropionate obtained from two different HFA-BDP formulations (Clenil Modulite® 
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MDI and Qvar® inhalers) with and without different spacers. In addition, to test the 
effect of different spacers’ handling methods on the aerodynamic particle size 
distribution of the studied aerosols.  
4. To determine the effect of increasing the inspiratory flow rate on the aerodynamic 
characteristics of the emitted dose of beclometasone dipropionate from Clenil 
Modulite® MDI and Qvar® inhalers when used alone without spacers.  
5. To demonstrate the application of the previously validated urinary pharmacokinetic 
method of beclometasone to investigate the effect of different spacers on the lung and 
systemic bioavailability following inhalation from either Clenil Modulite® MDI, 
Qvar® EB or Qvar® MDI  with and without spacers. In addition, to test the effect of 
different spacers’ handling methods on the in-vivo drug delivery. 
1.3. Thesis structure 
The work in this thesis as follows: 
Chapter 1: a general introduction with a brief summary of work. 
Chapter 2: an overview of literature related to the areas of study. 
Chapter3: describes the validation of a sensitive, simple LC-MS assay for the 
determination of beclometasone dipropionate (BDP) and its metabolites 17-
beclometasone monopropionate (17-BMP) and beclometasone (BOH) in methanol and 
urine samples for subsequent in-vitro and in-vivo studies, respectively. Fluticasone 
propionate was used as the internal standard. The parent compound, metabolites, and the 
internal standard were extracted from urine samples using a solid phase extraction 
method. The intra-day and inter-day accuracy, precision, limit of detection, and limit of 
quantification of BDP, 17-BMP, and BOH by the extraction method and the LC-MS 
assay have been determined. In addition, this chapter describes a method developed for 
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hydrolysis of beclometasone dipropionate via an esterase enzyme with identification and 
separation of its metabolites.  
Chapter 4: describes the validation of the urinary pharmacokinetic method to determine 
the relative lung and systemic bioavailability of beclometasone following oral, oral with 
charcoal, inhaled and inhaled with charcoal administration. Furthermore, the intra- and 
inter-subject variability of the 30 minutes and the 24hr urinary excretion post inhalation 
was investigated.  
Chapter 5: it is divided into two sections: 
(a) In-vitro study to characterise the dose emitted from Clenil Modulite® MDI alone 
and when attached to different spacers. In addition, determination of the 
aerodynamic particle size distribution obtained from Clenil Modulite® MDI alone 
at different flow rates. 
(b) Application of the urinary pharmacokinetic method to determine the relative lung 
and systemic bioavailability of beclometasone following inhalation from Clenil 
Modulite® MDI alone and when attached to different spacers. 
Chapter 6: it is divided into two sections: 
(a) In-vitro study to characterise the dose emitted from Qvar® MDI and Qvar® EB 
alone and when attached to different spacers. In addition, determination of the 
aerodynamic particle size distribution obtained from Qvar® MDI and Qvar® EB 
alone at different flow rates. 
(b) Application of the urinary pharmacokinetic method to determine the relative lung 
and systemic bioavailability of beclometasone following inhalation from Qvar® 
MDI and Qvar® EB alone and when attached to different spacers. 
Chapter 7: it is divided into two sections: 
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(a) Comparison of the in-vitro emitted dose and aerodynamic particle size 
distribution of beclometasone dipropionate emitted from Qvar® EB, Qvar® MDI, 
and Clenil® inhalers with and without spacers by using the previously illustrated 
results in chapter 5.2 and 6.2 of this thesis. 
(b) Comparison of the relative lung and systemic bioavailability of beclometasone 
dipropionate post-inhalation from Qvar® EB, Qvar® MDI, and Clenil® inhalers 
with spacers by using the previous results illustrated in chapter 5.3 and 6.3 of this 
thesis. 
Chapter 8: describes a general conclusion from these studies and suggestions for future 
work.
  
 
 
 
Chapter 2: Literature Review
11 
 
2.1. The respiratory system 
The respiratory system may be defined as the organs and tissues through which air is 
passed into and out of the body to allow the necessary gaseous exchange to take place 
between the circulatory system and the outside world. When you breathe in or inhale, 
your body receives oxygen that is essential to the body to produce energy, perform its 
metabolic functions, and sustain life. When you breathe out or exhale, your body is 
cleared from carbon dioxide, a waste gas produced as result of chemical reactions within 
the cells, which must be continuously eliminated, as excessive amounts of carbon dioxide 
are toxic. The human respiratory system can be divided into two functional regions: 
upper respiratory tract (nasal passages, pharynx, and the larynx) and lower respiratory 
tract (the conducting airways and lungs). The lower respiratory tract structures are 
contained within the thoracic cavity. The upper respiratory tract passageways are lined 
with respiratory ciliated epithelium, which secretes mucus. These cilia prevent inhaled 
particles from reaching the lungs and help to propel secretion to the pharynx where they 
can be swallowed or coughed up (Waldron, 2008; Rogers, 2011).  
2.1.1. The conducting airways 
Atmospheric air is delivered in and out regularly into the respiratory portions of the lung 
through a system of airways called the conducting airways. They form a very complex 
branching tree of tubes, which become narrower, shorter and more numerous as they 
penetrate deeper into the lung. As illustrated in figure 2.1A, air is carried to and from the 
lungs by the trachea that extends from the larynx to the middle of the thorax where it 
divides into the right and left main bronchi, each of which feed air to one of the lungs. 
The trachea (windpipe) is a muscular tube supported by C-shaped cartilage rings that 
help to protect it and prevent it from collapse. The bronchial tubes subdivide and with 
each subdivision, their walls get thinner. After about 16 levels of branching, the airways 
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become the respiratory zone where gaseous exchange occurs. The airways from the 
trachea through and including the terminal bronchioles down to the 16th branch are 
known as conducting airways. This region actually contains no alveoli, so no gas 
exchange takes place in this area and it is often referred to as anatomical dead space.  
 
Figure 2.1: Lung structures (A) respiratory organs (B) respiratory bronchioles and 
alveoli (C) gaseous exchange. From 
(http://www.nhlbi.nih.gov/health/dci/Diseases/hlw/hlw_respsys.html). 
The conducting airways have two major functions. First is to lead the inspired air to the 
more distal gas-exchange regions of the lung and second is to warm and humidify the air 
to avoid any damage to the delicate structure of the alveoli by excessive exposure to dry, 
cold air. The structures distal to the terminal bronchioles branch more into the respiratory 
bronchioles, these tiny respiratory bronchioles eventually become alveolar ducts, which 
terminate into groups of thin walled sacs called alveoli. This is the site where respiratory 
gas exchange takes place. The region, from the respiratory bronchioles through the 
alveoli, is known as the respiratory zone (Kelly, 2003; Ethier and Simmons, 2007; 
Whittemore, 2009).  
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As shown in figure 2.1 (B), the pulmonary circulation functions to bring blood into 
close contact with the alveoli (air sacs), where gas exchange takes place at the blood-gas 
interface. A dense network of blood vessels called pulmonary capillaries in the lung 
surrounds alveoli. The blood in these capillaries picks up oxygen from the alveoli to be 
transferred round the body, and transport carbon dioxide back to the alveoli to be 
excreted. The very small distance of 1µm and in some cases 0.1µm between the blood in 
an alveolar capillary and the air inside the alveolus is the reason behind the quick and 
efficient gas transfer between the blood and the lungs. Oxygen and carbon dioxide move 
between air and blood by simple diffusion, that is from an area of high concentration to 
an area of low concentration as illustrated in figure 2.1 (C). Fick’s Law of diffusion 
states that, the amount of gas that moves across a sheet of tissue is proportional to the 
area of the sheet (A) but inversely proportional to its thickness (T). It is expressed by the 
following equation VGas α A.D (P1 – P2)/T, where VGas= gas flow, A= area, T= 
thickness, D= Diffusivity, and P1-P2 = partial pressure gradient (West, 2008).  
Figure 2.2, shows that the airway branching system of the lung undergoes 23 
bifurcations and the surface area of the alveoli is enormous compared to airways surface 
area, which allows the efficient gas exchange. Several studies in human adults have 
shown that the surface area of the airways averaged 2.5m2 (Mercer et al., 1994; Patton, 
1996; Leach et al., 2002), while the  total surface area of the alveolar walls has been 
estimated to be as large as 140m2, which is about 75 times the body’s external surface 
area. This is attributed to the fact that the human lung has about 500 million alveoli and 
the walls of each alveolus are completely lined with an enormous number of capillaries; 
there are 280 billion pulmonary capillaries or almost 1000 capillaries per alveolus, 
resulting in a massive surface area available for gas diffusion inside the limited thoracic 
cavity. 
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 In addition, the extreme thinness of the blood gas interface facilitates gas exchange by 
diffusion and therefore, it is very well suited to the gas exchange function. The 
combination of an enormous alveolar surface area and the very thin tissue layer between 
blood and air makes the lung a very effective mass transfer device. Carbon dioxide 
moves into the alveolus, as the concentration is much lower than in the blood. Oxygen 
moves out of the alveolus due to the continuous flow of blood through the capillaries 
that prevents saturation of the blood with oxygen and thereby allowing maximal transfer 
across the membrane; this is known as gas exchange process or respiration (Kelly, 2003; 
Ethier and Simmons, 2007; West, 2007; Whittemore, 2009). 
 
Figure 2.2: Schematic design of airway branching in the human lung. Reproduced from 
(Weibel, 1963). 
2.1.2. The lungs 
The lungs are spongy, cone shaped structures. The left lung has two lobes and is slightly 
smaller than the right lung, which has three lobes. The base of the lungs rest on the 
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diaphragm (the main muscle of respiration) and the top, which is called the apex, starts at 
the root of the neck. The two lungs are each enclosed within a double membrane known 
as the pleura. The visceral pleura is the membrane adhered to the external surface of the 
lungs and the parietal pleura lines the wall of the thoracic cavity. The space in between 
the two layers, the pleural space is normally filled with the intra-pleural fluid. This fluid 
lubricates the membranes and reduces friction between the layers as they slide over each 
other during breathing. The elasticity or capacity of the lung to stretch is due to the 
presence of elastic fibres and collagen in lung tissue, which gives the lung the ability to 
inflate and deflate during breathing (Ward et al., 2006; Waldron, 2008; Whittemore, 
2009). As shown in figure 2.3, contraction and relaxation of the muscles of the chest and 
the diaphragm are responsible for inspiration and expiration. During inspiration 
(inhalation), the diaphragm contracts, flattens, and moves downward and the inter-costal 
muscles between the ribs contract, pulling the ribcage upwards and outwards. Thereby, 
increasing the volume of the thoracic cavity and air is drawn into the lung by a negative 
intra-thoracic pressure.  
 
 
 
 
 
 
Figure 2.3: Mechanisms of respiration.  
Expiration (exhalation) is a passive process that depends on the natural tendency of the 
lungs to collapse. The inter-costal muscles relax and the diaphragm falls back to its 
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original position, pulling the ribcage down and contracting the lungs. This reduces the 
volume of the chest and forces the air out of the lungs (Kelly, 2003; Ethier and Simmons, 
2007; West, 2007; Waldron, 2008).  
2.2.  Diseases of the respiratory system 
The respiratory system is susceptible to a number of diseases, caused by genetic factors, 
infections, and pollutants. The most common problems of the respiratory system are 
asthma and chronic obstructive pulmonary disease (COPD). 
2.2.1. Asthma 
Asthma is one of the most common chronic pathological conditions throughout the 
world. It has been estimated that asthma affects around 300 million people worldwide, a 
total that is expected to rise by an additional 100 million mainly in children over the next 
20 years. In the UK, it is estimated that 5.2 million people are currently receiving asthma 
treatment, which is costing the National Health Service (NHS) over £889 million a year 
in terms of emergency room visits and hospitalisations (Masoli et al., 2004a; Adcock et 
al., 2008b; Waldron, 2008). 
The international consensus report for the management and diagnosis of asthma defined 
it as a chronic inflammatory disorder of the airways in susceptible individuals, in which 
many cells and cellular elements play a role. This chronic inflammation is usually 
associated with widespread but variable airflow obstruction and an increase in airway 
response to a variety of stimuli. Obstruction is often reversible, either spontaneously or 
with treatment (GINA, 2010; Rees et al., 2010). A detailed explanation of asthma 
pathogenesis is provided in APPENDIX A.1 (refer to the enclosed DVD). 
2.2.1.1. Asthma management and treatment 
Asthma is more accurately thought as a multi-factorial overlapping syndrome rather than 
a single disease. Thus it is usually difficult to find a cure for asthma; hence the goals of 
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optimum asthma control according to GINA (2010) guidelines is the avoidance and 
removal of stimulus that induces airway constriction, control the symptoms, minimise the 
use of rescue medication, prevent asthma exacerbations and achieve best possible normal 
level of daily activity and lung function. 
Asthma is a disease of two main components, inflammation, and bronchoconstriction, so 
treatment regimens that address both issues provide the most efficacious asthma 
treatment. Asthma medications fall into one of two groups: relievers (the mainstay 
therapy for bronchoconstriction) including inhaled short acting beta agonists (e.g. 
salbutamol, terbutaline), anti-cholinergics (e.g. ipratropium), and preventers (the main 
stay therapy for inflammation) mainly inhaled corticosteroids (ICS). In addition, 
controllers namely long acting beta agonists (e.g. salmeterol, formoterol) used in 
conjunction with ICS have been shown to provide extra benefits in the control of asthma 
symptoms (Barnes et al., 1998). Other agents used are inhaled anti-allergic non-steroidal 
agents (e.g. cromoglycate and nedocromil), leukotriene inhibitors, Xanthines (e.g. 
theophylline). However, current guidelines have pointed out that inhaled corticosteroids 
are the gold standard of control therapy for asthma (Suissa et al., 2000; Pauwels et al., 
2003; Murphy, 2007; GINA, 2010). 
 The quick relievers group are best represented by the inhaled short-acting beta agonists 
or SABAs, which are effective bronchodilators with a rapid onset of action (Volovitz, 
2008). Short-acting beta agonists (SABAs) should be used on an as-needed basis and are 
commonly prescribed to relieve acute asthmatic episodes, by relaxing the airway smooth 
muscle, inhibit mediators release from mast cells and reduce vascular permeability 
(Kassianos et al., 2005).  
The British Thoracic Society’s guidelines (BTS) (BTS/SIGN, 2008) in its stepwise 
approach, as illustrated in figure 2.4, recommends that inhaled short-acting ß2 agonists 
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are the first line treatment in case of mild intermittent asthma and inhaled corticosteroids 
are the cornerstone of asthma management. Using β2-agonists on as required basis was 
proven to be as good as regular administration (Dennis et al., 2000; Walters et al., 2003; 
BTS/SIGN, 2008). 
 
Figure 2.4: Summary of the stepwise management of asthma according to the most 
recent proposed BTS/SIGN guidelines (BTS/SIGN, 2008). 
Asthma is a dynamic as well as chronic condition, this is why the treatment plan should 
include both a step up and a step down approach, in which the number and frequency of 
medications are increased or decreased according to the symptoms. The concept of self-
management in asthma therapy is very important and has been shown to reduce 
morbidity and health care resource utilisation, so the patient initiates changes in therapy, 
according to the degree of symptoms, ß2-agonist use (Lahdensuo et al., 1998; Miller-
Larsson and Selroos, 2006; Bernstein, 2008). The increased use of short-acting β2-agonist 
by asthmatic patients should be used as an index of worsening asthma control mandating 
the addition of an anti-inflammatory therapy (Holgate and Polosa, 2006). It is very 
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important to reduce treatment as asthma comes under control, so that the patient is on the 
minimal therapy required. 
Inflammation is an early and persistent feature of asthma and many studies suggest that 
the early introduction of ICS anti-inflammatory treatment leads to a better improved 
asthma and less additional asthma medication use (Haahtela, 1995; Selroos et al., 1995; 
Bernstein, 2008; Busse et al., 2008; Corrigan et al., 2009). These studies also support 
current national and international asthma treatment guidelines which emphasize the 
importance of this early intervention with inhaled corticosteroids (ICS) as an initial anti-
inflammatory treatment for asthma (NAEPP, 2007; BTS/SIGN, 2008). 
Inhaled corticosteroids were found to be very effective in reducing the severity of 
symptoms, diminishing airway hyperresponsiveness, preventing exacerbations, 
improving asthma control, and quality of life (Pauwels et al., 2003; Adams et al., 2005; 
Adams et al., 2008; Reddel et al., 2008; GINA, 2010). Also, inhaled corticosteroids were 
beneficial in decreasing the need for hospitalizations (van Ganse et al., 1997), and deaths 
due to severe asthma (Suissa et al., 2000; Kips and Pauwels, 2001b; Neffen et al., 2006). 
ICS doses should be adjusted according to the level of control obtained and the dose 
should be titrated to the minimum dose required to achieve asthma control, thus reducing 
the potential for side effects (BTS/SIGN, 2008).  
Nevertheless, a substantial proportion of asthmatic patients with more severe disease are 
insufficiently controlled with a low to moderate dose of ICS. For these patients several 
therapeutic options exist as recommended by the current guidelines, the first option is to 
add another form of controller medication to an unchanged dose of ICS such as long 
acting beta agonists or LABAs (e.g. salmeterol, formoterol); the second option is to 
increase the ICS dose (Kips and Pauwels, 2001a; BTS/SIGN, 2008). 
Different clinical trials have found that ICS and LABA in a combination inhaler are 
superior to increasing the dose of ICS (Shepherd et al., 2008). ICS/LABA combination 
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therapy complements each other by working on two different components of the disease: 
inflammation and bronchoconstriction. They provide greater improvement in lung 
function, better symptoms control, and lower exacerbations compared with ICS alone, 
even at much higher doses of ICS (Shapiro et al., 2000; Masoli et al., 2005; Fabbri et al., 
2008; Shepherd et al., 2008; Ducharme Francine et al., 2010). Long-acting β2-agonists 
are believed to interact synergistically with inhaled corticosteroids and permit lower 
dosing of corticosteroid, but they should never be used as a mono-therapy but only as an 
additional therapy (Pauwels et al., 1997b; Kips and Pauwels, 2001a; Naedele-Risha et al., 
2001; Miller-Larsson and Selroos, 2006). Corticosteroids have been shown to up-regulate 
the β-2 receptor in the human airways, leading to more receptors available for β2-agonist 
activation. On the other hand, LABA was shown to facilitate the entry of the 
glucocorticoid receptor ligand complex into the nucleus, hence enhancing its anti-
inflammatory effects (Mak et al., 1995; Schmidt et al., 2001). A recent Cochrane review 
concluded that the use of LABA allows up to 57% reduction of inhaled corticosteroids 
use (Gibson et al., 2005). Importantly, no safety issues have been identified with this 
combination in patients with asthma and COPD (Miller-Larsson and Selroos, 2006).  
Alternative to the addition of LABA therapy, leukotriene receptor antagonists (Currie et 
al., 2005) or theophylline (Ukena et al., 1997; Tee et al., 2007) can be added to the 
combination therapy with ICS for patients with persistent asthma. However, these 
combinations are less effective than ICS/LABA dual therapy, which is the preferred 
therapy (Busse et al., 1999a; Nelson et al., 2000; Meltzer, 2003).  
Nevertheless, other patients with severe persistent, uncontrolled asthma will need to use 
oral corticosteroids at the lowest possible dose as adjunct to SABAs to speed recovery 
and prevent recurrence of exacerbations. Patients at this stage should be referred for 
specialist care (BTS/SIGN, 2008; Waldron, 2008).  
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2.2.2. Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder and a 
huge health problem that causes considerable morbidity, patient suffering, and mortality 
throughout the world. Chronic obstructive pulmonary disease is the fifth leading cause of 
death in the UK and fourth worldwide and set to become the third leading cause of death 
worldwide by the year 2020 (Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), 2009; NICE, 2010). Approximately 835,000 people in England have been 
diagnosed with COPD only in 2008-9 (NHS Information Centre for Health and Social 
Care, 2009).Chronic obstructive pulmonary disease (COPD) is a preventable and 
treatable disease characterised by a slow progressive airways limitation that is not fully 
reversible. It is caused by an abnormal inflammatory response of the lungs to chronic 
inhalation of noxious particles, often cigarette smoke. It may also be associated with 
significant extra pulmonary effects that may contribute to its severity (Global Initiative 
for Chronic Obstructive Lung Disease (GOLD), 2009). Information about the 
pathogenesis of COPD is provided in APPENDIX A.2 (refer to the enclosed DVD). 
2.2.2.1. Management and treatment 
Patients suspected of having COPD should undergo complete pulmonary function testing 
to confirm airway obstruction, quantify its severity, reversibility and to distinguish 
COPD from other diseases. The primary diagnostic test is the forced expiratory volume 
(FEV1), which is the volume of air, expired during the first second after a full breath; 
forced vital capacity (FVC) which is the volume of air exhaled with maximum effort and 
speed after a full inspiration. As COPD progresses with increasing airway wall 
thickening, loss of alveolar attachments, and loss of lung elastic recoil, both FEV1 and 
FVC decrease. Reductions of FEV1, FVC and the ratio of FEV1/FVC are markers for 
airway obstruction (Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
2009). 
22 
 
The aim of chronic treatment of COPD is to improve the symptoms, exercise tolerance, 
and the quality of life by slowing down the progression of the disease, i.e. by improving 
FEV1 or reduce the decline in FEV1. Many studies have examined the efficacy of certain 
drugs in COPD by determining their ability to improve FEV1(Lopez-Encuentra et al., 
2005). Another further aim of COPD management and treatment is to reduce 
exacerbations and increase life expectancy. As shown in figure 2.5, the current global 
initiative for chronic obstructive pulmonary disease (GOLD) guidelines for the treatment 
of stable COPD disease, suggested simple classification of the disease severity, 
according to FEV1, into four stages and a step wise management as the patient’s airflow 
limitation and symptoms worsen (Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), 2009). 
 
Figure 2.5: Diagrammatic representation of GOLD guidelines for the treatment of stable 
COPD disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2009). 
The first step in the proper management of COPD is the avoidance of risk factors; 
smoking cessation is a very effective intervention procedure to stop the progressive 
worsening of COPD and significantly influences the long-term evolution of the disease 
(Pauwels, 2000; Wise et al., 2003). Smoking cessation was found to decrease the 
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accelerated decline in FEV1 characteristic of this disease (Anthonisen et al., 1994) and 
even decrease lung cancer mortality in COPD patients (Anthonisen et al., 2005).  
The most recent comprehensive guidelines (Global Initiative for Chronic Obstructive 
Lung Disease (GOLD), 2009; NICE, 2010) recommend that the next important 
consideration for long term management of COPD is the introduction of inhaled 
bronchodilators. Bronchodilators such as anti-cholinergic agents, theophylline, and β2-
agonists are considered the cornerstone in symptomatic management of COPD. Despite 
the substantial differences in their sites of action within the cell, the most important 
consequence of bronchodilator therapy appears to be airway smooth muscle relaxation 
and improved emptying during tidal breathing; they improve the symptoms, exercise 
tolerance, and partially reverse the airflow limitation. Short-acting agents are best used 
for the rescue of symptoms; whereas long-acting agents are best used for maintenance 
therapy. The choice between different bronchodilators should depend on the patient 
symptomatic response. A systematic review showed that regular use of short-acting β2-
agonists in COPD was associated with an improvement in lung function and dyspnoea 
(Sestini et al., 2002). Many studies highlighted that long acting inhaled bronchodilators 
are at least as effective as the short acting ones and even more convenient (Mahler et al., 
1999; Littner et al., 2000; Barnes et al., 2001; Hanania et al., 2005; Berger and Nadel, 
2008). Furthermore, other studies have indicated the superiority of treatment of COPD 
with long acting bronchodilators compared to short acting ones, recommending them as a 
first line option for treatment of stable COPD (van Noord et al., 2000; Cazzola and 
Matera, 2004; Tashkin and Cooper, 2004).  
Combination of more than one class of bronchodilators was found to be more beneficial 
than the use of single agents. The rationale behind that is not only due to the additional 
benefits of their different pharmacological action but also to avoid side effects of  using 
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higher doses of single agents (Cazzola et al., 2004; van Noord et al., 2005; Di Marco et 
al., 2006; Kerstjens et al., 2007; Vogelmeier et al., 2008).  
The addition of inhaled corticosteroids to maintenance treatment with long-acting β2-
agonists led to a more significant reduction in respiratory symptoms, exacerbation rates, 
improvement in FEV1, and statistically significant improvements in health related quality 
of life compared to those provided with either treatment alone (Mahler et al., 2002; 
Calverley et al., 2003; Hanania et al., 2003; Barnes et al., 2006; Bourbeau et al., 2007; 
Puhan et al., 2009). Calverley et al (2003) reported that the budesonide/formoterol 
combination in a single inhaler were more effective than either component drug alone or 
placebo in stabilizing lung functions and decreasing exacerbations. The TORCH study 
was the first interventional study in COPD with mortality as a primary outcome measure. 
This study showed that mortality was significantly better in the combination therapy 
compared to fluticasone propionate therapy. Thus, it appears that the addition of 
salmeterol to fluticasone significantly modified the therapeutic effects of the ICS 
(Calverley et al., 2007; Seemungal et al., 2009). There is evidence from systematic 
reviews that suggests that an ICS in combination with a LABA appears to modestly 
reduce the risk of exacerbations, when compared to LABAs, by approximately 20%–
25% (Nannini Luis et al., 2007). These previous findings suggest that treatment of both 
inflammation and bronchoconstriction with COPD patients may actually achieve 
clinically important effects. 
The ability of corticosteroids to effectively suppress airway inflammation in asthma has 
led to this treatment becoming the cornerstone of asthma therapy whilst in COPD the role 
of corticosteroids is more controversial. A detailed explanation of the role of inhaled 
corticosteroids in COPD is presented in APPENDIX A.3 (refer to the enclosed DVD). 
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2.2.3. Summary 
The above information about the guidelines highlight that inhaled therapy is the mainstay 
for the management of both asthma and COPD. It is important that the emitted dose is 
able to deposit in the airways during an inhalation. 
2.3. Pulmonary drug delivery 
The pulmonary route has several advantages, which makes it an attractive option for 
local drug delivery as illustrated in figure 2.6. There are many local lung diseases that are 
considered as prime candidates for inhalation therapy, such as asthma and chronic 
obstructive pulmonary disease (COPD). This type of topical application of the drug to the 
lung epithelium  spares the patient the potential side effects caused by the high systemic 
concentrations typical of conventional delivery methods, maximises pulmonary 
specificity with a rapid onset of action and can reduce costs because smaller doses can be 
used (Chrystyn, 1994; Chrystyn, 2007; Vincken et al., 2010).  
The decreased incidence of side effects is especially important for inhaled 
corticosteroids, where asthma control can be achieved at doses far lower than those 
required to cause adrenal suppression. However, some suppression does occur when high 
inhaled doses are used. The inhaled route also offers a better efficacy to safety ratio 
compared to systemic therapy and allows the use of drugs, which are not absorbed in the 
gastrointestinal tract (e.g. cromones). Therefore, this route of drug delivery has become 
the preferred route of administration in the therapy of a number of respiratory disorders 
(Smola et al., 2008; Virchow et al., 2008; Broeders et al., 2009). 
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Figure 2.6: Advantages of the inhaled route of drug administration (Vincken et al., 
2010). 
2.3.1. Mechanisms of pulmonary particle deposition 
Deposition means the event of a particle to adhere to the surface. There are three major 
mechanisms, by which inhaled particles deposit in the human respiratory tract: inertial 
impaction, gravitational sedimentation, and Brownian diffusion. Other deposition 
mechanisms include interception and electrostatic precipitation. These mechanisms are 
shown in figure 2.7 and described below. 
 
Figure 2.7: Mechanisms of deposition of inhaled particles in the respiratory tract from 
http://scribd.com/doc/28978774/Particle-Depsoition-in-the-Lung. 
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2.3.1.1. Inertial impaction 
A particle with a large diameter and high density that is travelling in the airstream at high 
velocity will be very liable to impact because it will be unable to follow the changing 
direction of the airways. Deposition of particles by impaction occurs at airway 
bifurcations when a particle, owing to its momentum and the aerodynamic forces exerted 
on it by the air stream in which it is carried, fails to make the turn into either of the 
daughter branches and impacts at the branching junction. Impaction accounts for the 
majority of particle deposition on a mass basis; that is particle size and density, and it 
depends on the particle travelling velocity, which is determined by the inspiratory flow 
velocity prevailing in the airways. Deposition of particles by impaction becomes 
significant for particles > 2µm and it is most likely to occur in extra thoracic and large 
conducting airways in which there is a high flow velocity, short residence time of 
particles and rapid changes in airflow direction often take place (Schulz, 1998). 
Deposition by impaction increases with the branching angle and is independent on 
airway length. Rapid and shallow breathing increases impaction in the large airways 
producing a centralised particle deposition pattern (Rom and Markowitz, 2007; Adcock 
et al., 2008a). As, the gas velocity decreases due to the splitting of the airflow, impaction 
is expected to cease to be an important mechanism of deposition in small airways. 
2.3.1.2. Sedimentation 
Gravitational sedimentation is the settling of particles onto airway surfaces under the 
force of gravity. Particles reach their terminal settling velocity when the gravitational 
force equals the opposing resistive forces of the air. It occurs primarily for smaller 
particles (0.5-5µm) that do not impact and are carried by the inspired air into the lower 
parts of the airways where they settle under the effect of gravity when the airstream 
velocity becomes slow, e.g. the bronchioles and the alveolar region. The low air velocity 
in these regions gives enough time available for particles to settle within the airways. It is 
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important that a breath hold is included after an inhalation to allow this process to occur. 
Deposition by sedimentation increases with airway length and is independent on the 
branching angle. Therefore, slow, deep breathing enhances sedimentation and lead to 
relatively uniform distribution of particles throughout the airways (Rom and Markowitz, 
2007; Adcock et al., 2008a).  
2.3.1.3. Brownian diffusion 
Unlike impaction and sedimentation, which increase with increasing particle size, 
deposition by Brownian diffusion increases with decreasing particle size. As the diameter 
of a suspended particle become smaller than 0.5 µm, they are more affected by the 
random thermal kinetic bombardment of the gas molecules in the air around them. 
Collision of gas molecules with these small particles lead to their irregular random 
wiggling motion called Brownian motion. Consequently, the small airway dimensions of 
the lung periphery, favour deposition by diffusion due to very low or absent airflow (i.e. 
alveoli), a short particle travelling distance before hitting an airway and long residence 
time giving particles enough time to diffuse to the surrounding surfaces (Rom and 
Markowitz, 2007; Adcock et al., 2008a). Similar to sedimentation a breath hold after 
each inhalation facilitates deposition by this mechanism. 
All these mechanisms act simultaneously. Inertial impaction and gravitational 
sedimentation are most important for deposition of large particles (1-10µm), whereas 
Brownian diffusion is the main deposition determinant of smaller submicron particles 
(<1µm). Secondary, less important deposition mechanisms that occur within the 
respiratory tract such as interception and electrostatic precipitation do not significantly 
contribute to the deposition of inhaled therapeutic medical aerosols (Martonen and Katz, 
1993; Adcock et al., 2008a). 
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2.3.2. Factors affecting pulmonary particle deposition 
Aerosol drug deposition in the lung is not a simple matter, since the respiratory tract can 
be considered as a filter that efficiently removes particles from the inspired air. The 
effectiveness of this filter largely affect the resulting aerosol deposition pattern  and is 
governed by several factors including; the physical characteristics of aerosol inhaled e.g. 
particle size, density and shape or the patient variables including; the individual 
breathing pattern and lung morphology (Heyder, 2004). 
2.3.2.1. Aerosol physical properties 
Considering the previously described deposition mechanisms, it becomes evident that 
particle size is one of the major variables influencing not only the extent but also the site 
of inhaled drug deposition within the airways (Heyder and Gehr, 2000; Usmani et al., 
2003). Aerosol particles are often characterised by their mass mean aerodynamic 
diameter (MMAD) and the geometric standard deviation (GSD) of their median 
aerodynamic diameter. The MMAD is the diameter around which the mass of particles 
are equally distributed. The GSD is a measure of dispersion of particle diameters in the 
aerosol (Schulz, 1998). 
The respiratory anatomy has evolved in such a complex way to actively prevent 
inhalation of airborne particulate matter. Both, the upper airways and the branching 
anatomy of the trachea-bronchial tree act as a series of filters for inhaled particles. 
Particles between 2 and 10µm in aerodynamic diameter correspond to the inhalable 
particles capable to be deposited, in the upper respiratory tract. Aerosol drug particles 
with a MMAD larger than 8µm tend to impact on the throat and the first few airway 
generations, whereas sub-micrometer particles with MMAD less than 0.5µm diameter 
penetrate the lung deeply, but have a high tendency to be exhaled without deposition and 
thus contribute little to the therapeutic effect. However, some studies have found that 
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breath holding can minimize expiration of such small particles (Suarez and Hickey, 
2000; Usmani et al., 2003; Haughney et al., 2010; Carvalho et al., 2011). 
It is generally accepted that lung deposition is greater with particles in the size range 2-5 
µm, particularly in obstructive lung disease, where the airways are narrowed and an 
aerosol will penetrate less deeply. Whilst particles with MMAD less than 2 µm will tend 
to deposit in the alveoli (Suarez and Hickey, 2000; Gradon and Marijnissen, 2003; 
Usmani et al., 2003; Pedersen et al., 2010).  
Clay & Clarke (1987) investigated whether the size distribution of aerosols released from 
a jet nebuliser affects the amount of aerosol delivered to the lungs and reported that small 
nebulised aerosols (MMAD < 2 um) deliver a larger dose to the lungs and should be used 
to maximise lung deposition. They also indicated that utilising the optimum nebulised 
aerosol size is very beneficial not only to maximise lung deposition but also to use 
smaller doses to achieve the same therapeutic effect, thus patients would not be given 
unnecessarily large amounts of drugs (Clay and Clarke, 1987). Therefore, decreasing and 
increasing the particle size shifts the site of deposition from distal to proximal. 
Targeting particles to deposit in a specific site within the respiratory tract may be 
desirable for pharmaceutical aerosols whereby effective treatment is only possible if 
therapeutic aerosols can reach the desired site (Asgharian et al., 2006). The ideal lung 
regions for optimal drug deposition differ with the class of drugs used and largely depend 
on selection of the appropriate particle size for target air space. For bronchodilators, e.g. 
β2-agonists and anti-cholinergic agents, it is more beneficial to target drug deposition in 
the larger conducting airway regions to achieve a more effective therapy. As, although 
β2-receptors are highly concentrated in the alveolar region, the airway muscles are 
relatively sparse, being predominantly located in the conducting airway region. In 
addition, the receptor sites for anti-cholinergic agents lie predominantly in the larger 
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airways (Newman, 1985; Martonen and Katz, 1993; Usmani et al., 2005; Haughney et 
al., 2010). The larger particle size aerosol (>3-6µm) is more preferred for bronchodilator 
therapy to avoid the penetration of the smaller sized particles (<2.5µm diameter) to the 
alveoli where they exert no pharmacodynamic effect and are rapidly absorbed and 
increase the risk of systemic adverse effects (Usmani et al., 2005; Virchow et al., 2008). 
For inhaled corticosteroids, a uniform lung distribution is preferred to reach the smaller 
airways, which are important and significant sites of airway inflammation (Hamid et al., 
2003; Hamid and Tulic, 2007). 
The optimum aerosol cloud should contain particles that are neither too small (often 
exhaled), nor too large (these mainly deposit in the upper airways, mouth and throat). 
Therefore, in order to target the lower respiratory tract, the aerosol aerodynamic diameter 
for an inhalation formulation should be between 2 to 5µm (Usmani et al., 2003; Usmani 
et al., 2005; Patton and Byron, 2007). Using the optimum drug particle size would in turn 
have a profound effect on the drug dose required to achieve a given clinical response 
(Adcock et al., 2008a). 
2.3.2.2. Patient variables 
Differences in particle deposition patterns between human lungs may be attributed to 
factors related to the patient itself. These factors are primarily differences in their 
breathing pattern and airway morphology. 
2.3.2.2.1. Breathing pattern 
The difference in the inhalation flow rate can substantially affect the regional deposition 
of aerosol particles in human subjects. An increase in tidal volume, while keeping the 
flow rate constant, will transport particles by convection deeper into the lung and 
increase their mean residence time. Hence, more particles reach, peripheral lung 
structures and more time is available for gravitational and diffusional particle transport 
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(Heyder and Gehr, 2000; Musante et al., 2002). However, keeping the tidal volume 
constant while increasing inhalation flow rate will increase the efficiency of the velocity 
dependent deposition mechanism (impaction) and decrease that of the time dependent 
deposition mechanisms (sedimentation and diffusion). The high flow rate will enhance 
deposition of particles larger than 2µm by impaction in the extra-thoracic and large 
conducting airways, but particles transport by diffusion and sedimentation are decreased 
because of the shorter time available for deposition. When inhaling aerosol particles, 
patients should inhale slowly over 3–4 s (to minimise impaction in the upper airways) 
and hold their breath (to maximise sedimentation and deposition in the peripheral areas 
of the lung). The optimum aerosol deposition in the lung was achieved during inhalation 
from a pressurized aerosol with 10 seconds breath hold after each puff (Newman et al., 
1982b). The importance of the breath holding technique in optimising lung deposition 
was also illustrated by Hindle et al (1993) who recommended that this technique should 
be universally adopted.  
In another study by Heyder et al (2004), the slow inhalation of aerosol with 
monodisperse particles of 1µm in conjunction with breath holding was found to be a very 
effective means of targeting drug to the lung periphery for the topical treatment of 
peripheral respiratory disease. Heyder et al (2004) also reported that breath holding not 
only allows targeting sub regions of the alveolar regions but also increases the dose 
delivered to these regions under consideration. Furthermore, the significance of the 
inhalation speed differs with the particle size. While small particles (1.5µm) were found 
to have a comparable effect on the forced expiratory volume in one second (FEV1) 
regardless of the inhalation speed, the slow flow inhalation led to greater bronchodilator 
activity of larger aerosol particles (3 - 6µm) (Usmani et al., 2005; Virchow et al., 2008). 
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Generally speaking, lung deposition increases with the duration of breathing cycle; that is 
deposition is inversely related to the inspiratory flow rate (except for particle sizes 
>10µm) (Martonen and Katz, 1993). This slow airflow with breath holding will lead to 
substantial increase in the particles residence time and drug penetration index in the 
conducting airways regardless of the drug particle size, so that increased particle 
deposition by both sedimentation and diffusion in the trachea-bronchial region and 
alveoli (Pavia et al., 1977; Schulz, 1998; Stockley, 2005; Virchow et al., 2008). The 
smaller airways deposited fraction can be increased by 70% using a slow flow rate 
compared to inhalation with a normal flow rate even for drug particles as large as 6µm 
(Svartengren et al., 1996). This enhanced deposition of therapeutic aerosols in the 
peripheral airways would be of value, particularly with regard to treatment with inhaled 
corticosteroids for targeting the significant small airways inflammation in both asthma 
and COPD diseases (Tanaka et al., 2004; Corren, 2008; Hogg, 2008). In addition, this 
slow breathing is essential in decreasing the variation in lung deposition leading to a 
uniform drug deposition pattern (Newhouse and Ruffin, 1978; Häkkinen et al., 1999). 
For this reason, slow deep inhalation with breath holding is generally recommended after 
inhaling a medical aerosol and is incorporated in the patient instruction leaflet for many 
inhaled drug products. These principles apply when using MDIs and MDIs with spacers 
but when using dry powder inhalers (DPIs), patients must break these rules and inhale 
rapidly and forcefully, because unlike MDIs, DPIs do not dispense a gas, but a dry 
powder. These inhalers require users to increase their inspiratory flow to provide the 
energy required to disaggregate the drug powder formulation into small respirable 
particles that have the potential for lung deposition (Everard, 2001; Everard, 2003; 
Chrystyn, 2007; Haughney et al., 2010). 
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In summary, particles deposit more in the proximal airways with an increase in particle 
size and breathing rates, whereas enhanced pulmonary deposition take place with small 
sized particles and slow breathing rates (Kim and Hu, 1998). 
2.3.2.2.2. Anatomy of the respiratory tract 
Natural variation in airway geometry from one individual to another (e.g. airway length, 
airway diameter, branching angles and alveolar size) is an important determinant for the 
aerosol deposition pattern. Even in healthy subjects, inhaling the same aerosol with the 
same inhalation manoeuvre provides a wide inter-subject variation in aerosol deposition 
patterns, which represents the effect of random variation in airway anatomy (Heyder et 
al., 1982; Asgharian et al., 2001; Stockley, 2005).  
Furthermore, structural changes caused by the presence of respiratory disease may 
considerably affect both the amount and location of particle deposition in the lung 
(Lipworth and Clark, 1997). Obstructive lung diseases, such as asthma and COPD, 
increase particle deposition in the central zones of the lungs and decreases particle 
penetration to the peripheral airways (Lipworth, 1996; Anderson, 1997; Kim and Hu, 
1998; Dolovich and Dhand, 2011). The increased airway narrowing due to oedema, 
increased secretions, or smooth muscle constrictions led to lower total lung deposition 
and more central deposition post inhalation from MDI, MDI+ spacer and DPI for 
asthmatic subjects compared to normal subjects (Melchor et al., 1993; Dolovich and 
Dhand, 2011). Several other studies have reported lower systemic availability of 
salbutamol (Lipworth and Clark, 1997) and fluticasone propionate (Harrison et al., 2001; 
Harrison and Tattersfield, 2003) in asthmatic patients compared to healthy volunteers. 
These findings can be attributed to reduced lung deposition with more central deposition 
coupled with greater mucociliary elimination in patients than in healthy individuals 
(Weiner et al., 1999; Edsbäcker and Johansson, 2006). 
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2.4. Inhalation devices 
The availability of an efficient aerosol delivery system or inhaler is very critical to the 
success of the inhaled treatment (Pedersen et al., 2010; Vincken et al., 2010). As 
illustrated in figure 2.8 there are several criteria that characterise an ideal inhaler 
including; the generation of  aerosols with the optimum particle size ideally in the range 
0.5-5µm for  deep lung penetration post inhalation,  accurate and uniform drug dosing, 
easy to use,  preferable by patients, robust, portable and inexpensive (O'Connor, 2004; 
Brand, 2005; Chrystyn, 2007).  
 
Figure 2.8: Criteria for an ideal inhaler (Chrystyn, 2007). 
There are three principal types of devices that are widely used in aerosol administration; 
metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulisers. Several 
clinical studies reported that these devices can be equally efficacious (Brocklebank et al., 
2001; Dolovich et al., 2005; Cates  et al., 2006). However we must bear in mind when 
selecting an aerosol delivery device for asthmatic and COPD patients,  that the most 
efficacious device will be the one that is preferable by the patient and used correctly and 
consistently (Barry and O'Callaghan, 2003; Berger, 2009). 
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2.4.1. Metered dose inhalers 
2.4.1.1. Conventional pressurised metered dose inhaler 
Pressurised metered-dose inhalers (pMDIs) have been the dominant means of delivery of 
drug to the lungs since the early 1950s, and world-wide, they still constitute more than 
80% of the global market (O'Connor, 2004). The reason behind its great popularity is that 
they are cheap, simple to manufacture and available with a wide range of drugs 
(Chrystyn, 2007). Pressurised metered-dose inhalers (pMDIs) are used to administer 
bronchodilators, anti-cholinergics, anti-inflammatory agents, and steroids and if properly 
used, they are at least as effective as other systems of aerosol drug delivery systems 
(Fink, 2000). 
Metered dose inhalers (MDIs) are pressurized self-propelled aerosol devices that use 
propellants to administer the therapeutic agent. As shown in figure 2.9, the MDI consists 
of two major components: the canister and an actuator with a mouthpiece. The canister 
contains a metering dose valve with an actuating stem. The formulation resides within 
the canister and contains a liquid propellant with the drug either in solution or as a 
suspension of micronized particles. Actuation of the device triggers the release of a 
single metered dose of liquid propellant that contains the medication. The release of these 
contents under pressure combined with the low boiling point of the propellants rapidly 
evaporates the liquid mixture into an inhaled aerosol cloud of medication, enabling 
subsequent deposition within the lungs during an inhalation (Adams, 2007; Hickey, 
2007; Mitchell et al., 2007b; Patterson et al., 2009). 
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Figure 2.9: Schematic diagram of a metered dose inhaler from 
http://emedicine.medscape.com/article/1413366-treatment. 
Although, MDIs are cheap, small, portable, quick to use and can deliver a precise unit 
dose giving a reproducible lung deposition, they are far from being perfect. Over the 
years, a number of deficiencies have been identified to MDIs in terms of both 
effectiveness and usability. Poor patient inhalation technique remains the most concern in 
clinical applications and has been reported in up to 94% of patients (Brocklebank et al., 
2001; Crompton et al., 2006; Lavorini et al., 2008b; Rootmensen et al., 2010). 
Furthermore, many patients even after training are still unable to operate the device 
properly (Epstein et al., 1979; Kamps et al., 2000; Burkhart et al., 2005; Al-Showair et 
al., 2007b). The inability of many patients to synchronise aerosol actuation with 
inspiration is a very common problem (Crompton, 1982; Zeng et al., 2000; Crompton, 
2004) and poor coordination can result in medication being released either two early or 
too late in the inspiratory cycle (Crompton, 1982; McFadden, 1995; Donnell, 2001). 
Although good coordination is required for MDIs and many patients have problems with 
this step, the most important problem of a MDI inhalation technique is failure to initiate a 
slow inhalation technique with insufficient breath-hold duration (Newman et al., 1982b; 
Everard et al., 1995; Tomlinson et al., 2005; Al-Showair et al., 2007a; Chrystyn and 
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Price, 2009; Haughney et al., 2010). However breath holding only improves lung 
deposition if preceded by slow deep inhalation (Newman et al., 1981b).  
Moreover, the inhaler technique in MDIs can be complicated by what is known as the 
cold Freon effect. The cold Freon effect refers to the phenomenon caused by the forceful 
blast of high velocity cold liquid propellant impacting on the back of the throat, stopping 
the patient from inhalation or causing nose inhalation instead of mouth inhalation 
(Crompton, 1982; Broeders et al., 2009). The cold Freon effect is uncomfortable for the 
user and can cause inconsistent or non-existent drug delivery to the lung. It occurs 
particularly with CFC-containing inhaler devices. This problem is less important with 
hydrofluoroalkane (HFA) propellant aerosols due to their higher boiling points, which 
means a slower delivery speed and lower throat deposition (Gabrio et al., 1999). 
Effective use of a MDI is technique-dependent and the inability to use the inhaler 
correctly may result in failure to get the intended dose of medication to the airways and 
hence poorer asthma control (Giraud and Roche, 2002; Chrystyn and Price, 2009). Fink 
and Rubin (2005) have stated that, ―Management of chronic airways disease is 10% 
medication and 90% education.‖ Therefore, adequate patient education about the proper 
inhalation technique is one of the keystones of successful inhalation therapy. Several 
studies have shown that correct inhalation can dramatically improve the lung delivery of 
inhaled medications as well as the clinical and economical outcome measures (Kamps et 
al., 2003; Fink and Rubin, 2005; Al-Showair et al., 2007a; Lavorini et al., 2010; 
Rootmensen et al., 2010). Lenney et al (2000) studied 100 adults naive to inhaler devices 
and found that only 21% could use the MDI efficiently after reading the instruction 
leaflet, while 52% could do so after expert training. Similar findings were also reported 
by Al-Showair et al (2007) who found that post-training of the proper inhalation 
technique reduced the flow rate markedly in both mild and severe COPD patients when 
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using their MDIs. Other studies even suggested that inhalation instructions should be 
given repeatedly to achieve and maintain the proper inhalation technique as patients 
readily fall into a habit of using an incorrect technique post-training (Crompton, 1990; 
Kamps et al., 2000; Kamps et al., 2002; Brand, 2005; Crompton et al., 2006; 
Deerojanawong et al., 2009). Another study highlighted the importance of  a 2Tone 
Trainer (Canday Medical, UK) to maintain a trained slow inhalation flow and help 
patients to maintain the recommended MDI technique post-training (Al-Showair et al., 
2007a). 
Even with correct inhalation technique, most MDIs are inefficient due to their relatively 
high throat deposition. The combination of the high propellant velocity (>30m/sec) and 
initially large sized aerosol particles increase the likelihood of drug deposition in the 
oropharynx immediately following MDI actuation (Donnell, 2001; Newman, 2005). 
Typically, they deliver only about 1/3 of the amount of drug delivered to the lung 
compared to the newer dry powder inhalers (Newman et al., 1981c; Newman, 1985; 
Newman et al., 2000a; O'Connor, 2004; Virchow et al., 2008). 
The growing awareness of the patients’ limitations of MDI administration (hand-breath 
coordination problems, cold Freon effect, and high oropharyngeal deposition) has led to 
further development of devices that overcome these problems such as the addition of 
spacers and breath-actuated MDIs that will be discussed in the following sections. The 
formulation of some MDIs with HFA propellants as solution aerosols with the emission 
of extrafine particles has helped with the problems of inefficient lung deposition of 
inhalation techniques; this will also be discussed later. 
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2.4.1.2. Pressurized metered dose inhaler with a spacer device 
Metered dose inhalers are sometimes used with add-on devices referred to as spacers, 
which are tubes attached to the inhaler that act as a reservoir or holding chamber. As 
shown in figure 2.10, there are several types of spacers available.  
 
Figure 2.10: Example of spacer devices, (a) Babyhaler (b) Aerochamber with mask (c) 
Volumatic and (d) Optimiser.  
Spacers are cheap, easy to use and place less demand on a patient’s inhaler technique. 
They overcome problems of poor technique in both adults and children, which occurs 
when using MDIs alone (Newman, 2004; Dolovich et al., 2005; Rubin and Fink, 2005). 
The recent British guidelines on asthma management have supported the wider use of 
spacer devices (BTS/SIGN, 2008). 
The attachment of a spacer device to MDIs compels the patient to inhale at some distance 
from the actuator to the mouth, consequently allowing time for the aerosol speed to slow 
down and propellant to evaporate with a reduction in particle size. Larger particles are 
entrapped on the spacer walls and more of the therapeutically beneficially respirable 
fraction is delivered to the lung. This makes it easier to use the inhaler and helps to 
ensure that more medication gets into the lungs instead of just into the mouth or air 
(Broeders et al., 2009; Nair et al., 2009).  
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As shown in figure 2.11, the proper use of spacers, increases lung deposition of the drug, 
limits oropharyngeal impaction and systemic absorption. Besides, it reduces drug loss 
that occurs with poor patient coordination, eliminates the cold Freon effect, and makes an 
inhaler somewhat more effective in delivering medicine (Crompton, 1982; Hindle and 
Chrystyn, 1994; Clark and Lipworth, 1996a; O'Callaghan and Barry, 2000). Hindle & 
Chrystyn (1994), reported that based on the 30 minutes urinary salbutamol excretion, the 
mean percentage increase for the relative bioavailability of salbutamol to the lung 
compared with the MDI alone were 19%,  23.5%, and 53.4% for the Volumatic, Bricanyl 
spacer, and Nebuhaler, respectively. However, the issue of electrostatic charge effect on 
drug output from spacers were not known at this time of study. Subsequently, Silkstone 
et al (2002) showed that the Volumatic spacer attached to salbutamol MDI was 2.3 times 
more efficient for lung delivery with less systemic concentrations than the same dose of 
the MDI alone used with a highly trained technique. In addition, Aswania & Chrystyn 
(2001) reported that a metered dose inhaler attached to a large volume spacer delivers an 
eight-fold improvement in the relative amounts deposited in the lung compared to the 
MDI without spacer. Another study that investigated the effect of spacers’ attachment on 
aerosol deposition from a pressurised metered dose inhaler reported a reduction in the 
oropharyngeal deposition from 81% to 17% and an increase the lung deposition from 
8.7% to 21% with 56% of the emitted dose deposited in the spacer (Newman et al., 
1984). The previous results and many similar findings suggest that the size of the spacer 
may affect the amount of drug available for inhalation, and this will vary with the drug 
prescribed (Barry and O'Callaghan, 1996). 
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Figure 2.11: A diagram showing improved lung delivery and reduced oropharyngeal 
deposition with spacers use from 
http://www.clinicasubiza.com/Dispositivos/Optichamber/tabid/222/language/es-
ES/Default.aspx. 
Spacers can be especially helpful to adults and children who find a regular metered dose 
inhaler difficult to use (Pedersen, 1996). Furthermore, the MDI + spacer has proven to be 
a practical lower cost alternative to the use of nebuliser therapy in the management of 
severe acute asthma or chronic obstructive pulmonary disease (Newman, 2004; Cates  et 
al., 2006; Fayaz et al., 2009; Lavorini and Fontana, 2009). Although the use of spacers 
did not always increase lung deposition, they always reduced oropharyngeal deposition 
(Newman and Newhouse, 1996). Thus patients who use corticosteroid inhalers should 
use a spacer to limit oropharyngeal deposition, minimise drug reaching the 
gastrointestinal tract, thus helping to prevent both systemic (adrenal suppression) and 
local oropharyngeal side effects ( thrush and dysphonia) (Dolovich et al., 2005; Hickey, 
2007; Pedersen et al., 2010). Their popularity has led to a rapid increase in the number of 
different spacer types available with considerable variations in the proportion of drug that 
reaches the airways (Barry and O'Callaghan, 1996; O'Callaghan and Barry, 1997; 
O'Callaghan and Barry, 2000). However, since the amount of drug that deposits in the 
airways is critical and traditionally considered to reflect lung dose, thereby each unit of 
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spacer-MDI combination can elicit profound effects on aerosol cloud characteristics 
(Berg et al., 1998).  
The drug delivery from spacer devices may be affected by different factors, such as 
spacer volume, electrostatic charge, type of valve, dead space between inlet and outlet, 
mode of inhalation breathing and the drug/spacer combination. Furthermore, electrostatic 
charge is a commonly reported cause of inconsistent medication delivery from plastic 
spacers (Bisgaard, 1999; Dolovich, 1999; Dubus et al., 2001).  
Most spacers are made from non-conducting plastic materials and hence, can easily 
accumulate electrostatic charge on their surface and negatively affect dose delivery. The 
net effect of these electrostatic charges is enhancing the attraction and deposition of 
charged drug particles on spacer walls upon dose aerolisation from the metered dose 
inhaler (O'Callaghan et al., 1993; Dewsbury et al., 1996; Wildhaber et al., 1996b; Pierart 
et al., 1999; Wildhaber et al., 2000b). The higher the electrostatic charge, the higher the 
amount of aerosolised drug attracted and retained  within the spacer device, leading to a 
significant reduction in the drug aerosol available for inhalation (Dubus et al., 2003). 
Moreover, electrostatic charge causes significant dose variation due to different patient 
handling of the spacer (Kenyon et al., 1998; Janssens et al., 1999; Wildhaber et al., 
2000a; Wildhaber et al., 2000b). 
Several studies have shown that the level of electrostatic charge on a plastic spacer 
depends on the treatment of the spacer (Barry and O'Callaghan, 1995; Dewsbury et al., 
1996; Wildhaber et al., 1996b; Wildhaber et al., 1998). In-vitro studies have shown that 
drug delivery is enhanced by more than two fold when using an antistatic lining 
(O'Callaghan et al., 1993; Barry and O'Callaghan, 1995) or when  using non-electrostatic 
spacers (steel spacer) (Bisgaard, 1995; Nair et al., 2009). Steel is a conducting material 
that holds no electrostatic charge no matter how it is handled, and requires no chemical 
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treatment. Therefore, steel spacers readily solve the problem of reduced drug delivery 
due to electrostatic charge but issues of cost and availability retain simple plastic spacer 
as the device of choice worldwide (Bisgaard, 1995; Kenyon et al., 1998). Also a metallic 
walled spacer will not enable patients to see the formation of the aerosol plume that gives 
them the confidence that the medication was delivered (Mitchell et al., 2007b). 
Another more practical widely used method that effectively overcomes electrostatic 
charge and significantly improves in-vitro (Barry and O'Callaghan, 1996; Dewsbury et 
al., 1996; Wildhaber et al., 1996a; Wildhaber et al., 1996b; Berg et al., 1998; Kwok et al., 
2006) and in-vivo (Pierart et al., 1999; Wildhaber et al., 2000a; Wildhaber et al., 2000b) 
drug delivery is by simply washing plastic spacer devices in a detergent without 
subsequent rinsing and allowing them to air dry. This washing procedure was found 
effective to reduce or even eliminate electrostatic charge and increase total drug output  
through the spacer in both small (Wildhaber et al., 1996a) and large volume plastic 
spacers (Wildhaber et al., 1996b). Several Scintigraphic studies, providing better 
measurements of lung deposition, with labelled salbutamol and budesonide have 
confirmed the previous in-vitro work. These studies have reported that the reduction in 
the electrostatic charge of the plastic spacer devices provides a 10–35% increase in lung 
deposition, in both adult and asthmatic children due to an increase in the fine particle 
mass (Janssens et al., 1999; Pierart et al., 1999; Wildhaber et al., 2000a; Wildhaber et al., 
2000b). Furthermore, there was  a 10% increase in pulmonary function obtained with less 
drug  when using treated rather than untreated Volumatic® spacers (Wildhaber et al., 
2000b). Other  pharmacokinetic studies have shown that the electrostatic charge in 
plastic spacers decreases the delivery of salbutamol to the lungs with an approximate 
twofold reduction in lung bioavailability with the Volumatic® in adults (Clark and 
Lipworth, 1996a) and the Babyhaler® in children  (Anhoj et al., 1999). To limit static 
effects, it is recommended that plastic spacers should be soaked in a dilute solution of 
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household detergent and then allowed to drip-dry without water rinsing. It is very 
important not to wash the spacer in water post treatment with detergent or to dry the 
plastic with a cloth, since this immediately recharges the spacer (Bisgaard, 1999; Pierart 
et al., 1999; Mitchell et al., 2007b).  
In summary, previous findings leave no doubt that the building of electrostatic charge on 
plastic spacers negatively affect lung deposition of inhaled drugs and may lead to 
significant under-dosing. By simply reducing electrostatic charge, the dose deposited in 
the lungs can be greatly increased with markedly reduced variability. Bearing in mind, 
the attention to the details of washing spacers, can effectively allow for a greater and 
more predictable drug delivery to the airways, and thus, may indicate the potential for 
dose reduction of inhaled medications while retaining similar therapeutic effect (Kenyon 
et al., 1998; Pierart et al., 1999; Mitchell and Nagel, 2007). 
 
2.4.1.3. Breath actuated pressurized metered dose inhaler 
In view of the difficulty some patients have in coordinating MDI actuation with 
inspiration, great interest has been devoted to the development of breath actuated metered 
dose inhaler for example, the Autohaler (Teva, UK) and the Easi-Breathe (Teva, UK)  
devices. As shown in figure 2.12 they contain a conventional pressurised canister with a 
flow-triggered system driven by a spring which automatically actuate the MDI and 
release the dose with patient inhalation (Newman et al., 1991c; Broeders et al., 2009; 
Patterson et al., 2009).  
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Figure 2.12: Cross-sectional diagram of a breath-actuated metered dose inhaler 
(Newman et al., 1991c). 
The breath-actuated mechanism of these inhalers is designed to aid coordination by being 
actuated early in the inspiratory cycle by low inhalation flow rates (approximately 
20L/min and 30L/min for the Easi-Breathe and Autohaler respectively). These inhalation 
flows are readily achievable by most patients even those with severe airflow obstruction 
and dose delivery does not change with increasing inspiratory effort (Hardy et al., 1996; 
Terzano, 2001). The audible click on actuation and the taste of the propellant in the dose 
of a breath-actuated MDI serves to reassure the patient that the dose has been dispensed, 
hence improving patient confidence, and compliance (Newman et al., 1991c; Donnell, 
2001). 
Despite the fact that these devices are of little additional benefit to patients with good 
inhalation techniques (Newman et al., 1991c; Soria et al., 2002), they greatly improved 
lung deposition in patients with poor coordination (Newman et al., 1991c; Schecker et 
al., 1993; Marshik et al., 1995). As shown in figure 2.13, the mean (SD) lung deposition 
was only 7.2% (3.4%) in subjects with poor coordination compared to 18.6% (2.9%) in 
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those with good coordination. This compares to a mean (SD) lung deposition of 20.8 % 
(1.7%) when the poor coordinators used a breath actuated metered dose inhaler (Newman 
et al., 1991c). 
 
Figure 2.13: Mean (SD) lung deposition in good and poor coordinators and when the 
poor coordinators used a breath actuated device (Newman et al., 1991c). 
Several studies have suggested that breath actuated MDIs are useful alternatives to MDIs 
due to their simple operation, they are easier to use, easier to teach and preferable by 
patients (Newman et al., 1991c; Chapman et al., 1993; Lenney et al., 2000). Many 
elderly patients have demonstrated a more efficient use of breath actuated MDI compared 
to either conventional MDIs or the Rotahaler® DPI (Diggory et al., 1991; Chapman et al., 
1993). Also,  a group of asthmatic children aged between 4 and 12 years old with acute 
exacerbations showed more successful Autohaler actuations (99%) compared to 
actuations from a dry powder device (74%) (Ruggins et al., 1993). Moreover, more cost 
savings were associated with the use of the Autohaler device as opposed to the 
conventional press and breathe MDI (Langley, 1999). This reduced cost associated with 
Breath actuated MDI can be attributed to their easy use and more optimal therapy in 
patients, with fewer emergency room visits and hospitalizations. In addition, the 
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Autohaler was reported to decrease drug usage by 23% compared to a conventional MDI 
(Kelloway and Wyatt, 1997). Patients using breath actuated MDIs were prescribed 25% 
less short-acting β2-agonist, 64% less oral steroid, and 44% less antibiotics, than their 
counterparts using traditional MDIs. Consequently, these breath-actuated inhalers may 
result in clinically and economically important outcomes in real-world practice due to 
improved patient compliance and improved lung deposition (Price et al., 2003; Chrystyn 
and Price, 2009). 
2.5. Transition of chlorofluorocarbon (CFC) propellants to hydrofluoroalkane 
(HFA) propellants in MDIs 
Ozone in the stratosphere is a layer above the earth surface that absorbs the harmful high-
energy ultraviolet (UV) radiations emitted from the sun, thus protecting the earth surface. 
The Nobel Prize winners M. Molina and S. Rowland were the first to find that the man 
made chlorofluorocarbon (CFCs) had been added to the environment in steadily 
increasing amounts and had caused  an accelerated depletion of ozone in the Earth's 
stratosphere as shown in figure 2.14 (Molina and Rowland, 1974).  
 
Figure 2.14: shows the ozone hole size. 
Chlorofluorocarbons (CFCs) were developed in the early 1930s and were widely used in 
refrigerators, air conditioners, solvents, fire suppressants and as propellants for aerosols. 
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Chlorofluorocarbons (CFCs) are remarkably simple molecules with great stability and 
are characterised by being non-toxic, non-flammable, and non-reactive with other 
chemical compounds. These desirable safety and stability characteristics make them ideal 
to be used as aerosol propellants (Ariyananda et al., 1996). Ironically, this very high 
stability is also behind its damage to the ozone layer. In fact, the CFCs are so stable that 
they can reach the stratosphere intact and cause the release of chlorine fragments under 
the effect of sunlight, which is responsible for their ozone depleting potential (Manzer, 
1990; Leach, 2005). As shown in figure 2.15 chlorine radicals catalyse the breakdown of 
ozone to molecular oxygen. One chlorine atom can be repeatedly recycled catalyzing 
thousand of reactions prior to formation of molecular chlorine. It has been estimated that 
one chlorine radical can destroy approximately 100.000 molecules of ozone  (Leach, 
2005), thus depleting the ozone concentration. 
 
Figure 2.15: Proposed halogen disruption of stratospheric oxygen/ozone equilibrium 
(Noakes, 1995; McDonald and Martin, 2000). 
Thinning of the ozone layer increases the levels of harmful UV radiations that reach the 
earth surface, consequently increasing levels of skin cancers, melanomas, cataracts, and 
causing important environmental damage (Partridge et al., 1998; Leach, 2005). 
Subsequent to The Montreal protocol in 1987 which banned the use of CFC propellants 
(Montreal, 2000), a primary objective for researchers and the pharmaceutical industry in 
addressing this issue has been the replacement of chlorofluorocarbon (CFC) propellants 
by the more environmentally friendly hydrofluoroalkane (HFA) propellants. HFA-
propellants have been found to be safe, have no ozone damaging potential , with much 
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less global warming effect than CFC-propellants and was considered to be suitable 
alternatives to CFCs used in the formulation of medicinal products (Partridge et al., 
1998). In addition to HFA-propellant desirable safety characteristics, their higher plume 
temperature (5ºC) than that of CFC-BDP (-20ºC), were beneficial in reducing the 
undesirable cold Freon effect. Also, the necessary manual force to press down the HFA-
BDP spray is three times smaller than that which is required for CFC-BDP sprays 
(Ibiapina et al., 2004). 
However, the replacement of chlorofluorocarbon propellants in metered dose inhalers 
with hydrofluoroalkane propellants was simple on the surface but scientifically very 
challenging. The conventional surfactants used in CFC MDIs were not soluble in HFA 
MDIs. The insolubility of surfactants such as oleic acid and lecithin in HFA propellants 
necessitated the use of co-solvents such as ethanol to solubilise the surfactants to create a 
stable suspension formulation or to dissolve the drug substance for a solution 
formulation. Consequently, these differences mandated the development of new 
formulations, and manufacturing processes for HFA inhalers. Because of a major 
research and development effort, pharmaceutical companies have made good progress in 
the reformulation of existing corticosteroid compounds into two distinct classes of 
corticosteroid aerosols HFA suspensions and HFA solutions. The new HFA preparations 
of fluticasone propionate, triamcinolone acetonide, and mometasone furoate were 
formulated as suspensions that retained the same particle size, deposition, and efficacy 
profiles as their CFC counterparts. Whereas other drugs such as flunisolide, budesonide 
and beclometasone dipropionate necessitated a shift in design from suspension 
formulations to solutions due to formulation problems and stability issues. The 
development of MDI solution formulations has provided a way to manipulate the quality 
of the aerosol cloud generated by MDIs and obtain precise control of the delivered dose 
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with a chosen particle size by what is known as Modulite® technology (Ganderton et al., 
2003; Acerbi et al., 2007).  
2.5.1. Modulite® technology  
Modulite® platform technology is an HFA-based aerosol solution that contains 12–15% 
(w/w) ethanol with up to a 1.3% (w/w) non-volatile excipient. Modulite solutions are 
capable of tailoring aerosol solution speed and particle size distribution to meet specific 
needs by controlling two interdependent variables, the addition of non-volatile 
component, and the actuator orifice geometry. Two other minor variables; change in 
vapour pressure of the propellant and the volume of the metered solution are also used to 
improve performance (Ganderton et al., 2002; Brambilla et al., 2011). Interestingly, an 
added non-volatile component decreases the system vapour pressure and increases the 
aerosol particle size upon propellant evaporation to values close to those of the CFC 
suspension formulations (Newman et al., 1982a; McDonald and Martin, 2000).  
The spray characteristics of solution aerosols can also be manipulated by a reduction in 
actuator orifice diameter which is consistent with the widely known fact that a larger 
actuator orifice produced a coarser spray (Polli et al., 1969). Using finer apertures were 
not possible with suspension aerosol formulations due to the potential for clogging. 
Conversely, the solution technology used in Modulite® frees the formulation from this 
constraint and enables variations in aperture diameter to control the properties of the 
aerosol cloud. The smaller actuator orifices produce a finer spray and generate a slower 
moving aerosol cloud over longer dose emission periods (Brambilla et al., 2011). These 
functions combine to reduce oropharyngeal deposition. Studies comparing the plume 
profiles of CFC-MDIs and HFA-MDIs showed that despite similar plume geometries, a 
slower plume velocity with the HFA solution was observed, allowing the dose to be 
generated over a longer period (Acerbi et al., 2007).  
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Moreover, Modulite® solution technology ensures the stability and consistency of the 
formulation throughout the life of the MDI canister. The use of a co-solvent to dissolve 
the drug in the propellant precludes any phase separation and dose variation caused by 
differences in shaking, storage and handling of  the canister that occur with suspension 
formulations (Cyr et al., 1991; McDonald and Martin, 2000; Ganderton et al., 2003).  
The manipulation of these variables, by Modulite® technology, led to an aerosol 
technology that overcomes the problems of the coarse fast moving aerosol clouds usually 
associated with the conventional CFC-MDIs, which can interfere with optimal drug 
deposition in the lung. Using this Modulite® approach led to the successful seamless 
transition of a number of CFC-based aerosols, including, formoterol (Houghton et al., 
2004) , budesonide (Vastagh et al., 2003) , and beclometasone dipropionate  (Bousquet 
and Cantini, 2002; Ganderton et al., 2002) to HFA systems.  
Modulite® technology was successfully used to reformulate HFA-BDP to match the 
CFC-BDP particle size, hence this allowed for a much faster and less expensive switch to 
new HFA inhalers (e.g., Clenil Modulite®; Chiesi, Italy). In addition, using HFA-solution 
technology made it possible for the first time to engineer the size and distribution of drug 
particles to produce an extrafine HFA-BDP formulation (1.1µm) for better targetting to 
different parts of the lung by values greater than 50% (e.g., Qvar,3M Pharmaceuticals) 
(Leach et al., 2009).   
2.5.1.1. The extra-fine HFA formulation of beclometasone dipropionate (Qvar®, 3M 
Pharmaceuticals) 
The reformulation of CFC-BDP with a non-CFC propellant, hydrofluoroalkane-134a 
(HFA-BDP) has provided the opportunity to tailor the size and distribution of particles to 
be targeted to different parts of the lung. The fact that BDP in the HFA-based 
formulation is in solution rather than in suspension, as in the case with CFC preparations 
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together with the improved inhaler technology led to the development of superfine 
particle HFA solution systems.  
Qvar ® (Teva Pharmaceuticals, UK) is an example of a newly developed HFA-BDP 
formulation that is available as a press-and-breathe (PB) MDI, an Autohaler (AH) and an 
Easi-Breathe (EB) device. It was the first CFC-free MDI formulation for an inhaled 
corticosteroid. Qvar produces an extra-fine aerosol that has a MMAD of 1.1µm versus 
3.5 µm for the CFC-propelled formulation and its fine respirable mass has a greater 
proportion of particles with a diameter less than 4.7 µm (approximately 60%) compared 
to the conventional CFC-BDP MDIs (approximately 30%) (Leach, 1998a; Donnell, 
2000). In addition, HFA-BDP inhalers have a lower spray force, and a warmer 
temperature than CFC-BDP inhalers (Roller et al., 2007). 
Consequently, these changes in HFA aerosol properties equate to better lung deposition 
(in both peripheral and central airways) together with 30% less oropharyngeal deposition 
(Leach et al., 2002; Agertoft et al., 2003; Leach et al., 2009), a decreased likelihood of 
experiencing the cold Freon effect due to decreased velocity of particles exiting the 
inhaler device (Gabrio et al., 1999), improved asthma control (Ederle, 2003) and better 
health related quality of life (Juniper et al., 2002). The increased efficiency of 
homogenous drug delivery to the lungs using the extrafine aerosol makes it ideal for use 
in both adults and children even when inhaled with a poor technique (Devadason et al., 
2003; Lasserson et al., 2006; Roller et al., 2007). Many studies have confirmed that 
asthma control can be fully maintained when switching patients from CFC-BDP to Qvar 
inhalers, despite switching to a lower dose of BDP in the HFA-BDP inhalers (Davies et 
al., 1999; Szefler et al., 2002).  
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2.5.1.1.1. Effect of particle size  
It is well documented that the particle size characteristics of the respired aerosol play a 
significant role in determining the total amount and the relative distribution of inhaled 
corticosteroid to the large and small airways (Leach et al., 1998a; Leach et al., 2002; 
Agertoft et al., 2003).  
Theoretical mathematical models such as the ICRP model published by the Task group 
of the International Committee on Radiological Protection have been proposed to predict 
the fraction of inhaled particles deposited in each region of the respiratory tract as a 
function of particle size. According to this model presented in figure 2.16, there is a 
major increase in alveolar deposition of fine particles (0.1-1µm). This is attributed to 
their deposition predominantly by a diffusion mechanism that increases inversely with 
particle size and become negligible for larger particles.  
 
Figure 2.16 : The fate of inhaled particles depending on particle size reproduced from 
(ICRP, 1994; Köbrich et al., 1994). 
On the other hand, particles that are 1-5µm in diameter are deposited mainly in the lower 
bronchial airways and alveoli due to sedimentation, whereas those larger than 5µm are 
deposited mainly in the large bronchial airways and the oropharynx due to inertial 
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impaction. The less total deposition seen for submicron particles may be due  to  a 
balance between a predominance of diffusion versus impaction/sedimentation 
mechanisms based on their particle size as these two modalities of particles deposition 
decrease with decreasing particle size (ICRP, 1994; Schulz, 1998). 
A major advantage of the small particle ICS is their improved total lung deposition 
resulting in achieving effective asthma control at lower daily doses than the bigger 
particle ICS. As shown in figure 2.17, the site of particle deposition in the respiratory 
tract appears to be strongly related to the particle size of inhaler used, as the smaller 
particles of HFA-BDP Qvar product was associated with greater lung deposition and less 
oropharyngeal deposition than the bigger particles of CFC-BDP (Leach et al., 2002).  
 
Figure 2.17: Distribution as percentage of ex-actuator dose of radiolabeled HFA-BDP 
and CFC-BDP to the lungs, oropharynx, mediastinum, abdomen, and expiratory filter. 
Reproduced from (Leach et al., 2002). 
Despite that, experimental data and mathematical models predict an increased total lung 
deposition with increasing particle size from 0.5 to 10µm under tidal breath conditions, 
the use of slow deep inhalations followed by a breath hold increased particles residence 
time. This increased residence time together with the low inertial losses of small particles 
greatly favoured their total deposition and lung penetration to exceed that of larger 
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particles. The minimal upper airway aerosol losses for small particles are expected due to 
their greater ability to largely bypass the filtering mechanisms and abrupt airway 
geometry of the upper airways, which accounts for their less oropharyngeal deposition. 
Whereas the greater inertia of larger particles makes them more susceptible to leave the 
inspired, air stream during sudden changes in airflow direction and deposit mainly by 
impaction in the oropharynx and at airway bifurcations (Usmani et al., 2005; Asgharian 
et al., 2006).  
The study by Usmani et al (2005) quantified lung deposition after 12 asthmatics inhaled 
radiolabeled monodisperse aerosols with a MMAD of 1.5, 3.0, and 6.0µm. They 
observed an increased lung deposition and penetration index values with decreasing 
particle size as shown in figure 2.18.  
 
Figure 2.18: Effect of fast and slow inhalation rates on aerosol deposition in central (C), 
intermediate (I) and peripheral (P) regions of the lung. Reproduced from (Usmani et al., 
2005). 
This gamma scintigraphy study clearly confirmed the increased total and peripheral lung 
deposition of the 1.5µm particles than the 3 µm or 6 µm particles, whereas 6µm particles 
were more proximally distributed throughout the airways that present larger calibre. 
Moreover, oropharyngeal deposition increased with increasing particle size, whereas the 
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exhaled aerosol fraction was greatest with the 1.5 µm aerosols. Similarly, a more recent 
gamma scintigraphy study using an Aerolizer DPI device showed a more diffusive and 
greater deposition of small particles throughout the lung especially in the peripheral lung 
zone, alternatively, the deposition in the upper airways was significantly higher for 
bigger particles (>70%) (Glover et al., 2008) 
Consequently, another advantage of the small particle ICS formulation is that they are 
more able to reach the small airways and consequently result in increased efficacy 
(Gentile and Skoner, 2010). The fact that both large and small airways are clearly 
involved in the pathophysiological processes of asthma together with the availability of 
the glucocorticoid receptors throughout the bronchial tree and especially in the alveolar 
walls (Adcock et al., 1996) provided the rationale for the need for small particles ICS 
therapy.  The  extra fine aerosol produced by HFA-BDP formulations (1.1µm) offered 
more even deposition throughout the airways with better targeting to small airways 
inflammation compared to the poor distal delivery offered by the larger particle size 
CFC-MDIs (3.5-4 µm) (Richards et al., 2001; Leach et al., 2002; Leach, 2005; Newman 
et al., 2006; Corren, 2008).  
Moreover, the production of ultrafine particles MDI was found not only to improve lung 
deposition both peripherally and centrally, but it  also produces similar deposition 
patterns when inhaled with a fast and a slow inhalation rate or without a breath hold 
(Janssens et al., 2003; Usmani et al., 2005). Leach et al (2005) compared drug delivery 
from HFA-BDP (Qvar® Autohaler) with proper and improper inhalation technique from 
Qvar® MDI. As shown in table 2.1, the breath activated Qvar® Autohaler and the proper 
Qvar® MDI technique provided optimal lung deposition of 60%, and 59% respectively. 
Furthermore, the smaller particle size and longer duration spray of Qvar® MDI resulted 
in patients receiving more than 30% lung deposition even under severe discoordination 
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of actuating before inhaling and as late as 2.5 seconds after the start of inhalation. A 
result that is extremely important to eliminate problems associated with patients’ failure 
to achieve proper inhalation techniques when using MDIs. 
Inhaler technique Lungs Oropharynx Mediastinum Abdomen Exhaled 
Autohaler (on time) 60 ± 7 31 ± 8 1 ± 1 0 ± 0 8 ± 4 
P&B (on time) 59 ± 9 30 ± 8 2 ± 1 2 ± 1 7 ± 2 
P&B (early) 37 ± 21 56 ± 22 1 ± 0 0 ± 1 5 ± 2 
P&B (late) 50 ± 8 25 ± 7 1 ± 0 0 ± 0 24 ± 4 
 
Table 2.1: Overall deposition of 99m Tc-HFA-BDP (Leach et al., 2005). 
Comparison between the post treatment of Qvar and CFC-BDP subjects showed better 
ability of Qvar treated subject to reduce regional hyperinflation (Goldin et al., 1999) and 
effectively suppress the production of alveolar macrophages (Marshall et al., 2000), 
presumably because of better Qvar deposition in the peripheral airways and the alveoli. 
Hydrofluoroalkane (HFA-BDP) formulations provided more improvements in asthma 
outcomes due to their greater potential to effectively penetrate and suppress inflammation 
at the level of the small airways, which are the predominant site of obstruction in mild 
asthma (Goldin et al., 1999; Tanaka et al., 2004; Dolovich, 2009). A recent study showed 
that patients receiving Qvar therapy were more likely to achieve successful asthma 
control with less exacerbations (Kemp et al., 2009). In addition, these smaller particles 
largely bypass the filtering mechanisms of the upper airways, which accounts for their 
less oropharyngeal deposition (Usmani et al., 2005). 
2.5.1.1.2. Lung deposition 
Several lung deposition studies have demonstrated that the extra-fine HFA-BDP  aerosol 
formulations were more effective than their CFC counterparts at equivalent doses due to 
their smaller aerosol particle size causing more efficient lung deposition of about 40% of 
nominal dose (Borgström, 1999) or 55-60% of the emitted dose (Leach et al., 1998a; 
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Leach, 1999). HFA-BDP formulations showed similar lung deposition patterns and 
equivalence to CFC-BDP formulations but at half the nominal dose (Busse et al., 1999b; 
Leach, 1999; Harrison, 2002).  
Comparative deposition patterns of radiolabelled Qvar HFA-BDP and CFC-BDP as 
shown in figure 2.19 revealed that HFA-BDP was distributed in central, intermediate, 
and peripheral airways, whereas drug that reached the lungs from CFC-BDP was mostly 
in the central airways. Moreover, HFA-BDP delivered most of the drug to the lungs (55-
60%) and less in the oropharynx (29-33%), with 9-14% being exhaled. Conversely, the 
majority of drug from CFC-BDP was deposited in the oropharynx (90-94%), and only (4-
7%) reached the lung (Leach, 1998b; Leach et al., 1998a).  
 
Figure 2.19: Comparative deposition pattern of radiolabelled BDP from Qvar (HFA-
BDP) and CFC-BDP aerosol systems (Leach, 1998b; Donnell, 2000). 
Since the HFA-BDP extrafine aerosol delivers most of the ICS dose directly to the lungs 
rather than to the oropharynx and gut, it should result in greater therapeutic benefit with a 
reduced incidence of oropharyngeal adverse events. 
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2.5.1.1.3. Pharmacokinetics and Pharmacodynamics 
Several pharmacokinetic studies investigated the greater lung delivery of Qvar compared 
to CFC-BDP and reported that serum levels of beclometasone esters, as measured by 
AUC following HFA-BDP was approximately 2-2.5 times those obtained  following 
CFC-BDP. In addition, the rate and extent of total beclometasone absorption increased 
with increasing the dose of HFA-BDP formulation (Harrison et al., 1997; Seale and 
Harrison, 1998; Harrison et al., 1999a; Harrison et al., 1999b; Agertoft et al., 2003). The 
greater efficiency and systemic drug delivery of the HFA formulation compared with the 
CFC formulation as shown in figure 2.20 can be attributed to greater swallowed and 
orally absorbed portion of CFC-BDP dose, whereas most of each inhalation from HFA-
BDP is absorbed through the lungs due to its smaller particle size. However, time to 
maximum plasma concentration (Tmax) was later with CFC-BDP than Qvar (2hours vs 
0.6hours). This rapid Tmax with Qvar is due to its rapid absorption from the lung 
compared to the slower absorption from the gut with CFC-BDP.  
 
Figure 2.20: Mean serum concentration of beclometasone esters following 200µg HFA-
BDP, 400µg HFA-BDP, and 400µg CFC-BDP from (Harrison et al., 1999b). 
A clinical study by Busse et al (1999) demonstrated a dose response relationship for 
HFA-BDP and CFC-BDP and investigated the effect of treatment of multiple doses on 
lung functions. In this study, Busse et al (1999) reported that increasing doses of inhaled 
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corticosteroids lead to improved lung function and asthma control. Moreover, as shown 
in figure 2.21, a given dose of HFA-BDP requires 2.6 times the dose of CFC-BDP to 
achieve the same improvement in FEV1. Similarly, several other clinical studies have 
also showed an improved asthma control with Qvar at half the daily dose of CFC-BDP 
(Davies et al., 1998; Gross et al., 1999; Magnussen, 2000). 
 
Figure 2.21: Dose-comparison calculation shows that it would take 2.6 times the dose of 
a large particle inhaled steroid (CFC-BDP) to achieve the same improvement in FEV1 
compared with an ultrafine particle inhaled steroid (HFA-BDP) reproduced from (Busse 
et al., 1999b). 
The increased distal lung deposition of Qvar might be expected to be associated with 
increased systemic effects, including adrenal suppression. However, reassuring data from 
several clinical trials have not documented any increased risk of systemic effects. 
Compared to other ICS, Qvar® inhalers have been found to be highly effective  and well 
tolerated in both asthmatic adults (Van Schayck and Donnell, 2004a) and children 
(Szefler et al., 2002; Van Schayck and Donnell, 2004b). It produces equivalent asthma 
control to CFC-BDP at approximately half the daily dose with  no clinically relevant 
adverse effects on adrenal function, bone metabolism or growth at recommended doses 
(Gentile and Skoner, 2010). The overall incidence of adverse effects that is related to 
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beclometasone dipropionate treatment was significantly lower with Qvar (11%) 
compared to CFC-BDP formulations (16%). In addition, the total incidence of local side 
effects such as dysphonia and cough was significantly lower in Qvar treated patients 
(8%) than in CFC-BDP treated ones (12%) (Thompson et al., 1998; Davies et al., 1999; 
Busse et al., 2000). Even without using spacers, its oropharyngeal deposition was 
efficiently reduced from 90% to 30% (Leach, 1998b). Furthermore, several clinical 
studies suggested that Qvar does not adversely affect the adrenal function at its 
maximum recommended dose and as shown in figure 2.22 may even produce less adrenal 
suppression than CFC-BDP at a comparable efficacious dose (Davies et al., 1998; 
Harrison et al., 1999a; Lipworth, 2000; Harrison, 2002).  
 
Figure 2.22: Mean Percent change from baseline in 24hr urinary free cortisol reproduced 
from (Harrison, 2002). 
Even when the maximum daily doses are exceeded, the incidence of relevant systemic 
adverse effects is lower than expected (Lipworth, 2000).  Some have suggested that this 
could be due to the shorter Tmax for Qvar compared to CFC-BDP which may provide less 
stimulus for the HPA axis to change its output corticotrophin-releasing hormones and 
adrenocorticotropic hormone (Dekhuijzen and Honour, 2000). Furthermore, this 
extrafine spray plume does not produce serum or tissue accumulation when given at 12 
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hour intervals between doses (Lipworth, 2000). However, there is no firm evidence for 
the reduced systemic effects. 
The overall therapeutic ratio of the HFA-BDP formulations is more favourable than that 
of the conventional CFC-BDP formulations due to equivalent efficacy with a lower dose 
and equivalent safety at the same dose (Thompson et al., 1998; Harrison et al., 1999a; 
Boulet et al., 2004). Although, smaller particles improve lung deposition, it also reduces 
systemic absorption from the upper respiratory tract  and gastrointestinal tract and 
decrease adverse effects (Amirav et al., 2010). The enhanced delivery characteristics of 
the finer HFA-BDP aerosol even when inhaler technique is not ideal when compared to 
CFC-BDP suggest that it is possible to reduce the nominal BDP dose without 
compromising asthma control, which is considered a significant clinical advancement in 
asthma management.  
2.5.1.2. The non extra-fine HFA formulation of beclometasone dipropionate (Clenil 
Modulite®; Chiesi, Italy) 
Modulite® technology was originally applied to the development of BDP inhalers by 
matching CFC-BDP based inhalers in terms of aerosol characteristics and particles size, 
thus allowing a seamless transition of CFC-BDP MDI to HFA-BDP inhalers on a 1:1 
nominal dose ratio basis (Bousquet and Cantini, 2002; Acerbi et al., 2007). The addition 
of glycerol as a non-volatile co-solvent together with the selection of an appropriate 
actuator orifice diameter, provides an aerosol with particle size characteristics, that 
closely resemble that of the conventional CFC-BDP (Ganderton et al., 2002).   
Clenil Modulite® (Chiesi, Italy) is the first CFC-free metered dose inhaler directly 
interchangeable with CFC-containing inhalers. In the UK, it is currently the only 
available inhaled HFA-BDP MDI that can be used in place of the CFC-BDP without 
changing the prescribed dose of corticosteroid (Bousquet et al., 2009). The median 
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particle size in the aerosol generated by Clenil Modulite is 2.9μm and the distribution of 
particle sizes more closely matches that of CFC containing MDIs than Qvar (Ganderton 
et al., 2002). Several clinical studies have shown no differences in lung function, asthma 
control, tolerability, and systemic exposure between Clenil Modulite® and CFC inhalers 
in both healthy adults and asthmatic patients (Anderson et al., 2002; Bousquet and 
Cantini, 2002; Woodcock et al., 2002a). Consequently, the lung deposition from Clenil 
Modulite® is not as efficient as that with Qvar® which provides the same efficacy and 
safety profile as Clenil but at half the dose. However, this new non-extra fine HFA-BDP 
formulation allows a seamless transition to CFC-free BDP inhalers and minimizes 
difficulties for both patients and prescribers as the same dosage schedule is used. Clenil® 
Modulite is likely to minimise both NHS staff time and disruption for the patient. The 
differences between the newly developed CFC-free beclometasone inhalers; Clenil 
Modulite® and Qvar® inhalers are summarized in table 2.2. 
 
Table 2.2: Differences between Clenil® and Qvar® inhalers. 
Clenil® 
 
Qvar® 
 
- Requires no dose adjustment from 
CFC-BDP inhalers 
- Requires 50 - 60% dose reduction from 
CFC-BDP inhalers 
- Metered dose inhalers (MDIs) only - Metered dose inhalers (MDIs), Autohalers, and Easi-Breathe inhalers 
- 50 µg, 100 µg, 200 µg, and 250 µg 
strengths available. - 50 µg and 100 µg strengths available 
- Licensed in adults and children (any 
age) 
- Licensed in adults, but not licensed in 
children <12 years. 
- Similar lung and oropharynx 
deposition as CFC-BDP inhalers 
 
- Increased lung deposition and reduced 
oropharynx deposition compared with 
CFC-BDP inhalers 
 
- Optimal slow inhalation flow with 
good coordination is required 
- Optimal slow inhalation with good 
coordination is less critical than when 
using traditional MDIs 
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Due to these differences, the Medicines and Healthcare Products Regulatory Agency 
(MHRA) have recommended that beclometasone MDIs must be prescribed by brand and 
not generically. 
2.6. Methods of studying particle deposition 
The assessment of drug deposition provides important information for evaluating the 
performance of inhalers and inhalation techniques. Studies have shown the important role 
of drug deposition in the lung on predicting clinical response and efficacy of inhaled 
drugs (Pauwels et al., 1997a; Snell and Ganderton, 1999; Newman, 2000). Several 
methods have been developed and validated for the assessment of pulmonary drug 
deposition. 
2.6.1. Pharmacokinetic methods 
Pharmacokinetic methods can be successfully used to predict lung deposition, 
bioavailability, and the systemic effects of an inhaled dose. They are indirect 
measurements that use plasma or urine concentrations to estimate the amount of drug 
which enters the systemic circulation via the pulmonary and the gastrointestinal routes 
(total systemic delivery), and thus provide valuable data which predict extra-pulmonary 
effects (Newnham et al., 1993). 
As illustrated in Figure 2.23, after an inhalation, a portion of the dose is delivered to the 
lungs whilst the majority is swallowed (Chrystyn, 1997). The proportion of the dose that 
enters the lungs is cleared from the body, either by mucociliary clearance (Borgstrom et 
al., 1992) then swallowed or by absorption through the airway wall into the systemic 
circulation. It is this portion of the dose that has the potential to exert a therapeutic effect; 
this is termed the effective lung dose. Whether the dose is deposited in the lungs or 
swallowed, it will enter the systemic circulation. The total amounts delivered can 
therefore give rise to systemic side effects. Since inhaled medications are delivered 
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directly onto the therapeutic sites in the airways the dose is low; hence the potential for 
systemic side effects is markedly reduced (Chrystyn, 2001). 
 
 
Figure 2.23: Schematic representation of the fate an inhaled drug (Chrystyn, 2001; 
Barnes, 2007). 
Identification of lung deposition using pharmacokinetic methods requires absorption via 
the pulmonary and oral route to be separated except for drugs that are poorly absorbed, 
such as, sodium cromoglycate or drugs with a high first pass effect, such as, fluticasone 
propionate. Virtually, all the systemic delivery of fluticasone propionate is by the 
pulmonary route (Mollmann et al., 1998).  
Borgstrom and Nelson (1990) first developed a charcoal block urinary excretion method 
to identify the relative lung deposition. They reported that the concurrent oral 
administration of activated charcoal blocked all absorption of the drug from the 
gastrointestinal tract. In this case the amount of drug eliminated in the urine gives an 
absolute value for the total lung dose. However, because this method uses oral charcoal it 
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would be unethical to extend it to patient studies due to the concomitant oral therapy 
patients receive (Chrystyn, 2001). 
Drugs delivered to the lungs are very rapidly absorbed into the body whereas there is a 
lag time after oral administration before its delivery to the systemic circulation. The body 
starts eliminating drugs as soon as they are delivered to the body. Using this principle, 
plasma (Lipworth, 1996; Lipworth and Clark, 1997; Lipworth and Clark, 1998b) or urine 
samples (Hindle and Chrystyn, 1992; Hindle et al., 1993; Hindle and Chrystyn, 1994; 
Hindle et al., 1995) over the first 20 and 30 minutes, respectively, post inhalation have 
been used as useful indices of lung deposition. This is due to the negligible contribution 
of swallowed drug to systemic levels during these time periods (Hindle and Chrystyn, 
1992). 
Direct measurements of plasma salbutamol concentrations given by different inhaler 
devices over the first 20 minutes provided an effective and simple method to quantify 
and measure the relative bioavailability of salbutamol to the lung following inhalation 
(Lipworth, 1996). Indeed, the delayed gastrointestinal absorption compared to lung 
absorption and the very low oral bioavailability of salbutamol (<0.3) during the first 30 
minutes post inhalation provided a  sensitive index for lung deposition (Chrystyn et al., 
1996; Clark and Lipworth, 1996a). This pharmacokinetic approach was successfully used 
to compare different inhaler devices (Lipworth and Clark, 1998b), different inhalation 
techniques (Engel et al., 1992), and to study the effects of multiple actuations and 
inhalations delay on lung deposition. Moreover, this pharmacokinetic method was used 
to investigate the effect of using an antistatic lining or washing the spacers to eliminate 
electrostatic charge, and evaluate the bioequivalence of different formulations (Clark et 
al., 1996; Clark and Lipworth, 1996b). This plasma pharmacokinetic method has also 
been used to compare the pharmacokinetic profile of Beclazone® (beclometasone 
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dipropionate) in its CFC and HFA based formulations and reported up to two fold greater 
drug absorption with the HFA-BDP than the CFC-BDP formulation at the same nominal 
dose (Lipworth and Jackson, 1999). 
Hindle & Chrystyn (1992) were the first to report a urinary pharmacokinetic method to 
determine the relative bioavailability of salbutamol to the lung and to the body following 
an inhalation. As shown in figure 2.24, this study reported that the amount of salbutamol 
excreted in the urine over the first 30 minutes post inhalation was significantly greater 
than the amount eliminated following oral administration. They have validated how this 
index represents the amount of the inhaled dose deposited into the lungs. This 
measurement represents the effective lung dose because it measures the drug that is 
delivered to the body following passage through the airway wall. Hindle & Chrystyn 
(1992) also reported that the amount of salbutamol and its metabolites excreted in urine 
over the 24 hours period post-inhalation is an index of systemic delivery. This index is 
the relative bioavailability to the body following inhalation. 
 
Figure 2.24: Mean and individual amounts of urinary salbutamol excreted 30 minutes 
post inhalation and oral dosing reproduced from (Hindle and Chrystyn, 1992). 
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The reproducibility of the Hindle and Chrystyn method has been reported (Tomlinson et 
al., 2003) and found to be more sensitive than a  bronchoprovocation challenge test using 
methacholine in detecting  a difference between inhalation techniques (Tomlinson et al., 
2005). This index (relative lung bioavailability) of salbutamol to the lungs following 
inhalation has been useful to compare different inhalation devices, e.g. spacer devices 
(Chege and Chrystyn, 1994; Hindle and Chrystyn, 1994; Mazhar and Chrystyn, 2008), 
dry powder inhalers (Hindle et al., 1995; Hindle et al., 1997; Chege and Chrystyn, 2000),  
nebulisers (Silkstone et al., 2000; Silkstone et al., 2002; Mazhar et al., 2008), different 
inhalation techniques (Hindle et al., 1993), and different formulations (Chege and 
Chrystyn, 1995). The method is simple, non-invasive and has already been extended to 
determine the relative bioavailability of different drugs e.g, inhaled sodium cromoglycate 
(Aswania et al., 1997; Aswania et al., 1999; Aswania and Chrystyn, 2001; Aswania and 
Chrystyn, 2002), nedocromil (Aswania et al., 1998), gentamycin (Nasr and Chrystsyn, 
1997; Al-Amoud et al., 2002; Al-Amoud et al., 2005) and formeterol (Nadarassan et al., 
2007). However, the methodology has not been extended to inhaled corticosteroids.  
The urinary pharmacokinetic method provides a simple and effective method of 
assessing the relative bioavailability of many drugs to the lung. An advantage of this 
method is that it uses the patient’s own inhaler whereas other investigations of lung 
deposition following inhalation may require the use of a radiolabelled inhaled marker, 
which alters the formulation of the inhaled product. The disadvantage of this method is 
that it relates only to total lung deposition and does not differentiate between drug 
distributions into different regions of the lung; however, total lung deposition is probably 
more related to clinical response than regional lung deposition (Zainudin et al., 1990; 
Zanen et al., 1994; Zanen et al., 1996; Chrystyn, 1997; Chrystyn et al., 1998). The 
redistribution of drug deposited in the alveolar region is possible by the pulmonary 
circulation or via mucocilliary clearance (Chrystyn, 2001). Also, an even distribution of 
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drug throughout the lungs may not occur, especially in severe asthmatic subjects due to 
their altered airway calibre (Lipworth and Clark, 1997). 
The plasma concentrations of drugs such as inhaled corticosteroids are very low, because 
of the small doses used and the very large volume of distribution of these drugs in the 
body. The analysis of these drugs in plasma requires highly sensitive analytical methods 
(Derendorf et al., 2001); however the concentrations of drugs in urine are much higher 
and offer a much easier solution to the required sensitivity of assays. 
Several pharmacokinetic safety studies have provided useful information on drug 
absorption from different aerosol devices and answered several questions on the 
performance of these aerosols. Harrison et al (1999) compared the systemic delivery of 
the original CFC-BDP formulation to HFA-BDP formulations and found that the serum 
levels of beclometasone esters, as measured by AUC, was approximately 2.5 times 
greater following the HFA-BDP compared to the CFC-BDP. The smaller particle size of 
HFA-BDP resulted in a more rapid and greater efficiency of systemic delivery than did 
the larger particle size of the CFC formulation. Moreover, these pharmacokinetic safety 
studies were also successfully used in investigating the dose proportionality of BDP and 
the ability of one strength to substitute for the other strength  by measuring 17-BMP 
maximum plasma concentrations (Harrison et al., 2002b) . The observation of the 
comparable efficacy of CFC-BDP to much lower doses of HFA-BDP suggested that 
HFA-BDP may have less safety concerns than CFC-BDP. Despite the fact that the 
measured serum profiles of beclometasone showed an increased extent of drug 
absorption of  HFA-BDP compared to CFC-BDP, it was at least as favourable as CFC-
BDP with regard to adrenal suppression (Harrison et al., 1999a).   
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2.6.2. Lung imaging techniques 
The non-invasive imaging technique of gamma scintigraphy was developed to be used 
for the assessment of pulmonary drug delivery by labelling the formulation with a 
gamma ray emitting radionuclide, e.g.99mTc. This process enables direct visualization and 
quantification of where the drug has been deposited by a gamma camera. In addition to 
providing accurate assessments of whole lung deposition, it provides data on regional 
deposition by dividing the lung into central, intermediate, and peripheral zones 
representing airways of different sizes. The peripheral zone/central zone deposition ratio 
enables differences in regional deposition between treatments regimens to be detected 
(Newman et al., 1989; Steed et al., 1997; Newman et al., 2003), but it has not been 
established whether efficacy depends upon whole or regional  lung deposition (Chrystyn, 
1997).  
Originally, radiolabelled Teflon particles were used (Newman et al., 1981a); however, 
these techniques were soon replaced by methods to adhere the radionuclide (usually 99 m 
Technetium) to either the formulation or the drug molecule (Kohler et al., 1988). 
Gamma scintigraphy is based on reformulating an existing inhaled product to incorporate 
a radiolabel. Prior to each study validation measurements are carried out in-vitro to show 
that the aerodynamic particle size characteristics are not altered in the radiolabeled 
product and similar to the original product (Farr, 1996; Snell and Ganderton, 1999; 
Newman et al., 2003). 
There are two gamma scintigraphy methods, two-dimensional and three-dimensional 
imaging (Newman and Wilding, 1998a; Chrystyn, 2001). Two-dimensional gamma 
scintigraphy (planar imaging) studies drug deposition and the extent to which the drug is 
available at the site of action. If two inhalation products deliver the same amount of drug 
and have similar whole lung and regional deposition patterns then their clinical effect 
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within the lung should be the same. Thus, planar imaging provides a powerful tool to 
indicate if two delivery systems are either equivalent or not. Planar imaging studies have 
been used extensively to compare different inhalation devices, e.g. metered dose inhalers 
(Newman et al., 1995), spacer devices (Newman et al., 1981c; Newman et al., 1984; 
Vidgren et al., 1987; Newman et al., 1989; Newman and Newhouse, 1996), Dry powder 
inhalers (Vidgren et al., 1988; Borgstrom et al., 1994; Newman et al., 1994a) and 
nebulisers (Zainudin et al., 1990; Hardy et al., 1993; Newman et al., 1994b). A 
disadvantage of this method is that it is two-dimensional and thus some drug deposited in 
the smaller airways will be classified as in the central or the intermediate zones. 
Although, this is partially overcome by correcting for the distance from the imaging 
apparatus, the 2D problems do remain.  
Three-dimensional imaging methods e.g., SPECT (single photon emission computed 
tomography) and PET (positron emission tomography) have been developed to overcome 
planar imaging problems. These more advanced techniques, SPECT and PET relate 
deposition pattern to anatomy better than planar imaging, as the gamma camera rotates 
through 360º allowing for a full three dimensional intrapulmonary deposition pattern. 
The three-dimensional imaging methods allow identification of pulmonary deposition 
with higher resolution and provide a better distinction between central and peripheral 
lung deposition (Usmani et al., 2005; Leach et al., 2006). This technique has been used 
by Newman, (2006) and revealed that ciclesonide deposition within the lungs was 
highest in the peripheral regions for HFA-MDI in asthmatic patients (Newman et al., 
2006).  
Positron emission tomography (PET) has an additional advantage in that it enables the 
drug itself to be labelled without modifying its chemical structure and can thereby 
overcome some of the limitations of gamma scintigraphy. It involves the direct chemical 
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incorporation of positron emitters such as 11C, 1 8F, 13 N, and 15O into the drug molecule 
(Rhodes and Hughes, 1995; Newman et al., 2003). This technique has been applied to 
assess drug deposition of several drugs (Dolovich and Labiris, 2004; Dolovich, 2009). 
Gamma scintigraphy produces data of the total lung dose that is absorbed through the 
lung and that is cleared by mucocilliary clearance. Since only the former is responsible 
for the therapeutic effect, then gamma scintigraphy will overestimate the effective dose 
reaching the lung (Chege and Chrystyn, 2000; Chrystyn, 2000). This is why gamma 
scintigraphy studies showed higher values than those of urinary excretion with charcoal 
block (Borgstrom et al., 1992; Newman et al., 1995). Similar results have been reported 
for sodium cromoglycate in that gamma scintigraphy indicates a total lung deposition of 
8.8%  (Newman et al., 1991a) while urinary excretion suggests less than 3% (Aswania et 
al., 1999). Gamma scintigraphy also involves modifications to the formulation of the 
inhaled product and consequently the product tested by this method is not the same as the 
one that the patient actually uses. Thus, accurate in-vitro studies are essential to ensure 
that the dose emission characteristics have not been changed (Newman et al., 1995). 
Some in-vitro studies have shown changes to the aerodynamic particle characteristics of 
the emitted dose when a radiolabel is incorporated into the inhaled product (Newman et 
al., 1982b). Despite the fact that, 3D scintigraphy gives more detailed information on 
deposition site, the larger doses of radiation dose invoke ethical consideration 
particularly if intended to be used in children (Newman et al., 1995; Chrystyn, 2001). In 
clinical practice, scintigraphic studies cannot accurately predict the performance of the 
inhaled drug in terms of efficacy and safety. It gives precise information about the 
distribution pattern of the aerosol without information of the subsequent fate of the drug.  
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2.6.3. Pharmacodynamic methods 
The bioequivalence of inhaled products is complicated as the therapeutic effect is due to 
topical deposition of drug, whereas the safety is determined by systemic delivery via the 
oral and gastrointestinal route. Clinical endpoints such as spirometry and 
bronchoprovocation are regarded as the gold standard by the Regulatory Authorities to 
demonstrate the efficacy of inhaled products. However, systemic delivery using either 
pharmacokinetic or adrenal suppression methods is used to demonstrate the safety of 
inhaled products (Adams et al., 1994; Newman, 2000).  
For inhaled medications, bioequivalence ensures that different doses of different drugs or 
different formulations of the same drug produce equivalent pharmacodynamic effect. 
Current guidelines recommend the use of a dose scale approach to demonstrate 
bioequivalence between different inhaled products. The bioequivalence of inhaled 
products is evaluated as the ratio of drug doses producing similar effects (relative 
potency) rather than comparing the magnitude of responses following the administration 
of different preparations. The most widely used dose scale approach is the Finney 
bioassay method that involves the determination of the relative potency of two inhaled 
products by calculating horizontal differences between their regression lines following 
inhaled administration (Adams et al., 1994; Lavorini et al., 2008a).   
Measurement of lung functions by spirometry has been used to determine the degree of 
bronchodilatation produced and compare new inhalers. Busse et al (1999) reported that 
FEV1, which is a clinically relevant marker for asthma control, was sensitive enough to 
distinguish between increasing dose effects of BDP. This study showed that increasing 
doses of inhaled corticosteroids in patients with severe asthma led to an improved lung 
function and asthma control. In addition, they compared the effects of CFC-BDP and 
HFA-BDP on lung function by calculating the dose of each product required to obtain the 
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same improvement in FEV1 (Finney Bioassay method). Their results showed that it 
would require 2.6 times the dose of CFC-BDP to obtain the same change in FEV1. The 
improved lung deposition of HFA-BDP due to its smaller particle size compared to CFC-
BDP formulations accounts for their clinically relevant difference in efficacy (Leach et 
al., 1998a). 
However, this measurement alone is often insufficient to discriminate between the 
potency of drug products due to the maximum spirometric response from therapeutic 
inhaled doses (Chrystyn, 1994; Buck and Parry-Billings, 2001; Chrystyn, 2001). Some 
have argued that standard measures of improvement in baseline function may be too 
insensitive to detect real differences in potency. Measurement of FEV1 failed to 
distinguish dose effects in previous studies with inhaled corticosteroids leading to the use 
of bronchoprovocation challenge testing to demonstrate dose effects (Barnes et al., 
1998).  
The fact that airway hyperresponsiveness (AHR) is a persistent key feature in asthma has 
encouraged the development of bronchoprovocation challenge testing as an objective 
diagnostic tool (Britton, 1998). The FDA guidelines have recommended 
bronchoprovocation challenge for assessing the equivalence of  inhaled products by the 
determination of PD20 in asthmatic patients (Adams et al., 1994). The PD20 is the dose of 
bronchoconstrictor (usually histamine or methacoline) required to produce 20% 
reduction in FEV1, following protection by the beta agonist. This method has been 
successfully used to compare the efficacy of different inhalation products (Wong et al., 
1997; Eiser et al., 2001; Mallol et al., 2001; Creticos et al., 2002) and found to be a more 
sensitive measure than bronchodilatation alone (Buck and Parry-Billings, 2001).  
However, there are several problems associated with direct measurements of the clinical 
response. As, although bronchodilators produce a rapid measurable response indicated by 
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rapid improvements in spirometric tests of lung function, their marketed doses are close 
to the top of the dose response curve. Consequently, two products that are deposited 
differently in the lungs may give a maximal response, causing the failure of spirometric 
tests to detect important differences in drug delivery between inhaled products (Newman 
et al., 1991b; Borgstrom et al., 1996; Snell and Ganderton, 1999; Mallol et al., 2001). On 
the other hand, inhaled corticosteroids show no rapid response, and the usual approach 
for comparing two inhalers is much more complex due to the need to conduct longer-
term clinical trials of at least 4 weeks' duration (Barnes et al., 1998; Rhodes et al., 2001). 
Drug deposition in the lung should predict clinical response, but the flat nature of the 
dose response curve of most marketed doses of inhaled corticosteroids masks this 
relationship. Thus, for example, an 8-fold increase in deposition of beclometasone 
dipropionate from an HFA formulation (Leach, 1998b) is only associated with an 
observed 2-fold increase in efficacy (Davies et al., 1998; Busse et al., 1999b). 
Furthermore, the response to inhaled corticosteroids is highly variable, so that a large 
number of patients must be studied to achieve an appropriate statistical power (Zanen 
and Lammers, 1995; Newman and Wilding, 1998b). 
The clinical response study failed to differentiate between different inhalation techniques 
(Giannini et al., 2000). In contrast differences have been observed for salbutamol urinary 
excretion (Silkstone et al., 2002; Tomlinson et al., 2005) and plasma drug concentrations 
(Lipworth and Clark, 1998b) and also when using gamma scintigraphy (Newman et al., 
1984; Newman et al., 1991b). Newman et al. (1991) measured lung deposition in 
asthmatic subjects using both gamma scintigraphy and spirometry and reported that when 
subjects inhaled radiolabelled salbutamol from a MDI and a MDI attached to a large 
volume spacer the total lung deposition was 12.3 and 23.1% (of the dose), respectively, 
whilst, there was no difference in spirometry measurements (Newman et al., 1991b). The 
large inter-subject variability in the response to inhaled methacoline dosing 
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bronchoprovocation studies indicates that larger numbers need to be used in this type of 
bioequivalence study. Furthermore the bronchoprovocation agents may stimulate 
different receptors to those of the drug studied causing deterioration of lung function 
(Chrystyn, 2001; Barry and O'Callaghan, 2003).  
In summary, the clinical response data should be combined with lung deposition data, in 
order to provide a much better assessment of inhaled drug delivery. 
2.6.4. In-vitro methods 
The particle size of inhalation aerosols is one of the key factors that governs the site and 
extent of drug deposition in the human respiratory tract and consequently affects its 
elicited clinical response. Therefore, in-vitro studies have been used extensively to reach 
a judgement about the relative efficiencies of different inhalation delivery systems 
(Bisgaard, 1996; Pauwels et al., 1997a; Weda et al., 2000). They are characterised by 
their relative ease of operation, high power to detect differences and the relatively low 
variability in the measurements compared to in-vivo experiments. 
Several in-vitro studies have shown that the aerodynamic particle size distribution of 
inhalation aerosols correlates well with their in-vivo drug deposition in the lungs and can 
even predict clinically relevant differences in their systemic side effects (Zanen et al., 
1996; Leach et al., 2002; Weda et al., 2004). 
However, in-vitro studies can still be limited by the ability of the laboratory apparatus to 
mimic the complexity of the airway anatomy. In addition, it does not take into account 
patient handling factors and the difficulties that some patients have using their inhalers 
properly. Furthermore, in-vitro determinations use a fixed set of parameters that provides 
very consistent delivery at low variability and lacks inter- and intra-patient variability, 
which can greatly affect regional deposition in the lung. Thus, in-vitro measurements 
may not accurately predict the relative performance of drugs in-vivo and may even tend 
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to overestimate lung deposition (Holzner and Müller, 1995; Newman, 1998; Borgström 
et al., 2000; Newman et al., 2000b; Dunbar et al., 2002). Several gamma scintigraphic 
studies have shown that DPIs’ whole lung deposition expressed as percent metered dose 
averaged 1.5 times that of MDIs, despite similar in-vitro performance. As shown in 
figure 2.25 the data shows that MDIs and DPIs have, on average, similar FPFs, but that 
DPIs actually deposit more drug in the lungs (Newman et al., 2003).  
 
 
Figure 2.25: Comparison of in-vivo whole lung deposition data obtained by gamma 
scintigraphy and in-vitro fine particle fraction (FPF) data. Reproduced from (Newman et 
al., 2003). 
Although good description of particle size distribution of inhaled aerosols may give 
predictive information on its intrapulmonary behaviour, in-vivo pulmonary deposition 
studies will always be necessary to bridge between in-vitro measurements and the 
clinical effect. 
2.6.4.1. Characterisation of the emitted dose 
The aerodynamic particle size distribution (APSD) of an aerosol cloud defines where the 
particles in the cloud are to be deposited following inhalation. Therefore, the APSD 
together with the delivered dose is widely known as a critical quality attribute in the in-
vitro characterization of inhalation products. It is generally accepted that the 
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therapeutically effective particles should be in the range of 1-5µm. Above that range; 
particles tend to impact in mouth and throat and then swallowed. Below this range, 
particles will have the possibility to remain entrained in the airstream and then exhaled 
rather than deposition. 
Inertial separation techniques have been widely considered the instruments of choice for 
measuring the APSD of inhaled products based on their mass and inertia for both 
regulators and pharmacopoeias. These systems are the golden standard for in-vitro 
inhaler testing, because they yield mass fractions of the drug dose in aerodynamic size 
classes that are relevant to particle deposition in the human respiratory tract (De Boer et 
al., 2002; Mitchell and Nagel, 2003).  
The in-vitro methods vary from simple devices like the twin impinger to more complex 
apparatus with multiple collection stages including; the Multi-Stage Liquid Impinger 
(MSLI), the Andersen Cascade Impactor (ACI) and the more recently developed Next 
Generation Impactor (NGI) (Hickey, 2004; European Pharmacopoeia, 2005; British 
Pharmacopoeia, 2009). All these systems depend on the same principle, by which air is 
drawn through the system at a predetermined flow rate causing drug particles to be 
collected on a series of stages, each of which represents a certain size band. The stages 
are washed by a solvent to collect the drug and these solutions are analysed to obtain the 
mass of drug on each stage. Parameters such as the mass median aerodynamic diameter 
(MMAD), geometric standard deviation (GSD), fine particle fraction (FPF) and fine 
particle dose (FPD) are determined and used for comparisons of the in-vitro performance 
of different inhaler devices and drug combinations. The aerodynamic diameter of a given 
particle is defined as the diameter of a unit density sphere having the same settling 
velocity as the particle. The mass median aerodynamic diameter (MMAD) of an aerosol 
is the diameter that separates the mass of the particles equally by 50%. The GSD is a 
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measure of the polydispersity, or spread, of an aerosol. A monodisperse aerosol has a 
GSD of 1 and heterodisperse aerosol has a GSD greater than 1.2 (Newman, 1991). Of 
these parameters, the FPF and FPD have particular relevance, since they express 
respectively the percentage of the drug dose and the mass of drug contained in particles 
smaller than 5µm (respirable particles). The fine particle dose is the mass of particles less 
than 5µm, while the FPF can be represented as either the FPD divided by the nominal 
dose or by the emitted dose. This causes confusion because the nominal dose and the 
emitted dose are never the same. 
In general, the higher the fine particle dose, the higher the proportion of the emitted dose 
that is likely to reach the lung (Newman et al., 2000b; European Pharmacopoeia, 2004). 
Particles with a diameter less than 5µm are often said to constitute the respirable range 
which provide an estimate of the fraction of the dose that has the potential to be 
deposited in the lung (Dolovich, 1993; Barry and O'Callaghan, 2003) 
The reliability of Cascade Impactors data can be greatly influenced by several factors 
such as wall loss, particle bounce, and the nature of collection surfaces (Holzner and 
Müller, 1995; Dunbar and Mitchell, 2005; Kamiya et al., 2009). Upon contact with the 
collection plate, some particles may bounce due to impaction and be re-entrained into the 
airstream and carried to a lower stage. Several studies have found that coating of the 
collection surfaces of the Cascade Impactor with a media that provides a tacky surface 
(glycerol or silicone oil) is an appropriate precaution to minimize particle bounce and re-
entrainment, especially when testing dry powder inhalers (DPIs) (Dunbar and Mitchell, 
2005; United States Pharmacopeia, 2005; British Pharmacopoeia, 2009; Kamiya et al., 
2009; Copley, 2010). It may also be required for some formulations delivered by 
pressurized metered dose inhalers (pMDIs), especially when measurements are being 
made with a low number of actuations from the inhaler (Nasr et al., 1997). 
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2.6.4.1.1. Andersen Cascade Impactor 
The eight-stage Andersen Cascade Impactor (ACI) is widely used to characterize and 
control the aerodynamic particle size distribution emitted from therapeutic inhalation 
aerosols. The Andersen Cascade Impactor (ACI), illustrated in figure 2.26 is based on the 
assessment of the aerodynamic particle size of an emitted dose using a multi-stage 
approach yielding information about the mass fraction that has the potential to enter the 
deeper part of the lung. (European Pharmacopoeia, 2005; United States Pharmacopeia, 
2005; British Pharmacopoeia, 2009). 
 
Figure 2.26: Schematic diagram of ACI components (Dunbar and Mitchell, 2005). 
The ACI consists of a stack of eight plates with a series of precision drilled holes, and a 
final filter stage. They fractionate the incoming aerosol onto a series of stages arranged 
such that successively finer particles are removed as the aerosol passes through the 
instrument. Each stage of the impactor is associated with a cut-off diameter, a figure that 
defines the size of particles that are retained on the collection surface of that stage. All of 
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the particles above a certain size would be captured and those below it would pass 
through. At the end of the test, the amount of drug present on each collection stage is 
recovered using a suitable solvent and analysed. The ACI provides the required degree of 
resolution in the most important particle size range for inhalation products (0.5-5 µm). It 
operates at a flow rate of 28.3 L min-1 with cut-off diameters of 9, 5.8, 4.7, 3.3, 2.1, 1.1, 
0.7, and 0.4µm, respectively. It has also been modified to work at higher flow rate at 60 
and 90 L min-1 whilst retaining the 28.3 L min-1 cut-off diameters. As shown in table 2.3 
in the 60 L/min version, stages 0 and 7 are removed and replaced with two additional 
stages, -0 and -1. Similarly, in the 90L/min version, stages 0, 6, and 7 are removed and 
replaced with three additional stages, -0, -1, and -2. Changes are also made to the 
configuration of the collection plates (with and without centre holes).  
Stage Flow rate (L/min) 
28.3 60 90 
-2 ---- ---- 9.0 
-1 ---- 9.0 5.8 
-0 ---- 5.8 4.7 
0 9.0 - 10.0 ---- ---- 
1 5.8 - 9.0 4.7 3.3 
2 4.7 - 5.8 3.3 2.1 
3 3.3 - 4.7 2.1 1.1 
4 2.1 - 3.3 1.1 0.7 
5 1.1 - 2.1 0.7 0.4 
6 0.7 - 1.1 0.4 ---- 
7 0.4 - 0.7 --- ---- 
 
Table 2.3: Stage cut-off diameter values (µm) for the various configurations of the 
Andersen cascade impactor at different flow rates (Copley, 2010). 
Cascade Impactors have been extensively used for two distinct roles, the first is for 
quality control assessment of inhalers, and the second is for in-vitro bioequivalence 
studies of pulmonary drug products. The ACI is superior to both the twin impinger and 
the MSLI as it provides a more detailed particle size distribution of the aerosolised drug. 
As shown in figure 2.27, the particle size distribution obtained from the ACI simulates 
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the aerosol behaviour after leaving the inhaler and provides data that may be predictive 
of particle deposition in the respiratory tract (Weda et al., 2004; Dunbar and Mitchell, 
2005; Mitchell et al., 2007a; British Pharmacopoeia, 2009).  
 
Figure 2.27: Presentation of regional lung deposition relative to ACI size range (Dunbar 
and Mitchell, 2005). 
On MDI actuation, the drug dose delivered beyond the mouthpiece is typically separated 
into three fractions: the induction port deposition fraction (IPF), the coarse particle 
fraction (CPF), and the fine particle fraction (FPF). Induction port deposition 
approximates the drug that is deposited in the throat or mouth. The coarse particle 
fraction represents aerosol particles deposited in stages 0, 1, and 2 of the ACI. These 
large particles of 5-10 µm size deposit preferentially in the upper airways. The FPF 
represents aerosol particles deposited in stages 3, 4, and 5 of the ACI. These particles are 
1-5 µm in size and have a high probability of penetrating into the deep lung (Guo et al., 
2008). While, aerosol particle collected on stages 6 and 7 and in the final filter of the 
ACI correspond to particles less than 1µm in size (Asmus et al., 2003). 
The ACI values provide a direct link with the mass of therapeutically active 
pharmaceutical agent and particle aerodynamic size by the precise determination of the 
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MMAD and the GSD, which have been shown to greatly affect lung deposition 
efficiency (Martonen and Katz, 1993; Newman, 1998; Thorsson and Geller, 2005). 
However, there are some limitations to the Andersen Cascade Impactor data, as it cannot 
perfectly simulate the respiratory tract, since it operates at a constant flow rate, while the 
real respiratory cycle has more variable flow rates. In addition, deposition in the impactor 
is by inertial impaction only, whereas in the respiratory tract particle deposition is also 
affected by sedimentation and diffusion, especially for small particles in deep lung 
regions. Besides, the method uses a vacuum pump generating a square wave airflow 
profile unlike the sinusoidal pattern of human inspiration(De Boer et al., 2002). 
2.7. Inhaled corticosteroids 
Inhaled corticosteroids (ICS) are the standard controller medications for asthma in both 
adults and children and additionally they are used in COPD treatment. Inhaled 
corticosteroids (ICS) have a positive effect on lung function, symptoms, exercise 
capacity, and may decrease disease exacerbations. At present there are many inhaled 
corticosteroids used to varying degrees in different countries for asthma treatment, e.g., 
beclometasone dipropionate (BDP), budesonide (BUD) , fluticasone propionate (FP), 
triamcinolone acetonide (TA), flunisolide, mometasone furoate and ciclesonide (CIC) 
(Derendorf et al., 2006; Barnes, 2007). 
2.7.1. Mechanism of action 
As illustrated in figure 2.28, the broad anti-inflammatory profile of corticosteroids and 
their ability to interfere with the multiple pathways involved in the inflammatory process 
accounts for their marked clinical effectiveness in asthma (Pelaia et al., 2003). Inhaled 
corticosteroids elicit their effects by diffusion across the cell membrane and subsequent 
binding to cytoplasmic glucocorticoid receptors in target cells; promoting their activation 
and translocation to the cell nucleus, where they bind to specific DNA sequences that 
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repress transcription of inflammatory genes and promote transcription of anti-
inflammatory genes. 
 
              Figure 2.28: Cellular effects of corticosteroids (Barnes and Adcock, 2003). 
In addition, ICS markedly reduce the survival of certain inflammatory cells, such as 
eosinophils, decrease mucosal mast cells number, and decrease the immediate response 
to allergen and exercise (Barnes and Adcock, 2003; Derendorf et al., 2006; Sobande and 
Kercsmar, 2008).  
2.7.2. Adverse effects 
The ideal goal of all inhaled corticosteroids is to provide a localized and long lasting 
therapeutic effect at the pulmonary target, minimize oral bioavailability, and minimize 
local and systemic side effects in combination with a convenient and easy to use inhaler 
(Cerasoli, 2006; Barnes, 2007). The therapeutic benefit from ICS is often achieved at 
relatively low doses (Masoli et al., 2004b), thus ICS have a very favourable benefit-to-
risk ratio. However, despite their effectiveness and their improved safety profile relative 
to oral corticosteroids, there is still a concern about local (in the oropharyngeal cavity) 
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and systemic side effects (due to absorption of ICS into the circulation through the lungs 
and the GI tract), especially with high-dose and long-term use (Hanania et al., 1995; 
Kelly and Nelson, 2003). Although high pulmonary availability is required for efficacy, 
it may increase systemic absorption and the potential for unwanted side effects (Lipworth 
and Jackson, 2000; Barnes, 2007). However, these is not always the case, since higher 
lung deposition and more than double the systemic concentrations with 400µg/day HFA-
BDP formulations, were associated with even less adrenal suppression with a comparable 
efficacious dose of 800µg/day CFC-BDP. The reason behind the reduced systemic 
effects is not known. In addition, equivalent doses of each product showed no difference 
in adrenal suppression despite the dose potency difference (Harrison et al., 1999a; 
Harrison, 2002). The key in reducing the risk of adverse events and achieving an optimal 
balance between safety and efficacy is to titrate the maintenance dose of ICS to the 
lowest possible dose that achieves asthma control.  
2.7.2.1. Local side effects 
The main local adverse effects of ICSs are oral candidiasis, dysphonia, and pharyngitis, 
as well as cough at the time of inhalation (Allen et al., 2003; Kelly and Nelson, 2003). 
Oral candidiasis is a dose related side effect that is observed in 5% of treated patients and 
can be prevented by rinsing the mouth with water or using a spacer or if required 
additional topical antifungal therapy . The decreased oral deposition of ciclesonide has 
led to decreased incidence of local candidiasis of 1% compared to 11% with fluticasone 
(Pedersen et al., 2006; Sobande and Kercsmar, 2008). The cough is due to a local 
irritation and is often resolved by changing the delivery device, pre-treatment with a 
bronchodilator, using a valved holding chamber, or slowing the rate of inhalation 
(Hanania et al., 1995; Sobande and Kercsmar, 2008). Dysphonia is also observed in 
patients receiving ICS, and it appears to be a direct effect of ICS administration, as it was 
absent when the propellant or excipients were administered without the ICS (Toogood et 
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al., 1980). It is caused by steroid induced myopathy of laryngeal muscles and it is 
reversible with cessation of the drug. However, this problem can be easily resolved by 
using a spacer device or mouth rinsing after inhalation (Hanania et al., 1995; Zainudin, 
1997; Buhl, 2006).  
2.7.2.2. Systemic side effects 
There are two routes by which inhaled corticosteroids can enter the systemic circulation. 
The majority of the inhaled fraction that is delivered into the lung easily enters the 
pulmonary circulation and is systemically available before inactivation in the liver takes 
place. The fraction deposited in the oropharynx is swallowed and its systemic availability 
depends on the gastrointestinal absorption and first-pass effect in the liver. 
Systemic adverse effects are caused by long-term treatment with high doses of ICS. 
These systemic effects include, osteoporosis, skin thinning, skin bruising, cataracts, 
glaucoma, bone fractures, reduced bone mineral density, and suppression of 
hypothalamic-pituitary-adrenal axis function (HPA) (Kelly and Nelson, 2003; Cerasoli, 
2006; Irwin and Richardson, 2006). However, despite some safety concerns, the over-
riding evidence generally supports the conclusion that ICS are well tolerated and safe. At 
the recommended dosages, ICS produced  no clinically significant adverse effects on 
bone density (Lung Health Study Research Group, 2000; Calverley et al., 2007; 
Anthracopoulos, 2008; Iles et al., 2008) or on suppression of the hypothalamic-pituitary-
adrenal axis (The Childhood Asthma Management Program Research Group, 2000; 
Bisgaard et al., 2004; Martinovic, 2008; Skoner, 2008). In addition, inhaling steroids 
through spacers and mouth rinsing post inhalation may significantly reduce to some 
extent its local and systemic adverse effects (Selroos and Halme, 1991; Brown et al., 
1993; Trescoli and Ward, 1998).  
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2.7.3. Beclometasone dipropionate 
2.7.3.1. Chemical structure  
Beclometasone dipropionate was the first inhaled corticosteroid used for the treatment of 
asthma in adults and children. It was first used in 1972 in a pressurized metered dose 
inhaler and later in a dry powder inhaler and an aqueous nasal spray.  
 
         Figure 2.29: The structural formula of BDP, 17-BMP, 21-BMP, and BOH.            
2.7.3.2. Pharmacokinetics and pharmacodynamics of inhaled beclometasone 
dipropionate 
Pharmacokinetic (PK) and pharmacodynamic (PD) properties of ICS are directly related 
to safety and efficacy of the drug. The efficacy of an ICS is dependent on high 
glucocorticoid receptor binding, high pulmonary deposition and retention, enhanced 
lipophilicity, and lipid conjugation. Safety is optimised by low oral bioavailability, high 
protein binding and rapid systemic clearance (Derendorf et al., 2006; Quizon and Colin, 
2010). 
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2.7.3.2.1. Prodrug 
Beclometasone dipropionate is the parent compound and has low activity. As shown in 
figure 2.30, BDP is a prodrug that is metabolised by esterases in the human lung, liver 
and other parts of the body to three different metabolites, 17-beclometasone 
monopropionate (17-BMP), 21-beclometasone monopropionate (21-BMP) and 
beclometasone (BOH). 17-Beclometasone monopropionate (17-BMP) is the active 
metabolite whereas BOH and 21-BMP have a very low binding affinity to the 
glucocorticoid receptor (Foe et al., 2000; Derendorf et al., 2006; Rossi et al., 2007). This 
metabolism readily occurs in the lungs, hence, a high degree of pulmonary pre-systemic 
metabolism for BDP is essential for its topical activity in the lung (Wurthwein and 
Rohdewald, 1990).  
 
Figure 2.30: Major in-vivo degradation pathway for BDP and its main metabolites (Foe 
et al., 2000; Daley-Yates et al., 2001). 
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2.7.3.2.2. Receptor-binding affinity 
The pharmacological effect of ICS is mediated through binding to glucocorticoid 
receptors that are widely distributed throughout the body. The receptor binding affinity 
has implications for the clinical safety profile, since both positive effects in the lung and 
side effects of the drug are mediated through the same receptors. It was found that the 
relative receptor binding affinity of 17-BMP to the glucocorticoid receptor is 30 and 18 
times greater than the parent drug and BOH respectively, whereas 21-BMP is practically 
inactive. Therefore the anti-inflammatory activity of inhaled BDP is due mainly to the 
active metabolite 17-BMP, which is rapidly formed from the parent drug in lung tissues 
(Wurthwein and Rohdewald, 1990).  
2.7.3.2.3. Bioavailability 
Inhaled corticosteroids such as beclometasone dipropionate are intended to provide 
localized therapy in the lungs. There is a proportion of the ICS dose that is swallowed 
and systemically absorbed from the GI tract (oral bioavailability) and another proportion 
of the dose delivered to and absorbed by the lungs (pulmonary bioavailability). 
Consequently, the blood concentration of an ICS is a function of the sum of its 
pulmonary and orally absorbed fractions (Derendorf, 1997). The systemic bioavailability 
of an ICS has a very strong implication on the safety profile of the drug, since the orally 
absorbed fraction does not contribute to the beneficial pulmonary effects of the drug and 
only causes systemic side effects. It is advantageous, therefore, for the oral 
bioavailability of the ICS to be low. Inhaled BDP has a high systemic contribution from 
the swallowed fraction, due to its higher oral bioavailability and lower first pass 
inactivation compared to other ICS. The first pass inactivation values of BDP, 
fluticasone, and budesonide are 60-70%, 99, and 89% respectively (Lipworth, 1996; 
Trescoli and Ward, 1998).  
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The appearance of the new HFA-BDP formulations and the availability of adequate 
sensitive assays encouraged investigators to study the pharmacokinetics of inhaled BDP 
formulations.  
Several pharmacokinetic studies used serum BOH concentrations to investigate the 
pharmacokinetic properties of BDP due to the initial lack of the appropriately sensitive 
analytical methods for 17-BMP (Harrison et al., 1997; Soria et al., 1998). However, due 
to the fact that beclometasone is only a small component of the material in the serum as 
compared with beclometasone esters, further pharmacokinetic studies have developed 
methods to measure the total amount of beclometasone in a hydrolyzed sample. The total 
BOH in a sample after hydrolysis should represent the sum of any BDP, 17-BMP, 21-
BMP and BOH present (Seale and Harrison, 1998; Harrison et al., 1999a; Harrison et al., 
1999b).  
However, later on this approach was invalidated by a recent study by Daley-Yates et al 
(2001), who developed a sensitive assay to quantify 17-BMP and found that estimates of 
oral absorption and pulmonary bioavailability based on total BOH measurements were 
approximately half of those found for 17-BMP. Daley-Yates et al (2001), performed 
intravenous, intranasal, inhalation and oral studies to investigate 17-BMP 
pharmacokinetics. This study reported that following oral administration of BDP, either 
with or without activated charcoal, no unchanged BDP was detected in plasma while the 
total oral bioavailability of 17-BMP was 41% relative to an intravenous dose. However, 
the administration of traditional CFC-BDP by inhalation produced detectable 
concentrations of both BDP and BMP and the total inhaled bioavailability for 17-BMP 
was estimated as 62% relative to the intravenous dose. In addition, an oral charcoal 
procedure was used to differentiate the pulmonary absorbed and the orally absorbed 17-
BMP in the total systemic available 17-BMP. The lung and gut were assumed to 
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contribute 36% and 26% to the  systemic exposure, respectively (Daley-Yates et al., 
2001).  
Plasma levels of BDP post inhalation were very low due to its rapid hydrolysis to the 
active metabolite 17-BMP which is the main metabolite detected in plasma as indicated 
by several pharmacokinetic studies (Harrison et al., 2002a; Harrison et al., 2002b; 
Agertoft et al., 2003). However, it was surprising to find that the elimination of 17-BMP 
in plasma was not associated with a corresponding increase in BOH levels. These low 
levels of BOH in plasma may be explained either by that in-vivo 17-BMP is not 
eliminated primarily via metabolism to BOH or that BOH is very rapidly cleared from 
the plasma (Daley-Yates et al., 2001). 
Systemic absorption of unchanged BDP occurs mainly through the lungs with negligible 
oral absorption of the swallowed dose. The rapid hydrolysis of swallowed BDP to 17-
BMP will leave no intact BDP left after first pass metabolism and accounts for its 
negligible oral absorption. The charcoal block procedure did not affect the bioavailability 
of BDP, which confirmed the lack of oral absorption of unchanged BDP. Therefore, the 
detectable BDP after inhalation is due to the pulmonary-deposited BDP (Daley-Yates et 
al., 2001, Wang, 2003, Foe et al., 1998. On the other hand, the systemic absorption of 17-
BMP arises mainly from lung deposition and to lesser extent from oral absorption of the 
swallowed dose. Using, the charcoal block procedure, 17-BMP plasma levels were only 
slightly reduced (less than 20%), confirming that the pulmonary absorption is the main 
source of systemic exposure to 17-BMP. There is an approximately linear increase in 
systemic exposure with increasing inhaled dose (Woodcock et al., 2002a). 
The absence of detectable concentrations of BDP following oral administration is 
predictable due to its very high clearance, which leads to its extensive first pass 
metabolism. In contrast to BDP, the oral bioavailability of 17-BMP was high despite its 
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similar high clearance. These findings can be attributed to the predominance of systemic 
rather than first pass metabolism for 17-BMP elimination, While, the predominant 
elimination mechanism for BDP was through gut and hepatic metabolism (Daley-Yates 
et al., 2001). 
Several pharmacokinetic studies showed that the extent of appearance of beclometasone 
esters from HFA-BDP in the serum as measured by the AUC was approximately 2-2.5 
times greater following CFC-BDP. This can be explained due to the smaller particle size 
of HFA-BDP leading to its main lung deposition while most of the larger particle size 
CFC-BDP dose is swallowed and orally absorbed (Seale and Harrison, 1998; Harrison et 
al., 1999a; Harrison et al., 1999b; Harrison, 2002). This is in agreement with a previous 
pharmacokinetic study by Seale and Harrison (1998) who observed the poor orally 
bioavailability of beclometasone dipropionate as shown in figure 2.31. The same study 
also showed that Tmax for the oral route was later than for inhaled HFA-BDP, thus 
suggesting a slower absorption with the oral route. 
 
Figure 2.31: Inhaled HFA-BDP gives similar BOH concentration to 2.5 times the oral 
BDP dose (Seale and Harrison, 1998). 
The more enhanced efficacy of the newly formulated HFA-BDP formulations compared 
to their CFC-BDP counterparts may be attributed to their different metabolic profiles. 
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Hydrofluoroalkane beclometasone dipropionate (HFA-BDP) showed better activation 
efficiency in the lung (Wang, 2003) and  gave more of the active metabolite 17-BMP in 
the systemic circulation (after its main absorption from the lungs) in both adults 
(Harrison et al., 1999b; Lipworth and Jackson, 1999) and children (Agertoft et al., 2003). 
However, chlorofluorocarbon beclometasone dipropionate (CFC-BDP) gives mainly 
BOH in the systemic circulation after oral absorption and first pass metabolism in the 
liver (Seale and Harrison, 1998; Dekhuijzen and Honour, 2000; Wang, 2003).  
The extensive (95%) pre-systemic conversion of BDP to the potent and more hydrophilic 
degradation product 17-BMP leads to extensive absorption of the drug from the lower 
respiratory tract into the systemic circulation. However, the high therapeutic index of 
inhaled BDP despite its high systemic absorption may result from a combination of high 
local potency in the lung, rapid metabolic inactivation and rapid clearance of BDP and its 
metabolites, especially 17- BMP, that reach the systemic circulation. Also, 17-BMP as 
the active metabolite, showed very high plasma protein binding and tissue binding in the 
liver, lung and kidney, suggesting a possible reason for the low systemic side effect of 
long term BDP treatment for asthma (Foe et al., 2000; Wang, 2003). Moreover, the high 
clearance values reported for both BDP and 17-BMP resulted in a very low accumulation 
ratio after multiple dosing with HFA-BDP (Seale and Harrison, 1998; Harrison et al., 
1999a). Seale and Harrison (1998) examined the pharmacokinetics of total BOH 
measured following the first and 27th steady state doses of three HFA-BDP dose levels 
administered twice daily for 14 days. As shown in figure 2.32, the small difference seen 
in total BOH serum concentrations confirmed the little accumulation on multiple dosing 
and the good proportionality of the pharmacokinetic parameters for the three HFA-BDP 
doses studied.  
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Figure 2.32: Comparison of total BOH Cmax values on day 1 (single dose) and day 14 
(steady state, reproduced from (Seale and Harrison, 1998). 
This is in contrast to fluticasone propionate which has longer elimination half life; 
extensive tissue binding and prolonged receptor binding (Clark and Lipworth, 1997) that 
caused significant drug accumulation in plasma upon multiple dosing and hence an 
increased systemic safety risk (Thorsson et al., 1997). Irrespective of the route of 
administration (injection, oral or inhalation), BDP and its metabolites are mainly 
excreted in the faeces by biliary elimination while, approximately about 15 % of the dose 
is excreted as free and conjugated polar metabolites in the urine (Foye et al., 2008). 
2.8. Summary 
Inhaled corticosteroids are used extensively in the management of asthma and COPD. 
Beclometasone dipropionate is the first inhaled corticosteroid and it is widely prescribed. 
Beclometasone dipropionate MDIs have now been formulated with the ozone friendly 
HFA-propellants. This has resulted in two BDP MDIs with different dose 
recommendations, such that the MHRA has recommended that they should be prescribed 
by brand name and not generic. A urinary pharmacokinetic method has been applied to 
inhaled drugs to identify the relative lung and systemic bioavailability after an inhalation. 
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The feasibility of extending this urinary pharmacokinetic method for inhaled BDP needs 
to be investigated.  
Similarly, the in-vitro aerodynamic particle size distribution of the dose emitted from the 
inhalation methods need to be determined to identify if these measurements can be 
related to in-vivo measurements of lung and systemic delivery. The application of this 
method could be demonstrated by comparing these two MDI formulations and 
investigate the effect of spacers. 
  
 
 
 
 
Chapter 3: HPLC Materials and Methods
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3.1 Introduction 
Inhaled corticosteroids provide a favourable benefit/risk ratio for many therapeutic 
applications due to the low inhaled doses together with the large volume of distribution 
of these drugs. The resultant low plasma drug concentrations achieved, necessitate the 
use of highly sensitive analytical methods. This renders the evaluation of corticosteroid 
pharmacokinetics (PK) following inhaled administration a significant challenge. The 
concentrations of these drugs in urine are much higher and offer a much better 
assessment for lung and systemic bioavailability after an inhalation (Hindle and 
Chrystyn, 1992; Derendorf et al., 2001; Qu et al., 2007). Methods using liquid 
chromatography coupled to mass spectrometry (LC/MS) have been found to be useful 
techniques for solving the problem of corticosteroids analysis. This technique has been 
applied for the quantification of corticosteroids in biological fluids with high selectivity 
and sensitivity (Pujos et al., 2005). Previous attempts to measure the plasma systemic 
concentrations of BDP post administration relied on the conversion of BDP and 17-BMP 
to BOH, prior to measurement of total BOH (Harrison et al., 1997; Soria et al., 1998; 
Harrison et al., 1999b). However, this approach appeared to be not reliable and 
underestimated BDP oral and lung bioavailability. The use of total BOH data for 
pharmacokinetics data analysis is not accurate as some BDP would be counted more than 
once (as BDP and again after conversion to 17-BMP and BOH metabolites) and it is also 
unlikely that BDP, 17-BMP and BOH have the same clearance values (Daley-Yates et 
al., 2001). Several liquid chromatographic mass spectrometric methods (LC-MS) have 
been developed and validated for simultaneously quantifying BDP and its metabolites in 
rat and human plasma (Daley-Yates et al., 2001; Harrison et al., 2002a; Wang and 
Hochhaus, 2004) and in equine plasma and urine (Guan et al., 2003) for studying its 
detailed pharmacokinetics.  
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The aim of the work in this section was to develop a sensitive, robust, and reliable LC-
MS assay for the determination of beclometasone dipropionate and its metabolites in 
methanolic samples for in-vitro testing of inhaled products and in human urine samples 
following oral and inhaled administrations to subjects. This method could, therefore be 
used to study the relative deposition of the drug in the lung. A solid phase extraction 
method was developed to separate and isolate BDP, 17-BMP and BOH from urine matrix 
interferences. 
3.2 Analysis of beclometasone dipropionate in methanolic samples 
3.2.1 Experimental 
3.2.1.1 Chemicals 
Beclometasone dipropionate (BDP): supplied by GlaxoSmithKline (GSK), UK. 
Fluticasone propionate (FP): supplied by GlaxoSmithKline, (GSK), UK. 
Methanol: HPLC grade; supplied by Fisher Scientific (UK). 
3.2.1.2 Mobile phase 
Acetonitrile: HPLC grade; supplied by Fisher Scientific (UK). 
Water: HPLC grade; supplied by Fisher Scientific (UK). 
3.2.1.3 Chromatographic conditions 
Column: Sphereclone ODS (2) 5µm column, 2x250mm, Phenomenex, UK. 
Mobile phase:  Acetonitrile: water in the ratio of 60:40% v/v. The mobile phase was                   
filtered through a 45mm membrane filter with a pore size of 0.45µm (Vaccubrand, UK) 
and degassed under vacuum in an ultrasonic bath for 10 minutes prior to use.  
Flow rate:          0.3ml/minute.  
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Pump: Merck Hitatchi L-6200 A (intelligent pump). 
Injector: Rheodyne 7125 fitted with 150µl loop. 
Temperature: Ambient temperature. 
Mass spectrometer: Bruker Esquire HCT ion trap mass spectrometer.  
Electrospray ionization source: positive ion source. 
Desolvation temperature: 280 ºC. 
Capillary and skimmer voltages:  4.0 kV and 40V respectively. 
3.2.1.4 Preparation of standards 
Each stock standard solution (1µg/ml) of beclometasone dipropionate (BDP) and the 
internal standard fluticasone propionate (FP) was prepared by dissolving the dry 
chemical powder in HPLC-grade methanol and stored at 4ºC. From the BDP stock 
solution, working standards were prepared by serial dilution to yield nominal 
beclometasone dipropionate concentrations of 30, 50, 70, 90, 100, 120, 140, and 
160ng/ml (w/v). Working solutions were stored at 4ºC in well closed containers. From 
the FP stock solution, a working solution of 90ng/ml was prepared by dilution with 
methanol and stored at 4ºC. Stability studies through three thawing cycles, over 24 hours 
at room temperature and over 2 months at -20ºC showed no significant change in the 
analyte concentration.  
3.2.2 Results 
3.2.2.1 Calibration 
An eight-point calibration curve was made using eight beclometasone dipropionate 
standards between 30ng/ml and 160ng/ml of BDP with 90ng/ml fluticasone propionate as 
the internal standard. Each standard was injected three times on three different days. The 
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peak area ratio of the extracted ion chromatogram of pseudo-molecular ions of 
beclometasone dipropionate (521.2m/z ratio) and the extracted ion chromatogram of 
pseudo-molecular ions of the internal standard fluticasone propionate (501m/z ratio) was 
plotted against the nominal concentration (x) of the calibration standards. A straight line 
was fitted to the data using linear regression. A representative plot, described by the 
equation y = 0.0184x-0.0689 (r2=0.9986) was obtained as in figure 3.1. A representative 
chromatogram is shown in figure 3.2. The detector response was found to be linear over 
the concentrations range used with correlation coefficient of ≥ 0.9986. 
 
Figure 3.1: A representative calibration curve of the peak area ratio of beclometasone 
dipropionate and fluticasone propionate against the concentration of beclometasone 
dipropionate. 
 
Figure 3.2: Extracted ion chromatogram obtained from the analysis of standard samples 
containing 120ng/ml beclometasone dipropionate (BDP), and 90ng/ml fluticasone 
propionate (FP). 
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3.2.2.2 Validation 
The analytical method validation was carried out according to ICH method validation 
guidelines (ICH, 1994). 
3.2.2.2.1 Precision 
According to ICH and FDA guidelines, precision is the closeness of agreement (degree 
of scatter) between a series of individual measurements obtained from multiple sampling 
of the same homogenous sample under the prescribed conditions (ICH, 1994; Food and 
Drug Administration (FDA), 2001). While the term precision relates to the concept of 
variation around a central value, imprecision is actually, what is measured. For a normal 
distribution, the measure of imprecision is the standard deviation (SD). The precision 
determined at each concentration level should not exceed 15% of the coefficient of 
variation (CV), except for the LOQ, where it should not exceed 20% (Chesher, 2008). 
The precision of the assay was determined by injecting three concentrations of BDP (low 
35, medium 80 and high 150ng/ml) five times on the same day to determine the intra-day 
variation. The same experiment was repeated on five different days to determine the 
inter-day variation. The intra-day and inter-day variation, expressed as the coefficient of 
variation in peak area ratio, were calculated by dividing the standard deviation of the 
calculated concentrations by the mean concentration and multiplying by hundred. The 
intra-day assay variability, determined for the three standard concentrations of BDP on 
five occasions and the inter-day assay variability, determined at the same three 
concentrations and repeated for five different days are illustrated in table 3.1.  
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Table 3.1: Precision of the assay, (n=5). 
 
 
 
 
3.2.2.2.2 Accuracy 
The accuracy of an analytical method describes the closeness of the test results obtained 
by the method to the true value (concentration of the analyte). Accuracy is determined by 
replicate analysis of a sample containing known amounts of the analyte. Accuracy should 
be measured using a minimum of five determinations per concentration. A minimum of 
three concentrations in the range of expected concentrations is recommended (Food and 
Drug Administration (FDA), 2001).The accuracy of the assay was calculated as the 
percentage ratio of the measured concentration (obtained from the linear regression line 
over the concentration range investigated) to the nominal concentration. The results are 
shown in table 3.2. 
Table 3.2: Accuracy of the assay, (n=5). 
Nominal Concentration 
(ng/ml) 
Mean ±SD ng/ml of 
measured Concentration  
Mean ±SD % of measured 
Concentration 
(Accuracy) 
Intra-assay variation 
35 33.4 ± 2.6 95.5 ± 7.3 
80 73.2 ± 2.4 91.5 ± 3 
150 143.1 ± 4.7 95.4 ± 3.1 
Inter-assay variation 
35 35.7 ± 3.2 102.1 ± 9.2 
80 78.2 ± 4.5 97.8 ± 5.6 
150 144.4 ± 14.7 96.2 ± 9.8 
 
 
 
Nominal BDP 
Concentration (ng/ml) Intra-day %CV  Inter-day %CV  
35 11.1 12.2 
80 5.5 7.2 
150 7.0 10.6 
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3.2.2.2.3 Detection and quantification limits 
According to ICH guidelines, the limit of detection (LOD) is defined as the lowest 
concentration of an analyte in a sample that can be detected but not quantified. The limit 
of quantification (LOQ) is the lowest amount of analyte in a sample that can be 
quantitatively determined with suitable precision and accuracy under the standard 
operational conditions of the method. The ICH has listed two options available to 
determine both the LOD and the LOQ of an assay. One of these options are expressed as 
a concentration at a specified signal to noise ratio, usually 3:1 and 10:1 for the signal to 
noise ratio for LOD and LOQ respectively. The LOD and LOQ may also be calculated 
based on the standard deviation of the response (SD) and the slope (S) of five calibration 
curves using the linear regression method. The LOD and LOQ are calculated according 
to the following equations: The LOD = 3.3 (SD/S) and the LOQ = 10 (SD/S). The 
standard deviation of the response can be determined based on the standard deviation of 
y-intercepts of regression lines (ICH, 1994). The linear regression line method was used 
here to determine LOD and LOQ. The LOD and LOQ of beclometasone dipropionate 
with 10µl injection volumes were 6.3ng/ml and 19.0ng/ml, respectively. 
3.2.3 Conclusion 
According to ICH guidelines, the LC-MS assay developed in this section for the 
determination of beclometasone dipropionate in methanolic samples was found to be 
simple, sensitive and have acceptable limits for both accuracy and precision and has been 
successfully used to analyze samples from this study, and other subsequent studies. 
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3.3 Analysis of beclometasone dipropionate and its metabolites in human urine  
 
3.3.1 Experimental 
3.3.1.1 Chemicals 
Beclometasone dipropionate (BDP): supplied by GlaxoSmithKline (GSK), UK. 
 Fluticasone propionate (FP): supplied by GlaxoSmithKline, (GSK), UK. 
17-Beclometasone monopropionate (17-BMP): supplied by GlaxoSmithKline, (GSK), 
UK. 
Beclometasone (BOH): supplied by GlaxoSmithKline, (GSK), UK. 
Methanol: HPLC grade; supplied by Fisher Scientific (UK). 
3.3.1.2 Mobile phase 
Acetonitrile: HPLC grade; supplied by Fisher Scientific (UK). 
Water: HPLC grade; supplied by Fisher Scientific (UK). 
3.3.1.3 Solid phase extraction 
Solid phase extraction cartridge: DSC-CN (cyanopropyl), 3ml/500mg, (Supelco, UK). 
Extraction station: VAC-ELUT 10 manifold (Varian limited, UK). 
Sample concentrator: Savant DNA 120, Speed Vac concentrator (Thermo Electron 
Corporation). 
Methanol: HPLC grade; supplied by Fisher Scientific (UK). 
Water: HPLC grade; supplied by Fisher Scientific (UK). 
3.3.1.4 Chromatographic conditions 
Column:    Sphereclone ODS (2) 5µm column, 2x250mm, Phenomenex, UK. 
106 
 
Mobile phase:  acetonitrile: water in the ratio of 60:40% v/v. The mobile phase was 
filtered through a 45mm membrane filter with a pore size of 0.45µm (Vaccubrand, UK) 
and degassed under vacuum in an ultrasonic bath for 10 minutes prior to use.  
 Flow rate:          0.3ml/minute.  
Pump: Merck Hitatchi L-6200 A (intelligent pump). 
Injector: Rheodyne 7125 fitted with 150µl loop. 
Temperature: ambient temperature. 
Mass spectrometer: Bruker Esquire HCT ion trap mass spectrometer. 
Electrospray ionization source: positive ion source. 
Desolvation temperature: 280 ºC. 
Capillary and skimmer voltages:  4.0 kV and 40V respectively. 
3.3.2 Methodology 
3.3.2.1 Preparation of standards 
Primary stock solutions (1µg/ml) were prepared by dissolving beclometasone 
dipropionate, 17-beclomethasone monopropionate, beclometasone and fluticasone 
propionate (the internal standard) in HPLC-grade methanol. These were each stored at 
4ºC. From the BDP, 17-BMP and BOH stock solutions, working standards were prepared 
by serial dilution using pooled 24 hour urine collected from six volunteers (3 females) to 
yield nominal concentrations of 30, 50, 70,  90, 100, 120, 140 and 160ng/ml. Working 
solutions were stored at -20ºC prior to analysis. Stability studies through three thawing 
cycles, over 24 hours at room temperature and over 2 months at -20ºC showed no 
significant change in the analyte concentrations. 
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3.3.2.2 Solid phase extraction method (SPE) 
Analysis of drugs in biological fluids such as plasma or urine usually requires an initial 
pre-treatment step, in order to remove endogenous interfering compounds that may 
otherwise interfere with the assay and block the column. Techniques such as liquid-liquid 
and solid phase extraction are frequently used. Solid-phase extraction (SPE) is a 
separation process by which analytes of interest are isolated from a wide variety of 
matrices, including urine, blood, water, beverages, soil, and animal tissue according to 
their physical and chemical properties. In SPE, a liquid sample is passed through a 
sorbent bed where analytes of interest are adsorbed while; other interfering compounds 
can be easily removed from the column by washing with suitable solvents. The desired 
analytes are then eluted from the column by using an appropriate elution solvent giving a 
highly pure sample.  
The HPLC applications group of Supelco (2003) have developed a systematic extraction 
method for the recovery of steroidal compounds from urine. They compared the recovery 
of corticosteroids in urine from both conventional C18 and DSC-CN SPE cartridges. 
They reported that the subsequent eluate analysis of the C18 SPE urine extracts carried a 
yellow tint signifying insufficient removal of endogenous urine interferences and led to 
HPLC system failure due to high backpressure early in the run sequence. In contrast, the 
DSC-CN SPE provided cleaner chromatograms with good recoveries. 
The solid phase extraction method using Discovery DSC-CN (monomerically bonded 
cyanopropyl chain) solid phase extraction cartridges developed by Supelco (2003) was 
applied in this study to extract BDP, 17-BMP and BOH from urine samples. The 
cartridges were prepared on a VAC Elut workstation (Varian limited, UK), allowing up 
to ten samples to be processed at the same time. The urine sample was first pre-treated by 
adding a 1ml urine sample to 1ml of the working concentration of the internal standard 
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and then diluted 1ml of HPLC grade water. Each DSC-CN cartridge was first 
conditioned with 3 ml methanol followed by equilibration with 3 ml HPLC grade water. 
This initial conditioning step is essential to wet the sorbent bed and ensure its interaction 
with the compounds of interest in the sample. Then 3ml of the pre-treated urine sample 
was then loaded to the cartridge and drawn through over 2-3 minutes. Interfering 
compounds were then removed by washing with 3ml 20% methanol. The column was 
then dried under a full vacuum for 5 minutes prior to elution with 1ml 100% methanol. 
After evaporating to dryness using a sample concentrator with a stream of nitrogen, the 
residue was reconstituted with 100µl of the mobile phase prior to injection and 10µl was 
injected into the LC-MS system. 
3.3.3 Results 
3.3.3.1 Calibration 
An eight-point calibration curve was performed using eight urine samples containing 
standards between 30ng/ml and 160ng/ml of BDP, 17-BMP and BOH with 90ng/ml 
fluticasone propionate as the internal standard. Each standard was injected three times on 
three different days and averages were used to construct the calibration curve.  
The peak area ratio of the extracted ion chromatograms of the pseudo-molecular ions of 
BDP (521.2m/z ratio), 17-BMP (465m/z ratio) and BOH (409m/z ratio) and the extracted 
ion chromatogram of the pseudo-molecular ion of the internal standard FP (501m/z ratio) 
(y) were plotted against the nominal concentration of the calibration standards (x). A 
straight line was fitted to the data using linear regression. The calibration curves obtained 
for BDP, 17-BMP and BOH when using fluticasone propionate (FP) as the internal 
standard are presented in figure 3.3. Figure 3.4 and figure 3.5 show the typical 
chromatograms for human blank urine and a human urine standard containing 100ng/ml 
BDP, 17-BMP and BOH and 90ng/ml I.S. The analysis time was 10 minutes and the 
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retention time for BDP, 17-BMP, BOH, and FP were 8.22, 3.98, 2.45, and 6.14 minutes 
respectively. Representative mass spectra are shown in figure 3.6. The detector response 
was found to be linear over the concentrations range used. 
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Figure 3.3:  A representative calibration curve of the peak area ratio of the extracted ion 
chromatogram of (a) BDP/FP against the concentration of BDP (b) 17-BMP/FP against 
the concentration of 17-BMP (c) BOH/FP against the concentration of BOH. 
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Figure 3.4: (a) Total ion chromatogram obtained from the analysis of an extracted blank 
urine sample, extracted ion chromatogram obtained from the analysis of (b) a standard 
urine sample containing 100ng/ml BOH (c) a standard urine sample containing 100ng/ml 
17-BMP (d) a standard urine sample containing 100ng/ml BDP (e) a standard urine 
sample containing 90ng/ml FP. 
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Figure 3.5: (a) Total ion chromatogram (b) extracted ion chromatogram of a volunteer 
urine sample 0-0.5hr post-inhalation of eight doses of beclometasone dipropionate from 
Clenil® Modulite MDI (250µg). 
 
 
 
 
 
(a) 
(b) 
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Figure 3.6: Positive ion mass spectrum of (a) beclometasone dipropionate (b) 17-
beclometasone monopropionate (c) beclometasone, and (d) fluticasone propionate. 
3.3.3.2 Validation 
3.3.3.2.1 Recovery 
Corticosteroids are characterised by a planar and relatively rigid configuration that 
contains a steroid nucleus with four fused rings, thus the aqueous nature of the sample 
matrix and the hydrophobic character of the analytes offers an excellent opportunity for 
reversed-phase retention. Most solid phase extraction methods use popular reversed 
phase chemistry such as DSC-18 cartridges due to their broad affinity for a wide range of 
compounds in aqueous solutions. However when dealing with contaminant rich samples 
114 
 
such as urine, their broad selectivity can lead to co-retention and elution of endogenous 
matrix interferences. However, the use of the less hydrophobic and more selective phase 
chemistry such as a cyanopropyl (CN) bonded silica bed as in this study can be more 
beneficial in discriminating between the analytes of interest and endogenous sample 
interferences (Supelco, 2003). The recovery of BDP, 17-BMP and BOH was determined 
by repeated solid phase extraction (n=3) of three quality control standards selected at 
high, mid and low points of the calibration range (35, 80 and 150ng/ml). The recovery 
was calculated by comparing the peak area of BDP, 17-BMP and BOH urine extracts to 
the peak area of BDP, 17-BMP and BOH obtained with the direct injection of methanolic 
standards assuming 100% recovery in order to provide an estimate of the extraction 
recovery. The results are illustrated in table 3.3. The same method was used to assess the 
recovery of the internal standard fluticasone propionate at the working concentration 
90ng/ml, the mean (SD) % relative recovery for FP was found to be 94.3 (1.6) %. 
Table 3.3: Recovery data of BDP, 17-BMP and BOH, (n=3). 
Nominal 
Concentration 
(ng/mL) 
% Relative Recovery  (%RR) 
BDP 17-BMP BOH 
% RR %CV % RR %CV % RR %CV 
35 95.3 2.6 89.6 4.5 94.1 2.0 
80 92.2 1.6 92.3 3.2 90.5 1.9 
150 94.4 1.1 90.8 4.3 93.6 2.9 
 
3.3.3.2.2 Precision 
The precision of the assay was determined by injecting three concentrations of BDP, 17-
BMP and BOH (low 35, medium 80 and high 150ng/ml) five times on the same day to 
determine the intra-day variation. The same experiment was repeated on five different 
days to determine the inter-day variation. The intra-day and inter-day variation were 
assessed as the coefficient of variation in peak area ratio. The results are illustrated in 
table 3.4. 
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Table 3.4: Precision of the assay, (n=5). 
 
3.3.3.2.3 Accuracy 
The accuracy of the assay was calculated as the percentage ratio of the measured 
concentration (obtained from the linear regression line over the concentration range 
investigated) to the nominal concentration. The Accuracy of the assay using FP as an 
internal standard is shown in tables 3.5.  
Table 3.5: Accuracy of the assay using FP as an internal standard, (n=5). 
 
 
3.3.3.2.4 Detection and Quantification limits 
The limit of detection (LOD) and the limit of quantification (LOQ) were calculated from 
the mean of the slope and SD of the intercept of five calibration curves when using 
fluticasone propionate as the internal standard. The LOD of BDP, 17-BMP, and BOH 
urine samples were 4.4, 3.6, and 6.6ng/ml, respectively. The LOQ of BDP, 17-BMP, and 
BOH urine samples were 13.3, 11.1, and 19.7ng/ml, respectively. 
Nominal 
concentration 
(ng/ml) 
BDP 17-BMP BOH 
Intra-day 
%CV 
Inter-day 
%CV 
Intra-day 
%CV 
Inter-day 
%CV 
Intra-day 
%CV 
Inter-day 
%CV 
35 9.6 11.3 12.6 13.3 9.4 13.2 
80 4.4 5.9 7.2 9.1 7.1 10.4 
150 4.6 7.3 6.5 8.0 11.7 13.1 
Nominal 
Conc 
(ng/ml) 
BDP 17-BMP BOH 
Mean ± SD 
measured 
Conc 
(ng/ml) 
Mean ± SD 
% 
measured 
Conc 
 
Mean ± SD 
measured 
Conc 
(ng/ml) 
Mean ± SD 
% of 
measured 
Conc 
 
Mean ± SD 
measured 
Conc 
(ng/ml) 
Mean ± SD 
% of 
measured 
Conc 
 Intra-assay variation 
35 34.6 ± 3.5 98.7 ± 10.0 35.7 ± 2.6 102.1 ± 7.5 34.0 ± 1.6 97.3 ± 4.7 
80 78.3 ± 2.4 97.8 ± 3.0 82.1 ± 6.6 102.6 ± 8.3 78.7 ± 2.0 98.3 ± 2.5 
150 141.2 ± 8.7 94.1 ± 5.8 148 ± 5.7 98.8 ± 3.8 150.7 ± 15.0 100.5 ± 10.0 
Inter-assay variation 
35 36.6 ± 3.0 104.6 ± 8.5 32.7 ± 4.4 93.4 ± 12.5 36.3 ± 3.2 103.6 ± 9.1 
80 83.5 ± 4.5 104.4 ± 5.6 77.2 ± 3.6 96.4 ± 4.5 76.8 ± 4.5 96.0 ± 5.6 
150 152.2 ± 13.3 101.5 ± 8.9 155.5 ± 9.4 103.7 ± 6.3 160 ± 8.0 106.7 ± 5.3 
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3.3.3.2.5 Stability 
Freeze and thaw stability for BDP, 17-BMP and BOH in urine matrix, were determined 
after three freeze and thaw cycles by analyzing triplicate quality control samples at the 
concentrations of 35, 80, and 150ng/ml. The samples were frozen for 24 hours at -20ºC, 
and then left to thaw unassisted at room temperature; when completely thawed, the 
samples should be refrozen again for 24 hours under the same conditions, the process is 
again repeated, and the sample is analyzed on the third cycle. The short-term stability of 
the analytes was evaluated at the same concentrations after the samples were thawed and 
kept at room temperature for 24 hours. The long-term stability was evaluated after 
storing the above-mentioned concentrations at -20ºC for 2 months. Stability was 
expressed as the percentage ratio of measured concentration to the nominal 
concentration; the results are shown in table 3.6. 
Table 3.6: Stability of BDP, 17-BMP and BOH under various conditions, (n=3). 
 
3.3.4 Conclusion 
A simple, sensitive and selective LC-(ESI+)-MS method was developed using a solid 
phase extraction procedure for simultaneously quantifying BDP and its two metabolites 
17-BMP and BOH in human urine samples and suitable for routine clinical studies. 
Positive ESI (ESI+) was chosen for the better sensitivity. The solid phase extraction 
method using Discovery DSC-CN cartridges was successfully applied in this study to 
extract BDP, 17-BMP, and BOH from urine samples. No significant interferences were 
 
Nominal concentration (ng/ml) 
BDP 17-BMP BOH 
35 80 150 35 80 150 35 80 150 
Freeze-thaw 
(Three cycles) 
95.6 
(5.1) 
94.6 
(3.8) 
93.6  
(2.5) 
90.6 
(4.2) 
89.6  
(3.6) 
91.3  
(4.8) 
93.6 
(7.1) 
90.7  
(1.8) 
94.3  
(5.9) 
Short term stability 
(24 hours) 
91.8  
(3.84) 
89.6  
(5.8) 
92.6 
(5.8) 
93.3  
(7.0) 
90.6  
(3.9) 
88.9  
(3.6) 
90.9  
(4.6) 
92.9  
(3.6) 
94.6  
(6.0) 
Long term stability 
(2 months) 
89.6  
(1.9) 
85.9  
(7.6) 
87.9  
(5.2) 
85.6  
(3.9) 
90.9  
97.0) 
88.9% 
(1.1) 
90.3 
(2.6) 
91.6  
(7.1) 
86.9  
(2.5) 
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observed at the retention times of BDP, 17-BMP and BOH and the internal standard FP 
in urine samples. Validation results have shown that the method has acceptable limits for 
both accuracy and precision (±15%) and has been successfully used to analyze samples 
from this study and subsequent studies. Fluticasone propionate can be used as the internal 
standard for all volunteers’ urine samples. The calibration curves obtained with this LC-
MS method were linear over the concentration range used. The SPE method was found to 
be reproducible and efficient as the recoveries were within the acceptable limits (± 15%). 
The stability results showed that the three analytes were stable under the conditions 
investigated in this study since the measured concentrations were all within 85-115% of 
nominal concentrations. 
3.4 Preparative chromatography to produce the metabolites of beclometasone  
Beclometasone dipropionate is a widely used inhaled corticosteroid for the inhalation 
therapy of asthma in both adults and children. Owing to the presence of the dipropionate 
ester functional group in its side chain, it is easily hydrolysed via esterases in the human 
lung, liver and other parts of the body to the more polar products 17-beclometasone 
monopropionate (17-BMP), 21-beclometasone monopropionate (21-BMP) and 
beclometasone (BOH). 17-beclometasone monopropionate is the active metabolite, 
whereas both 21-BMP and BOH have very low binding affinity to the glucocorticoid 
receptor. In this experiment, we reported the in-vitro hydrolysis of BDP using esterase 
enzyme as well as the isolation and characterisation of its degradation product.  
3.4.1 Chemicals 
Beclometasone dipropionate (BDP): supplied by GlaxoSmithKline (GSK), UK. 
Esterase enzyme: from porcine liver, supplied by Sigma, UK. 
Ethanol: HPLC grade; supplied by Fisher Scientific (UK). 
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Methanol: HPLC grade; supplied by Fisher Scientific (UK). 
Acetonitrile: HPLC grade; supplied by Fisher Scientific (UK). 
Water: HPLC grade; supplied by Fisher Scientific (UK). 
3.4.2 Methodology 
Incubation studies for metabolite preparation, separation and identification was first 
initiated by adding the solid esterase to a solution of BDP in ethanol / water (1:99 v/v) in 
order to yield a final concentration of 0.17mg/ml. This solution was incubated in a water 
bath shielded from light at 37ºC for 20hr. After incubation, the enzyme was removed 
using a 10.000 MWCO size-exclusion cartridge (Microcon, Millipore) by centrifugation 
and discarding the upper portion. Then the lower liquid portion was diluted with 
methanol to the desired concentration and the final product was purified by preparative 
HPLC. The gradient elution of metabolites were performed on a Dynamax C18 (21.4 mm 
X 250mm) column, the mobile phase used was acetonitrile: water (75: 25%) and the flow 
rate 10ml/min with UV detection at 240nm. The major peak was collected, freeze dried, 
and then reconstituted in 650µl deuterated solvent (d4-methanol) for 1H-NMR analysis. 
The NMR spectrum was recorded on a Bruker Avance NMR spectrometer operated at 
500MHz. 
3.4.3 Results 
The 1H-NMR spectrum of BDP and that of the hydrolysis reaction product is shown in 
figure 3.7 (a) and (b), respectively. As shown in Figure 3.7 (a) the signals corresponding 
to the protons in the 17- and 21-propionate groups of BDP appear at 2.43 ppm (CH2, 5H) 
and 1.12 ppm (CH3, 6H). The chemical shifts of these moieties are close together since 
their chemical environments are similar. On inspection of the signals from the enzyme 
hydrolysis product shown in figure 3.7 (b), it can be seen that one signal in each 
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environment has disappeared. Inspection of the integrals shows that two protons have 
been lost from the signal at 2.43 ppm and three from the signal at 1.12 ppm; this is 
consistent with cleavage of a propionate group. Evidence for the formation of 17-BMP 
(as opposed to the 21-BMP isomer) is provided by inspection of the signals for the 
protons at position 21 in the molecule. In the spectrum of BDP (top spectrum), these 
signals appear as doublets at 4.81 and 4.42 ppm (both 1H) indicating that the two protons 
of the CH2 group are diastereotopic. This is likely due to hindered rotation of the 
propionate group in solution. Following the hydrolysis reaction (bottom spectrum), these 
signals collapse into a singlet at 4.04 ppm (2H) which indicates that the propionate group 
has been hydrolysed at the ester group forming the hydroxyl derivative; the CH2 protons 
are now free to rotate and therefore become magnetically equivalent. The major shift in 
H21 and H21´ confirmed that it is the 21-dipropionate group which has been cleaved.  
The above results confirms previous findings that showed the rapid hydrolysis of BDP 
via the esterase enzyme to 17-BMP which was the major metabolite detected (Foe et al., 
1998; Nave et al., 2007). The rapid hydrolysis of BDP to its active metabolite 17-BMP 
will favour a potent local anti-inflammatory action. 
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Figure 3.7: (a) 1H-NMR spectrum of BDP (b) 1H-NMR spectrum of the hydrolysis reaction product. 
  
 
 
 
 
Chapter 4: Relative Bioavailability of Beclometasone 
to the Lung Following Inhalation using Urinary 
Excretion
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4.1 Introduction 
Aerosol inhalation is considered the optimal route of administering drugs for the 
treatment of obstructive airway diseases such as asthma and COPD (Everard, 2001). 
Reasons for this include both efficacy and safety. Inhaled drugs are delivered directly 
into the airways, producing higher local concentrations for better efficacy with 
significantly less systemic exposure and less risk of systemic side effects (Virchow et al., 
2008; Broeders et al., 2009; Vincken et al., 2010). Following inhalation, a small portion 
of the inhaled dose is deposited in the airways while the majority is deposited in the 
mouth and subsequently swallowed (Newman et al., 1981c; Chrystyn, 2001; Barnes, 
2007). The lung dose will be cleared either by mucociliary clearance or by absorption 
through the airway wall into the systemic circulation (Borgstrom et al., 1992). The latter 
is the fraction of the dose that will exert the clinical effect within the airway wall and it is 
termed the effective lung dose. The total amount of drug which enters the systemic 
circulation will be the sum of the amounts that entered via the pulmonary and 
gastrointestinal routes (Chrystyn, 2001).  
The application of the traditional pharmacokinetic studies to determine lung deposition is 
difficult due to the low inhaled doses resulting in very low systemic concentration that is 
difficult to assay accurately (Rogers and Ganderton, 1995). In addition, these methods 
are unable to discriminate between the pulmonary and the orally absorbed fractions in the 
systemic concentrations (Newman et al., 1981c; Aswania et al., 1999). Pharmacokinetic 
methods using plasma or urine samples have been used to identify the relative lung 
deposition of the drug and total systemic delivery. Borgstrom and Nilsson, (1990) 
developed a charcoal block method to identify the relative lung deposition following an 
inhalation. They reported that the concurrent oral administration of activated charcoal 
blocked all absorption of the drug from the gastrointestinal tract. In this case the amount 
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of drug eliminated in the urine gives an absolute value of the total lung dose (Borgstrom 
and Nilsson, 1990). However, because this method uses oral charcoal it would be 
unethical to extend it to patient studies due to their concomitant oral therapy (Chrystyn, 
2001). 
Other pharmacokinetic methods have exploited the principle that drugs delivered to the 
lungs are very rapidly absorbed into the body whereas there is a lag time after oral 
administration before it is delivered to the systemic circulation. The body starts 
eliminating drugs as soon as they are delivered to the body. Using this principle, plasma 
concentrations (Lipworth, 1996; Lipworth and Clark, 1997; Lipworth and Clark, 1998b) 
and urinary excretion (Hindle and Chrystyn, 1992; Hindle et al., 1993; Hindle and 
Chrystyn, 1994; Hindle et al., 1995) of drugs over the first 20 and 30 minutes, 
respectively, post inhalation have been shown to be useful indices of lung deposition.  
The urinary salbutamol pharmacokinetic method reported by Hindle and Chrystyn, 
(1992) demonstrated that the amount of salbutamol excreted in the urine over the first 30 
minutes post oral administration was negligible and that significantly greater amounts 
(p<0.001) were excreted 30 minutes post inhalation. Thus, they reported that the 30 
minutes urinary excretion post inhalation is representative of the amount of drug 
delivered to the lung because it measures the drug that is delivered to the body following 
passage through the airway wall. They called this index the relative bioavailability to the 
lungs following an inhalation. Hindle and Chrystyn, (1992)  also  reported that the 
amount of salbutamol and its metabolite excreted in urine over the 24 hour period post 
inhalation is an index of systemic delivery. They called this index the relative 
bioavailability to the body following inhalation. These two indices of salbutamol to the 
lung and to the body following inhalation have been shown to be useful to compare 
different inhalation devices, e.g. spacers (Chege and Chrystyn, 1994; Hindle and 
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Chrystyn, 1994; Mazhar and Chrystyn, 2008), dry powder inhalers (Hindle et al., 1995; 
Hindle et al., 1997; Chege and Chrystyn, 2000) nebulisers (Silkstone et al., 2000; 
Silkstone et al., 2002; Mazhar et al., 2008), different inhalation techniques (Hindle et al., 
1993), and different formulations (Chege and Chrystyn, 1995). This simple and non-
invasive method has also been extended to other drugs e.g, inhaled sodium cromoglycate 
(Aswania et al., 1997; Aswania et al., 1999; Aswania and Chrystyn, 2001; Aswania and 
Chrystyn, 2002), nedocromil (Aswania et al., 1998), gentamicin (Nasr and Chrystsyn, 
1997; Al-Amoud et al., 2002; Al-Amoud et al., 2005), and formeterol (Nadarassan et al., 
2007). However, the methodology has not been extended to inhaled corticosteroids.  
Inhaled corticosteroids are the most effective drugs available to clinicians for the control 
of inflammation in asthma. Clinical studies have demonstrated their efficacy in reducing 
airway inflammation and hyper-responsiveness, as well as in preventing acute 
exacerbations, and improving lung functions in asthma. Beclometasone dipropionate 
(BDP) is a powerful topically active inhaled corticosteroid that is used in the treatment of 
asthma. It is actually a prodrug that is metabolised by esterases (in the human lung and 
elsewhere) to three different metabolites, 17-beclometasone monopropionate (17-BMP), 
21-beclometasone monopropionate (21-BMP), and beclometasone (BOH). 17-BMP is 
the active metabolite whereas BOH and 21-BMP have a very low binding affinity to the 
glucocorticoid receptor (Wurthwein and Rohdewald, 1990; Derendorf et al., 2006). 
 A pressurized metered-dose inhaler (pMDI) is the most popular method for asthma 
inhalation therapy and it is well established as a safe and reliable delivery system. The 
phase out of chlorofluorocarbon (CFCs) propellants, stipulated in the Montreal protocol, 
due to its detrimental effect on the ozone layer (Montreal, 2000), led to the reformulation 
and design of pressurized metered dose inhalers with more environmentally safer 
propellants such as hydrofluoroalkane-134a (HFA). Clenil Modulite® and Qvar® are 
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newly developed CFC-free beclometasone inhalers. Clenil Modulite® (Chiesi, Italy) is 
the first CFC-free metered-dose inhaler directly interchangeable with CFC-containing 
inhalers and its particles distribution (MMAD 2.9μm) more closely matches that of CFC 
containing MDIs than Qvar (MMAD 1.2μm) (Ganderton et al., 2002). The smaller 
median particle size of the new Qvar® (HFA-BDP) has been shown to improve drug 
delivery compared with CFC-BDP in both adults and children, with a greater proportion 
of the drug deposited in the small airways and less deposited in the throat (Leach et al., 
1998a; Leach et al., 2002; Janssens et al., 2003). Despite the improved lung deposition of 
HFA-BDP, it has a favourable safety profile (systemic and overall) compared with other 
inhaled corticosteroids (Thompson et al., 1998; Ayres et al., 1999). The fact that Qvar® 
produces equivalent asthma control to chlorofluorocarbon-based BDP inhalers, at 
approximately half the daily dose is largely attributed to its greater fine particle fraction 
(approximately 60%) compared to conventional CFC-BDP MDIs (approximately 30%) 
(Leach et al., 1998a). 
The plasma concentrations of drugs such as inhaled corticosteroids are very low, because 
of the small therapeutic doses used and their very large volume of distribution in the 
body (Hindle and Chrystyn, 1992). Highly sensitive and reproducible analytical methods 
for the accurate assay of these low plasma concentrations is difficult (Derendorf et al., 
2001). In contrast, the concentrations of drugs in urine are much higher. We have 
developed a sensitive and robust assay for BDP, 17-BMP, and BOH in urine and so we 
have extended the urinary salbutamol method of Hindle and Chrystyn (1992) to 
beclometasone dipropionate. Within the validation study of this pharmacokinetic method 
for beclometasone dipropionate, we have included a comparison between Clenil 
Modulite® and Qvar® Easi-Breathe inhalers. 
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4.2 Validation of relative bioavailability of beclometasone dipropionate to the lung 
following inhalation using urinary excretion 
4.2.1 Method 
The aim of this investigation was to identify and validate a urinary pharmacokinetic 
method to determine the relative lung and systemic bioavailability of beclometasone 
following inhalation. The study was divided into two parts. In the first part, the dose of 
activated charcoal to completely block beclometasone dipropionate and its 
gastrointestinal absorption was determined. In the second part, the lung and systemic 
bioavailability of BDP given by a MDI was investigated. This was accomplished by 
identifying the amount of beclometasone dipropionate (BDP), 17-beclometasone 
monopropionate (17-BMP) and beclometasone (BOH) excreted in the urine after oral and 
MDI dosing with and without the co-administration of activated charcoal (concurrent 
oral charcoal will prevent absorption of any drug that is swallowed). Within this 
validation, this pharmacokinetic method has been applied to compare the urinary 
excretion of Qvar EB and Clenil MDI following inhalation. 
4.2.1.1 Equipment and inhalation devices 
- Inhaler devices: 
 Qvar® Easi-Breathe inhaler (EB) labelled as a nominal dose of 100µg 
beclometasone dipropionate per dose (Teva Pharmaceuticals, UK). 
 Clenil Modulite® metered dose inhaler (MDI) labelled as a nominal dose of 
250µg beclometasone dipropionate per dose (Chiesi, UK). 
- Activated Charcoal: Carbomix, Meadon, Laboratories Limited, UK. 
- LC-(ESI+)-MS method conditions: sample preparation, analysis procedures, and 
chromatographic conditions were as reported in section 3.3. 
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4.2.1.2 Subjects and study design 
Ethical approval for the study was obtained from the University of Huddersfield and 
healthy volunteers gave written consent to take part in the study. Subjects were non-
smokers and were allowed no medication during the study period. Healthy volunteers 
were used to limit inter-individual variability of the airways as lung deposition is affected 
by airway calibre (Lipworth and Clark, 1997). It is necessary to include both males and 
females in the study in order to obtain meaningful pharmacokinetic data. For the first part 
of the study, the initial quantities of charcoal taken to completely block beclometasone 
dipropionate gastrointestinal absorption were determined. This was accomplished by 
identifying the urinary excretion of four healthy, non-smoking volunteers (two females) 
following the oral administration of a 20ml solution containing 20% ethanol and 2000μg 
beclometasone dipropionate with 5g activated charcoal (5g activated charcoal suspended 
in 50 ml water and given before and after the inhaled dose). The charcoal was given as a 
slurry in water, swirled around the mouth before swallowing. Urine samples were 
collected at 0.5, 1, 2, 3, 5, 8, 12, and 24 hours post study dose administration for analysis. 
For the second part of the study, twelve healthy, non-smoking volunteers received the 
following study doses on separate study days, each separated by a minimum of 7 days: 
 Oral administration of a 20ml (20%) ethanolic solution containing 2000μg 
beclometasone dipropionate [O]. 
 Oral administration of a 20ml (20%) ethanolic solution containing 2000μg 
beclometasone dipropionate with 5g activated charcoal (a suspension of 5g 
activated charcoal in 50 ml water given before and after the inhaled dose) [OC]. 
 Ten 100μg (1mg in total) inhalations of beclometasone dipropionate from a 
Qvar® Easi-Breathe (Teva Pharmaceuticals, UK) [IQ]. 
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 Ten 100μg (1mg in total) inhalations of beclometasone dipropionate from a 
Qvar® Easi-Breathe with the concurrent oral administration of activated charcoal 
(5g in 50 ml water before and after the inhalation dose) [IQC]. 
 Eight 250μg (2mg in total) inhalations of beclometasone dipropionate from a 
Clenil® metered dose inhaler (Trinity; Chiesi, UK) [IC]. 
All subjects were trained on how to effectively use both the metered dose inhaler (MDI) 
and the Easi-breathe (EB) device according to the patient information leaflet. For the 
MDI, subjects were trained to remove the cap, exhale slowly as far as comfortable, put 
the MDI into their mouth, and seal their lips round the mouthpiece. They were then 
instructed to start a slow inhalation through their mouth and activate the MDI 
immediately after the start of this slow inhalation. This slow inhalation continued until 
their lungs were full of air (total lung capacity). After inhalation they held their breath for 
10 seconds and the next dose was repeated 30 seconds later (Hindle et al., 1993). The 
same inhalation process was repeated for the EB device, the only difference was that 
subjects did not need to actuate the device during their inhalation, as the Easi-Breathe 
device would automatically deliver the dose upon inhalation. A check was made that the 
breath actuation process occurred (sound, taste and visual check of an external lever on 
the device that moves when a dose is released). Subjects voided their urine pre-dosing 
and then provided urine samples at 0.5, 1, 2, 3, 5, 8, 12, and 24 hours post study dose. 
The volume of urine excreted was recorded and aliquots of each sample were frozen at 
minus 20°C prior to analysis. The order of the study doses was randomized with a 7-day 
washout period between administrations.  
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4.2.2 Analysis 
4.2.2.1 Urine sample analysis 
The LC-(ESI+)-MS method with solid phase extraction that has been developed and 
validated for the assay of beclometasone dipropionate and its metabolites in urine 
samples (previously described in section 3.3) was used to identify the urinary amounts 
excreted.  
4.2.2.2 Statistical analysis 
Statistical comparisons of the urinary excretion data of beclometasone dipropionate and 
its metabolites following oral, MDI and MDI + C administration in urine samples 
produced at different time intervals were compared using one way analysis of variance 
(ANOVA) using SPSS V17.0 (SPSS Inc., Chicago, USA). The mean difference with 
95% confidence interval was calculated. In addition, One-way analysis of variance with 
the application of Bonferroni correction was used to determine any difference between 
the urinary excretions from the inhalation methods. To identify equivalence of the 
urinary excretions between the inhalation methods, the 30 minutes and cumulative 24hr 
amounts, excreted for each inhalation method, were normalised for the nominal dose and 
then log transformed. From the mean square error of the analysis of variance, using 
patients and inhalation method as the main factors, the mean ratio (90% confidence 
interval) was calculated. 
4.2.3 Results 
Four healthy volunteers (two females), whose mean (SD) age, height and weight, were 
29.5 (1.3) years, 165.3 (10.1) cm and 59.3 (5.7) kg, respectively participated in the first 
part of the study. No urinary excretion of BDP or its metabolites were detected up to 
24hr following oral BDP (2mg in 20ml 20% ethanol solution) dosing with the 
concomitant administration of activated charcoal. The use of activated charcoal in this 
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dose was found to be sufficient to block the gastrointestinal absorption of beclometasone 
dipropionate and its metabolites in this study.  
Twelve healthy volunteers (four females), whose mean (SD) age, weight and height, 
were 33.8 (11.6) years, 69.3 (11.4) Kg and 171.0 (8.6) cm, respectively completed the 
second part of the study. The demographic details of the subjects that participated in the 
first and second part of the study are shown in table 4.1 and 4.2, respectively.  
Table 4.1: Demographic data of the volunteers that participated in the first part of the 
study, (n=4). 
 
 
 
 
Table 4.2: Demographic data of the volunteers that participated in the second part of the 
study, (n=12). 
 
 
 
 
 
 
 
 
Subject Sex Age (years) Height (cm) Weight (kg) 
1 Female 28 155 55 
2 Male 30 178 60 
3 Female 29 160 55 
4 Male 31 168 67 
Mean --- 29.5 (1.3) 165.3 (10.1) 59.3 (5.7) 
Subject Sex Age (years) Height (cm) Weight (kg) 
1 Male 58 183 85 
2 Female 50 165 60 
3 Female 28 155 55 
4 Male 30 178 60 
5 Female 29 160 55 
6 Male 31 168 67 
7 Male 23 181 80 
8 Male 32 170 69 
9 Male 19 179 83 
10 Male 23 174 69 
11 Female 40 166 63 
12 Male 42 173 85 
Mean (SD) --- 33.8 (11.6) 171.0 (8.6) 69.3 (11.4) 
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No BDP, 17-BMP, or BOH was detected after oral dosing with activated charcoal. The 
individual and mean (SD) urinary excretion of beclometasone dipropionate and its 
metabolites post IC, IQ, IQC, and O study doses is presented in APPENDIX B.1-B.22 
(refer to the enclosed DVD). All these urinary excretions of BDP and its metabolites are 
summarized in table 4.3 and APPENDIX B.23 (refer to the enclosed DVD) provide a 
summary of their excretion rate profiles.  
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Table 4.3: The mean (SD) cumulative urinary excretion of 17-beclometasone monopropionate, beclometasone and beclometasone dipropionate 
following the inhalation of 8 doses of Clenil Modulite® MDI (250 µg per actuation) [IC], 10 doses of Qvar® EB (100 µg per actuation) [IQ], 10 doses 
of Qvar® EB with simultaneous oral administration of 5g activated charcoal [IQC] and oral administration of an alcoholic solution of 2mgBDP [O], 
expressed in µg, (n=12). 
 
Urine 
collection 
period 
(hours) 
Amount of BOH (µg) Amount of (17-BMP) (µg) Amount of BDP (µg) 
IC IQ IQC O IC IQ IQC O IC IQ IQC O 
0.5 5.1 (1.5) 6.0 (1.6) 5.1 (1.8) 0 (0) 3.1 (0.8) 3.9 (1.4) 3.2 (1.2) 0 (0) 3.9 (1.4) 4.2 (0.9) 3.7 (1.0) 0 (0) 
1 12.0 (2.7) 13.5 (3.3) 11.3 (4.0) 2.5 (1.6) 7.7 (2.3) 8.9 (2.9) 6.7 (2.4) 0.8 (1.1) 8.8 (2.3) 9.1 (1.8) 8.9 (2.1) 0 (0) 
2 28.5 (6.5) 31.2 (7.8) 23.5 (7.4) 6.7 (2.4) 17.5 (6.5) 18.7 (8.6) 12.6 (4.6) 3.7 (1.9) 13.3 (2.7) 13.1 (2.4) 13.4 (3.0) 0 (0) 
3 47.4 (11.9) 52.1 (14.2) 34.9 (11.9) 11.4 (3.6) 21.3 (7.4) 24.6 (10.8) 15.0 (4.9) 6.3 (1.9) 16.6 (2.6) 16.1 (3.0) 16.7 (3.6) 0 (0) 
5 61.1 (20.1) 66.8 (18.7) 42.1 (14.1) 17.7 (6.3) 24.5 (7.7) 27.4 (10.6) 17.1 (5.6) 9.1 (2.3) 20.3 (2.8) 19.2 (4.0) 20.1 (4.1) 0 (0) 
8 69.8 (23.1) 76.6 (18.9) 48.5 (16.3) 23.5 (7.8) 26.5 (7.7) 30.2 (10.3) 19.0 (6.1) 12.4 (3.2) 24.1 (3.3) 20.9 (5.2) 21.8 (5.4) 0 (0) 
12 74.8 (25.0) 81.4 (20.2) 53.5 (18.3) 28.1 (8.0) 28.5 (7.9) 32.5 (10.6) 20.9 (7.0) 14.6 (4.0) 24.1 (3.3) 20.9 (5.2) 22.2 (5.4) 0 (0) 
24 78.5 (27.5) 86.2 (21.6) 57.8 (19.1) 33.6 (9.8) 30.2 (8.1) 34.4 (10.6) 22.7 (7.9) 16.1 (5.2) 24.1 (3.3) 20.9 (5.2) 22.2 (5.4) 0 (0) 
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Table 4.3 shows that no BDP, 17-BMP, or BOH was excreted in the first 30 minutes post 
oral administration. In contrast, significantly more amounts of BDP, 17-BMP, and BOH 
(p<0.001) were excreted post inhalation of both Qvar® and Clenil® study doses. In 
addition, no parent drug (BDP) was detected in any sample up to 24hrs post oral 
administration. The mean (SD) urinary excretion of BOH over the 0.5hr and 24hours 
period post dosing of inhaled Qvar®, inhaled Clenil®, inhaled Qvar®  plus charcoal and 
oral administration is 6.0 (1.6), 5.1 (1.5), 5.1 (1.8), 0 (0) µg and 86.2 (21.6), 78.5 (27.5), 
57.8 (19.1), 33.6 (9.8) µg, respectively. The 0.0-0.5hr and the 0-24hr urinary 17-BMP 
excretion following IQ, IC, IQC and O administration is 3.9 (1.4), 3.1 (0.8), 3.2 (1.2), 0 
(0) µg and 34.4 (10.6), 30.2 (8.1), 22.7 (7.9), 16.1 (5.2) µg, respectively. The urinary 
BDP excreted were 4.2 (0.9), 3.9 (1.4), 3.7 (1), and 0 (0) µg during the first 0.5hr 
collection period and were 20.9 (5.2), 24.1 (3.33), 22.2 (5.4) and 0 (0) over the 24hr 
period post administration of IQ, IC, IQC and O study doses µg, respectively. Figures 
4.1- 4.3 show the urinary excretion profiles for BOH, 17-BMP and BDP, while figures 
4.4- 4.6 show their cumulative urinary excretion, respectively.  
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Figure 4.1: The mean (SD) urinary beclometasone (BOH) excretion rates post inhalation 
of IC, IQ, IQC and oral study doses, expressed in µg/hr, (n=12).  
 
 
Figure 4.2: The mean (SD) urinary 17-beclometasone monopropionate (17-BMP) 
excretion rates post inhalation of IC, IQ, IQC and oral study doses, expressed in µg/hr, 
(n=12). 
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Figure 4.3: The mean (SD) urinary beclometasone dipropionate (BDP) excretion rates 
post inhalation of IC, IQ, IQC and oral study doses, expressed in µg/hr, (n=12). 
 
 
Figure 4.4: The mean (SD) cumulative urinary excretion of beclometasone (BOH) post 
study doses excreted in the urine post inhalation of IC, IQ, IQC and oral study doses, 
expressed in µg, (n=12). 
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Figure 4.5: The mean (SD) cumulative urinary excretion of 17-beclometasone 
monopropionate (17-BMP) excreted in the urine post inhalation of IC, IQ, IQC and oral 
study doses, expressed in µg, (n=12). 
 
 
Figure 4.6: The mean (SD) cumulative urinary excretion of beclometasone dipropionate 
(BDP) excreted in the urine post inhalation of IC, IQ, IQC and oral study doses, 
expressed in µg, (n=12).  
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Table 4.4 describes the mean (SD) cumulative urinary excretion of BDP and its 
metabolites expressed as percentage of the nominal dose. The mean ratio of the 
cumulative urinary excretion excreted in the urine 0.5 and 24hrs, following the 
administration of [IC], [IQ], and [O] study doses is summarized in table 4.5. The 
individual 0.5hr urinary excretion of BDP and its metabolites recovered in urine post 
study doses expressed in µg and as % of nominal dose are presented in figures 4.7 and 
4.8, respectively. These figures highlight that the 30 minutes urinary excretion post-oral 
administration shows that no BDP, 17-BMP, or BOH were detected in urine during that 
collection period. Figures 4.9 and 4.10 represent the individual 24hr urinary amounts of 
BDP and metabolites expressed in µg and as percentage of nominal dose, respectively.  
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Table 4.4: The mean (SD) of the cumulative urinary excretion of 17-beclometasone monopropionate, beclometasone and beclometasone dipropionate , 
expressed as percentage of nominal dose following the inhalation of 8 doses of Clenil Modulite® MDI (250 µg per actuation) [IC], 10 doses of Qvar® 
EB (100 µg per actuation) [IQ], 10 doses of Qvar®  EB with simultaneous oral administration of 5g activated charcoal [IQC] and oral administration 
of an alcoholic solution of 2mg BDP [O], (n=12). 
Urine 
collection 
period 
(hours) 
Amount of BOH (%) Amount of (17-BMP) (%) Amount of BDP (%) 
IC IQ IQC O IC IQ IQC O IC IQ IQC O 
0.5 0.3 (0.1) 0.6 (0.2) 0.5 (0.2) 0 (0) 0.2 (0.1) 0.4 (0.1) 0.3 (0.1) 0 (0) 0.2 (0.1) 0.4 (0.1) 0.4 (0.1) 0 (0) 
1 0.6 (0.1) 1.4 (0.3) 1.1 (0.4) 0.1 (0.1) 0.4 (0.1) 0.9 (0.3) 0.7 (0.3) 0.1 (0.1) 0.4 (0.1) 0.9 (0.2) 0.9 (0.2) 0 (0) 
2 1.4 (0.3) 3.1 (0.8) 2.4 (0.7) 0.3 (0.1) 0.9 (0.3) 1.9 (0.9) 1.3 (0.5) 0.2 (0.1) 0.7 (0.1) 1.3 (0.2) 1.3 (0.3) 0 (0) 
3 2.4 (0.6) 5.2 (1.4) 3.5 (1.2) 0.6 (0.2) 1.1 (0.4) 2.5 (1.1) 1.5 (0.5) 0.3 (0.1) 0.8 (0.1) 1.6 (0.3) 1.7 (0.4) 0 (0) 
5 3.1 (1.0) 6.7 (1.9) 4.2 (1.4) 0.9 (0.3) 1.2 (0.4) 2.8 (1.1) 1.7 (0.6) 0.5 (0.1) 1.0 (0.1) 1.9 (0.4) 2.0 (0.4) 0 (0) 
8 3.5 (1.2) 7.7 (1.9) 4.9 (1.6) 1.2 (0.4) 1.3 (0.4) 3.0 (1.0) 1.9 (0.6) 0.6 (0.2) 1.2 (0.2) 2.1 (0.5) 2.2 (0.5) 0 (0) 
12 3.7 (1.3) 8.1 (2.0) 5.4 (1.8) 1.4 (0.4) 1.4 (0.4) 3.3 (1.1) 2.1 (0.7) 0.7 (0.2) 1.2 (0.2) 2.1 (0.5) 2.2 (0.5) 0 (0) 
24 3.9 (1.4) 8.6 (2.2) 5.8 (1.9) 1.7 (0.5) 1.5 (0.4) 3.4 (1.1) 2.3 (0.8) 0.8 (0.3) 1.2 (0.2) 2.1 (0.5) 2.2 (0.5) 0 (0) 
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Table 4.5: The mean ratio of the cumulative urinary excretion of 17-BMP, BOH and 
BDP, excreted in the urine 0.5 and 24hrs following the inhalation Clenil® MDI [IC], 
Qvar® EB [IQ], and the administration of the oral study doses [O], (n=12). 
 
 
 
 
 
 
 
Time (hr) 0.5 24 
O : IC Amount (µg) BOH --- 1:2.3 
17-BMP --- 1:1.9 
O: IQ Amount (µg) BOH --- 1:2.6 
17-BMP --- 1:2.1 
IC: IQ Amount (µg) 
BOH 1:1.2 1:1.1 
17-BMP 1:1.2 1:1.1 
BDP 1:1.1 1:0.9 
IC: IQ (%ND) 
BOH 1:2.4 1:2.2 
17-BMP 1:2.0 1:2.0 
BDP 1:2.0 1:1.8 
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Figure 4.7: The 0.5hr urinary amounts of (a) 17-BMP (b) BOH (c) BDP recovered in 
urine post dosing via the oral solution, inhaled Clenil®, inhaled Qvar®, and inhaled Qvar® 
plus charcoal, expressed  in µg, (n=12).  
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Figure 4.8: The 0.5hr urinary amounts of (a) 17-BMP (b) BOH (c) BDP recovered in 
urine post dosing via the oral solution, inhaled Clenil®, inhaled Qvar® , and inhaled 
Qvar® plus charcoal, expressed   as % of nominal dose, (n=12).  
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Figure 4.9: The 24hr urinary amounts of (a) 17-BMP (b) BOH (c) BDP recovered in 
urine post dosing via the oral solution, inhaled Clenil®, inhaled Qvar® , and inhaled 
Qvar® plus charcoal, expressed  in µg, (n=12).  
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Figure 4.10: The 24hr urinary amounts of (a) 17-BMP (b) BOH (c) BDP recovered in 
urine post dosing via the oral solution, inhaled Clenil®, inhaled Qvar® , and inhaled 
Qvar® plus charcoal, expressed   as % of nominal dose, (n=12). 
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A summary of the statistical analysis of the data obtained from different study doses is 
presented in tables 4.6 - 4.8. Figures 4.7 - 4.10 and tables 4.6 and 4.7 show that when 
comparing the cumulative amount of BOH and 17-BMP excreted in the urine following 
inhaled Qvar®, inhaled Clenil and inhaled Qvar® plus charcoal administration compared 
with oral administration, a significant difference (p<0.001) was found at all time intervals 
investigated. The mean difference (95% confidence interval) of 0.0-0.5hr urinary drug 
excretion following IQ, IC and IQC administration compared with oral administration 
were 3.9 (3.1,4.6) µg ,3.1 (2.4, 3.9) µg, 3.2 (2.5,4.0) µg and 5.5 (4.4, 6.6) µg ,4.6 (3.5, 
5.7) µg,  4.6 (3.5,5.7) µg for 17-BMP and BOH respectively (p<0.001). The mean 
difference (95% confidence interval) of 0.0-24hrs cumulative urinary drug excretion 
following IQ, IC and IQC administration compared with oral administration were 18.2 
(14.7, 21.7) µg , 14.7 (11.1, 18.2) µg, 6.6 (3.0, 10.1) µg and 52.5 (43.1, 61.9) µg , 44.9 
(35.5, 54.2) µg, 24.2 (14.8, 33.5) µg for 17-BMP and BOH respectively (p<0.001). A 
summary of the mean ratio (90% confidence limits) between Qvar and Clenil with 
respect to the nominal dose and between each product and the oral dose is presented in 
table 4.9. These values are presented separately for BDP, 17-BMP, and BOH, as well as 
for all three metabolites combined. The latter, which represents an overall ratio, shows a 
mean ratio (90% confidence interval) for Qvar compared to Clenil of 231.4 (209.6 - 
255.7)%, and 204.6 (189.6, 220.6) % for the 30 minute, and the 24hr urinary excretion, 
respectively. Figure 4.11 shows the mean ratio (90% confidence limits) between Qvar 
and Clenil with respect to the nominal dose. 
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Table 4.6: Statistical comparison of the mean difference (95% confidence interval) between the cumulative amounts of beclometasone excreted in the 
urine post different times of the following study doses; IQ vs O, IC vs O, IQC vs O, IQ vs IQC and IC vs IQ. 
Time IQ vs O (µg) IC vs O (µg) IQC vs O(µg) IQ vs IQC(µg) IC vs IQ(µg) 
0.5 5.5 (4.4, 6.6)*** 4.6 (3.5, 5.7)*** 4.6 (3.5,5.7)*** 0.9 (-0.2, 2.0) -0.9 (-2, 0.2) 
1 11.1 (8.9, 13.3)*** 9.5 (7.3, 11.7)*** 8.9 (6.6, 11.1)*** 2.2 (0.0,4.5)* -1.6 (-3.8, 0.7) 
2 24.4 (19.8, 29.1)*** 21.8 (17.1,26.4)*** 16.9 (12.2, 21.5) *** 7.6 (2.9,12.2)** -2.7 (-7.3, 2) 
3 40.7 (33.2, 48.2)*** 36.0 (28.5, 43.5)*** 23.5 (16, 31)*** 17.2 (9.7,24.7)*** -4.7 (-12.2,2.6) 
5 49.1 (40.1, 58.2)*** 43.4 (34.3, 52.4)*** 24.4 (15.4, 33.5)*** 24.7 (15.7, 33.8)*** -5.7 (-14.8, 3.3) 
8 53.1 (44, 62.1)*** 46.3 (37.2, 55.3)*** 25.0 (16, 34.0)*** 28.1 (19.0, 37.1)*** -6.8 ( -15.8, 2.2) 
12 53.3 (44.3, 62.3)*** 46.7 (37.7, 55.7)*** 25.4 (16.4, 34.4)*** 27.9 (18.9, 36.9)*** -6.6 (-15.6, 2.4) 
24 52.5 (43.1, 61.9)*** 44.9 (35.5, 54.2)*** 24.2 (14.8, 33.5)*** 28.4 (19, 37.8)*** -7.7 (-17.1, 1.7) 
 
Table 4.7: Statistical comparison of the mean difference (95% confidence interval) between the cumulative amounts of 17-beclometasone 
monopropionate excreted in the urine post different times of the following study doses; IQ vs O, IC vs O, IQC vs O, IQ vs IQC and IC vs IQ. 
Time IQ vs O (µg) IC vs O (µg) IQC vs O(µg) IQ vs IQC(µg) IC vs IQ(µg) 
0.5 3.9 (3.1, 4.6)*** 3.1 (2.4, 3.9)*** 3.2 (2.5, 4)*** 0.6 (-0.1, 1.4) -0.7 (-1.5, 0.001) 
1 7.7 (6.4, 9.1)*** 6.9 (5.5, 8.2)*** 5.9 (4.5, 7.2)*** 1.9 (0.5, 3.2)** -0.8 (-2.2, 0.5) 
2 15.0 (11.9, 18.2)*** 13.8 (10.6, 17)*** 8.9 (5.7, 12)*** 6.1 (3.0, 9.3)*** -1.2 (-4.4, 1.9) 
3 18.3 (14.4, 22.3)*** 15.1 (11.1, 19)*** 8.8 (4.84, 12.75)*** 9.5(5.6, 13.5)*** -3.2 (-7.2, 0.7) 
5 18.4 (14.4, 22.3)*** 15.4 (11.5, 19.4)*** 8.0 (4.0, 11.9)*** 10.4 (6.4, 14.3)*** -2.9 (-6.9, 1.0) 
8 17.8 (14.1, 21.4)*** 14.7 (11.1, 18.4)*** 6.6 (3, 10.2)*** 11.2 (7.6, 14.8)*** -3.04 (-6.7, 0.6) 
12 18.0 (14.4, 21.5)*** 14.5 (10.9, 18)*** 6.3 (2.7, 9.8)** 11.7 (8.1, 15.2)*** -3.5 (-7, 0.1) 
24 18.2 (14.7, 21.7)*** 14.7 (11.12, 18.2)*** 6.6 (3, 10.1)*** 11.6 (8.1, 15.2)*** -3.5 (-7, 0.04) 
For both tables* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference 
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Table 4.8: Statistical comparison of the mean difference (95% confidence interval) between the cumulative amounts of beclometasone dipropionate 
excreted in the urine post different times of IQ vs IQC and IC vs IQ study doses. 
 
 
 
 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference 
Table 4.9: Mean ratio (90% confidence interval) for Qvar compared to Clenil and between each product and the oral dose (when normalised for the 
nominal dose. 
Time IQ vs IQC(µg) IC vs IQ(µg) 
0.5 0.5 (-0.3, 1.2) -0.3 (-1.1, 0.5) 
1 0.6 (-1.2, 2.3) -0.4 (-2.1, 1.4) 
2 -0.2 (-2.5, 2.0) 0.2 (-2, 2.4) 
3 -0.6 (-3.1, 1.9) 0.5 (-1.9, 3) 
5 -0.9 (-3.9, 2.1) 1.1 (-1.9, 4.1) 
8 -1.0 (-4.9, 2.8) 3.2 (-0.5, 7.1) 
12 -1.3 (-5.1, 2.4) 3.2 (-0.6, 6.9) 
24 -1.3 (-5.1, 2.4) 3.2 (-0.6, 6.9) 
Urinary excretion 0.5hr urinary excretion c24 hour urinary excretion 
Qvar vs Clenil Qvar vs Clenil Qvar vs oral Clenil vs oral 
BDP 221.4(189.1,259.6) 170.7 (148.3,196.6) --- --- 
17-BMP 236.6 (192.1, 291.2) 223.9 (202.2, 247.7) 430.6 (385.7, 480.2) 192.3 (172.3, 214.5) 
BOH 236.8 (198.0, 283.5) 223.9 (206.7, 242.8) 517.6 (460.4, 581.8) 231.2 (205.6, 259.9) 
All combined 231.4 (209.6, 255.7) 204.6 (189.6, 220.6) 451.3 (412.9, 492.8) 220.6 (202.0, 241.1) 
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Figure 4.11: The overall mean ratio (90% confidence interval) for the 0.5hr and the 24hr 
urinary excretion between Qvar and Clenil with respect to the nominal dose. 
As shown in tables 4.6 - 4.8 and figures 4.7 - 4.10, no significant difference (95% 
confidence interval) was found between the urinary amount of BOH, and 17-BMP 
excreted 0.5hr post dose following IQ and IQC administrations, while their 24hr urinary 
excretion results showed significance for the same treatment groups. The mean 
difference (95% confidence interval) of 0.0-0.5hr urinary drug excretion following 
inhaled Qvar® administration compared with  inhaled Qvar® plus charcoal administration 
were 0.6 (-0.1, 1.4) µg , 0.9 (-0.2, 1.9) µg, and 0.5 (-0.3, 1.2) for 17-BMP, BOH, and 
BDP respectively. However, for BDP, no significant difference was found between the 
cumulative urinary BDP excretions post inhaled Qvar® and inhaled Qvar® plus charcoal 
administration at all time intervals investigated. As shown in tables 4.6 - 4.8, comparison 
of the amounts excreted for BDP and its metabolites between Qvar® and Clenil® at each 
sampling points showed no significant difference. 
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4.2.4 Discussion 
Administration of beclometasone dipropionate by inhalation produced detectable 
concentrations of unchanged BDP, 17-BMP, and BOH in urine samples. However, the 
minor and inactive metabolite 21-BMP was not detected in this study, which is consistent 
with the failure of previous studies to detect it in most samples post-inhaled dosing 
(Falcoz et al., 1996; Daley-Yates et al., 2001; Harrison et al., 2002a). The absence of any 
BDP or metabolites detected in the urine post oral dose with charcoal administration is 
consistent with previous studies (Trescoli and Ward, 1998; Daley-Yates et al., 2001) and 
confirms the ability of charcoal to block the oral absorption of the portion of inhaled dose 
of beclometasone dipropionate that would be swallowed and subsequently absorbed 
following inhalation. Therefore, any BDP or metabolites excreted in the urine following 
inhalation with activated charcoal must have been absorbed via the lungs. As illustrated 
in table 4.3, following oral administration of BDP, none of the parent drug was detected 
in any of the urine samples at all time intervals investigated. In addition, none of the 
metabolites 17-BMP and BOH was excreted at 30 minutes post the oral dose. 
The higher 30 minutes urinary excretions of 17-BMP, BDP, and BOH post inhalation 
compared to oral administration is due to its rapid and complete absorption from the 
lungs and the slow and negligible absorption from the gastrointestinal tract. This 
highlights the lag time for drug absorption from the gastrointestinal tract. This is in 
agreement with the salbutamol urinary excretion data post oral and inhaled 
administration initially reported by Hindle & Chrystyn (1992).  
The non-significant difference found between the 30 minutes urinary excretion of 17-
BMP, BDP and BOH in samples post inhalation from Qvar® EB and Qvar® EB with 
charcoal confirms the lag time for oral absorption and that charcoal blockage was not 
necessary. Moreover, the difference between the Qvar® and Qvar® plus charcoal is 
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similar to those expected post oral administration, which further confirms the prevention 
of oral absorption by the charcoal doses. 
Significantly (p<0.001) more amounts of BDP, 17-BMP, and BOH were excreted in the 
urine following inhalation compared with oral administration at all the time intervals 
investigated. The ratios of 24hr urinary amounts of beclometasone recovered in urine 
following oral to inhaled Clenil® administrations and following oral to inhaled Qvar® 
administrations were 1:2.3, and 1:2.6, respectively. For 17-BMP, the 24hr urinary 
excretion of 17-BMP post oral to inhaled Clenil® and oral to inhaled Qvar® 
administration was at the ratio 1:1.9 and 1:2.1, respectively. These ratios of 24hr inhaled 
to oral for BOH and 17-BMP are consistent with AUC data previously reported (Daley-
Yates et al., 2001). 
The low oral to inhaled bioavailability of beclometasone dipropionate can be attributed to 
the efficient absorption of BDP from the lungs, but not form the gastrointestinal tract. 
This is consistent with a previous study that determined the relative bioavailability of 
oral versus inhaled beclometasone dipropionate from the HFA-BDP inhaler and reported 
that the fraction of an oral dose that reaches the systemic circulation was estimated as 
40% relative to inhaled HFA BDP (Soria et al., 1998). 
The significant differences (p<0.001) between the amounts of urinary 17-BMP and BOH 
in samples taken from 0.5-24hr collection periods post inhalation from the inhaled Qvar® 
and inhaled Qvar® with charcoal also highlights the contribution of the orally absorbed 
fraction. The urinary amounts of BOH and 17-BMP were only slightly reduced by the 
charcoal block, confirming that the pulmonary route was the predominant route for 
absorption of these metabolites.  
The charcoal block did not affect the urine levels of BDP post inhalation, confirming that 
BDP, found in the systemic circulation arises from BDP absorbed unchanged from the 
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lung. The swallowed BDP is not available to the systemic circulation due to its extensive 
pre-systemic conversion. This is in agreement with previous studies that have also 
reported the absence of any detectable concentrations of BDP in the plasma following 
oral administration. This has been referred to the very high clearance of BDP, which 
would normally result in a high first pass metabolism. Although, 17-BMP also has high 
clearance values, it showed high oral bioavailability, suggesting that systemic rather than 
first pass metabolism predominated for 17-BMP elimination, while gut and hepatic 
metabolism predominated for BDP (Daley-Yates et al., 2001; Woodcock et al., 2002a). 
The amounts of BOH, 17-BMP, and BDP excreted in the urine during the first 30 
minutes post-inhalation can be used as an index of the relative bioavailability of 
beclometasone to the lungs following inhalation. This index could be used to compare 
the in-vivo lung deposition of different inhaled products/methods. The total amounts of 
beclometasone dipropionate and its metabolites excreted in the urine over the 24 hours 
post-inhalation represent the relative bioavailability of beclometasone to the body and 
can be used to compare the total systemic delivery following inhalation of different 
products or by different techniques.  
Inspecting the results in table 4.5, highlights that the 30 minutes urinary excretion ratios 
post inhalation of eight doses of Clenil® (250µg) to ten doses of Qvar® (100µg), 
expressed as percentage of nominal dose were  1:2.4, 1:2 and 1:2 for BOH, 17-BMP and 
BDP, respectively. The 24hr urinary excretion ratio following the same IC and IQ study 
doses, expressed as percentage of nominal dose were 1:2.2, 1:2.0 and 1: 1.8 for BOH, 17-
BMP and BDP, respectively. It is apparent from the small differences seen in the 
excretion ratios between BOH, 17-BMP, and BDP, that the 30 minutes excretions of any 
of them can be used to compare the bioequivalence of Qvar and Clenil. As shown in 
table 4.9 and figure 4.11, when combining all the data of the 0.5hr urinary excretion of 
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BDP and its metabolites, the overall mean ratio was 231.4% with 90% confidence 
interval of 209.6 - 255.7. While, the overall mean ratio was 204.6 with 90% confidence 
interval of 189.6 - 220.6 for the cumulative 24hr urinary excretion. 
The above findings confirm that the urinary excretion of Qvar®  was equivalent to 
Clenil® urinary excretion when administered at half the dose, these results are in 
agreement with previous findings that have shown that Qvar®  as an extra fine aerosol 
with a particle size of 1.1µm has a relatively higher lung deposition. This is consistent 
with several previous in-vitro, gamma scintigraphy (Leach et al., 1998a), 
pharmacokinetic (Soria et al., 1998; Harrison et al., 1999b; Bousquet et al., 2009), and 
clinical (Davies et al., 1998; Busse et al., 1999b) studies that have confirmed that a given 
dose of Qvar HFA–BDP would result in approximately 2-2.5 fold greater potency 
compared with other CFC-containing beclometasone MDIs. Although Clenil® is a 
different formulation to the innovator CFC-product, it has been formulated as a seamless 
dose transition (Chaplin and Head, 2007).  
4.3 Intra and inter- subject variability 
4.3.1 Method 
4.3.1.1 Equipment and inhalation devices 
Inhaler devices:   Qvar® Easi-Breathe inhaler (EB) labelled as a nominal dose of 100µg                 
beclometasone dipropionate per dose (Teva Pharmaceuticals, UK). 
LC-(ESI+)-MS method conditions: previously described in section 3.3 in this thesis. 
4.3.1.2 Subjects and study design 
Ethical approval for the study was obtained from the University of Huddersfield. Eight 
healthy, non-smoking subjects (4 females) gave written consent to participate in the 
study. All subjects were older than 18 years old with a FEV1 > 90%. On separate study 
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days, each participant received eight 100μg (0.8mg in total) inhalations of beclometasone 
dipropionate from Qvar® EB (Teva Pharmaceuticals, UK) on five separate occasions to 
determine the reproducibility and the reliability of the 30 minutes urinary excretion 
method. The volunteers were first instructed to exhale to residual volume, then to put the 
Easi-Breathe inhaler into their mouth and seal their lips around the mouthpiece. They 
inhaled slowly and the Easi-Breathe device delivered the dose. This slow inhalation was 
continued to total lung capacity (until their lungs were full of air), with breath holding for 
about 10 seconds after each inhalation. For the next dose, this was repeated 30 seconds 
later (Hindle et al., 1993). Subjects voided their urine pre-dosing, provided urine samples 
30 minutes after the start of the first dose, and cumulatively collected their urine for the 
24 hours post study dose. The volume of urine excreted was recorded and aliquots of 
each sample were frozen at -20° C prior to analysis. There was a 7-day washout period 
between administrations. The amount of BDP and its metabolites excreted in the urine 
were measured using the previously validated LC-(ESI+)-MS method described in 
section 3.3. 
4.3.2 Results 
Eight healthy non-smoking subjects (4 females) with mean (SD) age, height, and weight 
of 27.4 (5.9) years, 167.8 (9.0) cm and 62.6 (7.8) kg respectively completed this 
reproducibility study. Their demographic data are shown in table 4.10. 
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Table 4.10: Demographic data of the volunteers that participated in the study. 
 
 
 
 
 
The individual 0.5hr and 24 hours urinary excretion data and coefficient of variation of 
beclometasone dipropionate and its metabolites from analysed urine samples are 
presented in APPENDIX B.24 - B.26 (refer to the enclosed DVD). A summary of the 
mean (SD) 0.5hr and 24hr intra-subject CV% and inter-subject CV% of BDP and its 
metabolites post eight inhalations from  Qvar® EB (100μg) on five separate occasions are 
presented in table 4.11. The mean (SD) intra-subject coefficient of variation was 10.6 
(4.2) %, 10.7 (5.2) %, and 9.5 (2.9) % for the 0.5hr urinary excretion and was 8.2 (2.6) 
%, 8.4 (1.5) %, and 8.9 (3.0) % for the 24hr urinary excretion for 17-BMP, BOH and 
BDP, respectively. The mean (SD) inter-subject coefficient of variation was 18.1 (3.2) 
%, 25.4 (3.1) %, and 33.4 (3.3) % for the 0.5hr urinary excretion and was 30.6 (3.8) %, 
24.4 (1.4) %, and 27.7 (4.7) % for the 24hr urinary excretion for 17-BMP, BOH and 
BDP, respectively. 
Table 4.11: The mean (SD) intra-subject and inter-subject CV% of 17-BMP, BDP, and 
BOH post inhalations.  
 0.5hr 24hr 
17-BMP BOH BDP 17-BMP BOH BDP 
Intra-subject 
CV% 
10.6 
(4.2) 
10.7 
(5.2) 
9.5 
(2.9) 
8.2 
(2.6) 
8.4 
(1.5) 
8.9 
(3.0) 
Inter-subject 
CV% 
18.1 
(3.2) 
25.4 
(3.1) 
33.4 
(3.3) 
30.6 
(3.8) 
24.4 
(1.4) 
27.7 
(4.7) 
 
Subject Sex Age (years) Height (cm) Weight (kg) 
1 Female 29 155 55 
2 Male 31 168 67 
3 Male 23 175 65 
4 Female 32 170 75 
5 Male 19 180 66 
6 Male 23 174 50 
7 Female 25 160 60 
8 Female 37 160 63 
Mean (SD) --- 27.4 (5.9) 167.8 (9.0) 62.6 (7.8) 
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4.3.3 Discussion 
The observed intra-subject variability in healthy volunteers in this study was generally 
low (<11%) and there was a higher inter-subject variability (ranged from 18.1-33.4%). 
The high inter-subject variability is largely attributed to the variability between subjects’ 
lung deposition together with their renal excretion. This variability between subjects and 
within the same subject is consistent to that previously reported for salbutamol (Hindle 
and Chrystyn, 1992), gentamicin (Al-Amoud et al., 2005), formoterol (Nadarassan et al., 
2007), sodium cromoglycate (Aswania and Chrystyn, 2002), and terbutaline (Abdelrahim 
et al., 2011). The urinary excretion pharmacokinetic method for the determination of the 
relative and total lung bioavailability of beclometasone dipropionate post-inhalation is 
reproducible, and can be effectively used to compare different inhalation products and 
techniques. 
4.4 Conclusion 
The comparison of the 30 minutes urinary excretion highlights the usefulness of this 
index as a measure of the relative bioavailability of beclometasone to the lung following 
inhalation. The amounts of BDP and its metabolites recovered in urine samples post 
study doses of inhaled Qvar® EB with an oral dose of activated charcoal represents the 
pulmonary absorbed fraction. Since, there was no difference found between the 0.5hr 
urinary excretion of inhaled Qvar® EB and inhaled Qvar® EB plus charcoal, then the use 
of activated charcoal is not necessary. The lack of BDP or metabolites in the urine 
samples at 30 minutes post oral dose together with their high significant amounts post 
inhalation highlights that the urinary salbutamol pharmacokinetic of Hindle and Chrystyn 
(1992) can be applied to beclometasone dipropionate post inhalation.  
  
  
 
 
 
Chapter 5: In-vitro Dose Emission and Aerodynamic 
Particle Size Distribution, Relative Lung and 
Systemic Bioavailability of Beclometasone Inhaled 
From Clenil® MDI With and Without Spacer
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5.1. Introduction  
The assessment of pulmonary drug absorption and deposition is becoming increasingly 
important in drug development as this information can be effectively used to maximize 
pulmonary selectivity for locally acting drugs and to help determine the bioequivalence 
of generic inhalation products. There are several techniques available to describe lung 
deposition, including in-vitro approaches (the most well known being the Andersen 
Cascade Impactor). The use of in-vitro testing for inhalation methods has significantly 
improved the understanding of complex factors affecting aerosol delivery during 
inhalation. The information about size distribution of aerosol particles may be critical 
with regard to aerosol potential to deliver a dose to the lung. Cascade Impactors give 
information about the aerodynamic particle size distribution of the emitted dose. The 
Andersen Cascade Impactor (ACI) is the most commonly used impactor within the 
pharmaceutical industry for testing inhaled products (British Pharmacopoeia, 2009). In-
vitro methods have been found to be simpler, less expensive to perform than in-vivo 
experiments with human subjects, have limited variability and allow a more detailed 
analysis. The standard Andersen Cascade Impactor (ACI) is designed to be operated at 
low flow rates, 28.3 L/min, however more recently, modifications are available that 
allow it to be operated at higher flow rates of 60L/min and 90 L/min. The understanding 
of the behaviour of different formulations under different airflow rates provides 
information on how patients can get the most out of their inhaler devices by using an 
optimum inhalation technique.  
The potential of pharmacokinetic methods to successfully determine and predict lung 
deposition, bioavailability, and the systemic adverse effects of inhaled drug have been 
thoroughly investigated (Hindle and Chrystyn, 1992; Chege and Chrystyn, 1994; Hindle 
and Chrystyn, 1994; Hindle et al., 1997; Chege and Chrystyn, 2000; Aswania and 
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Chrystyn, 2001; Chrystyn, 2001; Aswania and Chrystyn, 2002). They are indirect 
measurements that uses plasma or urine concentrations to estimate the amount of drug 
which enters the systemic circulation via the pulmonary and the gastrointestinal tract 
routes (total systemic delivery), and thus provide valuable data which predict extra-
pulmonary effects (Newnham et al., 1993).   
Mazhar and Chrystyn (2008) used the Andersen Cascade Impactor and the urinary 
salbutamol pharmacokinetic method to compare the in-vitro and in-vivo drug delivery, 
respectively of a salbutamol MDI and when it was used with a Volumatic and an 
Aerochamber spacer. They found that there was no difference between the spacers. The 
fine particle dose for the spacers was similar to the MDI but the 30 minutes urinary 
excretion was greater due to inhalation from a static cloud, which occurs when using a 
spacer. The total dose emission was lower with the spacers, which was reflected by the 
lower 24hr urinary excretion. 
The pressurized metered dose inhaler is still one of the most frequently prescribed inhaler 
devices despite the fact that most patients cannot use it correctly. The most common 
mistake made by patients using a MDI is failure to continuously inhale slowly after 
inhaler activation (Chrystyn and Price, 2009). In addition, the high velocity of the inhaled 
particles leads to most of the dose from metered dose inhalers to deposit on the throat 
causing both local and systemic effects even with good patient coordination between 
actuation and inhalation (Toogood et al., 1980; Aswania and Chrystyn, 2001). 
Consequently, the development of the spacer was a major addition to the use of MDIs. 
Spacers allow the aerosol jet emitted from the MDI orifice to slow down and thus 
decrease throat deposition and either improve or not affect pulmonary deposition 
(Terzano, 2001). However, most spacers are made from plastic materials that are prone to 
the accumulation of electrostatic charge on their surface, especially during patient 
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handling. This electrostatic charge (ESC) developed on spacer surfaces can attract the 
charged aerosol particles from a metered dose inhaler and thus they stay in the spacer and 
become not available for inhalation (Clark and Lipworth, 1996a). The presence of this 
electrostatic charge can dramatically affect drug output from spacers and requires 
cautious handling procedures to avoid it. Using a metal spacer (Bisgaard et al., 1995), 
washing it in detergent without subsequent rinsing (Pierart et al., 1999) or firing several 
puffs into the spacer, can avoid static charge accumulation (Berg et al., 1998; Kenyon et 
al., 1998). 
There are now two brands of CFC-free beclometasone MDIs in the UK (Clenil 
Modulite® and Qvar®). These devices are not equipotent, and in order to limit prescribing 
errors and avoid confusion, the MHRA advises that CFC-free beclometasone MDIs 
should be prescribed by brand name. Qvar® contains beclometasone in solution and has 
been shown to deliver the drug as an extra-fine aerosol that results in a 2-2.5 fold greater 
potency compared with other CFC-containing beclometasone MDIs (Leach et al., 2002). 
Clenil Modulite® is equipotent to the CFC- innovator product (Becotide®), therefore, a 
straightforward substitution of doses can be performed (Chaplin and Head, 2007). The 
summary of product characteristics (SPC) for Clenil® MDI recommends using the 
Volumatic spacer. 
The first study was designed to investigate the in-vitro dose emission characteristics for 
Clenil® MDI when used alone and when attached to different spacers. The second study 
was designed to use the urinary beclometasone dipropionate pharmacokinetic method to 
investigate the relative lung and systemic bioavailability of these spacers. 
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5.2. In-vitro dose emission and aerodynamic particle size distribution of the dose 
emitted from Clenil® inhaler  
5.2.1. Method 
The aim of this investigation is to use the Andersen Cascade Impactor (ACI) to 
determine the aerodynamic particle size distribution of the dose emitted from Clenil® 
MDI: 
I. With different spacers at a flow rate of 28.3L/min. 
II. Alone at different flow rates (28.3, 60, and 90 L/ min). 
5.2.1.1. Equipment and inhalation devices 
Equipment: 
- MDI sampling apparatus: Copley Scientific Ltd, UK. 
- Andersen MKII Cascade Impactor: Copley Scientific Ltd, UK. 
- A/E fibre glass filter discs: 25mm; Pall Corporation, USA. 
- GF 50 filter: Copley Scientific Ltd, UK. 
- HCP5 pump:  High Capacity Pump, Copley Scientific Ltd, UK. 
- An Electronic Digital Flow Meter: DFM2000, Copley Scientific Ltd, UK. 
- Parafilm M Laboratory film: Pechiney Plastic Packaging, USA. 
- Silicone fluid spray: Releasil B silicone spray, Propower silicone lubricant, Premier 
Farnell, PLC, UK. 
- Critical Flow Controller Model TPK2000: Copley Scientific Ltd, UK. 
LC-(ESI+)-MS method conditions: sample preparation, analysis procedures, and 
chromatographic conditions were as reported in section 3.2. 
Inhaler and spacer devices used as follows: 
 Clenil® metered dose inhaler (MDI) labelled as a nominal dose of 250µg 
beclometasone dipropionate per dose (Chiesi, UK). 
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 The Aerochamber Plus spacer [APLUS], 145ml holding chamber, (Trudell Medical 
International Europe Ltd, UK). 
 The Volumatic spacer device [VOL] 750ml holding chamber, (GlaxoSmithKline, 
UK). 
 The Optimiser spacer [OPT], 50ml small plastic tube spacer having a cross section 
of 2.5 x 3.3cm (Teva Pharmaceuticals, UK). 
5.2.1.2. Procedure  
5.2.1.2.1. Total emitted dose 
The nominal dose is the labelled dose and is the amount that is metered in the device 
during the inhalation process. The total emitted dose (TED) is the total amount of drug 
exiting the device and hence available to the user. The dose emitted from Clenil® MDI 
(labelled as a nominal dose of 250µg beclometasone dipropionate per puff, Chiesi, UK) 
was determined using the MDI Dose sampling unit (DSU) ; Copley Scientific Ltd, UK. 
Determinations were made for Clenil® metered dose inhaler alone and when it is attached 
to each of the following spacers: 
 The Aerochamber Plus spacer that is washed in detergent solution, followed by 
either rinsing [APLUSR] or not rinsing [APLUSNR] with water, and then 
allowed to air dry. 
 The Optimiser spacer that is washed in detergent solution, followed by either 
rinsing [OPTR] or not rinsing [OPTNR] with water, and then allowed to air dry. 
 The Volumatic spacer device that is washed in detergent solution, followed by 
either rinsing [VOLR] or not rinsing [VOLNR] with water, and then allowed to 
air dry. 
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The MDIs were first primed by firing two doses to waste before use (Barry and 
O'Callaghan, 2003). The Clenil® MDI either alone or connected to each spacer was 
inserted tightly into the mouthpiece adaptor of the dose sampling unit (DSU) and aligned 
along the horizontal axis. A High Capacity Vacuum Pump (HCP5, Copley Scientific Ltd, 
UK) was connected to the apparatus outlet in order to achieve the desired airflow. The 
MDI sampling unit apparatus (Copley Scientific Ltd, UK) with a critical flow controller 
model TPK (Copley Scientific Ltd, UK) was used to produce sonic flow conditions 
according to Pharmacopoeia recommendations (European Pharmacopeia, 2001; British 
Pharmacopoeia, 2005; United States Pharmacopeia, 2005). The final filter was a 25 mm 
A/E fibreglass filter (Pall Corporation, USA). Parafilm M Laboratory film (Pechiney 
Plastic Packaging, USA) was used to seal the apparatus. Two separate doses from Clenil 
(250µg) were discharged into the DSU. The flow through each MDI / MDI + Spacer was 
28.3 L min-1 with flow duration of 8.5 sec such that the inhalation volume was 4L. The 
flow was measured by an electronic digital flow meter (DFM2000, Copley Scientific Ltd, 
UK). Ten determinations were made for each dose emission (n=10). During each 
determination, one dose was discharged into the spacer followed by the in-vitro 
inhalation manoeuvre. The procedure was repeated until the set number of doses has 
been discharged. Following dose emission the dose sampling unit was dismantled and 
washed with 60:40% methanol: water and the filter was completely immersed in 60:40 
methanol: water and sonicated for 5 minutes to remove any filter entrained drug. All 
solutions collected from the dose sampling unit post Clenil® MDI and Clenil® MDI + 
spacer actuation was made up to 250ml, and 50ml volume, respectively, while solutions 
collected from any spacer was made up to 100ml. The amount of drug in the dose 
sampling unit and the spacer was determined by using the previously developed and 
validated LC-(ESI+)-MS method previously described in section 3.2 in this thesis. 
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5.2.1.2.2. The aerodynamic particle size characterization 
The aerodynamic particle size characterization is the size of particles or droplets that 
make the emitted aerosol cloud. It determines the percentage of the total emitted dose 
that reaches the lungs during an inhalation. The particle size analysis of aerosols from 
pressurized metered dose inhalers (pMDIs) was determined by using the Andersen 
Cascade Impactor (ACI) according to compendial procedures (European Pharmacopeia, 
2001; United States Pharmacopeia, 2005). This technique provides a direct link with the 
mass of therapeutically active ingredient and the aerodynamic particle size of the emitted 
dose, which has been accepted as an indication of the likely site of particles deposition 
within the respiratory tract (Mitchell et al., 2003). The study was divided into two parts, 
in the first part the aerodynamic particle size distribution of Clenil® MDI either alone or 
plus spacers was measured with the Andersen Cascade Impactor (ACI) at a flow rate of 
28.3L/min. In the second part, the aerodynamic particle size distribution of Clenil® MDI 
alone is determined at higher flow rates of 60L/min and 90L/min. 
The Andersen Cascade Impactor (ACI) consists of eight stages and a final collection 
filter (25 mm A/E fibre glass filter, Pall Corporation, USA). All parts of the ACI were 
first washed in deionised water and acetone and allowed to dry. The collection plates 
were then coated with Silicone fluid spray (Releasil B silicone spray, Pro-power silicone 
lubricant, Premier Farnell, PLC, UK) and left to dry for one hour prior to analysis. 
Parafilm M Laboratory film (Pechiney Plastic Packaging, USA) was used to seal the 
apparatus. Two actuations from Clenil® MDI (250µg) were delivered into the impactor 
for each inhaler or inhaler/spacer combination. For the first part of the study, the ACI 
was assembled with the coated impaction plates according to the effective cut-off 
diameter of each stage at a flow rate of 28.3L/min for each Clenil® MDI or Clenil® 
MDI/spacer combination. A Critical Flow Controller model TPK2000 (Copley Scientific 
Ltd, UK) and an electronic digital flow meter (DFM2000, Copley Scientific Ltd, UK) 
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was used to adjust the flow rate at 28.3 L/min with flow duration of 8.5 seconds 
(equivalent to 4L inhalation volume).  
For the second part of the study, the ACI was assembled and connected to Clenil® MDI 
alone to determine the aerodynamic particle size distribution at 60L/min and 90L/min. 
The modified ACI was used for operating at 60L/min and 90L/min. The Critical Flow 
Controller Model TK2000 (Copley Scientific, UK) was again used to ensure sonic flow 
and provide the required inhalation flow and volume. In the 60L/min version, stages, 0 
and 7 are removed and replaced with two additional stages, -1 and -0. Similarly, in the 
90L/min version, stages 0, 6, and 7 are replaced with three additional stages, -2,-1, and -
0. The vacuum flow was provided by a HCP5 (High Capacity Vacuum Pump, Copley 
Scientific, UK). Five determination were made for each inhaler or inhaler/spacer 
combination (n=5). The apparatus was dismantled and washed with 60:40% methanol: 
water and the filter was completely immersed in 60:40 methanol: water and sonicated for 
5 minutes to remove any filter entrained drug. All solutions collected from the induction 
port post Clenil® MDI and Clenil® MDI + spacer actuation was made up to 100ml and 25 
ml volume, respectively, while solutions collected from any spacer and from different 
ACI stages post MDI and MDI+ spacer actuation was made up to volumes 100ml, and 
25ml, respectively. The amount of beclometasone dipropionate deposited in the induction 
port (IP), spacer, and the various ACI stages were determined using the previously 
developed and validated LC-(ESI+)-MS method described in section 3.2. The amount 
deposited at the various stages was expressed in µg. 
The mass mean aerodynamic diameter (MMAD), geometric standard deviation (GSD), 
total emitted dose (TED),  percentage of fine particle fraction (%FPF) and fine particle 
dose (FPD) were calculated for each MDI and MDI + spacer using CITDAS software 
program (Copley Scientific Ltd, UK).  
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The total emitted dose (TED) is the dose that leaves the inhaler device and is available to 
the patient. The fine particle dose (FPD) is the cumulative amount of drug particles with 
size <5µm. The fine particle fraction (% FPF) is the FPD expressed as a percentage of 
the total amount deposited ex-mouth piece. The mass mean aerodynamic diameter 
(MMAD) was obtained from the logarithm of the effective cut-off diameter 
corresponding to 50% undersize. The geometric standard deviation (GSD) is the square 
root for the size corresponding to 84.1% less than the stated size divided by the square 
root of the size for 15.9% (GSD= , where d15.9 and d84.1 are the sizes 
corresponding to the mass-percentile values of 15.9% and 84.1% respectively, for the 
cumulative size distribution (United States Pharmacopeia, 2005). 
5.2.2. Statistical analysis 
Statistical analysis of the total emitted dose and aerodynamic particle size 
characterization of Clenil® MDI alone at different flow rates (28.3, 60, and 90 L/min) 
and Clenil® MDI alone or with different spacer combinations were carried out by one 
way analysis of variance (ANOVA) test using SPSS V17.0 (SPSS Inc., Chicago, USA). 
5.2.3. Results 
5.2.3.1. Total emitted dose  
The individual total emitted dose of two 250 µg actuations of beclometasone 
dipropionate from Clenil® MDI alone or plus different spacers expressed in µg and as 
percentage of nominal dose is presented in APPENDIX B-27, and B-28 (refer to the 
enclosed DVD), respectively. A summary of the mean (SD) data is shown in table 5.1. 
The results are expressed graphically in figure 5.1. 
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Table 5.1: Mean (SD) Dose emission from two 250µg doses of BDP from Clenil® MDI 
determined at a flow 28.3 L min-1, expressed in µg and as percentage of nominal dose, 
(n=10). 
 
 
Dose (µg) % of nominal dose 
MDI TED 390.8 (45.6) 78.2 (9.1) 
VOLNR TED 227.9 (21.1) 45.6 (4.2) Spacer 232.8 (34.9) 46.6 (7.0) 
APLUSNR TED 205.2 (48.5) 41.0 (9.7) Spacer 206.0 (47.4) 41.2 (9.5) 
OPTNR TED 158.7 (17.4) 31.7 (3.5) Spacer 220.9 (43.1) 44.2 (8.6) 
VOLR TED 163.0 (54.0) 32.6 (10.8) Spacer 252.3 (39.8) 50.5 (8.0) 
APLUSR TED 152.3 (31.5) 30.5 (6.3) Spacer 295.9 (38.3) 59.2 (7.7) 
OPTR TED 118.4 (24.1) 23.7 (4.8) Spacer 319.3 (47.0) 63.9 (9.4) 
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Figure 5.1: Beclometasone dipropionate amounts (a) total emitted dose (b) deposited in 
each spacer (c) mean (SD) total emitted dose and the amount deposited in each spacer 
expressed as a percent of the nominal dose obtained from Clenil® MDI at a flow rate 28.3 
L min-1, (n=10). 
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5.2.3.2. Aerodynamic particle size characterization 
A summary of the aerodynamic particle size distribution data obtained from the 
Andersen Cascade Impactor (ACI) for Clenil® MDI (250µg) either alone or plus different 
spacers at 28.3 L/min are illustrated in table 5.2 and figure 5.2. In addition, the effect of 
flow rate on particle size distribution of Clenil® MDI was investigated. The results 
obtained from the Andersen Cascade Impactor for Clenil® MDI at 28.3, 60, and 90L/min 
are summarized in table 5.3 and figures 5.3 - 5.5. 
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Table 5.2: A summary of the mean (SD) data obtained from the Andersen Cascade Impactor (ACI) following two actuations of Clenil® MDI (250µg) 
either alone or plus different spacers at 28.3 L/min. Values quoted in µg unless specified, (n=5). 
 Stage Cut-off MDI VOLNR APLUSNR OPTNR VOLR APLUSR OPTR 
Amount left in spacer 
 
------- 224.3 (35.0) 233.9 (25.7) 240.9 (26.6) 271.8 (20.9) 301.6 (49.3) 305.5 (33.9) 
Induction Port (IP)  251.3 (22.0) 27.5 (5.7) 31.6 (10.7) 28.7 (7.1) 19.2 (3.4) 26.2 (5.4) 24.3 (6.7) 
0 10 7.3 (1.3) 11.2 (2.9) 13.2 (2.9) 11.5 (0.6) 9.0 (1.5) 11.5 (0.6) 5.9 (1.7) 
1 9 15.3 (4.1) 12.6 (3.0) 16.1 (3.2) 15.2 (3.1) 12.9 (3.5) 16.0 (2.6) 10.1 (3.6) 
2 5.8 15.5 (2.3) 20.4 (5.0) 17.6 (5) 20.1 (7.6) 15.3 (2.4) 15.7 (4.1) 14.2 (3.7) 
3 4.7 19.6 (2.8) 24.1 (4.9) 19.3 (5.8) 18.0 (6.4) 21.8 (2.3) 18.4 (6.3) 14.2 (2.6) 
4 3.3 18.8 (5.4) 34.2 (4.8) 28.6 (7.9) 19.7 (4.0) 28.3 (5.4) 25.5 (4.7) 18.4 (4.7) 
5 2.1 24.8 (9.4) 41.6 (9.7) 36.9 (3.6) 20.6 (2.1) 25.8 (1.9) 17.2 (8.5) 10.6 (0.5) 
6 1.1 13.8 (2.7) 23.9 (5.2) 28.8 (8.1) 12.9 (3.3) 14.5 (2.7) 9.8 (2.7) 6.4 (1.6) 
7 0.7 11.8 (1.7) 14.2 (4.9) 13.1 (4.6) 8.7 (4.0) 7.0 (2.1) 7.1 (2.4) 3.9 (2.0) 
Filter 0.4 3.8 (1.4) 9.4 (1.2) 6.9 (2.9) 7.9 (2.7) 8.4 (1.7) 7.5 (3.3) 4.4 (2.6) 
Total emitted dose (TED) (µg) 381.8 (6.3) 218.9 (23) 212.1 (21.0) 163.4 (15.2) 162.2 (13) 155.3 (15.4) 112.5 (8.0) 
Total emitted dose (% of nominal dose) 76.4 (1.7) 43.8 (4.6) 42.4 (4.2) 32.7 (3.0) 32.44 (2.6) 31.1 (3.1) 22.5 (1.6) 
FPD (µg) 97.6 (20.8) 153.9 (19.4) 138.8 (22.2) 93.3 (17.6) 110.6 (7.4) 90.6 (18.8) 62.7 (8.2) 
% FPF of nominal dose 19.5 (4.2) 30.8 (3.9) 27.8 (4.4) 18.8 (3.5) 22.1 (1.5) 18.1 (3.8) 12.5 (1.6) 
%FPF of TED 25.6 (5.4) 70.3(5.6) 65.2 (4.9) 57.6 (5.3) 68.3 (2.1) 58.1 (7.2) 55.6 (3.6) 
MMAD (µm) 2.8 (0.4) 2.3 (0.1) 2.2 (0.1) 3.1 (0.2) 2.7 (0.2) 3.1 (0.3) 3.3 (0.3) 
GSD (no units) 2.2 (0.2) 2.3 (0.2) 2.7 (0.3) 2.3 (0.1) 2.2 (0.1) 2.2 (0.1) 1.8 (0.1) 
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Table 5.3: A summary of the mean (SD) data obtained from the Andersen Cascade Impactor (ACI) following two actuations of Clenil® MDI (250µg) 
alone at 28.3, 60, and 90 L/min flow rates. Values quoted in µg unless specified, (n=5). 
 
 
 
 
 
 
 
 
 
 
 
 
 28.3L/min 60L/min 90L/min 
Induction Port (IP) 251.3 (22.0) 200.8 (19.4) 187.3 (14.7) 
-2 --- --- 17.2 (4.8) 
-1 --- 13.1 (3.1) 17.1 (3.6) 
-0 --- 19.1 (3.3) 14.7 (3.5) 
0 7.3 (1.3) --- --- 
1 15.3 (4.1) 17.4 (2.4) 12.2 (1.7) 
2 15.5 (2.3) 20.1 (4.1) 20.2 (5.7) 
3 19.6 (2.8) 23.0 (2.4) 42.1 (3.2) 
4 18.8 (5.4) 38.6 (2.1) 19.6 (1.1) 
5 24.8 (9.4) 27.9 (1.5) 10.2 (1.0) 
6 13.8 (2.7) 14.5 (6.0) --- 
7 11.8 (1.7) 8.6 (0.7) --- 
Filter 3.8 (1.4) --- 8.0 (2.0) 
Total emitted dose (TED) (µg) 381.8 (6.3) 383.2 (22.7) 348.6 (19.0) 
Total emitted dose (% of nominal dose) 76.4 (1.7) 76.6 (4.5) 69.7 (3.8) 
FPD (µg) 97.6 (20.8) 138 (7.1) 116.5 (5.7) 
% FPF of nominal dose 19.5 (4.2) 27.6 (1.4) 23.4 (1.1) 
%FPF of TED 25.6 (5.4) 36.1 (3.3) 33.6 (0.5) 
MMAD (µm) 2.8 (0.4) 2.2 (0.1) 2.2 (0.2) 
GSD (no units) 2.2 (0.2) 2.9 (0.2) 3.3 (0.2) 
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Figure 5.2: Mean beclometasone dipropionate emitted from Clenil MDI alone or with 
different spacers at a flow rate of 28.3 L min-1 (a) deposited in each stage of the ACI (µg) 
(b) aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose, (n=5). 
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Figure 5.3: Mean amount of beclometasone dipropionate deposited in each stage of the 
ACI from Clenil® MDI alone at 28.3, 60, and 90 L min-1 flow rates, expressed in µg, 
(n=5). 
 
 
Figure 5.4: The mean aerodynamic distribution of the emitted dose of beclometasone 
dipropionate emitted from Clenil® MDI alone at 28.3, 60, and 90 L min-1 flow rates, 
(n=5). 
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Figure 5.5: Mean (SD) fine particle dose and induction port deposition of  
beclometasone dipropionate emitted from Clenil MDI alone at 28.3, 60, and 90 L min-1 
flow rates, expressed in µg, (n=5).  
5.2.3.3. Statistical analysis 
A summary of the statistical analysis when using different spacers with Clenil® MDI at 
28.3L/min is presented in table 5.4. The statistical analysis data of Clenil® MDI operated 
at different flow rates is summarized in table 5.5. The FPD and % FPF of the emitted 
dose of the MDI operated at 28.3L/min was significantly lower than that at 60 L/min 
(p<0.05). In addition, the amount of drug deposited in the induction port was 
significantly lower (p<0.05) for the 90L/min when compared to that obtained at 
28.3L/min. 
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Table 5.4: Mean difference (95% confidence interval) for different spacers used with Clenil® MDI. 
 
Comparator FPD (µg) FPF% MMAD TED (µg) Spacer deposition(µg) 
VOLNR 
C-MDI 56.3 (26.5,86.2)** 44.7 (35.8, 53.6)*** -0.5 (-1,-0.04)* -162.9 (-192.4, -133.4)*** --- 
APLUSNR -15.07 (-44.9,14.8) -5.1 (-14,3.9) -0.03 (-0.5,0.4) -6.9 (-36.4, 22.6) 9.7 (-55.3, 74.6) 
OPTNR 60.6 (30.7, 90.4)*** 12.7 (3.7, 21.6)** -0.8 (-1.3, -0.3)** 55.5 (26, 85)** -16.7 (-81.6, 48.3) 
VOLR 43.3 (13.5, 73.1)** 2.0 (-6.9,10.9) -0.4 (-0.9,0.1) 56.7 (27.2, 86.2)** -47.6 (-112.5, 17.4) 
APLUSR 63.3 (33.5,93.2)*** 12.2 (3.2, 21.1)* -0.8 (-1.3,-0.4)** 63.7 (34.2, 93.2)*** -77.3 (-142.2,-12.4)* 
OPTR 91.3 (61.4, 121.1)*** 14.7 (5.8, 23.6)** -1.0 (-1.5, -0.6)*** 106.5 (77, 136)*** -81.2 (-146.2, -16.2)* 
APLUSNR 
C-MDI 41.3 (11.4, 71.1)* 39.6 (30.7, 48.6)*** -0.5 ((-1,-0.08)* -169.7 (-199.2, -140.2)*** --- 
OPTNR 45.5 (15.7,75.3)** 7.6 (-1.3,16.5) -0.8 (-1.3,-0.4)** 48.6 (19.1,78.1)** -7.0 (-72,58) 
VOLR 28.2 (-1.6,58.1) -3.1 (-12,5.9) -0.4 (-0.9,0.02) 49.9 (20.4,79.4)** -37.9 (-102.9,27.1) 
APLUSR 48.3 (18.4, 78.1)** 7.1 (-1.8,16) -0.9 (-1.3, -0.4)** 56.8 (27.3, 86.1)** -67.7 (-132.6,-2.7)* 
OPTR 76.2 (46.3,106)*** 9.6 (0.7,18.6)* -1.1 (-1.5,-0.6)*** 99.6 (70.1, 129.1)*** -71.5 (-136.5, -6.6)* 
OPTNR 
C-MDI -4.2 (-34.1,25.6) 32.0 (23.1, 41)*** 0.3 (-0.2, 0.8) -218.4 (-247.9, -188.9)*** --- 
VOLR -17.3 (-47.1,12.6) -10.7 (-19.6,-1.7)* 0.4 (-0.06,0.9) 1.2 (-28.3, 30.7) -30.9 (-95.9,34.1) 
APLUSR 2.8 (-27.1,32.6) -0.5 (-9.4,8.4) -0.03 (-0.5,0.4) 8.2 (-21.3,37.7) -60.7 (-125.6, 4.3) 
OPTR 30.7 (0.8, 60.5)* 2.0 (-6.9,11) -0.2 (-0.7,0.2) 51.0 (21.5, 80.5)** -64.5 (-129.5, 0.5) 
VOLR 
C-MDI 13.0 (-16.8,42.9) 42.7 (33.8, 51.6)*** -0.1 (-0.6, 0.4) -219.6 (-249.1, -190.1)*** --- 
APLUSR 20.0 (-9.8,49.9) 10.2 (1.2, 19.1)* -0.4 (-0.9,0.02) 6.9 (-22.6,36.4) -29.8 (-94.7, 35.2) 
OPTR 48.0 (18.1,77.8)** 12.7 (3.8, 21.6)** -0.6 (-1.1, -0.2)* 49.7 (20.2, 79.2)** -33.6 (-98.6, 31.3) 
APLUS R C-MDI -7.0 (-36.8,22.8) 32.5 (23.6, 41.5)*** 0.3 (-0.1, 0.8) -226.5 ((-256, -197)*** --- OPTR 27.9 (-1.9, 57.8) 2.5 (-6.4, 11.5) -0.2 (-0.7, 0.3) 42.8 (13.3, 72.3)** -3.9 (-68.8, 61.1) 
OPTR C-MDI -34.9 (-69.8, -5.1)* 30.0 (17.5, 42.5)*** 0.5 (0.08,1)* -269.3 (-298.8, -239.8)*** --- 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
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Table 5.5: Mean difference (95% confidence interval) for Clenil® MDI operated at different flow rates. 
 
Comparator FPD (µg) FPF% MMAD TED (µg) Induction port deposition (µg) 
28.3L/min 
60 L/min -40.4 (-71.5, -9.3)* -10.6 (-20.6, -0.5)* 0.6 (-0.07,1.27) -1.4 (-37.6, 34.9) 50.6 (-1.4, 102.5) 
90L/min -19.3 (-50.5, 11.7) -8.0 (-18.1, 2.1) 0.6 (-0.07,1.27) 33.2 (-3.0, 69.5) 64.0 (12.1, 116)* 
60 L/min 90L/min 21.04 (-10.1, 52.1) 2.6 (-7.5, 12.6) -2.4x10-16 (-0.7, 0.7) 34.6 (-1.7, 70.9) 13.5 (-38.5, 65.4) 
 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
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5.2.4. Discussion 
This study clearly demonstrates that the total amount of drug as well as the FPD and the 
FPF obtained from the same dose of Clenil® MDI was greatly affected by the different 
spacers used. The results show that the total emitted dose from the MDI alone is 
significantly (p<0.001) greater than that from all MDI/spacers combinations used. This is 
consistent with the markedly greater amounts of drug deposited in the induction port 
when using the MDI compared to other inhalation methods using the spacer. This amount 
deposited in the induction port is considerably important as it represents the 
oropharyngeal cavity of the patient. This is very beneficial in the case of inhaled steroids 
as the spacer walls becomes the major site of drug deposition and not the oropharynx. 
The reduction in the oropharyngeal drug deposition by spacers limits the occurrence of 
local side effect (e.g., oral candidiasis and dysphonia) (Salzman and Pyszczynski, 1988; 
Fergusson et al., 1991; Hanania et al., 1995; Hardy et al., 1996; Zainudin, 1997; Buhl, 
2006) and systemic side effects (Brown et al., 1990; Selroos and Halme, 1991; Meeran et 
al., 1995; O'Callaghan and Barry, 1999) following inhaled corticosteroids therapy. 
Salzman and Psyszczynski (1988) compared the administration of BDP to systemic 
steroid dependent patients using the MDI alone or the MDI attached to the Aerochamber 
spacer. The addition of the Aerochamber spacer in this study was very advantageous as 
besides eliminating the oropharyngeal thrush and reducing candida colonisation from 
66% to 33%, it also improved the FEV1 gradually leading to cessation of the systemic 
corticosteroid therapy to many patients over 6 months.  
This different behaviour of the MDI when used with or without a spacer is due to the 
space that the spacer provides. This distance reduces the primary droplet size by 
providing extra time for the complete evaporation of the propellant and slows down the 
fast moving aerosol. Thereby, it increases the sedimentation of these large particles on 
the spacer walls. In contrast, when using the MDI alone, the aerosol particles travel at 
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high speed, which enhances their deposition in the induction port and therefore, 
decreases the FPF. This is in agreement with a previous beclometasone dipropionate 
study that reported a significant reduction in the amount of non-respirable BDP available 
for inhalation when using a spacer. In this study using the large Volumatic spacer device 
increased the amount of drug delivered to the lung while decreasing the total steroid dose  
available to the patient (O'Callaghan et al., 1994).  
It is evident from the above results that differences in handling and washing the spacers 
greatly affected the aerodynamic particle size distribution of inhaled aerosols. This may 
be explained by the different electrostatic properties of both not rinsed (NR) and rinsed 
(R) spacers. Several studies have demonstrated that most commercially available MDIs 
are highly charged especially the new HFA-formulations, which were found to even have 
greater electrostatic charge than their CFC predecessors (Peart et al., 2003; Kwok et al., 
2006; Mitchell et al., 2007b). In addition to the charge of the aerosol from the MDI, the 
electrically insulated material of plastic spacers is also prone to develop electrostatic 
charge (ESC) due to frictional contact during handling. Thus, when the highly charged 
aerosol particles comes into contact with the plastic spacer device inherent electrostatic 
charge, mutual repulsion between the charged particles causes them to move to the 
periphery of the aerosol cloud and contact the spacer walls. Consequently, this leads to 
aerosol drug retention within these devices, resulting in a significant reduction of the 
drug aerosol available for inhalation. However, several methods reported in the literature 
have been found to significantly avoid this electrostatic charge accumulation on spacer 
surfaces, thus allowing its optimum drug delivery. In-vitro studies have shown that 
coating plastic spacer with an antistatic lining increased the fine particle dose of sodium 
cromoglycate from a Fisonair spacer (O'Callaghan et al., 1993), and the fine particle dose 
of budesonide from the Nebuhaler spacer (Barry and O'Callaghan, 1995). Alternatively, 
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washing plastic spacers in detergent and leaving it to drip dry was also described as an 
effective method for reducing the electrostatic charge in spacer devices.  
As shown from the results, washing the spacer in detergent and leaving it to drip dry 
without subsequent water rinsing was found to give significantly more emitted dose and 
FPD from the spacer than when the same spacer is rinsed with water following detergent 
use. In addition, the lower MMAD of the not rinsed spacers compared to the rinsed ones 
implies that there are differences in the aerosol particles behaviour and distribution with 
these two different handling methods. This was also confirmed by the observed decrease 
in the amount of drug deposited in the not rinsed spacers compared to the rinsed ones. 
The mean (SD) amounts of BDP deposited in the spacer were 224.3 (35) vs 271.8 (20.9), 
233.9 (25.7) vs 301.6 (49.3), and 240.6 (26.6) vs 305.5 (33.9) for the VOLNR vs VOLR, 
the APLUSNR vs APLUSR, and for the OPTNR vs OPTR. This difference can be 
explained by the different levels of electrostatic charge accumulated on the surface of 
these NR and R plastic spacers. Soaking the spacer in detergent solution without 
subsequent rinsing was more successful in eliminating the electrostatic charge from the 
spacer surface leading to less attraction of the charged aerosol particles on the spacer 
walls, thus increasing drug output. In contrast, the detergent coated followed by water 
rinsing washing protocol did not provide adequate protection against electrostatic charge, 
which may further leads to inconsistent drug delivery. These findings are consistent with 
many studies that found this washing procedure more effective in reducing the spacers 
charge and increasing lung deposition. Coating with detergents without subsequent 
rinsing has been shown to increase the fine particle fraction of salbutamol by approx. 
55% to 70% compared to unwashed highly charged spacers (Wildhaber et al., 1996b). 
Pierart et al (1999) observed that water rinsed spacers had a substantial electrostatic 
charge and lower salbutamol fine particle delivery. The mean (SD) percentages of the 
178 
 
label claim emitted mass/actuation, were 53.1(3.1) % vs. 36.2 (3.5) % for the detergent 
treated when not rinsed and the detergent treated rinsed spacers, respectively.  
In addition, the results from this study show that the amount of drug in the potentially 
respirable aerodynamic particle size range varies considerably for a particular MDI, 
depending on the spacer used. The results clearly show a more significant FPD from the 
not rinsed Volumatic (VOLNR) at p<0.01 and the not rinsed Aerochamber Plus 
(APLUSNR) at p<0.05 combination with C-MDI than when using the MDI alone. 
However, the FPD from the MDI alone was non-significant when compared with the rest 
of the spacers used except with the rinsed Optimiser (OPTR) spacer that significantly 
decreased the FPD obtained from Clenil® inhaler (p<0.05). On the other hand, the % FPF 
of the emitted dose from the MDI alone was significantly lower (p<0.001) than that 
obtained when using any MDI/spacer combination.  
Terzano and Mannino (1999) have shown that using the Volumatic spacer with 
beclometasone dipropionate significantly reduced the MMAD and increased the 
percentage of fine particles than when using the MDI alone. This is also in accordance 
with another in-vitro study by Feddah et al (2001) who reported a significant increase in 
the fine particle mass (FPM) of BDP from different commercially available MDI 
products with the Volumatic spacer and suggested that the respirable dose appears to be a 
function of the shape and volume of the spacer device. Other studies investigated the 
effect of using spacer devices with an HFA solution formulation of BDP and reported a 
marked increase in the FPF when using the Aerochamber plus and the Ace spacer 
devices than when using the MDI alone (Williams et al., 2001; Smyth et al., 2004).  
The results showed that when comparing the three detergent-washed not water rinsed 
spacers, more FPD and lower MMAD was delivered at the following order via the 
Volumatic (VOLNR), the Aerochamber Plus (APLUSNR), and then, the Optimiser 
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(OPTNR). The not rinsed Volumatic (VOLNR) spacer used with the MDI showed the 
least amount of drug deposition inside the spacer with more BDP delivered to the 
impactor and consequently a higher FPF than all other methods. Both the not rinsed 
Aerochamber Plus (APLUSNR) and the not rinsed Volumatic (VOLNR) significantly 
increased the FPD when compared to the MDI alone while other spacers did not.  
This different BDP aerosol behaviour form these spacers may be due to their different 
shapes, sizes, and washing procedures. Despite of the spacers’ simple concept and 
structure, these variations between spacers were found to affect the amount of drug 
available for inhalation by altering its dose emission characteristics. When a dose is 
discharged into a spacer, impaction of particles on its walls is expected to increase with 
decreasing the spacer size due to the greater plume velocity in smaller spacers. 
Furthermore, the larger volume spacer such as the Volumatic would result in a more 
efficient evaporation of the aerosol dose (Mazhar and Chrystyn, 2008). Thus, in this 
study the smaller size of the Optimiser spacer may not have been sufficient to allow 
complete evaporation of the aerosol propellant before reaching the impactor. This was 
further confirmed by the smaller emitted dose from the smaller volume spacers compared 
to the larger volume ones. In this study the mean (SD) of the total emitted dose of the not 
rinsed Volumatic (750ml), the not rinsed Aerochamber Plus (150ml), and the not rinsed 
Optimiser (50ml) were 218.9 (23.0), 212.0 (21.0), and 163.4 (15.2), respectively.  
Mazhar and Chrystyn (2008) compared the in-vitro aerodynamic particle size distribution 
and the in-vivo drug delivery obtained from Ventolin Evohaler (GlaxoSmithKline, UK) 
when attached to the Volumatic (VOL) and Aerochamber Plus valved holding chamber 
(APLUSVHC). This study reported a higher fine particle dose, smaller MMAD, and 
small increase in lung bioavailability when using the larger Volumatic spacer when 
compared to the smaller APLUSVHC spacer. 
180 
 
Barry and O’Callaghan (1996) compared the output of sodium cromoglycate, salbutamol, 
and budesonide from different spacer devices and reported considerable differences in 
their drug delivery. In this study, the dose of sodium cromoglycate in small particles 
recovered from the large volume Fisonair and the small volume spacer were 118% and 
33%, respectively than that recovered from the MDI alone. However, this large 
difference in the spacer behaviour with sodium cromoglycate did not occur with 
budesonide as the amount of budesonide recovered from the larger and the small volume 
spacer were 92 and 78%, respectively which indicates that the effects of spacers can also 
change with the type of drug used. In addition, a year later O’Callaghan (1997) has 
reported that the output of sodium cromoglycate particles with an aerodynamic diameter 
of less than 5 µm increases with spacer length and diameter. Several previous studies 
have reported that more small particle beclometasone, fluticasone (125μg) and salmeterol 
was recovered from the Volumatic spacers than from the Aerochamber (p<0.001) (Barry 
and O'Callaghan, 1999). Similarly, a recent in-vitro study reported an increased 
respirable dose of  salbutamol exiting the large volume spacers (>500ml) compared to 
smaller ones (<250ml) (Hall et al., 2011).  Thus, as previously published (Agertoft and 
Pedersen, 1994; Ahrens et al., 1995; Barry and O'Callaghan, 2000) and further confirmed 
in this study, the size of the spacer may affect the drug amount available for inhalation. 
It was previously reported that small volume spacers (<100ml) can actually reduce the 
amount of respirable drug available to the patient, compared to the use of the MDI alone, 
and they offer no protection against hand-breath coordination. In contrast, large volume 
spacers have been shown to offer good protection against poor hand breath coordination 
as well as reducing oropharyngeal deposition without reducing the respirable dose 
available to the patient (Kim et al., 1987; Wilkes et al., 2001).  
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The influence of higher inspiratory flow rates (60 and 90L/min) on the aerosol particle 
size distribution of Clenil® MDI was also evaluated and compared to that at 28.3L/min. 
As shown from the results illustrated in tables 5.3 and 5.5, increasing the flow rate from 
28.3 L/min to 60 L/min showed a lower MMAD and a significant increase (p<0.05) in 
both the FPD and the % FPF. Also increasing the flow rate from 28.3L/min to 90 L/min 
were associated with lower MMAD and higher FPD for the 90L/min flow rate compared 
to the 28.3L/min flow rate, however, the results were non-significant (p>0.05). 
These results are consistent with a previous in-vitro study that reported a significant 
increase in the fine particle mass (FPM) of salbutamol when the flow rate was increased 
from 30 to 55L/min (Smith et al., 1998). Similarly a later study reported that the FPM of 
Becotide® inhaler (100µg BDP), Flixotide® inhaler (250µg FP), and Pulmicort® aerosol 
(200µg BUD) were significantly increased when the flow rate increased from 30L to 
60L/min and not much affected when the flow rate increased from 60L to 90L/min. This 
same study also demonstrated the effect of flow rate on the MMAD and showed 
significantly lower MMAD when increasing the flow rate from 30 to 60L/min for BDP 
and FP inhalers and when increasing the flow rate from 60 to 90L/min for the 
Budesonide inhaler (Feddah et al., 2000). These findings were further confirmed by a 
more recent study that demonstrated that the effect of different flow rates on the aerosol 
particles performance. This study reported that increasing the flow rate form 30L/min to 
60L/min led to a significant increase in the FPF from 35.4±0.5% to 41.5±1.3%  and from 
35.9±0.5% to 44.7±0.98% for FP in Flixotide®, and Seretide® inhalers, respectively (Hoe 
et al., 2009). However, these in-vitro studies are in contrast with previous in-vivo 
(Newman et al., 1982b; Tomlinson et al., 2005) and in-vitro lung deposition studies that 
showed that higher flows reduce (Terzano and Mannino, 1999) or even not affect lung 
deposition (Ross and Schultz, 1996).  
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Theoretically, if the flow is increased the impaction would be greater. However, the 
results show the opposite. This could be due to the design and the material of the 
induction port. However, the decrease in amounts deposited in the induction port needs 
some examination. The results show that particle bounce may be occurring. This should 
increase the amounts deposited on the first few stages. It is expected that the fine particle 
dose should remain the same. Whether particle bounce is occurring is difficult to explain 
because the plates were coated with silicone. At this stage no conclusion can be drawn 
except that others have replicated the same phenomenon (Smith et al., 1998) and thus 
warrants further investigation. 
5.3. Relative lung and systemic bioavailability of beclometasone dipropionate 
inhaled from Clenil® metered dose inhaler with different spacers using urinary 
drug excretion post inhalation 
5.3.1. Method 
The aim of this investigation is to apply the urinary pharmacokinetic method of 
beclometasone dipropionate after an inhalation to highlight the advantage of spacers to 
improve lung deposition, reduce systemic delivery, and compare different spacers when 
attached to a Clenil® metered dose inhaler. In addition, to determine the effect of 
different spacer handling procedures on drug delivery by comparing drug output from 
either water rinsed or not rinsed detergent coated spacers. 
5.3.1.1. Equipment and inhalation device 
Inhaler and spacer devices used as follows: 
 Clenil® metered dose inhaler (MDI) labelled as nominal dose of 250µg 
beclometasone dipropionate per dose (Chiesi, UK). 
 The Aerochamber Plus spacer [APLUS], 145ml holding chamber, (Trudell Medical 
International Europe Ltd, UK). 
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 The Volumatic spacer device [VOL], 750ml holding chamber, (GlaxoSmithKline, 
UK). 
 The Optimiser spacer [OPT], 50ml small plastic tube spacer having a cross section 
of 2.5 x3.3cm (Teva Pharmaceuticals, UK). 
LC-(ESI+)-MS method conditions: sample preparation, analysis procedures, and 
chromatographic conditions were as reported in section 3.3 in this thesis. 
5.3.1.2. Subjects and study design 
Ethical approval for the study was obtained from the University of Huddersfield. Twelve 
healthy (six females), non-smoking volunteers older than 18 years with an average 
FEV1> 90% of predicted, gave their written consent to take part in the study. Clenil 
Modulite® MDI was examined with different spacers, APLUS, VOL, and OPT. Each 
spacer-MDI combination was assessed following adequate washing of the spacer with 
detergent followed by either thoroughly rinsing (R) or not rinsing with water (NR). All 
spacers were allowed to air dry before each study. The order of administration was 
randomised and there was a 7-day break between each study inhalation.  
On separate study days, following a light breakfast each subject inhaled the following 
doses.  
Eight 250μg (2 mg in total) inhalations of beclometasone dipropionate from a Clenil 
Modulite® metered dose inhaler (Chiesi, UK) used with 
 No spacer [Clenil® MDI]. 
 The Aerochamber Plus spacer that is pre-washed in detergent solution, followed 
by either rinsing [C-APLUSR] or not rinsing [C-APLUSNR] with water, and then 
allowed to air dry. 
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 The Optimiser spacer that is pre-washed in detergent solution, followed by either 
rinsing [C-OPTR] or not rinsing [C-OPTNR] with water, and then allowed to air 
dry. 
 The Volumatic spacer device that is pre-washed in detergent solution, followed 
by either rinsing [C-VOLR] or not rinsing [C-VOLNR] with water, and then 
allowed to air dry. 
All subjects were trained on how to use the inhaler devices according to the patient 
information leaflet. When using the MDI, subjects were trained to remove the cap, exhale 
slowly as far as comfortable, put the MDI into their mouth, and seal their lips round the 
mouthpiece. They were then instructed to start a slow inhalation through their mouth and 
actuate the MDI immediately after the start of this slow inhalation. This slow inhalation 
continued until their lungs were full of air (total lung capacity) usually over 3-5 seconds. 
After inhalation they held their breath for 10 seconds and the next dose was  inhaled 30 
seconds later (Hindle et al., 1993). All subjects were also trained to standardize their 
inhalation technique when using spacers according to the instructions produced by the 
manufacturer. When using spacers, subjects exhaled to residual volume as much as 
possible, the dose was discharged into the spacer and within one second subjects inhaled 
slowly and deeply for about 3 to 5 seconds. This was followed by a breath hold for at 
least 10 seconds. The doses were repeated as required after waiting for about 30 seconds 
between doses. Subjects emptied their bladder prior to each study dose and then urine 
samples were collected at 30 minutes, and cumulatively for 24 hours post dosing of each 
study dose. The volume of urine excreted was recorded and aliquots of each sample were 
frozen at -20°C prior to analysis.  
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5.3.2. Analysis 
5.3.2.1. Sample analysis 
The LC-(ESI+)-MS method with solid phase extraction that has been developed and 
validated for the assay of beclometasone dipropionate and its metabolites from urine 
samples was used to identify amounts excreted in the urine samples as explained in 
section 3.3. In addition, the amount of drug left in each spacer device was determined by 
the LC-(ESI+)-MS method described in section 3.2. 
5.3.2.2. Statistical analysis 
Statistical analysis of the 30 minutes and the 24hr urinary excretion of beclometasone 
dipropionate and its metabolites following administration of Clenil® MDI either alone or 
with water rinsed or not rinsed detergent coated spacers and the amount left in the 
spacers were accomplished using a one way analysis of variance (ANOVA) test using 
SPSS V17.0 (SPSS Inc., Chicago, USA). The mean difference with 95% confidence 
interval was calculated for each inhalation method. In addition, One-way analysis of 
variance with the application of Bonferroni correction was used to determine any 
difference between the urinary excretions of Clenil when used alone and when it is 
attached to each spacer. To identify equivalence of the urinary excretions between the 
inhalation methods, the 30 minutes and cumulative 24hr amounts, excreted for each 
inhalation method, were normalised for the nominal dose and then log transformed. From 
the mean square error of the analysis of variance, using patients and inhalation method as 
the main factors, the mean ratio (90% confidence interval) was calculated. 
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5.3.3. Results 
Twelve (six females) healthy non smoking subjects completed the study. Their mean 
(SD) age, weight and height was 31.2 (8.9) years, 66.3 (8.1) kg and 166.7 (7.6) cm, 
respectively. The demographic details of the participants are described in table 5.6.  
Table 5.6: Demographic data of the volunteers that participated in the study, (n=12). 
 
 
 
 
 
 
 
The individual urinary amounts of beclometasone dipropionate and its metabolites 17-
BMP and BOH excreted at 0.5hr, and 24hr post dose, for each of the twelve volunteers 
post eight inhalation from Clenil® MDI alone or with different spacers are shown in 
APPENDIX B.29-B.31 (refer to the enclosed DVD) and figures 5.6 - 5.7. The amount of 
beclometasone dipropionate left in each spacer device following inhalation of Clenil® 
MDI (250µg) study doses is shown in APPENDIX B.32 (refer to the enclosed DVD). A 
summary of the mean (SD) amounts of urinary BDP and its metabolites excreted from 
the twelve subjects 0.5hr, 24 hours and the amount retained in each spacer device post 
inhalation from Clenil® MDI either alone or with different spacers is represented in table 
5.7 and figures 5.8 - 5.9.  
 
Subject Sex Age (years) Height (cm) Weight (kg) 
1 Female 27 160 65 
2 Male 30 165 75 
3 Male 28 166 55 
4 Male 33 178 60 
5 Female 29 155 60 
6 Male 23 168 67 
7 Male 32 174 71 
8 Female 19 160 71 
9 Male 23 168 71 
10 Female 51 161 63 
11 Female 37 165 56 
12 Male 42 180 82 
Mean (SD) - 31.2 (8.9) 166.7 (7.6) 66.3 (8.1) 
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Figure 5.6: The 0.5hr individual amounts of (a) beclometasone (b) 17-beclometasone 
monopropionate (c) beclometasone dipropionate excreted in urine post inhalation of 
Clenil MDI study doses with and without spacer, (n=12). 
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Figure 5.7: The 24hr individual amounts of (a) beclometasone (b) 17-beclometasone 
monopropionate (c) beclometasone dipropionate excreted in urine post inhalation of 
Clenil MDI study doses with and without spacers, (n=12). 
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Table 5.7: Mean (SD) amounts of beclometasone dipropionate and its metabolites excreted 0.5hr, and 24hr post inhalation of Clenil® MDI study doses 
with and without spacers, expressed in µg, (n=12). 
 
Device Amount left in 
spacer (µg) 
17-BMP (µg) BOH (µg) BDP (µg) 
0.5hr 24hr 0.5hr 24hr 0.5hr 24hr 
MDI --- 5.0 (1.8) 28.9 (6.0) 7.4 (1.9) 88.5 (15.4) 3.7 (0.6) 30.2 (6.6) 
VOLNR 670.8 (74.4) 6.3 (2.2) 21.0 (3.1) 10.0 (2.8) 67.7 (14.4) 4.8 (0.9) 19.8 (2.6) 
APLUSNR 758.0 (136.5) 5.6 (2.0) 16.3 (2.4) 8.6 (1.6) 57.4 (12.3) 4.0 (0.8) 19.4 (2.7) 
OPTNR 705.4 (84.4) 4.8 (1.6) 16.4 (2.7) 7.1 (1.4) 50.8 (13.7) 3.6 (0.6) 17.4 (2.3) 
VOLR 732.9 (74.9) 4.6 (1.2) 16.1 (2.8) 6.7 (1.1) 48.0 (10.4) 3.6 (0.6) 15.9 (1.9) 
APLUSR 784.8 (46.9) 4.2 (1.4) 14.7 (3.3) 5.7 (1.1) 44.8 (14.0) 3.5 (0.8) 14.2 (2.1) 
OPTR 807.0 (120.5) 4.1 (1.6) 13.6 (2.9) 6.2 (1.6) 44.9 (12.3) 3.3 (0.6) 14.7 (1.8) 
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Figure 5.8: The 0.5hr mean (SD) amounts of beclometasone dipropionate and its 
metabolites excreted post inhalation of Clenil MDI study doses with and without spacers, 
(n=12). 
 
Figure 5.9: The 24hr mean (SD) amounts of beclometasone dipropionate and its 
metabolites excreted post inhalation of Clenil MDI study doses with and without spacers, 
(n=12). 
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A summary of the statistical comparison between urinary amounts of BDP and its 
metabolites excreted 30 minutes and 24hrs post inhalation from Clenil® MDI for the 
twelve subjects is presented in tables 5.8 and 5.9, respectively. A summary of the 
statistical comparison between the amounts of beclometasone dipropionate retained in 
each spacer post inhalation of Clenil® MDI (250µg) study dose  via different detergent 
prewashed spacers that is followed by either rinsing or not rinsing with water is presented 
in table 5.10. A summary of the mean ratio (90% confidence limits) between Clenil when 
used alone compared to when it is attached to each spacer with respect to the nominal 
dose is presented in table 5.11. These values are presented separately for BDP, 17 BMP, 
and BOH, as well as for all three metabolites combined.  
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Table 5.8: Mean difference (95% confidence interval) for the amount of beclometasone dipropionate and its metabolites excreted post 30 minutes 
using Clenil® MDI and Clenil® MDI + spacers. 
Inhaler Comparator MDI VOLNR APLUSNR OPTNR VOLR APLUS R 
17-BMP 
VOLNR -1.3 (-1.7,-0.8)*** --- --- --- --- --- 
APLUSNR -0.6 (-1,-0.1)* 0.7 (0.2,1.1)** --- --- --- --- 
OPTNR 0.2 (-0.2,0.7) 1.5 (1,1.9)*** 0.8 (0.4,1.3)*** --- --- --- 
VOLR 0.5 (0, 0.9)* 1.7 (1.2,2.1)*** 1.0 (0.6,1.5)*** 0.2 (-0.2,0.7) --- --- 
APLUSR 0.9 (0.4,1.4)*** 
 
2.1 (1.7,2.6)*** 1.5 (1, 1.9)*** 0.7 (0.2,1.1)** 0.4 (-0.02, 0.9) --- 
OPTR 1.0 (0.5,1.4)*** 2.2 (1.7,2.6)*** 1.5 (1.1,2)*** 0.7 (0.3,1.2)** 0.5 (0.1,1 )* 0.1 (-0.4, 0.5) 
BOH 
VOLNR -2.6 (-3.3,-1.8)*** --- --- --- --- --- 
APLUSNR -1.1 (-1.9, -0.4)** 1.4 (0.7,2.2)*** --- --- --- --- 
OPTNR 0.4 (-0.4,1.1) 2.9 (2.2,3.7)*** 1.5 (0.8,2.2)*** --- --- --- 
VOLR 0.7 (-0.1,1.4) 3.2 (2.5,4)*** 1.8 (1.1,2.5)*** 0.3 (-0.4,1) --- --- 
APLUSR 1.7 (1,2.5)*** 4.3 (3.6,5)*** 2.9 (2.1,3.6)*** 1.4 (0.6,2.1)*** 1.1 (0.3,1.8)*** --- 
OPTR 1.3 (0.6,2)*** 3.9 (3.2,4.6)*** 2.5 (1.7,3.2)*** 1.0 (0.2,1.7)* 0.7 (-0.1,1.4) -0.4 (-1.1,0.3) 
BDP 
VOLNR -1.1 (-1.4,-0.8)*** --- --- --- --- --- 
APLUSNR -0.4 (-0.7,-0.1)* 0.8 (0.5,1.1)*** --- --- --- --- 
OPTNR 0.1 (-0.2,0.3) 1.2 (0.9,1.5)*** 0.4 (0.1,0.7)** --- --- --- 
VOLR 0.1(-0.2,0.3) 1.2 (0.9,1.5)*** 0.42 (0.12,0.7)** 0.009 (-0.3,0.3) --- --- 
APLUSR 0.2 (-0.1,0.5) 1.3 (1,1.6)*** 0.6 (0.3,0.9)*** 0.1 (-0.16,0.44) 0.1 (-0.7,0.4) --- 
OPTR 0.4 (0.1,0.7)* 1.5 (1.2,1.9)*** 0.8 (0.5,1.1)*** 0.4 (0.05,0.7)* 0.3 (0.04,0.6)* 0.2 (-0.1,0.5) 
 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
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Table 5.9: Mean difference (95% confidence interval) for the amount of beclometasone dipropionate and its metabolites excreted post 24hr using 
Clenil® MDI and Clenil® MDI + spacers. 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
Inhaler Comparator MDI VOLNR APLUSNR OPTNR VOLR APLUS R 
17-BMP 
VOLNR 7.9  (5.8, 10.1)*** --- --- --- --- --- 
APLUSNR 12.6 (10.5, 14.7)*** 4.7 (2.0, 7.3)*** --- --- --- --- 
OPTNR 12.5 (10.4, 14.6)*** 4.6 (1.9, 7.2)** -0.1 (-2.8, 2.6) --- --- --- 
VOLR 12.9 (10.7, 15.0)*** 4.9 (2.2, 7.6)*** 0.2 (-2.4, 2.9) 0.3 (-2.3,3.0) --- --- 
APLUSR 14.2 (12.1, 16.4)*** 6.3 (3.6, 9.0)*** 1.6 (-1.1, 4.3) 1.7 (-1.0, 4.4) 1.4 (-1.3, 4.0) --- 
OPTR 15.3 (13.2, 17.4)*** 7.4 (4.7, 10.0)*** 2.7 (0.01, 5.4) 2.8 (0.1, 5.5)* 2.4 (-0.2, 5.1) 1.1 (-1.6, 3.8) 
BOH 
VOLNR 20.8 (14.4, 27.1)*** --- --- --- --- --- 
APLUSNR 31.1 (24.8, 37.4)*** 10.3 (3.5, 17.2)** --- --- --- --- 
OPTNR 37.7 (31.3, 44.0)*** 16.9 (10.0, 23.7)*** 6.5 (-0.3, 13.4) --- --- --- 
VOLR 40.5 (34.2, 46.8)*** 19.7 (12.9, 26.5)*** 9.4 (2.5, 16.2)** 2.8 (-4.0, 9.7) --- --- 
APLUSR 43.7 (37.3, 50.0)*** 22.9 (16.0, 29.7)*** 12.5 (5.7, 19.3)*** 6.0 (-0.9, 12.8) 3.2 (-3.7, 10.0) --- 
OPTR 43.6 (37.3, 49.9)*** 22.8 (16.0, 29.6)*** 12.4 (5.6, 19.3)*** 5.9 (-0.9, 12.7) 3.1 (-3.7, 9.9) -0.1 (-6.9, 6.8) 
BDP 
VOLNR 10.3 (8.1, 12.5)*** --- ---- --- --- --- 
APLUSNR 10.8 (8.6, 13.0)*** 0.5 (-1.8, 2.7) --- --- --- --- 
OPTNR 12.8 (10.6, 15.1)*** 2.5 (0.3, 4.7)* 2.1 (-0.2, 4.3) --- --- --- 
VOLR 14.3 (12.1, 16.5)*** 4.0 (1.7, 6.2)*** 3.5 (1.3, 5.7)** 1.4 (-0.8, 3.6) --- --- 
APLUSR 16.0 (13.8, 18.2)*** 5.7 (3.5, 7.9)*** 5.2 (3.0, 7.4)*** 3.1 (0.9, 5.4)** 1.7 (-0.5, 3.9) --- 
OPTR 15.5 (13.3, 17.7)*** 5.1 (2.9, 7.3)*** 4.7 (2.5, 6.9)*** 2.6 (0.4, 4.8)* 1.2 (-1.0, 3.4) -0.5 (-2.7, 1.7) 
194 
 
Table 5.10: Mean difference (95% confidence interval) for the amount of beclometasone dipropionate retained in each spacer post inhalations of from 
Clenil® MDI. 
Inhaler Comparator VOLNR APLUSNR OPTNR VOLR APLUS R 
Clenil® 
MDI 
APLUSNR -87.1 (-151.1, -23.2)** --- --- --- --- 
OPTNR -34.6 (-98.5, 29.3) 52.5 (-11.4, 116.4) --- --- --- 
VOLR -62.1 (-126, 1.9) 25.1 (-38.8, 89.0) -27.4 (-91.4, 36.5) --- --- 
APLUSR -136.4 (-200.4, -72.5)*** -49.3 (-113.2, 14.6) -101.8 (-165.7, -37.9)** -74.4 (-138.3, -10.5)* --- 
OPTR -114 (-177.9, -50.0)*** -26.8 (-90.8, 37.1) -79.4 (-143.3, -15.4)* -51.9 (-115. 8,12) 22.5 (-415,86.4) 
 
 
 
 
 
 
 
 
195 
 
Table 5.11: Mean ratio (90% confidence interval) for Clenil MDI compared to Clenil MDI/spacer (when normalised for the nominal dose). 
 
Urinary excretion 
0.5hr 
BDP 17-BMP BOH All combined 
APLUSNR 91.0 (85.1, 97.3) 90.2 (83.3, 97.8) 85.5 (79.1, 92.5) 88.9 (84.9, 93.1) 
APLUSR 106.0  (99.1, 113.4) 121.4 (112.0, 131.5) 128.4 (118.8, 139.0) 118.2 (112.9, 124.0) 
VOLNR 76.8 (71.8, 82.1) 80.3 (73.6, 87.5) 74.8 (68.9, 81.0) 77.3 (73.9, 80.7) 
VOLR 101.5 (94.9, 108.5) 107.5 (98.5, 117.2) 108.2 (99.8, 117.2) 105.7 (101.1, 110.4) 
OPTNR 101.2 (95.3, 107.6) 105.3 (97.6, 113.7) 96.3 (90.3, 102.6) 102.2 (93.7, 111.4) 
OPTR 112.1 (105.5, 119.1) 125.5 (116.3, 135.4) 121.3 (113.9, 129.3) 120.3 (110.4, 131.3) 
24hr 
APLUSNR 153.0 (139.4, 168.0) 175.4 (159.2, 193.3) 155.1 (139.8, 172.1) 160.8 (152.0, 170.2) 
APLUSR 209.2 (190.6, 229.8) 197.2 (179.0, 217.3) 202.2 (182.2, 224.3) 202.8 (191.7, 214.5) 
VOLNR 149.3 (136.1, 164.0) 136.6 (125.9, 148.1) 131.7 (120.7, 143.5) 139.0 (132.3, 145.9) 
VOLR 186.3 (169.6, 204.4) 179.0 (165.0, 194.0) 185.9 (170.6, 202.8) 183.7 (174.9, 192.9) 
OPTNR 171.1 (154.8, 188.9) 174.9 (159.4, 192.1) 177.4 (157.8, 199.2) 170.7 (157.1, 185.7) 
OPTR 201.2 (182.2, 222.3) 212.3 (193.3, 233.3) 200.4 (178.2, 225.2) 212.8 (195.8, 231.1) 
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5.3.4. Discussion 
The effectiveness of inhaled therapy for topical diseases such as asthma depends on the 
ability of the inhalation device to deliver the correct dose of active drug substance to the 
lung, which is the site of action with minimal deposition to other unwanted regions that 
have no role in therapy and only contribute to side effects. Thus, the use of spacer 
devices is highly recommended with inhaled steroids therapy as they always reduce 
oropharyngeal deposition, may correct for poor hand-breath coordination and may 
increase lung deposition compared with MDI alone, and thus improve lung-targeting 
(Newman and Newhouse, 1996; Newman, 2004). 
Following Clenil MDI inhalation, the use of the Volumatic and the Aerochamber Plus 
spacers without rinsing (VOLNR and APLUSNR) resulted in significantly higher 
amounts of urinary beclometasone dipropionate and its metabolites after 30 minutes post 
dosing compared to the MDI alone which  indicates more efficient delivery of drug to the 
lungs using these spacers. However, the results were not significant when using the 
Optimiser spacer without rinsing (OPTNR). The above findings are consistent with 
several studies that confirmed that the use of spacers may be associated with a significant 
increase in the relative lung bioavailability compared to the MDI alone (Newman et al., 
1984; Hindle and Chrystyn, 1994; Aswania and Chrystyn, 2001; Silkstone et al., 2002; 
Mazhar and Chrystyn, 2008). 
As previously shown from the results, the use of any of the spacer devices whether large 
or small resulted in significantly (p<0.001) lower urinary excretion of BDP and its 
metabolite 24 hours post dosing from Clenil MDI for all the individuals. This decrease in 
systemic delivery of drug is due to deposition of part of the dose on the walls of the 
spacer devices themselves instead of deposition in the mouth (Newman and Newhouse, 
1996). This is due to the spacer ability to trap large particles and allow smaller particles 
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to pass through to the patient, hence only a small fraction of the inhaled dose is deposited 
in the oropharynx. This is consistent with previous studies using the urinary excretion 
method (Chege and Chrystyn, 1994; Hindle and Chrystyn, 1994).  
Silkstone et al (2002) used a urinary pharmacokinetic method to compare the lung and 
systemic delivery of salbutamol following inhalation from a MDI, a MDI attached to a 
spacer (MDI + SP), and a nebuliser (NEB). This study reported that doses inhaled from a 
metered dose inhaler attached to a spacer delivered more to the lungs and less to the 
systemic circulation than either the same doses from a MDI used alone or five times the 
dose given via a jet nebuliser (Silkstone et al., 2002).  
The decrease in the quantity of beclometasone dipropionate that is deposited in the 
oropharynx after inhalation is highly important for inhaled corticosteroids as it 
diminishes the risk of topical adverse effects like thrush and dysphonia, as well as 
minimizing oral beclometasone absorption that could results in unwanted systemic side 
effects (Derendorf, 1997). Other several studies have investigated the effect of using 
spacer devices with beclometasone dipropionate MDIs on the suppression of free cortisol 
levels, which is considered to be a sensitive marker of adrenal activity and hence 
systemic delivery and safety. These studies reported a reduction in systemic effect from 
the high dose inhaled corticosteroids with spacers without detrimental effect on control 
of asthma symptoms (Prahl and Jensen, 1987; Brown et al., 1990; Farrer et al., 1990). 
The results from this study and from previous findings clearly demonstrated the 
improved therapeutic index of ICS when used with spacer devices and accounts for the 
recent guidelines recommending using spacers when delivering high doses of 
beclometasone (BTS/SIGN, 2008).  
In all cases, more urinary amounts of BDP and its metabolites were excreted at 30 
minutes and 24hrs post dosing from detergent prewashed spacers without subsequent 
198 
 
rinsing (NR spacers) compared to the same type of spacer prewashed in detergent 
solution then rinsed (R spacers). The higher lung deposition with these not rinsed spacers 
is most likely explained by the anti-static effect of the detergent coating. These results are 
in agreement with previous in-vivo studies that found a small increase in the output of 
salbutamol from spacers only after soaking it in soapy water without subsequent rinsing 
and found it to be as effective as an antistatic lining in reducing the effect of electrostatic 
charge on drug delivery (Clark and Lipworth, 1996a; Wildhaber et al., 2000a). Similarly, 
Pierart et al (1999) reported an increase in mean lung deposition of radio labelled 
salbutamol in healthy subjects from 11.5% through a static spacer to 45.6% through a 
detergent-coated spacer and further indicated that the antistatic property of detergent can 
lasts for at least four weeks. The influence of an electrostatic charge in the Babyhaler and 
Aerochamber spacers with HFA salbutamol MDI was investigated and found to reduce 
drug delivery to the lung by more than two fold (Anhoj et al., 1999). The use of detergent 
coating signifies a reduction of electrostatic charge on spacer surfaces by lowering their 
surface potentials (Kwok et al., 2006) which increases the half life of medication within 
the spacer (Barry and O'Callaghan, 1999). Thus, the electrostatic charge present on the 
walls of the spacer can have a profound effect on the behaviour of the aerosol cloud 
within the holding chamber and decrease drug output from it. Conversely, reduction or 
elimination of electrostatic charges on spacer surfaces improves drug delivery. It was 
previously reported that pre-washing spacers with detergent solution and then air drying  
without subsequent water rinsing is a highly effective method that improved lung 
deposition (Kenyon et al., 1998; Pierart et al., 1999), and enhanced the clinical effect  
(Wildhaber et al., 2000b). This accounts for recommending detergent washing of spacers 
on a regular basis in at least one guideline (BTS/SIGN, 2008). These results support the 
Aerochamber Plus patient information leaflet (PIL) recommending its detergent washing 
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without subsequent rinsing and contradicts the patient information leaflet (PIL) 
recommendation to rinse the Volumatic after washing. 
The 30 minutes urinary excretion results also indicate that the use of the not rinsed 
Volumatic (VOLNR) spacer resulted in significantly higher amounts of urinary excretion 
of BDP and its metabolites compared to all other inhalation methods. This is in 
agreement with other studies that stated that large volume holding chambers such as the 
Volumatic appear to augment lung deposition to a greater degree than tube spacers or 
small holding chambers such as the Aerochamber (Newman and Newhouse, 1996).  
Another pharmacokinetic study that used plasma salbutamol as indicative of lung 
deposition showed considerable variations in lung deposition between different large and 
small volume spacers from an HFA inhaler system. This study reported that the relative 
lung deposition was greater when the MDI attached to a Volumatic spacer compared 
with the Aerochamber, and the latter was similar to the MDI used alone (Lipworth and 
Clark, 1998a). Aswania et al (2001) compared Cromogen® MDI either alone or attached 
to the Volumatic spacer. The mean (SD) urinary excretion of sodium cromoglycate was 
34.1 (20.2) and 211.7 (123.5) µg following MDI and MDI + Volumatic spacer, 
respectively. This shows that the MDI attached to a large volume spacer delivers more 
sodium cromoglycate to the lungs than the MDI alone (Aswania and Chrystyn, 2001). 
Other radiolabelled and clinical studies in both adults and children have shown that large 
volume spacers were more effective than the MDI alone especially during an asthma 
attack, whereas small volume spacers were only as effective as the optimally used MDI 
(Cushley et al., 1983; Newman et al., 1984; Levison et al., 1985; Keeley, 1992).  
The better performance of large volume spacers compared to smaller ones may be due to 
the increased drug residence time in the bigger spacer of the large volume spacer with 
better chance for drug delivery. In addition, small volume spacers have an increased 
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likelihood of particle impaction on device walls compared to large volume spacers. 
Inhalation from large volume spacers with few second delays between actuation and 
inhalation have the advantage of not significantly affecting drug deposition, while for 
small volume spacers, this delay would result in even greater loss of drug in the device 
(Newman et al., 1988; Pedersen, 1996).  
The difference in the 30 minutes urinary excretion for the not rinsed Volumatic compared 
to the MDI alone is not as large as that for other drugs. This agrees with previous 
evidence that suggests that HFA-MDIs lung deposition is not greatly affected by the 
addition of a spacer (Dubus et al., 2001; Woodcock et al., 2002a). This is may be due to 
the multimodal aerosol particle size distribution of HFA-MDIs; this is a phenomenon in 
which primary droplets can break up into smaller secondary droplets. Thus, the aerosol 
emitted from HFA MDIs has only a small portion of its volume occupied by droplets and 
appears to be pre-atomized prior to reaching the atomization nozzle. As a result, it will be 
expected to undergo limited particle size reduction following passage through the 
atomization nozzle. Furthermore, the presence of ethanol in these formulations, which is 
a vapour pressure suppressant, will further reduce the initial velocity required for the post 
nozzle break up of HFA-MDIs droplets (Smyth and Hickey, 2003; Smyth et al., 2004). 
Another explanation is that the results could be due to the greater electrostatic charge of 
the CFC-free beclometasone MDI (Kwok et al., 2006; Mitchell et al., 2007b) 
The in-vitro and in-vivo studies of BDP inhaled from Clenil® MDI discussed in this 
chapter suggest that all spacer devices employed substantially reduced the amount of 
drug deposited in the oropharynx. This was clearly indicated by the lower 24hr urinary 
excretions of BDP and metabolites and the lower amount of drug deposited in the 
induction port of the impactor with spacers use following the in-vivo and in-vitro studies 
respectively. Indeed, the in-vitro higher emitted dose for the MDI alone compared with 
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that of the spacers did translate into more in-vivo drug delivery to the systemic 
circulation. This is in agreement with several previous in-vitro (O'Callaghan et al., 1994; 
Feddah et al., 2001) and in-vivo (Vidgren et al., 1987; Hindle and Chrystyn, 1994; 
Aswania and Chrystyn, 2001) studies which demonstrated similar effects when using 
spacers with MDIs.  
The combination of the higher fine particle dose together with the higher total emitted 
dose of the not rinsed Volumatic in the in-vitro study accounts for its significantly higher 
30 minutes and 24hr urinary excretion amounts post inhalation compared to all other 
inhalation methods. Also, comparison of the MDI vs the not rinsed Optimiser (OPTNR) 
post inhalation showed significantly more 24hr urinary excretion (p<0.001) and non 
significant 30 minutes urinary excretion which was consistent with the in-vitro 
significant increase in TED (p<0.001), and the non-significant difference in the FPD. 
Yet, their in-vitro results showed non-significant difference in their MMAD and 
significant difference for their % FPF at p<0.001. In addition, the in-vivo significant 
difference (p<0.001) of BDP and metabolites between the not rinsed and the rinsed 
Volumatic spacer is consistent with the significant in-vitro FPD difference (p<0.01) for 
the same inhalation group; however, their % FPF and MMAD difference showed non-
significant difference.  
When comparing the MDI alone or plus the not rinsed spacers, both the in-vitro FPD and 
the in-vivo 30 minutes urinary excretion showed the same following order: the Volumatic 
> Aerochamber Plus > MDI > Optimiser. However,  the in-vitro TED and the in-vivo 
24hr urinary excretion following the same inhalation methods decreased in the following 
order; MDI > Volumatic > Aerochamber Plus > Optimiser. 
To sum up, the in-vitro and in-vivo results in this study showed that the FPD together 
with the TED are more important in-vitro parameters that represent the 30 minutes and 
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24hr urinary drug excretion, respectively post dosing. Seale and Harrison (1998) 
confirmed that the increase in fine particle mass is directly correlated to an increased 
lung absorption and hence an increased airway availability. This study further suggested 
that calculation of the fine particle mass of an administered dose rather the absolute dose 
given to the patient correlates well to the in-vivo drug delivery of both HFA-BDP and 
CFC-BDP. In addition, another study reported that determination of the in-vitro FPD of 
salbutamol from the ACI was found to be the most suitable impactor fraction that 
represents good in-vitro-in-vivo correlations (Weda et al., 2004). The observations from 
this study provide further evidence of good in-vitro- in-vivo correlations and in 
accordance with previous suggestions (Seale and Harrison, 1998; Silkstone et al., 2002; 
Barry and O'Callaghan, 2003; Mazhar and Chrystyn, 2008). 
5.4. Conclusion 
The significant reduction in the in-vitro amount deposited in the induction port, which 
represents the oropharyngeal cavity of the patient, and the significant reduction of the in-
vivo 24 hr urinary excretion results when using any of the spacers clearly emphasized the 
importance of using spacers with inhaled corticosteroids therapy. This supports the 
British Thoracic Society recommendation for the management of asthma to use spacers 
regularly especially with high doses of inhaled corticosteroids.  
Each brand of spacer device has different drug delivery characteristics and the efficiency 
of spacers depends upon its size and the control of electrostatic charge effects, which 
causes drug delivery to vary considerably according to how the spacer is handled. Large 
volume spacer devices improved drug delivery to the lungs from Clenil® MDI when 
compared to smaller volume ones, which was consistent with previous findings. These 
results were further supported by the in-vitro measurements of inhaled Clenil fine 
particle dose. In addition, simple variations in spacers handling techniques altered the 
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level of the electrostatic charge on the spacer walls. Both in-vitro and in-vivo studies 
confirmed the superiority of the both small and large detergent coated spacers without 
subsequent rinsing in improving lung deposition compared to the water rinsed ones. This 
emphasizes the potential of the electrostatic charge as a key determinant limiting aerosol 
drug delivery from MDI/spacer combination. However, it is still unknown whether these 
differences in handling will have a clinically significant effect. The use of the large 
volume spacer that is properly prewashed in soapy solution without subsequent rinsing to 
minimize the effects of static charge was the most efficient inhaler device used.  
The results of this chapter demonstrate that the urinary pharmacokinetic method that has 
been previously developed and validated for beclometasone dipropionate in Chapter 4 is 
a potential tool to compare different inhalation methods. 
  
  
 
 
 
Chapter 6: In-vitro Dose Emission and Aerodynamic 
Particle Size Distribution, Relative Lung and 
Systemic Bioavailability of Beclometasone Inhaled 
From Qvar® MDI and Qvar® EB With and Without 
Spacer 
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6.1. Introduction 
Beclometasone dipropionate is a well established inhaled corticosteroid in the 
prophylactic management of mild, moderate and severe asthma in adults and children. 
The combination between beclometasone dipropionate (BDP) and HFA-134a propellant 
results in an aerosol with much smaller particles than those produced by CFC-BDP 
inhalers. An example of an HFA-BDP inhaler is Qvar® developed by Teva 
Pharmaceuticals, UK that has reported a MMAD of 1.1 µm (Leach et al., 1998a; Smyth 
and Hickey, 2003). Qvar® is available as a metered dose inhaler (MDI) and as a breath-
actuated inhaler device. The extra-fine properties of Qvar® formulation accounts for its 
improved lung deposition, better penetration into the peripheral airways, improved 
asthma control and health related quality of life (Juniper et al., 2002). Previously, such 
peripheral airways could only be reached using systemically administered therapy (Leach 
et al., 2002; Skoner, 2008). Several clinical studies have shown that Qvar is effective at 
half the dose of CFC-BDP formulations (Davies et al., 1998; Leach et al., 1998a; Busse 
et al., 2000; Agertoft et al., 2003). This improved efficacy of Qvar® at a lower dose leads 
to equivalent asthma control and even fewer side effects (Lipworth and Jackson, 2000). 
Furthermore, the large proportion of extra-fine particles in this HFA-BDP formulation 
results in lung doses to become less dependent on breathing pattern compared with CFC-
BDP (Janssens et al., 2003; Leach et al., 2005). In addition, the use of devices such as the 
Easi-Breathe (Qvar® EB) aids coordination by actuating at a pre-determined point during 
inspiration and thus it does not require synchronisation of actuation and inhalation. These 
devices are highly valuable for individuals with poor inhalation techniques, however, 
they do not protect against oropharyngeal deposition (Newman et al., 1991c). 
The therapeutic ratio is the ratio between the clinical effect and the systemic effect of an 
inhalation. The systemic effect of an inhaled corticosteroid depends on the systemic 
absorption of both the amount of drug deposited in the airways and the amount of drug 
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that reaches the gastrointestinal tract, whereas the clinical effect only depends on the 
amount of drug deposited in the airways (Pedersen, 1996). Therefore, minimizing the 
amount of drug that reaches the gastrointestinal tract that has no therapeutic value and 
only contributes to systemic side effects is highly advantageous with inhaled 
corticosteroid therapy (Wildhaber et al., 2000a; Roller et al., 2007) and this is the reason 
behind the fact that spacers are highly recommended with inhaled corticosteroid therapy. 
Spacers reduce both the velocity and the size of the aerosol particles as they provide extra 
time for complete evaporation of the propellant and therefore eliminate the need for 
patient co-ordination between actuation of the MDI and inhalation of the aerosol 
(Newman, 2004). Moreover, spacers have a size selective function and retain the non-
breathable large particles by impaction on the spacer walls thus reducing the ―cold-Freon 
effect‖ and drug deposition in the oropharynx, with fewer local side effects from steroid 
aerosols such as coughing, hoarseness, throat discomfort, and oral candidiasis (Newman 
et al., 1981a; Terzano and Mannino, 1999). However it is still debatable whether or not 
spacers improve drug delivery to the airways, as spacers may offer no additional benefit 
to patients with good inhaler technique (Donnell, 2001).  
The fact that most spacers are constructed with lightweight plastic materials for 
portability and durability makes it highly prone to electrostatic charge accumulation that 
adversely affects drug output and lung deposition (Barry and O'Callaghan, 1995; 
Dewsbury et al., 1996). Several methods have been described to reduce static charge 
accumulation on plastic spacer surfaces (O'Callaghan et al., 1993; Barry and 
O'Callaghan, 1995; O'Callaghan, 1997; Kenyon et al., 1998). However the most simple 
and popular method is coating spacers with dilute surfactant solutions by simply 
immersing the spacer in a detergent solution followed by drip-drying without rinsing 
with water (Wildhaber et al., 1996a; Pierart et al., 1999).  
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6.2. In-vitro dose emission and aerodynamic particle size distribution of the dose 
emitted from Qvar® EB and Qvar® metered dose inhaler  
6.2.1. Method 
6.2.1.1. Equipment and inhalation devices 
- Equipment: 
As, described in section 5.2.1.1 of this thesis. 
- Inhaler and spacer devices used as follows: 
 Qvar® metered dose inhaler (MDI), and Qvar® EB labelled as nominal dose of 
100µg beclometasone dipropionate per shot (Teva Pharmaceuticals, UK). 
 The Aerochamber Plus spacer [APLUS], 145ml holding chamber, (Trudell Medical 
International Europe Ltd, UK). 
 The Volumatic spacer device [VOL] 750ml holding chamber, (GlaxoSmithKline) 
 The Optimiser spacer [OPT], 50ml small plastic tube spacer having a cross section 
of 2.5 x 3.3cm (Teva Pharmaceuticals, UK). 
- LC-(ESI+)-MS method conditions: sample preparation, analysis procedures, and 
chromatographic conditions were as reported in section 3.2. 
6.2.1.2. Procedure  
6.2.1.2.1. Total emitted dose 
In the present work, in-vitro measurements of the total emitted dose was performed with 
extrafine hydrofluoroalkane (HFA)-BDP inhalers available as Qvar® MDI and Qvar® EB 
either alone or when connected to different spacers using the metered dose inhaler dose 
sampling unit (DSU). Each type of spacer was tested after thoroughly washing in 
detergent solution then followed by either rinsing (R) or not rinsing with water (NR), and 
then air-dried. 
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Measurements were carried out for Qvar® EB either alone or when attached to each of 
the following spacers the Volumatic, the Aerochamber Plus, and the Optimiser (with and 
without rinsing). In addition, the total emitted dose determinations were carried out for 
Qvar® MDI either alone or when attached to the Aerochamber Plus (with and without 
rinsing). Each inhaler was first primed by firing two doses to waste before use. Each 
inhaler/inhaler-spacer was connected to the DSU and operated as previously described in 
section 5.2.1.2.1 and four separate doses from Qvar EB (100µg) or Qvar MDI (100µg) 
were discharged into the ACI. On each occasion, one dose was introduced into the spacer 
followed by the in-vitro inhalation manoeuvre. The procedure was repeated until the set 
number of doses has been discharged. The amount of drug in the dose sampling unit and 
spacer was determined by using the previously developed and validated LC-(ESI+)-MS 
method previously described in section 3.2 in this thesis. 
6.2.1.2.2. The aerodynamic particle size characterization 
The aerodynamic particle size distributions of Qvar® EB and Qvar® MDI used either 
alone or when attached to spacers  at a flow rate of 28.3L/min and the aerodynamic 
particle size distribution of the same inhalers used alone without spacers at higher flow 
rates (60, and 90 L/min) were determined. These distributions were measured with the 
Andersen Cascade Impactor (ACI). Four separate actuations from Qvar EB (100µg), and 
Qvar MDI (100µg) were delivered into the Andersen Cascade Impactor for each inhaler 
or inhaler/spacer combination. The procedure details were as previously described in 
section 5.2.1.2.2. Five determination were made for each inhaler or inhaler/spacer 
combination (n=5). The amount of beclometasone dipropionate expressed in µg 
deposited in the induction port (IP) and the various ACI stages were determined using the 
previously developed and validated LC-(ESI+)-MS method described in section 3.2 in 
this thesis.  
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6.2.2. Statistical analysis 
The data was statistically analyzed using one way analysis of variance (ANOVA) to 
compare the total emitted dose and aerodynamic particle size characterization of different 
MDIs and MDI/spacer combinations at a flow rate of 28.3 L/min and the aerodynamic 
particle size characterization of different inhalers used alone at higher flow rates using 
SPSS V17.0 (SPSS Inc., Chicago, USA).  
6.2.3. Results 
6.2.3.1. Total emitted dose  
The individual emitted doses of four 100µg actuations of beclometasone dipropionate 
from Qvar® EB alone or when attached to different spacers expressed in µg and as 
percentage of nominal dose are presented in APPENDIX B.33 and B.34 (refer to the 
enclosed DVD), respectively. While the individual emitted doses of Qvar® MDI with or 
without spacers expressed in µg and as percentage of nominal dose are shown in 
APPENDIX B.35 (refer to the enclosed DVD). A summary of the mean (SD) emitted 
doses for Qvar EB and Qvar MDI are illustrated in table 6.1. The results for Qvar® EB 
and Qvar® MDI are expressed graphically in figures 6.1, and 6.2, respectively. 
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Table 6.1: Mean (SD) dose emission from four 100µg doses of beclometasone dipropionate from a Qvar® EB and Qvar MDI determined at a flow 28.3 
L min-1, expressed in µg and as percent of nominal dose, (n=10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Qvar-EB Qvar MDI 
Dose (µg) % of nominal dose Dose (µg) % of nominal dose 
MDI TED 354.6 (29.9) 88.7 (7.5) 329.2 (37.3) 82.3 (9.3) 
APLUSNR 
TED 221.0 (34.2) 55.2 (8.6) 203.1 (34.2) 50.8 (8.6) 
Spacer 101.1 (28.2) 25.3 (7.1) 113.4 (16.7) 28.3 (4.2) 
APLUSR 
TED 170.9 (46.4) 42.7 (11.6) 164.4 (43.5) 41.1 (10.8) 
Spacer 189.8 (30.0) 47.5 (7.5) 163.3 (48.0) 40.8 (12.0) 
VOLNR 
TED 197.3 (30.3) 49.3 (7.6) --- --- 
Spacer 106.0 (23.4) 26.5 (5.9) --- --- 
VOLR 
TED 152.9 (52.9) 38.2 (13.2) --- --- 
Spacer 166.6 (39.8) 41.6 (10.0) --- --- 
OPTNR 
TED 212.8 (31.6) 53.2 (7.9) --- --- 
Spacer 146.3 (25.7) 36.6 (6.4) --- --- 
OPTR 
TED 165.7 (48.2) 41.4 (12.1) --- --- 
Spacer 217.4 (29.4) 54.4 (7.4) --- --- 
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Figure 6.1: Beclometasone dipropionate (a) total emitted dose (b) deposited in each 
spacer (c) mean (SD) total emitted dose and the amount deposited in each spacer 
expressed as a percent of the nominal dose from Qvar EB at a flow rate 28.3 L min-1, 
(n=10). 
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Figure 6.2: Beclometasone dipropionate (a) total emitted dose (b) deposited in each 
spacer (c) mean (SD) total emitted dose and the amount deposited in each spacer 
expressed as a percent of the nominal dose from Qvar MDI at a flow rate 28.3 L min-1. 
(n=10). 
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6.2.3.2. Aerodynamic particle size characterization 
A summary of the aerodynamic particle size distribution data obtained from the 
Andersen cascade impactor for Qvar® EB and Qvar® MDI either alone or plus different 
spacers at 28.3 L/min flow rate are shown in tables 6.2, 6.3, and figures 6.3 and 6.4 
respectively. 
In addition, the effect of higher flow rates conditions on the aerosol particle size 
distribution of both Qvar EB and Qvar MDI were investigated. Tables 6.4, and 6.5 and 
figures 6.5, and 6.6 represent the aerodynamic particle size distribution data obtained at 
different flow rates (28.3, 60, and 90L/min) from the Andersen Cascade Impactor for 
Qvar® EB and Qvar® MDI, respectively. 
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Table 6.2:  A summary of the mean (SD) data obtained from the Andersen Cascade Impactor (ACI) following four actuations of Qvar EB® (100µg) 
either alone or plus different spacers at 28.3 L/min. Values quoted in µg unless specified, (n=5). 
 
 Stage Cut-off Qvar-EB VOLNR APLUSNR OPTNR VOLR APLUSR OPTR 
Amount left in spacer 
 
---- 169.2 (18.7) 117.7 (16.5) 126.4 (8.1) 228.1 (20.1) 225.8 (36.9) 191.2 (22.9) 
Induction Port (IP)  121.8 (15.5) 5.0 (2.6) 9.3 (1.9) 7.5 (3.6) 3.4 (2.0) 4.7 (1.5) 3.6 (1.0) 
0 10 9.2 (1.8) 8.5 (4.1) 7.5 (2.2) 7.7 (2.4) 9.9 (3.3) 2.9 (2.0) 3.2 (0.9) 
1 9 12.9 (1.5) 9.6 (1.6) 10.3 (2.2) 7.8 (1.4) 10.9 (3.0) 4.6 (1.8) 4.0 (0.5) 
2 5.8 15.8 (4.9) 10.5 (1.8) 11.5 (3.6) 7.5 (2.4) 7.6 (1.7) 8.5 (3.4) 9.6 (4.5) 
3 4.7 20.5 (5.4) 13.8 (2.6) 21.8 (7.2) 12.9 (1.9) 9.7 (2.3) 10.3 (2.4) 9.7 (3.2) 
4 3.3 33.0 (5.5) 15.7 (1.6) 22.5 (4.5) 14.8 (3.2) 16.1 (5.7) 15.0 (4.6) 12.4 (1.3) 
5 2.1 34.8 (8.1) 41.1 (26.4) 30.4 (4.1) 37.4 (8.0) 24.0 (7.2) 17.5 (5.3) 23.4 (14.7) 
6 1.1 50.8 (13.6) 34.3 (4.9) 45.1 (15.4) 46.9 (17.1) 24.7 (10.3) 26.9 (11.6) 37.7 (12.1) 
7 0.7 37.0 (11.7) 36.3 (1.0) 37.9 (10.7) 40.2 (6.6) 19.3 (2.3) 21.1 (10.9) 25.6 (11.2) 
Filter 0.4 35.1 (8.9) 16.7 (2.9) 34.6 (9.2) 24.8 (7.9) 12.5 (0.8) 22.1 (5.5) 9.6 (1.4) 
Total emitted dose (TED) (µg) 372.6 (27.1) 191.6 (20.8) 230.7 (30.1) 207.5 (9.6) 138.1 (20.3) 133.6 (18.4) 138.8 (16.5) 
Total emitted dose (% of nominal dose) 93.16 (6.8) 47.9 (5.2) 57.7 (7.5) 51.9 (2.4) 34.5 (5.1) 33.4 (4.6) 34.7 (4.1) 
FPD (µg) 218.0 (29.1) 161.3 (22.2) 196.2 (27.0) 179.6 (15.1) 108.2 (19) 115.9 (22.9) 121.9 (20.9) 
% FPF of nominal dose 54.5 (7.3) 40.3 (5.6) 49.0 (6.8) 44.9 (3.8) 27.0 (4.7) 28.9 (5.7) 30.5 (5.2) 
%FPF of the TED 58.4 (5.2) 84.0 (2.4) 84.9 (1.4) 86.5 (4.1) 78.2 (2.5) 86.3 (5.5) 87.5 (5.0) 
MMAD (µm) 1.2 (0.1) 1.2 (0.1) 1.1 (0.3) 1.0 (0.2) 1.5 (0.2) 1.2 (0.5) 1.1 (0.2) 
GSD (no units) 3.8 (0.3) 3.8 (1.0) 3.8 (1.1) 3.4 (0.01) 4.2 (1.1) 3.3 (0.7) 2.6 (0.01) 
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 Table 6.3: A summary of the mean (SD) data obtained from the Andersen Cascade Impactor (ACI) following four actuations of Qvar® MDI (100µg) 
either alone or plus different spacers at 28.3L/min flow rate. Values quoted in µg unless specified, (n=5). 
 
 Stage Cut-off Q-MDI APLUSNR APLUSR 
Amount left in spacer 
 
---- 183.4 (30) 239.6 (66.2) 
Induction Port (IP)  130.9 (26.3) 10.1 (3.2) 6.8 (1.9) 
0 10 6.3 (1.4) 8.3 (1.6) 3.6 (0.9) 
1 9 9.03 (3.8) 16.0 (3.8) 5.8 (2.2) 
2 5.8 12.7 (3.1) 13.1 (4.9) 10.5 (2.8) 
3 4.7 17.8 (3.9) 22.4 (3) 13.2 (3.7) 
4 3.3 32.1 (8.2) 24.2 (3.7) 15.6 (4.3) 
5 2.1 37.7 (6.4) 31.4 (10.9) 18.3 (5.6) 
6 1.1 43.4 (3.1) 36.0 (4.4) 28.7 (9.4) 
7 0.7 34.9 (4.9) 36.7 (6.0) 27.2 (2.9) 
Filter 0.4 36.9 (1) 37.1 (8.4) 20.4 (9.5) 
Total emitted dose (TED) (µg) 362.2 (34.7) 235.3 (29.0) 150.1 (28.9) 
Total emitted dose (% of nominal dose) 90.6 (8.7) 58.8 (7.2) 37.5 (7.2) 
FPD (µg) 208.9 (16.3) 191.6 (23.8) 127.2 (27.2) 
% FPF of nominal dose 52.2 (4.1) 47.9 (6.0) 31.8 (6.8) 
%FPF of TED 57.6 (6.2) 81.4 (0.4) 84.5 (3.5) 
MMAD (µm) 1.2 (0.2) 1.1 (0.1) 1.1 (0.1) 
GSD (no units) 3.5 (0.4) 4.2 (0.3) 4.1 (0.4) 
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Table 6.4: A summary of the mean (SD) data obtained from the Andersen Cascade Impactor (ACI) following four actuations of Qvar® EB (100µg) 
alone at 28.3, 60, and 90 L/min flow rates. Values quoted in µg unless specified, (n=5). 
 
 
 
 
 
 
 
 
 
 
 
 
 28.3L/min 60L/min 90L/min 
Induction Port (IP) 121.8 (15.5) 100.2 (18.6) 81.6 (18.1) 
-2 --- --- 4.1 (0.5) 
-1 --- 7.3 (1.3) 6.8 (1.3) 
-0 --- 9.1 (1.7) 16.0 (3.6) 
0 9.2 (1.8) --- --- 
1 12.9 (1.5) 10.4 (1.4) 24.3 (3.8) 
2 15.8 (4.9) 29.5 (5.1) 38.3 (6.1) 
3 20.5 (5.4) 31.9 (5.5) 45.2 (5.5) 
4 33.0 (5.4) 37.0 (8.6) 74.3 (11.5) 
5 34.8 (8.1) 58.3 (3.9) 27.5 (4.9) 
6 50.8 (13.6) 36.1 (7.2) --- 
7 37.0 (11.7) --- --- 
Filter 35.1 (8.9) 29.1 (8) 19.8 (5.7) 
Total emitted dose (TED) (µg) 372.6 (27.1) 349.1 (41.9) 338.0 (22.2) 
Total emitted dose (% of nominal dose) 93.2 (6.8) 87.3 (10.5) 84.5 (5.5) 
FPD (µg) 218.0 (29.1) 225.9 (26.6) 235.7 (12.2) 
% FPF of nominal dose 54.5 (7.3) 64.8 (8.1) 58.9 (3.1) 
%FPF of TED 58.4 (5.2) 59.6 (1.9) 69.8 (3.8) 
MMAD (µm) 1.2 (0.17) 1.2 (0.2) 1.2 (0) 
GSD (no units) 3.8 (0.3) 3.4 (0.3) 3.1 (0.25) 
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Table 6.5: A summary of the mean (SD) data obtained from the Andersen Cascade Impactor (ACI) following four actuations of Qvar® MDI (100µg) 
alone at 28.3, 60, and 90 L/min flow rates. Values quoted in µg unless specified, (n=5). 
 
 
 
 
 
 
 
 
 
 
 28.3L/min 60L/min 90L/min 
Induction Port (IP) 130.9 (26.3) 116.8 (27.8) 99.6 (4.3) 
-2 --- --- 10.9 (3.2) 
-1 --- 8.9 (2.5) 10.7 (3.5) 
-0 --- 10.1 (3.8) 17.2 (2.1) 
0 6.3 (1.4) --- --- 
1 9.0 (3.7) 15.1 (4.8) 19.0 (5.6) 
2 12.7 (3.1) 20.5 (4.7) 41.3 (7.7) 
3 17.8 (3.9) 36.7 (6.7) 52.6 (7.4) 
4 32.1 (8.2) 49.0 (8.3) 65.9 (4.5) 
5 37.7 (6.4) 58.8 (11.1) 36.3 (11) 
6 43.4 (3.1) 44.3 (4.3) --- 
7 34.9 (4.9) --- --- 
Filter 36.9 (1.0) 27.2 (5.8) 26.5 (7.1) 
Total emitted dose (TED) (µg) 362.2 (34.7) 387.4 (16.6) 380.0 (10.4) 
Total emitted dose (% of nominal dose) 90.6 (8.7) 96.9 (4.2) 95.0 (2.6) 
FPD (µg) 208.9 (16.3) 241.8 (32.7) 247.4 (9.5) 
% FPF of nominal dose 52.2 (4.1) 60.4 (8.2) 61.8 (2.4) 
%FPF of TED 57.6 (6.2) 62.3 (6.1) 70.7 (7.7) 
MMAD (µm) 1.2 (0.2) 1.2 (0.1) 1.3 (0.2) 
GSD (no units) 3.5 (0.4) 3.4 (0.3) 3.4 (0.9) 
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Figure 6.3: Mean beclometasone dipropionate emitted from Qvar® EB alone or with 
different spacers at a flow rate 28.3 L min-1 (a) deposited in each stage of the ACI (µg) 
(b) the aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose, 
(n=5). 
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Figure 6.4: Mean beclometasone dipropionate emitted from Qvar® MDI alone or with 
spacer at a flow rate 28.3 L min-1 (a) deposited in each stage of the ACI (µg) (b) the 
aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose, (n=5). 
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Figure 6.5: Mean beclometasone dipropionate (a) deposited in each stage of the ACI 
(µg) (b) the aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose 
and induction port deposition emitted from Qvar® EB alone at 28.3, 60, and 90 L min-1 
flow rates, expressed in µg, (n=5). 
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Figure 6.6: Mean beclometasone dipropionate (a) deposited in each stage of the ACI 
(µg) (b) the aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose 
and induction port deposition emitted from Qvar® MDI alone at 28.3, 60, and 90 L min-1 
flow rates, expressed in µg, (n=5). 
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6.2.3.3. Statistical analysis 
Table 6.6 and table 6.7 represent a summary of the statistical analysis of data obtained 
from Qvar® EB and Qvar® MDI, respectively operated at 28.3L/min using the Andersen 
Cascade Impactor. The total emitted dose significantly decreased for both Qvar® EB and 
Qvar® MDI, when using any of the spacers studied than when using each inhaler alone. 
Table 6.8 summarizes the statistical analysis data for Qvar® EB and Qvar® MDI, 
operated at different flow rates.  
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Table 6.6: Mean difference (95% confidence interval) for different spacers used with Qvar® EB. 
Comparator FPD (µg) FPF% MMAD TED (µg) Spacer deposition(µg) 
VOLNR 
Qvar-EB -56.7 (-94.6, -18.8)** 25.6 (18.3, 32.9)*** -0.03 (-0.5, 0.5) -181 (-214.5, -147.5)*** --- 
APLUSNR -34.9 (-72.8, -18.8) -0.9 (-8.2, 6.4) 0.07 (-0.4, 0.6) -39 (-72.6, -5.5)* 51.5 (15.1, 87.9)* 
OPTNR -18.3 (-56.2, 19.6) -2.5 (-9.8, 4.8) 0.1 (-0.4, 0.6) -15.9 (-49.4, 17.7) 42.8 (6.4, 79.2)* 
VOLR 53.1 (15.2, 91)* 5.8 (-4.5, 13.1) -0.3 (0.8, 0.2) 53.5 (20, 87.1)** -58.9 (-95.3, -22.5)** 
APLUSR 45.3 (7.4, 83.2)* -2.3 (-9.6,5) -0.07 (-0.6, 0.4) 58 (24.5, 91.6)** -56.6 (-93, -20.2)** 
OPTR 36.1 (-2.8, 75) -4.4 (-11.9, 3.1) 0.09 (-0.4, 0.6) 49.4 (15, 83.8)** -17.4 (-54.9, 20.1) 
APLUSNR 
Qvar-EB -21.8 (-59.7, 16.1) 26.5 (19.2, 33.8)*** -0.1 (-0.6, 0.4) -142 (-175.5, -108.5)*** --- 
OPTNR 16.6 (-21.3, 54.5) -1.6 (-8.9, 5.7) 0.07 (-0.4,0.6) 23.2 (-10.4, 56.7) -8.6 (-45, 27.8) 
VOLR 88 (50.1, 125.9)*** 6.7 (-0.6, 14) -0.04 (-0.9,0.1) 92.6 (59.1, 126.1)*** -110.3 (-146.7, -73.9)*** 
APLUSR 80.2 (42.3, 118.1)*** -1.4 (-8.7, 5.9) -0.1 (-0.6, 0.4) 97.1 (63.6, 130.6)*** -108.1 (-144.5,-71.7)*** 
OPTR 71 (32.1, 109.9)** -3.5 (-10.9, 4) 0.02 (-0.5, 0.52) 88.5 (54.1, 122.8)*** -68.9 (-106.4, -31.4)** 
OPTNR 
Qvar-EB -38.4 (-76.3, -0.5)* 28.1 (20.8, 35.4)*** -0.2 (-0.7, 0.3) -165.1 (-198.7, -131.6)*** --- 
VOLR 71.4 (33.5, 109.3)** 8.3 (1, 15.6)* -0.4 (-0.9, 0.05) 69.4 ((35.9, 102.9)*** -101.7 (-138.1, -65.3)*** 
APLUSR 63.7 (25.8, 101.6)** 0.2 (-7.1, 7.5) -0.2 (-0.7, 0.3) 73.9 (40.4, 107.4)*** -99.5 (-135.9, -63.1)*** 
OPTR 54.4 (15.5, 93.3)* -1.9 (-9.4, 5.6) -0.04 (-0.5, 0.45) 65.3 (30.9, 99.7)** -60.2 (-97.8, -22.7)** 
VOLR 
Qvar-EB -109.8 (-147.7, -71.9)*** 19.8 (12.5, 27.1)*** 0.3 (-0.2, 0.8) -234.5 (-268.1, -201)*** --- 
APLUSR -7.8 (-45.7, 30.1) -8.1 (-15.4, -0.8)* 0.2 (-0.3, 0.7) 4.5 (-29, 38) 2.2 (-34.2, 38.6) 
OPTR -17 (-55.9, 21.9) -10.2 (-17.7, -2.7)* 0.4 (-0.1, 0.9) -4.1 (-38.5, 30.3) 41.5 (3.9, 79) 
APLUS R Qvar-EB -102.1 (-140, -64.2)*** 27.9 (20.6, 35.2)*** 0.03 (-0.5, 0.5) -239 (-272.6, -205.5)*** --- OPTR -9.2 (-48.2, 29.7) -2.1 (-9.6, 5.4) 0.2 (-0.3, 0.7) -8.6 (-43, 25.8) 39.2 (1.7, 76.7)* 
OPTR Qvar-EB -92.8 (-131.7, -53.9)*** 30 (22.5, 37.5)*** -0.1 (-0.6, 0.4) -230.4 (-264.8, -196)*** --- 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
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Table 6.7: Mean difference (95% confidence interval) for Qvar® MDI plus APLUS spacer rinsed and not rinsed. 
Comparator Spacer deposition (µg) FPD (µg) FPF% MMAD TED (µg) 
APLUSNR 
Q-MDI --- -17.3 (-70.2, 35.5) 23.8 (14.7, 32.9)** -0.03 (-0.3, 0.2) -127 (-174.2, -79.6)** 
APLUSR -56.2 (-292.8, 180.4) 64.4 (11.6, 117.3)* -3.1 (-12.2, 6) 0.07 (-0.2, 0.3) 85.2 (37.9, 132.5)** 
APLUSR Q-MDI --- -81.8 (-134.6, -28.9)* 26.9 (17.8, 36)** -0.1 (0.5, -0.3) -212.2 (-259.5, -164.8)** 
 
 
 
Table 6.8: Mean difference (95% confidence interval) for Qvar® EB and Qvar® MDI operated at different flow rates. 
 
Comparator FPD (µg) FPF% MMAD TED (µg) Induction port deposition (µg) 
Qvar-EB 
28.3L/min 
60 L/min -7.9 (-67.7, 51.9) -1.2 (-7.8, 5.5) 0.03 (-0.4, 0.4) 23.6 (-58.7, 105.9) 21.6 (-5.7,48.8) 
90L/min -17.7 (-77.5, 42.1) -11.4 (-18.1, -4.8)** 1.1x10-15 (0.4, 0.41) 34.6 (-47.7, 116.9) 40.2 (12.9, 67.5)* 
60 L/min 90L/min 9.8 (-69.6, 50) -10.2 (-16.9, -3.6) -0.03 (-0.4, 0.4) 11.1 (-71.2, 93.4) 18.6 (-8.6, 45.9) 
Qvar MDI 
28.3L/min 
60 L/min -32.8 (-71.8,6.2) -4.6 (-23.2,13.9) -0.03 (-0.4, 0.3) -25.2 (-55.8, 5.5) 14.1 (-40, 68.2) 
90L/min -38.4 (-77.4,0.6) -13.1 (-31.6, 5.5) -0.1 (-0.5, 0.3) -17.8 (-48.5, 12.8) 21 (-22.8, 85.3) 
60 L/min 90L/min -5.6 (-44.6, 33.4) -8.4 (-27, 10.1) -0.07 (-0.4, 0.3) 7.4 (-23.3, 38) 17.1 (-37, 71.2) 
 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
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6.2.4. Discussion 
The significant decrease in drug deposition in the induction port of the ACI when using 
spacers was evident for both Qvar® inhaler devices studied. Again, this was due to 
significant drug deposition on the spacer walls instead of the induction port of the ACI. 
Concomitantly, the deposition in the spacer led to a significant decrease in the total 
emitted dose delivered from it. This was consistent with several previous in-vitro 
(Rahmatalla et al., 2002) and in-vivo studies (Leach, 1998b; Leach et al., 1998a; Leach, 
1999).  
The fine particle dose is defined as the dose of the aerosolized drug particles with an 
aerodynamic diameter <5µm that is capable of penetrating the lung during inhalation 
(respirable). The fine particle fraction (% FPF) is the percentage ratio of FPD to the total 
recovered dose (the dose that leaves the inhaler device and is available to the patient) 
(Newman et al., 2000b; Zeng et al., 2002). The addition of the spacer to Qvar® EB 
inhaler was associated with either not affecting the FPD as in the case of the not rinsed 
Aerochamber Plus (APLUSNR) or with a small decrease in the FPD as with the rest of 
spacers used. However, the use of the not rinsed Volumatic (VOLNR) spacer caused 
even more lowering to the FPD compared to the not rinsed Optimiser (OPTNR) spacer. 
The above results revealed that the addition of a small volume spacer such as the 
Aerochamber Plus or the Optimiser had less effect on decreasing the FPD from Qvar® 
EB inhaler than the larger volume Volumatic spacer. The previous results clearly suggest 
that it is not necessary to use large volume spacers with such extra-fine aerosols. The 
small volume spacer devices maintained the extra-fine properties of these formulations. 
As shown from the above results, the non-significant influence of the not rinsed 
Aerochamber Plus (APLUSNR) spacer when attached to Qvar® inhalers on its 
aerodynamic particle size distribution together with its ability to significantly decrease 
the quantity of BDP trapped in the in-vitro oropharynx make it advisable to be used by 
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patients. The use of spacers with inhaled corticosteroids is preferred as they diminish the 
risk of topical side effects like thrush and dysphonia, as well as minimising unwanted 
systemic side effects that could results from oral beclometasone absorption (Derendorf, 
1997). 
These results are in accordance with previous studies that observed no significant 
changes in the in-vivo and in-vitro lung deposition with an Aerochamber spacer attached 
to the extrafine Qvar® formulation (Leach et al., 1998b; Rahmatalla et al., 2002). 
Similarly, another in-vitro study investigated the effect of spacers on the respirable dose 
delivery from Qvar MDI post adding the Aerochamber Plus valved holding chamber or 
the Optichamber valved holding chamber. Surprisingly, the results from this study did 
not demonstrate an equivalent in-vitro performance from these two spacers despite their 
similar sizes, which may be due to differences in their valve design and material. The 
mean ± SD respirable dose (1-5µm) of BDP from the Aerochamber Plus valved holding 
chamber (27.2±10µg/actuation) was not significantly different from the respirable dose 
produced by the MDI alone (29±7.0µg/actuation). In contrast, the Optichamber 
dramatically decreased the respirable dose to less than half that produced by either the 
MDI alone or with the Aerochamber Plus valved holding chamber (Asmus et al., 2003).  
In addition, the effect of the spacers’ electrostatic charge on the aerosol behaviour from 
Qvar® EB and Qvar® MDI was also investigated. Similar to the Clenil® MDI, the 
washing of the spacer with soap solution followed by water rinsing apparently 
significantly decreased the drug output from spacers. The FPD emitted from any Qvar® 
inhaler/spacer combination significantly decreased when using the water rinsed spacers 
than that obtained when not rinsing the same detergent coated spacer. Although some 
manufacturers have mentioned rinsing detergent washed spacers with water, it appears 
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that this rinsing actually removes the detergent from the spacer and thus the antistatic 
effect of the detergent coating is lost.  
This is in agreement with a previous study by Kwok et al (2006) who investigated the 
effect of detergent coated Aerochamber Plus spacers on drug output from Qvar (100µg) 
inhaler. In this study, coating the APLUS with detergent removed the surface charge 
leading to lower electrostatic retention of drugs and higher drug output from the spacer. 
Similarly, Dewsbury et al (1996) reported that the presence of high electrostatic charge 
on spacer surfaces gave the lowest respirable fraction whilst neutralisation of that charge 
gave the highest respirable fraction. 
The mass mean aerodynamic diameter obtained from the Andersen Cascade Impactor for 
Qvar EB and Qvar MDI was 1.2, which is consistent with previous studies (Leach, 
1998b; Stein, 1999). 
The effect of higher flow rates on Qvar® EB aerosol performance was investigated. The 
results showed that the amount of drug deposited in the induction port of the ACI 
decreased significantly (P<0.05) when increasing the flow rate from 28.3 to 90L/min, 
while this induction port deposition difference was non-significant when increasing the 
flow rate from 28.3 to 60L/min and from 60 to 90L/min. For the Qvar® MDI, a similar 
reduction in the induction port deposition was indicated when increasing the flow rate; 
however, the results were not significant. In addition, the results from this study show 
that increasing the flow rates from 28.3L/min to 60, and 90L/min have little effect on the 
FPD delivered from both inhalers. The mean FPD (SD) obtained from Qvar® EB were 
218 (29.1), 225.9 (26.6), and 235.7 (12.2) at a flow rate of 28.3, 60 and 90L/min, 
respectively. The mean FPD (SD) for Qvar® MDI were 208.9 (16.3), 241.8 (32.7), and 
247.4 (9.5) at a flow rate of 28.3, 60 and 90L/min, respectively. These results are 
consistent with previous studies that have shown a significant decrease in the induction 
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port deposition of HFA-BDP with increasing the flow rate from 28.3 L/min to 90 L/min 
and suggested that BDP in this extra-fine formulation have greater accessibility to the 
lung at higher flow rates (Rahmatalla et al., 2002). Other studies also reported a limited 
effect of higher inspiratory flow rates of 60 and 90L/min on respirable dose from MDIs 
when compared to that achieved at 30L/min (Smith et al., 1998; Feddah et al., 2000).  
6.3. Relative lung and systemic bioavailability of beclometasone dipropionate 
inhaled from Qvar® EB and Qvar® MDI with different spacers using urinary 
drug excretion post inhalation 
6.3.1. Method 
The aim of this investigation is to apply the urinary pharmacokinetic method of 
beclometasone dipropionate after an inhalation to compare the effect of different spacers 
on drug output from Qvar® EB and Qvar® MDI inhalers. Although, Qvar EB is not 
recommended to be used with spacers, its mouthpiece fits into the Volumatic, the 
Aerochamber Plus, and the Optimiser spacer. Qvar MDI can only be used with the 
Aerochamber Plus spacer. 
6.3.1.1. Equipment and inhalation device 
Inhaler and spacer devices used as follows:  
 Qvar® Easi-Breathe inhaler (EB) labelled as nominal dose of 100µg beclometasone 
dipropionate per dose (Teva Pharmaceuticals, UK). 
 Qvar® metered dose inhaler (MDI) labelled as nominal dose of 100µg 
beclometasone dipropionate per dose (Teva Pharmaceuticals, UK). 
 The Aerochamber Plus spacer [APLUS], 145ml holding chamber, (Trudell Medical 
International Europe Ltd, UK). 
 The Volumatic spacer device [VOL] 750ml holding chamber, (GlaxoSmithKline). 
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 The Optimiser spacer [OPT], small plastic tube spacer having a cross section of 2.5x 
3.3cm (Teva Pharmaceuticals, UK. 
 LC-(ESI+)-MS method conditions: sample preparation, analysis procedures and 
chromatographic conditions were as reported in section 3.3. 
6.3.1.2. Subjects and study design 
Twelve healthy non-smoking volunteers between 18-45 years consented to take part in 
the study and approval was obtained from the University of Huddersfield Ethics 
Committee. Healthy subjects received Qvar® EB or Qvar® MDI either alone or attached 
to different spacers. The order of these doses was randomized and each study dose was 
separated by 7 days. Each subject inhaled eight doses of the following study doses. 
Eight 100μg (800μg in total) inhalations of beclometasone dipropionate from a Qvar® 
MDI (Teva Pharmaceuticals, UK) with: 
 No spacer [Qvar® MDI]. 
 The Aerochamber Plus spacer that is washed in detergent solution, followed by 
either rinsing [Q-APLUSR] or not rinsing [Q-APLUSNR] with water, and then 
allowed to air dry. 
Eight 100μg (800μg in total) inhalations of beclometasone dipropionate from a Qvar® 
Easi breathe inhaler (Teva Pharmaceuticals, UK) with: 
 No spacer [Qvar EB®]. 
 The Aerochamber Plus spacer that is washed in detergent solution, followed by 
either rinsing [QEB-APLUSR] or not rinsing [QEB-APLUSNR] with water, and 
then allowed to air dry. 
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  The Optimiser spacer that is washed in detergent solution, followed by either 
rinsing [QEB-OPTR] or not rinsing [QEB-OPTNR] with water, and then allowed 
to air dry. 
 The Volumatic spacer device that is washed in detergent solution, followed by 
either rinsing [QEB-VOLR] or not rinsing [QEB-VOLNR] with water, and then 
allowed to air dry. 
On each occasion, there were eight separate actuations with each actuation followed by 
an inhalation. Each volunteer was trained on how to use the inhaler devices according to 
the patient information leaflet. The lungs were emptied as far as comfortable, the MDI 
was placed between the lips, actuated and at the same time the subjects breathed in 
through the mouth taking 5-10 seconds to fully inhale, then removed the inhaler, held 
their breath for 10 seconds, and slowly exhaled. The same inhalation steps were repeated 
for the Easi-Breathe device, however subjects were asked to preclude MDI actuation 
during inhalation, where the dose was delivered automatically as they breathed. The 
inhalation manoeuvre was a deep breath to ensure optimal drug delivery. A check was 
made that the breathe actuation process occurred (sound, taste and visual check of an 
external lever on the device that moves when a dose is released). All subjects were 
trained on how to use each spacer according to the instructions produced by the 
manufacturer. When using spacers subjects exhaled to residual volume as much as 
possible, the dose was discharged into the spacer and within one second subjects inhaled 
slowly and deeply for about 3 to 5 seconds. This was followed by a breath hold for at 
least 10 seconds. This inhalation manoeuvre was repeated every 30 seconds for each 
inhaled dose.  
Urine samples were collected at 30 minutes, and then cumulatively pooled up to 24hrs 
after inhalation. The volume of urine excreted was recorded and aliquots of each sample 
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were frozen at -20°C prior to analysis. The amount of drug left in each spacer device was 
also determined. 
6.3.2. Analysis 
6.3.2.1. Sample analysis 
The amount of BDP and its metabolites excreted in urine and the amount of BDP 
retained in each spacer device were measured using the previously developed and 
validated LC-(ESI+)-MS method described in section 3.3 and 3.2, respectively. 
6.3.2.2. Statistical analysis 
Statistical analysis of the 30 minutes and the 24 hours urinary excretion of 
beclometasone dipropionate and its metabolites following administration of Qvar-EB and 
Q-MDI either alone or with water rinsed or not rinsed detergent coated spacers and the 
amount left in each spacer were accomplished using a one way analysis of variance 
(ANOVA) test using SPSS V17.0 (SPSS Inc., Chicago, USA). In addition, One-way 
analysis of variance with the application of Bonferroni correction was used to compare 
the urinary excretions when using each inhaler alone and when it is attached to each 
spacer. The 30 minutes and the cumulative 24hr amounts excreted for each inhalation 
method were normalised for the nominal dose and then log transformed. From the mean 
square error of the analysis of variance, using patients and inhalation method as the main 
factors, the mean ratio (90% confidence interval) was calculated. 
6.3.3. Results 
Twelve (six females) healthy non smoking subjects completed the study. Their mean 
(SD) age, weight and height was 31.2 (8.9) years, 66.3 (8.1) kg and 166.7 (7.6) cm, 
respectively. Their demographic details were previously described in table 5.1.  
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The individual urinary excretion data of BOH, BDP, 17-BMP, and the amount of BDP 
retained in each spacer post inhalation of Qvar® EB and Qvar® MDI study doses either 
alone or with different spacers are presented in APPENDIX B.36 - B.42 (refer to the 
enclosed DVD). These urinary excretion data of BOH, BDP, and 17-BMP from Qvar® 
EB and Qvar® MDI are expressed graphically in figures 6.7 - 6.10. A summary of the 
mean (SD) amounts of parent drug and metabolites obtained from the twelve subjects 
post inhalation from Qvar® EB, Qvar® MDI either alone or with different spacers and the 
amount retained in each spacer are represented in table 6.9 and figures 6.11 - 6.14. 
Statistical analysis of the data is shown in tables 6.10 - 6.13. 
A summary of the mean ratio (90% confidence limits) between Qvar EB when used 
alone and when it attached to each spacer with respect to the nominal dose is presented in 
table 6.14. The mean ratio (90% confidence limits) between the Aerochamber Plus (with 
and without rinsing) and Qvar MDI is summarized in table 6.15. These values are 
presented separately for BDP, 17 BMP, and BOH, as well as for all three metabolites 
combined.  
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Figure 6.7: The 0.5hr individual amounts of (a) beclometasone (b) 17-beclometasone 
monopropionate (c) beclometasone dipropionate excreted post inhalation from Qvar® EB 
(100μg) alone or via different spacers, expressed in µg, (n=12).  
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Figure 6.8: The 24hr individual amounts of (a) beclometasone (b) 17-beclometasone 
monopropionate (c) beclometasone dipropionate excreted post inhalation from Qvar® EB 
(100μg) alone or via different spacers, expressed in µg, (n=12). 
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Figure 6.9: The 0.5hr individual amounts of (a) beclometasone (b) 17-beclometasone 
monopropionate (c) beclometasone dipropionate excreted post inhalation from Qvar® 
MDI (100μg) alone or via different spacers, expressed in µg, (n=12).  
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Figure 6.10: The 24hr individual amounts of (a) beclometasone (b) 17-beclometasone 
monopropionate (c) beclometasone dipropionate excreted post inhalation from Qvar® 
MDI (100μg) alone or via different spacers, expressed in µg, (n=12). 
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 Table 6.9: Mean (SD) amount of beclometasone dipropionate and its metabolites excreted 0.5hr, and 24hr post inhalation of different study doses with 
and without spacers, expressed in µg, n=12. 
Inhaler Device Amount left in 
spacer (µg) 
17-BMP (µg) BOH (µg) BDP (µg) 
0.5hr 24hr 0.5hr 24hr 0.5hr 24hr 
Qvar® EB 
EB --- 4.5 (0.8) 27.3 (3.9) 6.9 (1.4) 80.8 (14.6) 3.5 (0.5) 23.4 (3.9) 
VOLNR 355.5 (52.6) 3.4 (0.9) 13.7 (2.9) 6.5 (1.2) 47.2 (9.5) 3.1 (0.6) 11.7 (2.8) 
APLUSNR 336.9 (89.1) 4.3 (1.0) 18.6 (3.4) 7.2 (1.2) 60.5 (9.8) 3.7 (0.7) 17.4 (3.5) 
OPTNR 455.5 (76.8) 4.1 (1.0) 17.1 (2.6) 6.8 (1.3) 53.6 (10.0) 3.4 (0.8) 15.3 (3.5) 
VOLR 428.4 (52.5) 2.9 (0.7) 12.1(2.3) 5.5 (1.0) 37.2 (4.8) 2.8 (0.5) 10.3 (2.3) 
APLUSR 403.4 (97.8) 3.3 (0.6) 15.1 (2.8) 6.1 (1.0) 51.6 (7.0) 3.2 (0.7) 11.6 (3.9) 
OPTR 513.6 (101.8) 3.0 (0.7) 15.4 (2.9) 5.7 (1.2) 47.3 (7.3) 3.0 (0.6) 11.0 (2.5) 
Qvar® MDI 
MDI --- 4.7 (1.1) 25.8 (7.0) 6.1 (1.4) 77.7 (11.3) 3.3 (0.8) 23.1 (4.3) 
APLUSNR 370.1(67.5) 4.4 (0.8) 17.3 (3.8) 6.8 (2.1) 53.3 (10.7) 3.9 (0.7) 16.1 (3.0) 
APLUSR 431.4 (76.3) 3.5 (0.7) 15.0 (3.0) 5.0 (1.4) 43.0 (9.8) 2.8 (0.7) 11.8 (2.5) 
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Figure 6.11: The 0.5hr mean (SD) amounts of beclometasone dipropionate and its 
metabolites excreted post inhalation of Qvar EB study doses with and without spacers, 
(n=12). 
 
 
Figure 6.12: The 24hr mean (SD) amounts of beclometasone dipropionate and its 
metabolites excreted post inhalation of Qvar EB study doses with and without spacers, 
(n=12). 
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Figure 6.13: The 0.5hr mean (SD) amounts of beclometasone dipropionate and its 
metabolites excreted post inhalation of Qvar EB study doses with and without spacers, 
(n=12). 
 
 
Figure 6.14: The 24hr mean (SD) amounts of beclometasone dipropionate and its 
metabolites excreted post inhalation of Qvar EB study doses with and without spacers, 
(n=12).
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Table 6.10: Mean difference (95% confidence interval) for the amount of beclometasone dipropionate and its metabolites excreted post 30 minutes 
using Qvar® EB and Qvar® EB+ spacers. 
Inhaler Comparator Qvar-EB APLUSNR OPTNR VOLNR APLUSR OPTR 
17-BMP 
APLUSNR 0.2 (-0.3, 0.7) --- --- --- --- --- 
OPTNR 0.5 (-0.1, 1.0) 0.3 (-0.2, 0.8) --- --- --- --- 
VOLNR 1.1 (0.6, 1.6)* 0.9 (0.4, 1.4)** 0.6 (0.2, 1.1)* --- --- --- 
APLUSR 1.2 (0.7, 1.7)* 1.0 (0.5, 1.5)** 0.7 (0.2, 1.2)* 0.1 (-0.4, 0.6) --- --- 
OPTR 1.5 (1.0, 2.0)** 1.3 (0.8, 1.8)*** 1.0 (0.5, 1.5)* 0.4 (-0.1, 0.9) 0.3 (-0.2, 0.8) --- 
VOLR 1.6 (1.1, 2.1)*** 1.5 (1.0, 2.0)*** 1.2 (0.7, 1.7)*** 0.5 (0.03, 1.0)* 0.5 (-0.1, 1.0)** 0.2 (-0.3, 0.7) 
BOH 
APLUSNR -0.3 (-0.6, 0.04) --- --- --- --- --- 
OPTNR 0.1 (-0.3,0.4) 0.4 (0.03,0.7)* --- --- --- --- 
VOLNR 0.4 (0.1, 0.8)* 0.7 (0.4,1.1)*** 0.4 (0.03,0.7)* --- --- --- 
APLUSR 0.8 (0.5,1.1)*** 1.1 (0.8,1.4)*** 0.7 (0.4,1.1)*** 0.4 (0.02,0.7)* --- --- 
OPTR 1.1 (0.8,1.4)*** 1.4 (1.1,1.7)*** 1 (0.7,1.4)*** 0.7 (0.3,1)*** 0.3 (-0.02,0.7) --- 
VOLR 1.5 (1.1,1.8)*** 1.8 (1.4,2.1)*** 1.4 (1.1,1.8)*** 1 (0.7,1.4)*** 0.7 (0.4,1)*** 0.4 (0.04,0.7)* 
BDP 
APLUSNR -0.2 (-0.5, 0.2) --- --- --- --- --- 
OPTNR 0.1 (-0.2, 0.5) 0.3 (-0.1, 0.6) --- --- --- --- 
VOLNR 0.4 (0.1, 0.7)** 0.6 (0.3, 0.9)** 0.3 (-0.1, 0.6) --- --- --- 
APLUSR 0.3 (0.1, 0.6)* 0.5 (0.2, 0.8)** 0.2 (-0.1, 0.5) -0.1 (-0.4, 0.2) --- --- 
OPTR 0.5 (0.2, 0.8)*** 0.7 (0.3, 1.0)*** 0.4 (0.1, 0.7)* 0.1 (-0.2, 0.4) 0.2 (-0.2, 0.5) --- 
VOLR 0.7 (0.5, 1.1)*** 0.9 (0.6, 1.2)*** 0.6 (0.3, 1.0)*** 0.4 (0.02,0.7)* 0.4 (0.1, 0.8)** 0.3 (-0.1, 0.6) 
 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
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Table 6.11: Mean difference (95% confidence interval) for the amount of beclometasone dipropionate and its metabolites excreted post 24hr using 
Qvar® EB and Qvar® EB+ spacers. 
Inhaler Comparator Qvar-EB APLUSNR OPTNR VOLNR APLUSR OPTR 
17-BMP 
APLUSNR 8.7 (6.7, 10.7)*** --- --- --- --- --- 
OPTNR 10.2 (8.2, 12.2)*** 1.5 (-0.5, 3.5) --- --- --- --- 
VOLNR 13.5 (11.5, 15.5)*** 4.8 (2.8, 6.8)*** 3.3 (1.3, 5.3)** --- --- --- 
APLUSR 12.2 (10.2, 14.2)*** 3.5 (1.5, 5.5)*** 2.0 (0.02, 4.0)* -1.3 (-3.3, 0.7) --- --- 
OPTR 11.9 (9.9, 13.9)*** 3.2 (1.3, 5.2)** 1.7 (-0.3, 3.7) -1.6 (-3.6, 0.4) -0.3 (-2.3, 1.7) --- 
VOLR 15.2 (13.2, 17.2)*** 6.5 (4.5, 8.5)*** 5.0 (3.0, 7.0)*** 1.7 (-0.3, 3.7) 3.0 (1.0, 5.0)** 3.3 (1.3, 5.3)** 
BOH 
APLUSNR 20.3 (15.1, 25.4)*** --- --- ---  --- 
OPTNR 27.2 (22.0, 32.3)*** 6.9 (1.8, 12.0)** --- --- --- --- 
VOLNR 33.5 (28.4, 38.6)*** 13.3 (8.2, 18.4)*** 6.4 (1.4, 11.5)** --- --- --- 
APLUSR 29.2 (24.0, 34.3)*** 8.9 (3.8, 14.0)*** 2.0 (-3.1, 7.1) -4.4 (-9.5, 0.7) --- --- 
OPTR 33.5 (28.4, 38.6)*** 13.2 (8.1, 18.4)*** 6.3 (1.2, 11.4) -0.1 (-5.2, 5.1) 4.3 (-0.8, 9.5) --- 
VOLR 43.5 (38.4, 48.7)*** 23.3 (18.2, 28.4)*** 16.4 (11.3 (21.5)*** 10.0 (4.9, 15.1)*** 14.4 (9.3, 19.5)*** 10.1 (4.9, 15.2)*** 
BDP 
APLUSNR 6.1 (3.9, 8.2)*** --- --- --- --- --- 
OPTNR 8.1 (6.0, 10.3)*** 2.1 (-0.1, 4.3) --- --- --- --- 
VOLNR 11.7 (9.6, 14.0)*** 5.6 (3.5, 7.8)*** 3.5 (1.4, 5.7)** --- --- --- 
APLUSR 11.8 (9.6, 14.0)*** 5.7 (3.6, 7.9)*** 3.6 (1.5, 5.8)** 0.1 (-2.1, 2.3) --- --- 
OPTR 12.4 (10.3, 14.6)*** 6.4 (4.2, 8.5)*** 4.3 (2.1, 6.4)*** 0.7 (-1.4, 2.9) 0.5 (-1.5, 2.8) --- 
VOLR 13.1 (11.0, 15.3)*** 7.1 (4.9, 9.3)*** 5.0 (2.8, 7.2)*** 1.5 (-0.7, 3.6) 1.4 (-0.8, 3.5) 0.7 (-1.4, 2.9) 
 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
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Table 6.12: Mean difference (95% confidence interval) for the amount of beclometasone dipropionate and its metabolites excreted post 30 minutes and 
24hr using Qvar® MDI and Qvar® MDI + spacers. 
 
 
 
 
 
 
 
 
 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
 
 
Inhaler Time Comparator Q-MDI APLUSNR 
17-BMP 
0-0.5hr 
APLUSNR 0.3 (-0.4,0.9) --- 
APLUSR 1.2 (0.6,1.8)*** 0.9 (0.3,1.6)** 
0-24hr 
APLUSNR 8.7 (5.8,11.5)*** --- 
APLUSR 11 (8.1,13.9)*** 2.3 (-0.5,5.2) 
BOH 
0-0.5hr APLUSNR -0.7 (-1.7,0.3) --- 
APLUSR 1.0 (0.,2.0)* 1.7 (0.7,2.7)** 
0-24hr APLUSNR 
24.4 (16.9,31.9)*** 
 
--- 
APLUSR 34.7(27.2, 42.2)*** 10.3 (2.8,17.8)* 
BDP 
0-0.5hr 
APLUSNR -0.6 (-1.0,-0.2)* --- 
APLUSR 0.5 (0.1,1)* 1.1 (0.7,1.6)*** 
0-24hr 
APLUSNR 7.1 (5,9.1)*** --- 
APLUSR 11.4 (9.3,13.4)*** 4.3 (2.3, 6.3)*** 
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Table 6.13: Mean difference (95% confidence interval) for the amount of beclometasone dipropionate retained in each spacer post inhalations of 
beclometasone dipropionate Qvar EB and Qvar® MDI. 
Inhaler Comparator VOLNR APLUSNR OPTNR VOLR APLUS R 
Qvar® EB 
APLUSNR 18.6 (-44.5,81.7) --- --- --- --- 
OPTNR -100 (-163.1,-36.9)** -118.6 (-181.7,-55.5)*** --- --- --- 
VOLR -72.9 (-136,-9.8)* -91.5 (-154.6,-28.4)** 27.1 (-36,90.2) --- --- 
APLUSR -47.9 (-111.0,15.1) -66.5 (-129.6,-3.5)* 52.1 (-11,115.1) 24.9 (-38.1,88.0) --- 
OPTR -158.1 (-221.2,-95.0)*** -176.7 (-239.8,-113.6)*** -58.1 (-121,5.0) -85.2 (-148.3,-22.0)** -110.2 (-173.0,-47.0)*** 
Qvar® MDI APLUSR --- -61.3 (-111, -11.6)* --- --- --- 
 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
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Table 6.14: Mean ratio (90% confidence interval) for Qvar EB compared to Qvar EB/spacer (when normalised for the nominal dose). 
 
 
 
 
 
 
 
 
 
  
 
Urinary excretion 
0.5hr 
BDP 17-BMP BOH All combined 
APLUSNR 96.9 (87.7, 107.0) 105.1 (95.1, 116.2) 95.5 (89.9, 101.4) 99.1 (94.2, 104.3) 
APLUSR 112.3 (101.6, 124.0) 135.5 (122.6, 149.8) 112.4 (105.9, 119.2) 119.6 (113.7, 125.9) 
VOLNR 114.4 (104.4, 125.5) 134.9 (119.4, 152.5) 106.8 (102.6, 111.2) 118.2 (111.9, 124.9) 
VOLR 128.9 (117.6, 141.2) 158.6 (140.2, 179.1) 127.0 (122.0, 132.2) 137.4 (130.0, 145.2) 
OPTNR 105.9 (96.2, 116.6) 112.7 (101.2, 125.7) 101.1 (97.5, 104.8) 106.5 (101.0, 112.2) 
OPTR 117.9 (107.1, 130.0) 150.8 (135.4, 168.2) 119.5 (115.3, 123.9) 128.7 (122.0, 135.5) 
24hr 
APLUSNR 135.5 (113.0, 162.6) 147.7 (135.7, 160.8) 133.0 (123.9, 142.8) 138.5 (128.7, 149.2) 
APLUSR 215.5 (179.7, 258.6) 181.8 (167.0, 198.0) 155.4 (144.8, 166.9) 182.6 (169.6, 196.6) 
VOLNR 202.2 (176.3, 232.1) 200.0 (177.0, 225.9) 171.4 (157.6, 186.6) 187.0 (178.6, 203.6) 
VOLR 230.0 (200.6, 264.1) 227.7 (201.6, 257.3) 215.3 (197.8, 234.4) 224.3 (210.0, 239.4) 
OPTNR 155.0 (136.3, 176.1) 160.0 (146.5, 174.7) 150.8 (137.6, 165.4) 155.3 (145.9, 165.0) 
OPTR 214.4 (188.7, 243.8) 178.6 (163.2, 195.0) 170.0 (155.1, 186.6) 186.8 (176.0, 198.6) 
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Table 6.15 : Mean ratio (90% confidence interval) for Qvar MDI compared to Qvar MDI/APLUS spacer (when normalised for the nominal dose). 
 
 
Urinary excretion 
0.5hr 
BDP 17-BMP BOH All combined 
APLUSNR 83.4 (74.2, 93.9) 104.9 (92.7, 118.8) 92.4 (80.3, 106.4) 93.1 (86.7, 100.0) 
APLUSR 120.0 (106.6, 134.9) 133.6 (118.2, 151.3) 122.0 (106.0, 140.5) 125.1 (116.4, 134.4) 
24hr 
APLUSNR 143.6 (129.8, 159.0) 148.3 (133.4, 164.7) 147.3 (131.7, 164.7) 146.4 (137.9, 155.4) 
APLUSR 196.8 (177.7, 217.7) 170.2 (153.1, 189.1) 182.8 (163.3, 204.4) 182.9 (172.2, 194.3) 
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Significantly, more amounts of beclometasone dipropionate and its metabolites were 
excreted in the urine 30 minutes following inhalation by Qvar EB inhaler alone 
compared to that when attached to the Volumatic spacer with or without rinsing or when 
attached to the rinsed Aerochamber Plus and the rinsed Optimiser. However, as shown in 
table 6.10, the results were found to be non-significant when comparing Qvar EB alone 
vs attaching it with either the Aerochamber Plus or the Optimiser spacer without rinsing. 
Table 6.11 shows that the 24 hours urinary excretion post inhalation of Qvar EB and all 
differently treated spacers (VOLNR, APLUSNR, OPTNR, VOLR, APLUSR, and OPTR) 
showed a significant difference (p <0.001). 
More significant amounts of BDP and metabolites were excreted at 30 minutes and 24hrs 
post inhalation from the Volumatic NR vs R. However, the results were non-significant 
with the 24hr urinary BDP and 17-BMP amounts. Similarly, more 30 minutes and 24hr 
urinary excretion from QEB-APLUSNR vs QEB-APLUSR and QEB-OPTNR vs OEB-
OPTR was obtained. The results were statistically significant, except when comparing 
the 24hr urinary excretion of BMP and BOH for the not rinsed Optimiser vs the rinsed. 
For Qvar® MDI, the 30 minutes urinary amounts of BDP and metabolites excreted were 
similar post inhalation from Qvar® MDI alone or when attached to the Aerochamber Plus 
spacer without rinsing. While using the rinsed Aerochamber Plus (APLUSR) spacer led 
to a significant decrease in the 30 minutes urinary excretion of BDP (p<0.05), 17-BMP 
(p<0.001), and BOH (p<0.05), compared to that when using the MDI alone. The use of 
Aerochamber Plus spacer with and without rinsing significantly (p<0.001) decreased the 
24hr urinary excretion of BDP and metabolites than that when using the MDI alone. The 
30 minutes urinary amounts of BDP and metabolites excreted post inhalation from Q-
APLUSNR was significantly higher than that obtained from Q-APLUSR spacers. The 
results were significant at p<0.01for BOH and 17-BMP and at p<0.001for BDP. The 
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24hr urinary amounts excreted post inhalation from Q-APLUSNR vs Q-APLUSR was 
significant at p<0.001 for BDP and at p<0.05 for BOH and non-significant for 17-BMP.  
6.3.4. Discussion 
The mouthpiece of the Qvar EB fitted tightly into the Aerochamber Plus, the Volumatic, 
as well as the Optimiser Spacer. 
Non-significant urinary amounts of BDP and its metabolites were excreted at 30 minutes 
post inhalation from Qvar® EB alone compared to inhalation via the Qvar EB attached to 
the not rinsed Aerochamber Plus and the not rinsed Optimiser. However, significant 
more amounts of drug and metabolites were excreted from Qvar EB alone compared to 
when it was attached to any of the rest of spacers used. Similarly, for the Qvar® MDI, 
comparable amounts of BDP and metabolites were excreted when using the MDI alone 
or when attached to the not rinsed Aerochamber Plus spacer. In contrast, the Q-APLUSR 
spacer combination significantly reduced drug delivery. These results imply that patients 
with asthma would receive the same dose of beclometasone dipropionate from Qvar® EB 
alone or via the not rinsed Aerochamber Plus or the not rinsed Optimiser and from Qvar® 
MDI alone or via the not rinsed Aerochamber Plus if using an optimal inhaler technique. 
In addition, the 30 minutes and the 24hr urinary excretion post inhalation via the not 
rinsed Aerochamber Plus were higher than all other spacers used. The results were 
significant at all times except when comparing the 30 minutes and the 24hr urinary 
amounts of BMP and BDP delivered from the not rinsed Aerochamber Plus vs the not 
rinsed Optimiser where it failed to reach significance. 
The use of any of the spacer devices with Qvar® MDI or Qvar® EB resulted in 
significantly (p<0.001) lower amounts of BDP and metabolites 24 hours post dosing. 
This was due to deposition of part of the dose on the walls of the add-on device instead 
of the patient’s throat. 
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This is in agreement with a recent in-vivo gamma scintigraphy study that showed that the 
small particle HFA-BDP lung deposition averaged 52% and was not affected by the use 
of the Aerochamber. This study also reported a reduction in the oropharyngeal deposition 
of HFA-BDP from approximately 28% to 4% with the Aerochamber (Leach and Colice, 
2010). Another study showed that the use of the Aerochamber Plus spacer with the 
highly extra fine formulation of Ciclesonide MDI did not affect its pharmacokinetics, 
suggesting a similar lung deposition when using the Ciclesonide MDI with or without a 
spacer (Drollmann et al., 2006).  
Similarly, other studies reported that using small tube spacers (50ml) with HFA 
formulations were found to markedly reduce oropharyngeal deposition either without 
affecting (Hardy et al., 1996) or with increasing lung deposition (Richards et al., 2001). 
Previous findings by Hardy et al (1996) reported that the use of the Optimiser spacer 
with the Easi-Breathe inhaler removed most of the non-respirable drug, without 
compromising the fine particle dose delivered from the Easi-Breathe inhaler and 
significantly reduced oropharyngeal deposition in healthy subjects by 80%. Thus, the 
combination of a breath-operated inhaler with a small volume spacer offers the 
advantages of improved co-ordination and reduction in oropharyngeal deposition, 
without the inconvenience of a large volume spacer (Hardy et al., 1996).  
The inhalation of Qvar EB via the not rinsed Aerochamber Plus (APLUSNR) and the not 
rinsed Optimiser spacer (OPTNR) produced more drug and metabolites excreted than 
that inhaled via the not rinsed Volumatic. This may be attributed to that small volume 
spacers such as the Optimiser and Aerochamber Plus may be more suitable in 
maintaining the extra-fine particle fraction better than large volume spacers such as the 
Volumatic spacer.  
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Also, the comparison between different treatment methods for the same spacer showed 
superior lung deposition of the detergent coated spacers without subsequent water rinsing 
to those followed by rinsing for both Qvar® EB and Qvar® MDI. These results follow the 
same trend as those with Clenil®. 
Plastic spacers are highly prone to the build up of static charge through contact and 
friction, so when contacting the highly charged aerosol cloud confined inside the spacer, 
mutual repulsion between the charged particles cause them to move to the periphery of 
the aerosol cloud and contact the spacer walls. This drug retention within the spacer 
device results in significant reduction in the drug aerosol available for inhalation. Highly 
charged spacers have been shown to significantly reduce both in-vitro (O'Callaghan et 
al., 1993; Barry and O'Callaghan, 1995) and in-vivo (Kenyon et al., 1998; Anhoj et al., 
1999) drug output. These differences in dose delivered are due to less electrostatic 
attraction of charged aerosol particles to walls of the non-electrostatic spacer (detergent 
prewashed and air-dried). Another study showed that removal of the electrostatic charge 
from Nebuhaler, Volumatic, and the smaller Aerochamber by soaking in a household 
detergent increased drug output from CFC- and HFA-MDIs through all spacers by 17-
82% (Chuffart et al., 2001). 
As previously published and further confirmed in this study, the fine details of adequate 
handling of spacers can have a significant effect on maximizing drug delivery from 
various spacers and inhaler devices, thus improve therapeutic responses, and reduce 
treatment costs.  
The findings of this study of reduced FPD after rinsing are in line with the 30 minutes 
urinary excretion data. According to the results from the previous in-vitro and in-vivo 
studies, the FPD and the TED in-vitro parameters are more important in predicting the 
in-vivo 30 minutes and the 24hr urinary drug excretion, respectively. This is in agreement 
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with a previous study that reported that there is no discernible relationship between the 
MMAD and the in vivo indices of salbutamol lung deposition and suggested that the FPD 
is the more appropriate indicator for in-vivo lung deposition (Richardson et al., 2007).  In 
addition, Harrison et al (1997) showed good correlation between the in-vitro fine particle 
mass and the in-vivo drug delivery of three different strengths of an HFA-BDP 
formulation. Similarly, it was previously reported that plotting the dose response curve in 
terms of the emitted dose (for systemic response) and fine particle dose for (pulmonary 
effects) better represent the doses causing these specific responses when comparing 
different ICSs (Martin et al., 2002; Parameswaran et al., 2003). 
6.4. Conclusion 
The use of spacers with Qvar® inhalers always significantly reduced the oropharyngeal 
deposition, however, they did not increase the amount of drug excreted 30 minutes post 
dosing. The presence of the electrostatic charge on the surface of water rinsed spacers 
following detergent washing would have contributed to significant loss of drug output 
from the spacer compared to those not water rinsed post detergent treatment.  
Overall, the previous in-vivo and in-vitro results showed good correlation with each 
other. According to the results from these studies, the FPD and the TED in-vitro 
parameters are more important in predicting the in-vivo 30 minutes and the 24hr urinary 
drug excretion, respectively. 
   
 
 
 
 
 
Chapter 7: Comparison of In-Vitro Aerodynamic 
Particle Size Distribution and In-Vivo Relative Lung 
and Systemic Bioavailability of Beclometasone 
Inhaled from the Extra-Fine Qvar® and the Non-
Extrafine Clenil® Modulite Inhalers
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7.1. Introduction 
Inhalation aerosols such as metered dose inhalers are used largely for the treatment of 
lung diseases. Chlorofluorocarbons (CFCs) were the most widely used propellants in 
MDIs as it is cheap, safe and efficient, but recently its use has been universally restricted 
due to its deleterious effects on the ozone layer. The International Montreal Protocol 
agreement on phasing out the ozone depleting chlorofluorocarbons propellants (CFCs) 
has led to the search of a suitable alternative propellant for MDIs. Beclometasone 
dipropionate has been recently reformulated with the safer and more environmentally 
friendly HFA propellants. Despite the complexities and challenges faced in this 
reformulation process, considerable success has been achieved. The new Modulite® 
platform technology, allows for the manipulation of inhaled HFA based solution 
formulations to tailor the desired particle size for optimum lung deposition. These 
development in aerosol designs and technologies have facilitated the transition to CFC-
free products at unchanged doses, or to replace existing drugs at reduced nominal daily 
dose in case of extra-fine formulations.  
Beclometasone dipropionate has been recently reformulated into two CFC-free 
beclometasone inhalers that are available in the UK and licensed for asthma treatment. 
The extrafine Qvar® formulation (1.1µm) delivers most of the inhaled dose to both 
central and peripheral airways resulting in a uniform treatment of inflammation and 
bronchoconstriction throughout the lower respiratory tract. This feature is of particular 
interest for inhaled corticosteroids treatment as the asthmatic inflammation affects both 
large and small airways considerably. It was not until HFA solution technology was 
introduced that it was possible to produce a MDI with lung deposition values greater than 
50%. This improved lung deposition require halving the dosage down when switching 
patients from a CFC- inhaler to Qvar® (Davies et al., 1998). 
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The non-extrafine formulation Clenil® Modulite (2.9µm MMAD, Chiesi, UK), allows for 
an easy transition from CFC-BDP to HFA-BDP products as it is designed to deliver an 
aerosol with particle size and properties that more closely resembles those of a CFC-
MDI. Many studies have confirmed that Clenil® provided similar asthma control, 
efficacy (Anderson et al., 2002; Rocca-Serra et al., 2002; Woodcock et al., 2002a) and 
comparable adverse effects (Acerbi et al., 2007) when compared to CFC-BDP inhalers. 
In the UK, Clenil Modulite is the only available HFA-BDP that can be used in place of 
CFC-BDP without changing the prescribed dose of corticosteroid. Therefore, it has 
solved the technical difficulties in switching patients from CFC to HFA-BDP inhalers 
(Ganderton et al., 2002; Bousquet et al., 2009).  
7.2. In-vitro comparison of aerodynamic particle size distribution of beclometasone 
dipropionate post inhalation from different inhalers 
The aim of this section is to compare the aerodynamic particle size distribution of 
beclometasone dipropionate emitted from Qvar® EB (100µg), Qvar® MDI (100µg), and 
Clenil® MDI (250µg) with and without spacers by using the previously reported results 
in chapter 5.2 and 6.2 of this thesis.  
7.2.1. Statistical analysis 
The data was statistically analyzed using one way analysis of variance (ANOVA) to 
compare the aerodynamic particle size characterization of different inhalers and 
inhalers/spacer combinations at a flow rate of 28.3 L/min and the aerodynamic particle 
size characterization of different inhalers used alone at higher flow rates using SPSS 
V17.0 (SPSS Inc., Chicago, USA). 
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7.2.2. Results 
7.2.2.1. Aerodynamic particle size characterization 
A summary of the in-vitro data obtained from the ACI for Clenil® (250µg), Qvar® EB 
(100µg), and Qvar® MDI (100µg) at a flow rate of 28.3L/min with different spacers and 
at different flow rates of 28.3, 60, and 90L/min without spacers are summarized in tables 
7.1, and 7.2, respectively. Figures 7.1, 7.2, and 7.3 represent the data obtained from the 
three inhalers with the Optimiser, the Volumatic, and the Aerochamber Plus spacer 
respectively at a flow rate of 28.3L/min. Figures 7.4, 7.5, and 7.6 represent the data 
obtained from the three inhalers alone when operated at flow rates of 28.3, 60, and 
90L/min, respectively. A summary of the statistical analysis of the in-vitro data obtained 
from each of the three inhalers plus different spacers at a flow rate of 28.3L/min and 
obtained from each inhaler alone at different flow rates are shown in table 7.3, and 7.4, 
respectively. 
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Table 7.1: A summary of the mean (SD) data obtained from the Andersen Cascade Impactor (ACI) for Clenil ® (250µg), Qvar® EB (100µg), and Qvar 
MDI (100µg) used alone at 28.3, 60, and 90L/min flow rates. Values quoted in µg unless specified, (n=5). 
* TED: Total emitted dose, ND: Nominal dose. 
Inhalation 
method 
Spacer 
used 
Spacer 
deposition TED* (µg) 
TED 
(% ND)* FPD (µg) 
%FPF 
of (ND)* 
%FPF 
of (TED)* 
MMAD 
(µm) 
GSD 
(No units) 
Clenil MDI 
---- 
------ 381.8 (6.3) 76.4 (1.7) 97.6 (20.8) 19.5 (4.2) 25.6 (5.4) 2.8 (0.4) 2.2 (0.2) 
VOLNR 224.3 (35.0) 218.9 (23.1) 43.8 (4.6) 153.9 (19.4) 30.8 (3.9) 70.3 (5.6) 2.3 (0.1) 2.3 (0.2) 
APLUSNR 233.9 (25.7) 212.1 (21) 42.4 (4.2) 138.8 (22.2) 27.8 (4.4) 65.2 (4.9) 2.3 (0.1) 2.7 (0.3) 
OPTNR 240.9 (26.6) 163.4 (15.2) 32.7 (3.0) 93.3 (17.6) 18.7 (3.5) 57.6 (5.3) 3.1 (0.2) 2.3 (0.1) 
VOLR 271.8 (20.9) 162.2 (13) 32.4 (2.6) 110.6 (7.4) 22.1 (1.5) 68.3 (2.1) 2.7 (0.2) 2.2 (0.1) 
APLUSR 301.6 (49.3) 155.3 (15.4) 31.1 (3.1) 90.6 (18.8) 18.1 (3.8) 58.1 (7.2) 3.1 (0.3) 2.2 (0.1) 
OPTR 305.5 (33.9) 112.5 (8.0) 22.5 (1.6) 62.7 (8.2) 12.5 (1.6) 55.6 (3.6) 3.3 (0.3) 1.8 (0.1) 
Qvar EB 
----- ----- 372.6 (27.1) 93.2 (6.8) 218.0 (29.1) 54.5 (7.3) 58.4 (5.2) 1.2 (0.2) 3.8 (0.3) 
VOLNR 169.2 (18.7) 191.6 (20.8) 47.9 (5.2) 161.3 (22.2) 40.3 (5.6) 84 (2.4) 1.2 (0.1) 4.0 (1.0) 
APLUSNR 117.7 (16.5) 230.7 (30.1) 57.7 (7.5) 196.2 (27.0) 49 (6.8) 84.9 (1.4) 1.1 (0.3) 3.8 (1.1) 
OPTNR 126.4 (8.1) 207.5 (9.6) 51.9 (2.4) 179.6 (15.1) 44.9 (3.8) 86.5 (4.1) 1.0 (0.2) 3.4 (0.01) 
VOLR 228.1 (20.2) 138.1 (20.3) 34.5 (5.1) 108.2 (19) 27 (4.7) 78.2 (2.5) 1.5 (0.23) 4.17 (1.1) 
APLUSR 225.8 (36.9) 133.6 (18.4) 33.4 (4.6) 115.9 (22.9) 28.9 (5.7) 86.3 (5.5) 1.2 (0.49) 3.3 (0.7) 
OPTR 191.2 (22.9) 138.8 (16.5) 34.7 (4.1) 121.9 (20.9) 30.5 (5.2) 87.5 (5) 1.1 (0.15) 2.6 (0.01) 
Qvar MDI 
----- ----- 362.2 (34.7) 90.5 (8.7) 208.9 (16.3) 52.2 (4.1) 57.6 (6.2) 1.2 (0.15) 3.5 (0.4) 
APLUSNR 183.4 (30.0) 235.3 (29.0) 58.8 (7.2) 191.6 (23.8) 47.9 (6) 81.4 (0.4) 1.1 (0.06) 4.2 (0.3) 
APLUSR 239.6 (66.2) 150.1 (28.9) 37.5 (7.2) 127.2 (27.2) 31.79 (6.8) 84.5 (3.5) 1.1 (0.12) 4.1 (0.4) 
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Table 7.2: A summary of the data obtained from the ACI for Clenil® (250µg), Qvar® EB (100µg), and Qvar MDI (100µg), (n=5) 
 
 
 
 
 
 
 
 
 
 
 
 
Inhaler 28.3L/min 60L/min 90L/min 
Total emitted dose (TED) 
(µg) 
Clenil 381.8 (6.3) 383.2 (22.7) 348.6 (19.0) 
Qvar EB 372.6 (27.1) 349.1 (41.9) 338.0 (22.2) 
Qvar MDI 362.2 (34.7) 387.4 (16.6) 380.0 (10.4) 
TED 
(% of nominal dose) 
Clenil 76.4 (1.7) 76.6 (4.5) 69.7 (3.8) 
Qvar EB 93.2 (6.8) 87.3 (10.5) 84.5 (5.5) 
Qvar MDI 90.6 (8.7) 96.9 (4.2) 95.0 (2.6) 
FPD (µg) 
Clenil 97.6 (20.8) 138.0 (7.1) 116.5 (5.7) 
Qvar EB 218 (29.1) 225.9 (26.6) 235.7 (12.2) 
Qvar MDI 208.9 (16.3) 241.8 (32.7) 247.4 (9.5) 
% FPF of nominal dose 
Clenil 19.5 (4.2) 27.6 (1.4) 23.4 (1.1) 
Qvar EB 54.5 (7.3) 64.8 (8.1) 58.9 (3.1) 
Qvar MDI 52.2 (4.1) 60.4 (8.2) 61.8 (2.4) 
%FPF of TED 
Clenil 25.6 (5.4) 36.1 (3.3) 33.6 (0.5) 
Qvar EB 58.4 (5.2) 59.6 (1.9) 69.8 (3.8) 
Qvar MDI 57.6 (6.2) 62.3 (6.1) 70.7 (7.7) 
MMAD (µm) Clenil 2.8 (0.4) 2.2 (0.1) 2.2 (0.2) Qvar EB 1.2 (0.2) 1.2 (0.2) 1.2 (0) 
Qvar MDI 1.2 (0.2) 1.2 (0.1) 1.3 (0.2) 
GSD (no units) Clenil 2.2 (0.2) 2.9 (0.15) 3.3 (0.2) Qvar EB 3.8 (0.3) 3.4 (0.3) 3.1 (0.3) 
Qvar MDI 3.5 (0.4) 3.4 (0.3) 3.4 (0.9) 
Induction port deposition 
(µg) 
Clenil 251.3 (22.0) 200.8 (19.4) 187.3 (14.7) 
Qvar EB 121.8 (15.5) 100.2 (18.6) 81.6 (18.1) 
Qvar MDI 130.9 (26.3) 116.8 (27.8) 99.6 (4.3) 
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Figure 7.1: Mean beclometasone dipropionate (a) deposited in each stage of the ACI (µg) 
(b) aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose emitted 
from different inhalers with the Optimiser spacer at a flow rate 28.3 L min-1, (n=5). 
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Figure 7.2: Mean beclometasone dipropionate (a) deposited in each stage of the ACI (µg) 
(b) aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose emitted 
from different inhalers with the Volumatic spacer at a flow rate 28.3 L min-1, (n=5). 
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Figure 7.3: Mean beclometasone dipropionate (a) deposited in each stage of the ACI (µg) 
(b) aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose emitted 
from different inhalers with the Aerochamber Plus spacer at a flow rate 28.3 L min-1, 
(n=5). 
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Figure 7.4: Mean beclometasone dipropionate (a) deposited in each stage of the ACI (µg) 
(b) aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose and 
induction port deposition emitted from different inhalers at a flow rate of 28.3L min-1, 
(n=5). 
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Figure 7.5: Mean beclometasone dipropionate (a) deposited in each stage of the ACI (µg) 
(b) aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose and 
induction port deposition emitted from different inhalers at a flow rate of 60 L min-1, 
(n=5).  
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Figure 7.6: Mean beclometasone dipropionate (a) deposited in each stage of the ACI 
(µg)(b) aerodynamic distribution of the emitted dose (c) mean (SD) fine particle dose and 
induction port deposition emitted from different inhalers at a flow rate of 90 L min-1, 
(n=5).
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Table 7.3: Mean difference (95% confidence interval) for each spacer used with different inhalers at 28.3 L/min flow rate. 
 
Comparator %FPF of nominal dose %TED of nominal dose 
C-APLUSNR QEB- APLUSNR -21.3 (-29.1, -13.5)*** -15.3 9-23.1, -7.4)*** Q-APLUSNR -20.1 (-27.9, -12.4)*** -16.4 9-24.2, -8.6)*** 
C-APLUSR QEB- APLUSR -10.9 (-18.7, -3.1)** -2.3 (-10.2, 5.5) Q-APLUSR -13.8 (-21.5, -5.9)** -6.5 (-14.3, 1.4) 
Q-APLUSNR QEB- APLUSNR -1.1 (-8.9, 6.6) 1.2 (-6.7, 9.0) 
Q-APLUSR QEB- APLUSR 2.8 (-5.0, 10.6) 4.1 (-3.7, 11.9) 
C-VOLNR QEB-VOLNR -9.5 (-17.3, -1.8)* -4.1 (-11.9, 3.7) 
C-VOLR QEB-VOLR -4.9 (-12.7, 2.9) -2.1 (-9.9, 5.7) 
C-OPTNR QEB-OPTNR -26.2 (-34.0, -18.5)*** -19.2 (-2.7, -11.4)** 
C-OPTR QEB-OPTR -19.3 (-27.0, -11.5)** -12.2 (-20.0, -4.4)** 
 
Table 7.4: Mean difference (95% confidence interval) for different inhalers when used at various flow rates. 
 
 
 
 
 
 
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
Flow rate 
(L/min) Comparator %FPF of  nominal dose %TED of  nominal dose 
28.3 C-MDI 
Qvar-EB -35.0 (-42.8, -27.1)*** -16.8 (-27.7, 5.9)** 
Q-MDI -32.4 (-40.3, -24.6)*** -14.2 (-25.1, -3.3)* 
Qvar-EB Q-MDI 2.6 (-5.3, 10.4) 2.6 (-8.3, 13.5) 
60 C-MDI 
Qvar-EB -37.2 (-45.0, -29.3)*** -10.6 (-21.5, 0.3) 
Q-MDI -32.8 (-40.7, -25.0)*** -20.2 (-31.1, -9.3)** 
Qvar-EB Q-MDI 4.3 (-3.5, 12.2) -9.6 (-20.5, 1.3) 
90 C-MDI 
Qvar-EB -35.5 (-43.4, -27.7)*** -14.8 (-25.7, -3.9)* 
Q-MDI -38.5 (-46.3, -30.6)*** -25.3 (-36.2, -14.4)*** 
Qvar-EB Q-MDI -2.9 (-10.8, 4.9) -10.5 (-21.4, 0.4) 
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7.2.3. Discussion 
The comparison of two actuations of 250µg Clenil MDI to four actuations of 100µg Qvar 
inhalers alone without a spacer at different flow rates of 28.3, 60, and 90L/min showed 
significantly more % FPF of nominal dose (p<0.001), from either the Qvar® MDI or the 
Qvar® EB device than that obtained from the Clenil® MDI. Similarly, the % TED with 
respect to the nominal dose was higher for either the Qvar EB or the Qvar MDI when 
compared to the Clenil MDI at different flow rates. The results were always significant 
except when comparing Clenil vs Qvar-EB at a flow rate of 60 L/min where it failed to 
reach significance. 
According to the results from this study the mean (SD) MMAD obtained from the ACI at 
a flow rate of  28.3L/min for Clenil® MDI, Qvar® EB, and Qvar® MDI are 2.8 (0.4), 1.1 
(0.3), and 1.2 (0.2), respectively. As shown in figure 7.4, a great difference by more than 
half was found in the mean (SD) FPD obtained from either Qvar® EB 218.0 (29.1) or 
Qvar® MDI 208.9 (156.3) when compared to Clenil® MDI 97.6 (20.8).  
The greater total mass of fine particles obtained from Qvar® inhalers than Clenil® MDI at 
equivalent dosages would be expected to greatly increase lung deposition with better 
delivery to the small airways. This was in agreement with a previous study by Leach et al 
(2002) who showed that the MMAD of Qvar® HFA-BDP is in the range of 0.9-1.1µm 
and offers more improved delivery to the small airways. This study suggested that the 
HFA-BDP extra fine aerosol would provide equivalent efficacy to existing CFC-BDP but 
at half the nominal dose. Several other studies gave similar findings (Busse et al., 1999b; 
Harrison et al., 1999b; Agertoft et al., 2003). On the other hand, several clinical trials 
have consistently shown no differences in lung function, asthma control or tolerability 
between BDP Modulite® (2.9µm MMAD) and CFC-BDP inhaler (Anderson et al., 2002; 
Lee et al., 2002; Woodcock et al., 2002b).  
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The mean (SD) amounts of drug deposited in the induction port were 251.3 (22.0), 121.8 
(15.5), and 130.9 (26.3) for Clenil MDI, Qvar EB, and Qvar MDI, respectively. The 
greater induction port deposition associated with Clenil® MDI compared to Qvar® 
inhalers when used without a spacer is due to the greater particle size of Clenil®  which 
will be expected to  undergo greater impaction and sedimentation due to gravity within 
the induction port of the Andersen cascade Impactor (ACI). Alternatively, with the 
spacer addition to Clenil®, the high proportion of large particles in the formulation will 
be expected to deposit more on the spacer. In contrast, Qvar® formulations have higher 
proportion of smaller particles. These small particles escape from impaction on spacer 
surface and penetrate the airways more deeply. Similarly, a previous study reported a 
poor deposition of  the small particles of Qvar® formulation in three different mouth 
throat models studied  (Zhang et al., 2007) while aerosols with larger sized particles 
showed considerable mouth throat deposition due to inertial impaction (Grgic et al., 
2004).  
When comparing the FPF and the TED with respect to the nominal dose between Qvar® 
EB and Qvar® MDI either alone or when attached to the Aerochamber Plus with or 
without rinsing, the results were always non significant. The small drug particles in the 
Qvar BDP inhaler would be longer suspended in the air, thus allowing more time for 
inhalation after actuation and makes the inhalation technique less critical. Thus, using the 
Easi-breathe device may offer no extra advantage with these highly fine formulations. 
This was confirmed by a previous study by Leach et al (2005) whereby lung deposition 
results of Qvar MDI without spacers was only reduced from 59 to 37% under extreme 
discoordination circumstances. 
It is shown from the results that the use of the not rinsed Aerochamber Plus spacer with 
two actuations from Clenil® MDI (250µg) resulted in significantly lower % FPF of 
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nominal dose (p<0.001) and lower %TED (p<0.001) than that obtained from four 100µg 
actuations from Qvar® EB or Qvar® MDI attached to the same spacer. Similarly, using 
the rinsed Aerochamber Plus spacer with the same dose of Clenil® MDI resulted in lower 
%FPF and %TED of nominal dose than that obtained from four actuations of Qvar 
inhalers (100µg).The results for the % TED and the % FPF showed a non-significant 
difference for the former and a significant difference for the latter (p<0.01). 
In addition, using the Optimiser spacer either rinsed or not rinsed with Clenil® MDI, 
significantly reduced the %FPF of nominal dose to nearly half that obtained when the 
same spacer used with Qvar® EB inhaler. Similarly, the % TED for the combination 
between the Optimiser spacer (rinsed or not rinsed) and Clenil was significantly 
decreased when compared to Qvar EB attached to the same spacer (p<0.01). 
However, when comparing the combination of the Volumatic spacer (R or NR) with 
Clenil® MDI vs the same spacer combination with Qvar® EB, the results for % FPF of 
nominal dose showed a non-significant difference for the Volumatic spacer when rinsed 
and a significant difference when it is not rinsed (p<0.05). However, the results for % 
TED for both inhalers with the Volumatic spacer were non-significant. 
The above results revealed that the formulation particle size could greatly affect aerosol 
particle size distribution in the Andersen Cascade Impactor with or without a spacer 
device. The smaller particle size of Qvar® formulation (1.1µm MMAD) appears to be 
more suitable with smaller sized spacers such as the Optimiser and the Aerochamber 
Plus. In contrast, the large volume spacers such as the Volumatic were more suitable to 
the larger particle size of Clenil® MDI (2.9µm MMAD). This is may be due to that the 
large volume of the Volumatic spacer when attached to Clenil® MDI will create more 
space for this larger particle size aerosol (MMAD 2.9µm) to expand and have more 
sufficient time for the propellant to evaporate, thus it results in finer aerosol spray when 
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compared to smaller volume spacers. In addition, smaller volume spacers will be 
expected to undergo greater impaction of larger particles on their walls and thus reduce 
the amount of aerosol generated from them (Dolovich and Dhand, 2011). On the other 
hand, the extra-fine properties of Qvar® formulations will lead to limited or small 
capacity for particle size reduction or spacer impaction. Thus, the FPD will not be 
significantly influenced as a function of time or distance (Smyth et al., 2004). This 
explains why the use of the not rinsed Aerochamber Plus spacer device did not improve 
drug delivery from Qvar inhalers. This highly fine formulation allows the BDP aerosol 
particles to remain suspended in the inhaled air with better penetration to the small 
airways of the lung. Therefore, it decreases the need for spacers, since their main 
function is to improve fine particles by exclusion of larger particles.  
However, the use of any of the spacers with any inhalers was always associated with a 
substantial reduction in the amount deposited in the induction port compared to that 
obtained with any inhaler alone. This is consistent with a previous study by Rahmatallah 
et al (2002), who reported that using an Aerochamber plus with Qvar® MDI was not 
associated with any significant increase in the actual dose delivered to the respiratory 
tract. Instead, a significant decrease in the total inhaled dose due to greater deposition on 
the spacer walls. The spacers become the major site of drug deposition, thus reducing 
particles deposition in the induction port of the ACI.  
As shown in table 7.2, increasing the flow rate was associated with an increase in both 
the FPD and the % FPF with both Clenil and Qvar formulations. The mean (SD) FPD for 
Clenil were 97.6 (20.8), 138.7 (7.1), and 116.5 (5.7) at a flow rate of 28.3, 60, and 
90L/min, respectively. The mean (SD) FPD for Qvar EB was 218 (29.1), 225.9 (26.6), 
and 235.7 (12.2) while that for Qvar MDI was 208.9 (16.3), 241.8 (32.7), and 247.4 (9.5) 
at a flow rate of 28.3, 60, and 90L/min, respectively. This gives the indication that 
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smaller particles were emitted at higher flow rates. Despite that increasing the flow rate is 
expected to be associated with greater impaction in the induction port and hence lower 
FPD and lower FPF; however, this was not the case in this study or with previous studies 
that gave similar findings. This may give indication that inertial impaction is not the only 
mechanism by which particles are deposited in the induction port. This behaviour of 
aerosol particles can be due to turbulence mechanism affecting particle deposition in the 
induction port, which is inversely proportional to inhalation flow rate. This turbulence 
arises from the velocity difference between the MDI aerosol plume and the inspired air, 
which is expected to be greater at low flow rates. Therefore, the combined effect of both 
mechanisms; turbulence and impaction are the major determinant for particles deposition 
in the induction port (Feddah et al., 2000; Rahmatalla et al., 2002). 
It is apparent from previous studies with different spacers that considerable variations in 
spacers’ size can probably lead to a unique drug delivery characteristics form each 
spacer. Several studies have shown that spacers could act differently when attached to the 
same drug formulation (Agertoft and Pedersen, 1994; Ahrens et al., 1995; Barry and 
O'Callaghan, 2000; Feddah et al., 2001) or when attached to different formulations of the 
same drug (Miller and Bright, 1995; Barry and O'Callaghan, 1997; Finlay and 
Zuberbuhler, 1998; Dubus et al., 2001). Miller and Bright (1995) compared the in-vitro 
drug output of three different BDP inhalers from three different manufacturers when used 
with the Volumatic spacer and indicated a significant difference in the drug output 
between inhalers of different manufacturers. Another in-vitro study by Barry and 
O’Callaghan (1997) has shown large differences in the amount of drug obtained in small 
particles when the conventional and CFC-free formulations of salbutamol MDIs are used 
with different spacer devices. 
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Besides, the drug delivery from each plastic spacer can be greatly affected by different 
levels of electrostatic charge accumulated on its surfaces during handling. This may lead 
to significant reduction in the respirable dose (O'Callaghan et al., 1993), lung deposition 
(Kenyon et al., 1998) and clinical response (Wildhaber et al., 2000b). The presence of 
electrostatic charge on spacers’ surfaces leads to continuous and rapid loss of the aerosol 
to spacers’ walls, thus significantly reducing the aerosol half-life (the normal aerosol 
half-life may decrease from 30 sec to 10 sec in presence of electrostatic charge). The 
short half-life of the aerosol increases the need for coordination between actuation and 
inhalation as patients will not be able to empty the aerosol before a considerable fraction 
is lost within the spacer. Consequently, the full predictable dose will not be delivered 
(Mitchell et al., 2007b). According to the results from this study, which agreed with 
previous findings (Pierart et al., 1999; Wildhaber et al., 2000a), conditioning spacer 
devices by washing with a conductive surfactant (detergent) without subsequent water 
rinsing presented a simple solution to this problem and improved drug delivery from 
spacers with both inhalers used. 
7.3. In- vivo comparison of relative lung and systemic bioavailability of 
beclometasone dipropionate inhaled from Qvar® and Clenil® Modulite inhalers 
The aim of this section is to compare the relative lung and systemic bioavailability of 
beclometasone dipropionate post-inhalation from Qvar® EB, Qvar® MDI, and Clenil® 
inhalers with spacers by using the previous results illustrated in chapter 5.3 and 6.3 of 
this thesis.  
7.3.1. Statistical Analysis 
Statistical analysis of the 0.5hr and the 24 hours urinary excretion expressed as percent of 
nominal dose of beclometasone dipropionate and its metabolites following administration 
of C-MDI, Qvar EB and Q-MDI with different spacers were carried out using a one way 
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analysis of variance (ANOVA) test using SPSS V17.0 (SPSS Inc., Chicago, USA). In 
addition, one-way analysis of variance with the application of Bonferroni correction was 
used to determine any difference between the urinary excretions of different inhalers. To 
identify equivalence of the urinary excretions between the inhalation methods, the 30 
minutes and cumulative 24hr amounts, excreted for each inhalation method, were 
normalised for the nominal dose and then log transformed. From the mean square error 
of the analysis of variance, using patients and inhalation method as the main factors, the 
mean ratio (90% confidence interval) was calculated. 
7.3.2. Results 
The mean (SD) urinary amounts of BDP and its metabolites excreted 0.5hr, and 24hr post 
eight inhalations from Clenil® MDI (250µg), Qvar®  EB (100µg), and Qvar®  MDI 
(100µg) with and without spacers for the twelve subject studied are summarized in table 
7.5. Figures 7.7-7.10 represent the 0.5hr, the 24hr mean (SD) urinary amounts of BDP, 
and its metabolites excreted post different inhalation methods, expressed as percentage of 
nominal dose. A summary of the statistical data for the 30 minutes and the 24hr urinary 
excretion of BOH, 17-BMP, and BDP are represented in table 7.6. A summary of the 
mean ratio (90% confidence limits) between Qvar and Clenil inhalers with respect to the 
nominal dose is shown in table 7.7. These values are presented separately for BDP, 17 
BMP, and BOH, as well as for all three metabolites combined.  
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Table 7.5: Mean (SD) amount of beclometasone dipropionate and its metabolites excreted 0.5hr, and 24hr post inhalation of different study doses with 
and without spacers, expressed in µg, n=12. 
 
Inhaler Device Amount left in 
spacer (µg) 
17-BMP (µg) BOH (µg) BDP (µg) 
0.5hr 24hr 0.5hr 24hr 0.5hr 24hr 
Clenil 
MDI --- 5.0 (1.8) 28.9 (6.0) 7.4 (1.9) 88.5 (17.3) 3.7 (0.6) 30.2 (6.6) 
VOLNR 670.8 (74.4) 6.3 (2.2) 21.0 (3.1) 10.0 (2.8) 67.7 (14.4) 4.8 (0.9) 19.8 (2.6) 
APLUSNR 758.0 (136.5) 5.6 (2.0) 16.3 (2.4) 8.6 (1.6) 57.4 (12.3) 4.0 (0.8) 19.4 (2.7) 
OPTNR 705.4 (84.4) 4.8 (1.6) 16.4 (2.7) 7.1 (1.4) 50.8 (13.7) 3.6 (0.6) 17.4 (2.3) 
VOLR 732.9 (74.9) 4.6 (1.2) 16.1(2.8) 6.7 (1.1) 48.0 (10.4) 3.6 (0.6) 15.9 (1.9) 
APLUSR 784.8 (46.9) 4.2 (1.4) 14.7(3.3) 5.7 (1.1) 44.8 (14.0) 3.5 (0.8) 14.2 (2.1) 
OPTR 807.0 (120.5) 4.1 (1.6) 13.6 (2.9) 6.2 (1.6) 44.9 (12.3) 3.3 (0.6) 14.7 (1.8) 
Qvar EB 
EB --- 4.5 (0.8) 27.3 (3.9) 6.9 (1.4) 80.8 (14.6) 3.5 (0.5) 23.4 (3.9) 
VOLNR 355.5 (52.6) 3.4 (0.9) 13.7 (2.9) 6.5 (1.2) 47.2 (9.5) 3.1 (0.6) 11.7 (2.8) 
APLUSNR 336.9 (89.1) 4.3 (1.0) 18.6 (3.4) 7.2 (1.2) 60.5 (9.8) 3.7 (0.7) 17.4 (3.5) 
OPTNR 455.5 (76.8) 4.1 (1.0) 17.1 (2.6) 6.8 (1.3) 53.6 (10.0) 3.4 (0.8) 15.3 (3.5) 
VOLR 428.4 (52.5) 2.9 (0.7) 12.1(2.3) 5.5 (1.0) 37.2 (4.8) 2.8 (0.5) 10.3 (2.3) 
APLUSR 403.4 (97.8) 3.3 (0.6) 15.1 (2.8) 6.1 (1.0) 51.6 (7.0) 3.2 (0.7) 11.6 (3.9) 
OPTR 513.6 (101.8) 3.0 (0.7) 15.4 (2.9) 5.7 (1.2) 47.3 (7.3) 3.0 (0.6) 11.0 (2.5) 
Qvar MDI 
MDI --- 4.7 (1.1) 25.8 (7.0) 6.1 (1.4) 77.7 (15.1) 3.3 (0.8) 23.1 (4.3) 
APLUSNR 370.1(67.5) 4.4 (0.8) 17.3 (3.8) 6.8 (2.1) 53.3 (10.7) 3.9 (0.7) 16.1 (3.0) 
APLUSR 431.4 (76.3) 3.5 (0.7) 15.0 (3.0) 5.0 (1.4) 43.0 (9.8) 2.8 (0.7) 11.8 (2.5) 
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Figure 7.7: The 0.5hr mean (SD) urinary amounts of BDP and its metabolites excreted 
post- inhalation, expressed as percentage of nominal dose, (n=12). 
 
Figure 7.8: The 24hr mean (SD) urinary amounts of BDP and its metabolites excreted 
post-inhalation, expressed as percentage of nominal dose, (n=12). 
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Figure 7.9: The 0.5hr mean (SD) urinary excretion of (a) BOH (b) 17-BMP (c) BDP 
post eight inhalation from Qvar® EB (100µg), Qvar® MDI(100µg) and Clenil® MDI 
(250µg) attached to either rinsed or not rinsed spacers, expressed as percentage of 
nominal dose, (n=12). 
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Figure 7.10: The 24hr mean (SD) urinary excretion of (a) BOH (b) 17-BMP (c) BDP 
post eight inhalation from Qvar® EB (100µg), Qvar® MDI (100µg) and Clenil® MDI 
(250µg) attached to either rinsed or not rinsed spacer, expressed as percentage of nominal 
dose, (n=12). 
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Table 7.6: Mean difference (95% confidence interval) for the percent of nominal dose of BOH, 17-BMP, and BDP excreted 0.5hr and 24hr post study 
doses. 
  
* p < 0.05, ** p < 0.01, *** < 0.001 otherwise no significant difference. 
Comparator 
BOH 17-BMP BDP 
0.5hr 24hr 0.5hr 24hr 0.5hr 24hr 
Qvar EB Clenil 0.5 (0.4, 0.6)*** 5.7 (4.9, 6.4)*** 0.3 (0.2, 0.4)*** 2.0 (1.7, 2.3)*** 0.3 (0.2, 0.3)*** 1.4 (1.2, 1.7)*** Q-MDI 0.1 (0.0, 0.2)* 0.4 (-0.4, 1.1) -0.02 (-0.09, 0.05) 0.2 (-0.1, 0.5) 0.03 (-0.02, 0.1) 0.03 (-0.2, 0.3) 
Q-MDI Clenil 0.4 (0.3, 0.5)*** 5.3 (4.5, 6.0)*** 0.3 (0.3, 0.4)*** 1.8 (1.5, 2.1)*** 0.2 (0.2, 0.3)*** 1.4 (1.1, 1.6)*** 
C-APLUSNR 
QEB- APLUSNR -0.5 (-0.6, -0.4)*** -4.7 (-5.4, -4.0)*** -0.3 (-0.3, -0.2)*** -1.5 (-1.8, -1.2)*** -0.3 (-0.3, -0.2)*** -1.2 (-1.5, -0.9)*** 
Q-APLUSNR -0.4 (-0.5, -0.3)*** -3.8 (-4.5, -3.0)*** -0.3 (-0.3, -0.2)*** -1.3 (-1.6, -1.1)*** -0.2 (-0.2, -0.1)*** -1.0 (-1.3, -0.8)*** 
C-APLUSR 
QEB-APLUSR -0.5 (-0.6, -0.4)*** -4.2 (-5.0, -3.5)*** -0.2 (-0.3, -0.1)*** -1.2 (-1.4, -0.9)*** -0.2 (-0.3, -0.2)*** -0.7 (-1.0, -0.5)*** 
Q-APLUSR -0.3 (-0.4, -0.3)*** -3.1 (-3.9, -2.4)*** -0.3 (-0.3, -0.2)*** -1.1 (-1.4, -0.8)*** -0.1 (0.2, -0.1)*** -0.8 (-1.0, -0.5)*** 
Q-APLUSNR QEB- APLUSNR -0.1 (-0.1, 0.0) -0.9 (-1.7, -0.2)* 0.01 (-0.06, 0.08) -0.2 (-0.5, 0.1) 0.03 (-0.02, 0.07) -0.2 (-0.4, 0.1) 
Q-APLUSR QEB-APLUSR -0.1 (-0.2, -0.04)** -1.1 (-1.8, -0.4) 0.02 (-0.06, 0.09) 0.3 (0.0, 0.6) -0.06 (-0.1, -0.01)* 0.02 (-0.2, 0.3) 
C-VOLNR QEB-VOLNR -0.3 (-0.4, -0.2)*** -2.5 (-3.3, -1.8)*** -0.1 (-0.2, -0.04)** -0.7 (-1.0, -0.4)*** -0.2 (-0.2, -0.1)*** -0.5 (-0.7, -0.2)*** 
C-VOLR QEB-VOLR -0.3 (-0.4, -0.3)*** -2.3 (-3.0, -1.5)*** -0.1 (-0.2, -0.1)*** -0.6 (-1.0, -0.4)*** -0.2 (-0.2, -0.1)*** -0.5 (-0.7, -0.3)*** 
C-OPTNR QEB-OPTNR -0.5 (-0.6, -0.4)*** -4.2 (-4.9, -3.4)*** -0.3 (-0.3, -0.2)*** -1.3 (-1.6, -1.0)*** -0.2 (-0.3, -0.2)*** -1.0 (-1.3, -0.8)*** 
C-OPTR QEB-OPTR -0.4 (-0.5, -0.3)*** -3.7 (-4.4, -2.9)*** -0.2 (-0.2, 0.1)*** -1.2 (-1.5, -1.0)*** -0.2 9-0.3, -0.2)*** -0.6 (-0.9, -0.4)*** 
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Table 7.7: Mean ratio (90% confidence interval) for Qvar compared to Clenil (when 
normalised for the nominal dose). 
 
7.3.3. Discussion 
As shown in tables 7.5 - 7.6 and figures 7.7 - 7.8, comparable urinary drug excretion 
results were obtained post eight inhalations of 250µg Clenil, 100µg Qvar EB, and 100µg 
Qvar MDI. Table 7.7 shows that when combining all the data of the 0.5hr urinary 
excretion of BDP and its metabolites for Qvar EB vs Clenil and Q-MDI vs Clenil, the 
overall mean ratio was 237.0%, and 221.9% with 90% confidence interval of 217.2 - 
258.6, and 203.4 - 242.1, respectively. While, the overall mean ratio for Qvar EB vs 
Clenil and Q-MDI vs Clenil was 222.3%, and 231.2% with 90% confidence interval of 
203.2 - 243.5, and 194.8 - 233.5, respectively, for the cumulative 24hr urinary excretion. 
This is consistent with previous results reported in Chapter four of this thesis that showed 
that the overall mean ratio (90% confidence limits) between Qvar EB and Clenil with 
respect to the nominal dose were 231.4 (209.6 - 255.7)%, and 204.6 (189.6, 220.6) % for 
the 30 minutes, and 24hr urinary excretion, respectively. The above results also agrees 
with several previous studies that confirmed that a given dose of Qvar HFA–BDP would 
result in approximately 2-2.5 fold greater potency compared with other CFC-containing 
beclometasone MDIs (Leach et al., 1998a; Busse et al., 2000). Woodcock et al (2002) 
Cumulative urinary 
excretion 
Qvar EB Q-MDI 
Clenil Q-MDI Clenil 
BOH 
0.5hr 234.4 (204.8, 268.3) 114.1 (99.8, 130.6) 205.2 (179.3, 234.9) 
24hr 227.7 (201.8, 256.8) 103.4 (91.7, 116.6) 220.1 (195.2, 248.4) 
17-BMP 
0.5hr 234.4 (192.5, 285.8) 97.7 (80.2, 119) 240.1 (197.0, 292.4) 
24hr 238.5 (201.0, 282.9) 108.1 (91.1, 128.3) 220.6 (186.1, 282.9) 
BDP 
0.5hr 242.5 (212.5, 276.8) 109.3 (95.8, 124.7) 221.9 (194.8, 252.9) 
24hr 196.0 (171.8, 223.7) 101.4 (88., 115.7) 193.3 (169.7, 220.1) 
All 3 
combined 
0.5hr 237.0 (217.2, 258.6) 107.0 (98.0, 116.5) 221.9 (203.4, 242.1) 
24hr 222.3 (203.2, 243.5) 104.3 (95.2, 114.2) 231.2 (194.8, 233.5) 
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measured the area under the concentration time curve (AUC) for BDP and its metabolite 
17-BMP post-inhalation of a single 1000µg dose from three different BDP formulations; 
BDP Modulite® with spacer Jet® (Beclojet® 250, MMAD 2.6µm), extrafine HFA-BDP 
(Qvar® 100, MMAD 1.2µm), and CFC-BDP with spacer Jet® (Clenil Forte® 250, MMAD 
4.7µm). This study reported that the AUCs for both BDP and 17-BMP were significantly 
greater with the extrafine formulation than the CFC-BDP and BDP Modulite Jet 
formulations. The reduction of MMAD from 4.7 or 2.6 to 1.2µm markedly increased 
drug absorption, however, a negligible influence on drug absorption was observed when 
changing the MMAD from 4.7 to 2.6µm. The total systemic exposure of 17-BMP post 
administration of similar doses from either BDP Modulite® or CFC-BDP was 
comparable in asthmatic patients (Woodcock et al., 2002a), while that for Qvar 
formulation has been reported to be between 2-2.5 times higher than the CFC product 
(Harrison et al., 1999b; Agertoft et al., 2003). This explains the need to halve the dose 
when switching from Clenil® or from conventional CFC-beclometasone. Clenil® 
Modulite has been formulated with Glycerol in order to increase its particle size to 
closely match that of the older CFC-BDP inhalers (Chaplin and Head, 2007). 
When comparing the urinary excretions of BDP and its metabolites for Qvar EB and 
Qvar MDI, no significant difference was found. As shown from the results, when 
combining all the data of the 0.5hr urinary excretion of BDP and its metabolites for Qvar 
EB vs Q-MDI, the overall mean ratio was 107.0% with 90% confidence interval of 98.0 - 
116.5. The overall mean ratio for the 24hr urinary excretion of Qvar EB vs Q-MDI was 
104.3% with 90% confidence interval of 95.2 - 114.2. These similar urinary drug 
excretions from Qvar® MDI and Qvar EB highlight the good inhalation technique 
achieved by the highly trained volunteers in this study. Several studies have  shown that 
the HFA-BDP formulation in the Autohaler device has a similar lung deposition pattern 
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(Leach, 1999) and clinically equivalent (Woodman et al., 1993) to drug delivered from 
the MDI when used correctly. Furthermore, the extrafine properties of Qvar® were found 
to place less demand on the patient inhalation technique. The gentler and small particle 
size of this HFA-BDP formulation will be suspended longer in the airways and its lung 
deposition will not be greatly affected if there is a delay between dose actuation and 
inhalation, thus it produces an easy to use MDI. These previous findings confirm the 
equivalency of the Qvar EB and the Qvar MDI and agree with previous findings that 
reported similar deposition patterns of such extra-fine particles when inhaled with fast 
and a slow inhalation rate or without a breath hold (Janssens et al., 2003; Usmani et al., 
2005). A previous study also showed an optimal and comparable BDP lung deposition 
from the breath activated Autohaler (60%) and patients with good P&B MDI technique 
(59%). Nevertheless, the degree of lung deposition was decreased as patients 
demonstrated poor inhaler technique, however, those patients still received high BDP 
doses (≥37%) (Leach et al., 2005).  
As shown in table 7.5, the use of any detergent treated not water rinsed spacer with eight 
inhalations of Clenil® MDI (250µg) would increase the 30 minutes urinary excretion of 
BDP and metabolites than that obtained when adding the same spacer to eight inhalations 
of Qvar® formulation (100µg). This may be due to the differences in the particle size of 
the aerosol emitted from these two formulations. Qvar® inhalers have been formulated as 
an HFA-BDP solution system that are designed to generate an aerosol of smaller particle 
size (1.1µm MMAD), thus it is expected to achieve better penetration and lung 
deposition than CFC-BDP inhalers. In contrast, Clenil® inhaler was originally designed 
to deliver an aerosol with properties that more closely resembles that of the CFC-BDP 
inhaler. Therefore, in particular glycerol is added as a non-volatile solvent to the HFA-
BDP solution as a mass mean aerodynamic modulator to modify and increase the particle 
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size to 2.9µm MMAD (Chaplin and Head, 2007). The larger particle size of Clenil® MDI 
(2.9µm MMAD) would more benefit from the spacer presence that enhances its adequate 
evaporation and further particle size reduction before inhalation. However, Qvar® 
formulation is already emitted from the inhaler device as an extrafine aerosol spray with 
smaller MMAD of 1.1µm. In other words, the results showed that the non-extrafine 
formulation of Clenil was more dependent on the spacer presence than the extrafine Qvar 
formulation.  
Smyth et al (2004) investigated the effect of two formulations that have different 
proportions of the HFA propellant and different percentages of the non-volatile 
component added. This study reported that the formulation behaviour with larger MMAD 
due to greater non-volatile component (19.9 vs 2.5%) and lower HFA- propellant used 
(80 vs 97.5%), was more dependent on the type of spacer or whether a spacer is used. 
Another recent study by Leach et al (2010), also investigated the effect of using spacers 
on the in-vivo drug delivery from Qvar® HFA-BDP formulation and Becoforte® CFC-
BDP formulation radiolabeled with technetium-99m. This study reported that the smaller 
particle size formulation of Qvar® showed a very efficient lung deposition that averaged 
52% compared to 3-7% for the larger particle size formulation of the CFC-BDP. 
Furthermore, the use of Aerochamber or Volumatic spacers with HFA-BDP did not alter 
lung deposition but it did reduce oropharyngeal deposition. Several other studies reported 
similar findings confirming the effect of different particle sized formulations on lung 
deposition with and without spacers (Leach, 1998b; Leach, 1999). 
The effect of spacers on the 30 minutes urinary drug excretion, which is representative of 
lung dose, was different for both inhalers. For Clenil MDI, the not rinsed Volumatic 
showed the highest lung deposition followed by the not rinsed Aerochamber Plus, then 
the not rinsed Optimiser. This is in agreement with several studies that confirmed the 
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superior effect of large volume spacers on lung deposition compared to smaller ones 
(Barry and O'Callaghan, 1996; O'Callaghan, 1997; Aswania and Chrystyn, 2001). 
Aswania et al (2001) reported a much greater relative lung deposition obtained from 
Cromogen® MDI attached to the Volumatic than when the Cromogen® EB attached to 
the Optimiser spacer and attributed that to the large volume of the Volumatic spacer 
(750ml) compared to that of the Optimiser spacer (50ml). However, for Qvar MDI and 
Qvar EB, the highest lung deposition was with the not rinsed Aerochamber Plus and the 
not rinsed Optimiser, while the not rinsed Volumatic showed the least lung deposition. 
This indicates that these small volume spacers are more suitable for such extrafine 
formulations.  
These in-vivo results confirm that regardless of the spacer/inhaler combination used, the 
use of the spacer always substantially reduced the 24hr urinary excretion compared to the 
use of either inhaler alone. This is consistent with previous studies that illustrated that the 
use of spacers with steroid pressurized metered dose inhaler greatly reduced the 
oropharyngeal deposition, and hence the total body dose without much affecting the dose 
delivered (Selroos and Halme, 1991). Other studies have even documented their 
beneficial effect in reducing hypothalamic-pituitary axis suppression by beclometasone 
dipropionate (Brown et al., 1990). 
7.4. Conclusion 
Inhaled corticosteroids are the most effective anti-inflammatory drugs available to 
clinicians for the control of inflammation in asthma. Inhaled corticosteroids (ICS) have a 
positive effect on lung function, symptoms, exercise capacity, and may decrease disease 
exacerbations. However, gaining these beneficial effects is greatly dependent on the 
aerosol generating system and its particle size distribution. Despite the fact that MDIs 
appear to be simple in design, several interfering factors can influence its drug delivery to 
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the patient. Variations in aerosol particle size, spacer size, and washing methods were 
found to potentially influence drug delivery. 
The previous in-vitro and in-vivo results demonstrated appreciable differences in the 
urinary drug excretion and the aerodynamic particle size distribution of different HFA 
formulations of the same drug when used with or without spacers. The difference in the 
particle size of these formulations (Qvar®, 1.1µm vs Clenil®, 2.9µm) greatly affected 
drug deposition in different regions of the respiratory tract with or without a spacer 
device. Indeed, formulations rich in superfine particles such as Qvar® provided higher 
lung deposition and lower oropharyngeal impaction, thus reducing the need to use a 
spacer. In contrast, although the dose of Clenil does not have to be halved when 
switching from CFC-BDP inhalers, this products was associated with lower lung 
deposition and higher oropharyngeal impaction, and hence the need to use a spacer. 
This implies that particle size is one of the most important design variables in an aerosol 
formulation that can greatly affect drug delivery. When using spacers, the aerosol 
impaction and fine to coarse particle ratio largely depends on spacer size and the level of 
the electrostatic charge on its surface. The proper choice and treatment of spacers is 
therefore important for optimal drug delivery. The common rule that the larger the 
spacer, the greater the amount of drug that remains airborne and eventually delivered, 
does not apply to all MDIs. The optimal spacer length is specific to a particular MDI and 
cannot be assumed to others. Therefore, it is inappropriate to use any formulation with 
any spacer device just because it fits the mouthpiece adapter without first considering the 
aerosol characteristics. No doubt that each MDI formulation/spacer combination need to 
be fully assessed even if it contains the same drug in order to guide the optimum device 
selection. Nevertheless, all spacers used with MDIs in this study have been always found 
to significantly reduce the impaction of the larger drug particles in the oropharynx and 
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minimize gastrointestinal tract drug deposition. Therefore, the use of spacers is always 
associated with a more favourable therapeutic ratio, since it has little effect on lung dose 
but significantly reduces throat deposition.  
Indeed, the future of development in respiratory disease control will be more based on 
improvements in drug delivery to the lung rather than introduction of new inhaled 
therapies. Concerning the low therapeutic index and the high cost of inhaled 
corticosteroids, it is more demanding to optimise their drug delivery to the respiratory 
tract as variations in dose deposited in the lung could significantly influence their 
treatment outcomes. Based on these considerations, the presence of spacers routinely 
attached to BDP MDIs are of great value, especially in situations of administering high 
doses of ICS or when the correct use of a MDI is unlikely. This is particularly important 
for beclometasone dipropionate inhaled therapy compared to other inhaled 
corticosteroids, which is due to its lower first pass metabolism; its high oropharyngeal 
deposition would be expected to significantly contribute to its systemic effects without an 
additional increase in clinical benefit. Therefore, the addition of a spacer to an HFA-BDP 
MDI even in the ultra-fine formulation was found to somewhat improve the therapeutic 
ratio of beclometasone. Generally, using the appropriate spacer with beclometasone 
dipropionate inhaler was found to reduce the oropharyngeal deposition and hence the 
total body dose without much affecting the dose delivered to the airways. Furthermore, 
unlike bronchodilators frequent dosing, inhaled corticosteroids are dosed once or twice 
daily, thus reducing the spacers’ portability issue. 
Overall, whether using Qvar or Clenil inhalers, spacers should not be rinsed with water. 
For Qvar, the only advantage is the further reduction of the oropharyngeal deposition. 
For Clenil, lung deposition is improved but the more pronounced effect is in the 
reduction of its systemic bioavailability.  
  
 
 
 
 
Chapter 8: Summary and Future Work
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8.1. Summary  
Inhaled corticosteroids (ICS) are the standard first line anti inflammatory therapy for the 
management of persistent asthma in all current national and international guidelines 
(BTS/SIGN, 2008; GINA, 2010). Beclometasone dipropionate (BDP) was the first 
available inhaled corticosteroid used for the treatment of asthma. It was first introduced 
in 1972 in a pressurized metered dose inhaler and later in a dry powder inhaler. 
Beclometasone dipropionate (BDP) is a prodrug that is metabolized by esterases in the 
human lung, liver and other parts of the body to three different metabolites, 17-
beclometasone monopropionate (17-BMP), 21-beclometasone monopropionate (21-
BMP) and beclometasone (BOH) (Foe et al., 2000; Derendorf et al., 2006; Rossi et al., 
2007) 
The mandatory replacement of the ozone damaging CFC-propellants in MDIs by the 
safer HFA alternatives led to vast developments in aerosol technology to accommodate 
these new propellants. There are now two brands of CFC-free beclometasone MDIs in 
the UK (Clenil Modulite® and Qvar®). These devices are not equipotent, and in order to 
limit prescribing errors and avoid confusion, the MHRA advises that CFC-free 
beclometasone MDIs should be prescribed by brand name. Clenil Modulite® is 
equipotent to the CFC-innovator product (Becotide®), therefore, a straightforward 
substitution of doses can be performed (Chaplin and Head, 2007). Qvar® contains 
beclometasone in solution and has been shown to deliver the drug as an extra-fine aerosol 
that results in a 2-2.5 fold greater potency compared with other CFC-containing 
beclometasone MDIs (Leach et al., 2002).  
Aerosol deposition in the lung depends on several factors, including the aerosol 
generating system, the particle size distribution of the emitted dose, the inhalation 
manoeuvre, airflow obstruction and severity of lung disease (Dolovich and Dhand, 
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2011).  These factors can be studied using simple pharmacokinetic methodology post 
inhalation and by in vitro characterisation of the emitted dose. 
Hindle and Chrystyn (1992) reported that measurements of the 30 minutes urinary drug 
amounts post inhalation represent the absorption lag time of the orally swallowed portion 
and would account mainly for the drug absorbed from the lung, while the 24 urinary drug 
amounts post inhalation is an index of systemic delivery. This pharmacokinetic method 
was found to be simple, non-invasive and has been extended to determine the relative 
bioavailability of different drugs, e.g, inhaled sodium cromoglycate (Aswania et al., 
1999; Chrystyn, 2000; Aswania and Chrystyn, 2001; Aswania and Chrystyn, 2002), 
nedocromil (Aswania et al., 1998) , gentamycin (Nasr and Chrystsyn, 1997; Al-Amoud et 
al., 2002; Al-Amoud et al., 2005) and formeterol (Nadarassan et al., 2007). However, the 
methodology has not been extended to inhaled corticosteroids.  
The plasma concentrations of drugs such as inhaled corticosteroids are very low, because 
of the small doses used and their very large volume of distribution.(Derendorf et al., 
2006) The analysis of these drugs in plasma requires highly sensitive analytical methods, 
whereas these drugs in urine are more concentrated.  
The main aim of this work was to identify, validate, and apply a urinary pharmacokinetic 
method to determine the relative lung and systemic bioavailability of inhaled 
beclometasone following different inhalation methods from a metered dose inhaler using 
two different formulations of BDP (Qvar and Clenil) and to measure the in-vitro 
aerodynamic particle size distribution of the same inhalation methods.  
First, a simple, sensitive and selective LC-(ESI+)-MS method using a solid phase 
extraction procedure for simultaneously quantifying beclometasone dipropionate (BDP) 
and its two metabolites 17-beclometasone monopropionate (17-BMP) and beclometasone 
(BOH) in human urine samples and methanol samples after in-vivo inhalation and in-
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vitro dose emission of the drug, respectively was developed and presented in chapter 
three. The method validation results according to the FDA and ICH guidelines have 
shown that it has acceptable limits for both accuracy and precision (±15%) and has been 
successfully used to analyze samples from this study. In addition, the preparation, 
separation, and identification of BDP metabolites was carried out and the final product 
was purified by preparative HPLC and the resulting NMR spectrum was recorded. The 
NMR results confirmed the rapid hydrolysis of BDP to 17-BMP (the major metabolite) 
via esterase enzyme. 
Second, in chapter four we have used the original methodology reported by Hindle and 
Chrystyn (1992) to identify the feasibility of using this urinary pharmacokinetic method 
for inhaled BDP. The application of this approach has been determined by comparing 
urinary excretions of BDP and its metabolite post Qvar and Clenil inhalations. Twelve 
healthy, non-smoking volunteers completed an in-vivo urinary pharmacokinetic study to 
determine the relative lung bioavailability of beclometasone following inhalation. The 
urinary amounts excreted following an oral dose of a 20ml 20 % alcoholic solution of 
2000μg beclometasone dipropionate , an oral dose (2000µg) plus oral charcoal, ten 
100μg inhalations from a Qvar® EB inhaler, ten 100μg inhalations from a Qvar® EB 
inhaler plus oral charcoal, and eight 250μg inhalations from a Clenil® MDI were studied. 
No BDP, 17-BMP, or BOH was detected in any samples post oral with charcoal dosing 
or following the 0.5hr post the oral dose. In addition, there was no BDP detected up to 
24hr following the oral dose administration. Significantly more (p<0.001) BDP, 17-BMP 
and BOH were excreted in the first 30 minutes and cumulative 24 urinary excretion post 
inhalation of either Clenil or Qvar compared to oral administration. This suggests that the 
amount of drug and metabolites excreted 30 minutes and 24hrs post dosing can be used 
as an index of lung deposition and relative systemic bioavailability, respectively. No 
significant difference was found between the amount of drug or metabolites excreted in 
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the urine over the 24hr collection periods post dose following inhaled Clenil® and 
inhaled Qvar® administration. The urinary pharmacokinetic methodology to determine 
the relative lung and systemic bioavailability post inhalation applies to BDP. The inhaled 
Qvar to inhaled Clenil ratio is consistent with related clinical equivalence and 
pharmacokinetic data. The overall mean ratio (90% confidence limits) between Qvar and 
Clenil with respect to the nominal was 231 (209.6 - 255.7) %, and 204.6 (189.6-220.6) 
for the 30 minute, and the 24hr urinary excretion. The low inter- and intra- subject 
variability of the study confirms the reproducibility of this method. These results confirm 
that this method can be used to study the relative lung and systemic bioavailability of 
BDP after an inhalation. 
The use of various spacers attached to MDIs has been found to compensate for many of 
its problems. The role of spacers is to slow the velocity of the aerosol spray, allowing 
time for the propellants to evaporate and large drug particles to settle. Spacers decrease 
the oropharyngeal deposition and the need for coordination between actuation and 
inhalation while they may increase lung deposition (McFadden, 1995; Terzano, 2001). It 
is well documented that the type of spacer as well as the method of its handling can 
greatly affect the delivery of asthma medication (GINA, 2010). Chapter five, six, and 
seven of this thesis have focused on investigating and comparing the in-vitro 
aerodynamic characteristics as well as the in-vivo drug delivery from two formulations of 
HFA-BDP (Clenil and Qvar) with and without spacers. 
The in-vitro dose emission characteristics of beclometasone dipropionate from two 
actuations of Clenil Modulite® MDI (250µg) alone and with different spacers were 
measured using the Andersen Cascade Impactor (ACI) according to the standard 
compendial methodology at a flow rate of 28.3 L/min using a 4L inhalation volume. The 
spacers used were the Volumatic (VOL), the Aerochamber Plus (APLUS), and the 
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Optimiser (OPT). Each spacer was tested after adequate prewashing in detergent solution 
followed by either rinsing (R) or not rinsed with water (NR), then allowed to drip dry. 
The TED from the MDI alone was significantly higher than all MDI + spacers. The not 
rinsed Volumatic (VOLNR) spacer showed the highest FPD, and % FPF. The use of 
water rinsed spacers significantly decreased the FPD when compared to the not water 
rinsed spacers.  
The influence of higher inspiratory flow rates (60 and 90L/min) on the aerosol particle 
size distribution of Clenil Modulite® MDI alone was evaluated and compared to that at 
28.3L/min. Increasing flow rate from 28.3 L/min to 60 L/min lowered the MMAD and 
led to a small significant increase in the FPD and the % FPF. Increasing flow rate from 
28.3L/min to 90 L/min were associated with lower MMAD and higher FPD for the 
90L/min flow rate compared to the 28.3L/min flow rate, however, the results were non-
significant. 
The previous urinary pharmacokinetic method was then applied to highlight and compare 
the effect of different spacers on the in-vivo drug delivery of inhaled beclometasone from 
Clenil Modulite® MDI in twelve healthy volunteers. In addition, the study aimed to 
determine the effect of different spacer handling procedures on drug delivery by 
comparing drug output from either water rinsed or not rinsed detergent coated spacers. 
Each spacer was adequately prewashed in detergent solution followed by either rinsing 
(R) or not rinsing (NR) with water, then allowed to drip dry. Subjects inhaled eight doses 
from Clenil Modulite® MDI (250µg) either alone or when attached to one of the 
following spacers; the Volumatic, the Aerochamber Plus or the Optimiser with and 
without rinsing. Subjects emptied their bladder prior to each study dose and then urine 
samples were collected at 30 minutes, and cumulatively for 24 hours post dosing of each 
study dose. The volume of urine excreted was recorded and aliquots of each sample were 
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frozen at -20°C prior to analysis. The amount of drug left in each spacer device was also 
determined. The use of Clenil Modulite® MDI alone resulted in significantly higher 
amounts of drug excreted 24hrs post dosing than that when using the MDI + spacers. The 
use of the spacers had a little effect on the amount of drug excreted 30 minutes post 
dosing. The VOLNR spacer provided significantly greater amount of BDP and 
metabolites than the MDI alone or the MDI + any other spacer. Rinsing spacers with 
water markedly decreased drug output from spacers than not rinsed spacers and should 
not be used. The results were consistent with the previous in-vitro study. For Clenil, lung 
deposition was improved but the more pronounced effect is in the reduction of its 
systemic bioavailability.  
The Andersen Cascade Impactor (ACI) was used to determine the in-vitro particle size 
distribution of beclometasone dipropionate obtained from four actuations of Qvar® MDI 
(100µg) and Qvar® EB (100µg) alone and with different spacers at a flow rate of 28.3 
L/min using a 4L inhalation volume. The spacers used were the same as mentioned with 
the Clenil® study. The TED from the MDI alone was significantly higher than all MDI + 
spacers. The use of the spacers with Qvar® inhalers significantly reduced the 
oropharyngeal deposition; however, the FPD was not affected. In addition, the presence 
of the electrostatic charge on the surface of the water rinsed spacers contributed to 
significant loss of drug output from the spacer compared to the not rinsed spacers. 
The influence of higher inspiratory flow rates (60 and 90L/min) on the aerosol particle 
size distribution for Qvar® EB and Qvar® MDI was evaluated and compared to that at 
28.3L/min. For the Qvar® EB , the amount of drug deposited in the induction port of the 
ACI was found to decrease significantly (p<0.05) when increasing the flow rate from 
28.3 to 90L/min, while the induction port deposition decrease was non-significant when 
increasing the flow rate from 28.3 to 60L/min and from 60 to 90L/min. For the Qvar® 
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MDI, a similar reduction in the induction port deposition was indicated when increasing 
the flow rate; however, the results were not significant. 
The same urinary pharmacokinetic method was used to determine the effect of different 
spacers and different spacers’ washing procedures on the in-vivo drug delivery from eight 
inhalations from Qvar® MDI (100µg) and Qvar® EB (100µg) in healthy volunteers. 
Again subjects emptied their bladder prior to each study dose and then urine samples was 
collected at 30 minutes, and cumulatively for 24 hours post dosing of each study dose. 
The volume of urine excreted was recorded and aliquots of each sample were frozen at -
20°C prior to analysis. The amount of drug left in each spacer device was also 
determined. The use of Qvar® MDI (100µg) and Qvar EB (100µg) alone resulted in 
significantly higher amounts of drug excreted 24hrs post dosing than that when using the 
MDI + spacers. The use of spacers did not increase the amount of drug excreted 30 
minutes post dosing. The not rinsed Aerochamber Plus spacer provided greater amount 
of BDP and metabolites than other spacers did. Rinsing spacers with water had an 
obvious effect on reducing drug delivery compared to the not water rinsed spacers. 
Overall, the only advantage of using spacers with Qvar is the reduction in the systemic 
bioavailability. 
The previous in-vivo and in-vitro results demonstrated appreciable differences in the 
urinary drug excretion and the aerodynamic particle size distribution of different HFA 
formulations of the same drug. It was found that using eight inhalations of either 250µg 
of Clenil® or 100µg of Qvar® led to comparable urinary drug excretion. The fine particle 
dose emitted from two actuations of Clenil® (250µg) inhaler was approximately half that 
obtained from four actuations of Qvar® (100µg) inhalers. This Qvar: Clenil ratio is 
consistent with clinical equivalence data and explains the need to halve the dose when 
switching from Clenil® to Qvar® inhaled therapy. The use of the not rinsed spacers with 
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Clenil® inhaler may increase lung deposition; however, adding spacers to Qvar® inhalers 
will not affect it. Small volume spacers were found to be more suitable in maintaining the 
extrafine particle fraction for Qvar® EB and Qvar® MDI. While large volume spacers 
were more suitable for the larger particle size formulation such as Clenil® as it will create 
more space for more efficient particle size reduction. 
In conclusion, the urinary pharmacokinetic method originally pioneered for salbutamol 
can also be applied to inhaled beclometasone. The ratio between Qvar and Clenil is 
consistent with related clinical and pharmacokinetic lung deposition studies. Using this 
method, we found that there are several factors affecting drug delivery. These include; 
drug formulation, particle size, spacer size, as well as the method of handling spacers. 
This work confirms the concept that the efficacy of a particular spacer with one 
formulation cannot be assumed for another formulation, even for the same drug. 
Therefore, each drug formulation MDI/spacer combination should be first properly 
evaluated prior to use (GINA, 2010). This simple non-invasive methodology was found 
to be reproducible and can now be applied in clinical studies to study different 
formulations and products as well as inhalation methods. 
8.2. Future work  
Asthmatics are normally prescribed a salbutamol inhaler and an inhaled corticosteroid. 
Theoretically, salbutamol will open the airways and allow more inhaled corticosteroid to 
be deposited into the lungs. There has always been a debate that salbutamol should be 
given first but this has never been studied due to the unavailability of a simple method to 
identify lung deposition of inhaled corticosteroids. There are two different HFA-BDP 
formulations with different dosage recommendations, which is why the MHRA has 
recommended that inhaled beclometasone inhalers should be prescribed by brand. One of 
these formulations (Qvar; Teva Pharmaceuticals) has ultrafine particles with high lung 
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deposition, which may not be improved by prior inhalation of a bronchodilator. The other 
(Clenil®, Chiesi) has bigger particles because it was formulated to mimic Becotide 
(GlaxoSmithKline), the innovator product. Theoretically, inhalation of this after a 
bronchodilator should result in higher lung deposition. Using the urinary beclometasone 
method, we have designed a study to address these points. Measurement of the urinary 
excretion of beclometasone dipropionate, 17-beclometasone monopropionate, and 
beclometasone in the first 30 minutes after an inhalation of beclometasone dipropionate 
by adult asthmatics can be used to: 
 To determine if the bronchodilator effects of salbutamol, in asthmatic patients, 
affects lung deposition of inhaled beclometasone.  
 To compare the effect of salbutamol on the lung deposition of two different 
beclometasone formulations (Qvar® and Clenil®) to identify the influence of the 
particle size of a formulation that is inhaled following a bronchodilator.  
Local hospital research ethics committee approval was obtained for this study and 
presented in APPENDIX C (refer to the enclosed DVD); however, there was a difficulty 
in recruiting patients from Huddersfield Royal Infirmary. The study was designed as 
follows: Patients will be enrolled into the study from the outpatient clinic seven days 
before Study Day 1. Each patient’s metered dose inhaler technique will be checked and 
corrected if required. 
The study doses will be 
 Four doses of Qvar® Easi-Breathe (100µg), Salbutamol inhalation will be allowed 
after the urine sample and spirometry test at 30 minutes post inhalation 
 Two salbutamol 100µg doses 15 minutes before four doses of Qvar® Easi-Breathe 
(100µg).  
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 Four doses of Clenil® MDI (250µg), Salbutamol inhalation will be allowed after 
the urine sample and spirometry test at 30 minutes post inhalation 
 Two salbutamol 100µg doses 15 minutes before four doses of Clenil® MDI 
(250µg). 
The order of study dose administration will be randomised and there will be a minimum 
wash out period of seven days between each study day. On study days, patients will 
withhold all their inhaled doses for 12 hours except for salbutamol, which will be 
required to be withheld for 6 hours. All study doses will be administered in the morning 
so their last inhaled dose (except salbutamol) will be the previous night. Those that need 
rescue medication from their salbutamol within 6 hours of their planned attendance will 
be allowed to continue their medication and their study day will be re-scheduled. On 
study day1, spirometry will be measured and each patient’s inhalation technique will be 
checked with correction as required. Patients will void their urine 15 minutes before the 
inhalation of the first beclometasone dose. There will be 30 seconds between each 
inhaled dose. Thirty minutes after the inhalation of the first beclometasone dose patients 
will provide a urine sample and their spirometry will be measured. The volume of their 
urine will be recorded and an aliquot will be retained and frozen at minus 20oC prior to 
analysis. Our LC-(ESI+)-MS method with solid phase extraction assay that we have 
developed and validated for beclometasone dipropionate and its metabolites will be used 
to identify amounts excreted in the urine samples.   
Since, it has been shown that lung deposition of patients is affected by the inhalation 
flow and that coordination is not controlled. This simple non-invasive methodology can 
be used in patient studies to investigate the effect of coordination and inhalation flow. 
Besides, the methodology can be extended to budesonide and fluticasone propionate. 
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